fonc-13-1180084.en.ar

‫ﻣﺘﺮﺟﻢ ﻣﻦ ﺍﻹﻧﺠﻠﻴﺰﻳﺔ ﺇﻟﻰ ﺍﻟﻌﺮﺑﻴﺔ ‪www.onlinedoctranslator.
com -‬‬
‫ﻳﻜﺘﺐﻣﺮﺍﺟﻌﺔ‬
‫ﻧﺸﺮﺕ‪ 31‬ﻳﻮﻟﻴﻮ ‪2023‬‬
‫‪10.3389/fonc.2023.1180084DOI‬‬
‫ﻧﺒﺎﺗﺎﺕﺿﺪ ﺍﻟﺴﺮﻃﺎﻥ‪ :‬ﺍﻷﻋﺸﺎﺏ‬

‫ﺍﻟﻤﻌﺰﺯﺓﻟﻠﻤﻨﺎﻋﺔ‬ ‫ﺍﻟﻮﺻﻮﻝﺍﻟﻤﻔﺘﻮﺡ‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ‪:‬ﻟﻴﺲ ﻣﻦ ﺍﻟﻨﺒﺎﺕ‪ ،‬ﺑﻞ‬ ‫ﺣﺮﺭﺕﺑﻮﺍﺳﻄﺔ‬
‫ﻣﻴﻨﺞﻛﻮﺍﻧﺞ‪,‬‬
‫ﻓﻲﺍﻟﻨﺒﺎﺕ‪ .‬ﺍﻟﻤﻔﺎﻫﻴﻢ ﺍﻷﺳﺎﺳﻴﺔ‬

‫ﺍﻟﻤﺴﺘﺸﻔﻰﺍﻷﻭﻝ ﺍﻟﺘﺎﺑﻊ ﻟﺠﺎﻣﻌﺔ ﺻﻦ ﻳﺎﺕ ﺻﻦ‪ ،‬ﺍﻟﺼﻴﻦ‬
‫ﻭﺍﻟﻤﻘﺪﻣﺔﻭﺍﻟﻤﻮﺍﺭﺩ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ‬
‫ﺗﻤﺖﻣﺮﺍﺟﻌﺘﻪ ﻣﻦ ﻗﺒﻞ‬
‫ﺑﺮﺍﺗﻴﺒﻬﺎﺑﺎﻧﺪﻱ‪,‬‬
‫ﻣﻌﻬﺪﻧﻮﻳﺪﺍ ﻟﻠﻬﻨﺪﺳﺔ ﻭﺍﻟﺘﻜﻨﻮﻟﻮﺟﻴﺎ )‪،(NIET‬‬
‫ﻻﻛﺘﺸﺎﻑﺍﻟﻤﻮﺍﺩ ﺍﻟﻤﺴﺎﻋﺪﺓ ﻟﻠﻘﺎﺡ‬

‫ﺍﻟﻬﻨﺪ‬
‫ﺩﻳﺒﻴﻜﺎﺷﺎﺭﻣﺎ‪,‬‬
‫ﻣﻌﻬﺪﻋﻠﻮﻡ ﻭﺗﻜﻨﻮﻟﻮﺟﻴﺎ ﺍﻟﻨﺎﻧﻮ )‪ ،(INST‬ﺍﻟﻬﻨﺪ‬
‫* ﻣﺮﺍﺳﻠﺔ‬
‫ﻛﺮﻡﻓﺆﺍﺩ ﺳﻠﻴﻤﺎﻥ‬
‫‪karam.soliman@famu.edu‬‬
‫ﺇﻟﻴﺰﺍﺑﻴﺚﻣﺎﺯﻳﻮ‪ ،1‬ﺃﻧﺪﺭﻭ ﺑﺎﺭﻧﺰ‪1‬ﺭﺍﻣﻴﺶ ﺑﺎﺩﻳﺴﺎ‪ ،1‬ﻣﺠﻠﺲ ﺳﺘﻴﻔﻲ‪2‬ﻭﻛﺮﻡ‬ ‫ﺗﻠﻘﻰ‪ 05‬ﻣﺎﺭﺱ ‪2023‬‬
‫ﻓﺆﺍﺩﺳﻠﻴﻤﺎﻥ‪*1‬‬ ‫ﻗﺒﻠﺖ‪ 30‬ﻣﺎﻳﻮ ‪2023‬‬

‫ﻧﺸﺮﺕ‪ 31‬ﻳﻮﻟﻴﻮ ‪2023‬‬
‫‪1‬ﻗﺴﻢ ﺍﻟﻌﻠﻮﻡ ﺍﻟﺼﻴﺪﻻﻧﻴﺔ‪ ،‬ﻛﻠﻴﺔ ﺍﻟﺼﻴﺪﻟﺔ ﻭﺍﻟﻌﻠﻮﻡ ﺍﻟﺼﻴﺪﻻﻧﻴﺔ‪ ،‬ﻣﻌﻬﺪ ﺍﻟﺼﺤﺔ ﺍﻟﻌﺎﻣﺔ‪ ،‬ﻓﻠﻮﺭﻳﺪﺍ‪ ،‬ﺟﺎﻣﻌﺔ ﺇﻳﻪ ﺁﻧﺪ ﺇﻡ‪ ،‬ﺗﺎﻻﻫﺎﺳﻲ‪ ،‬ﻓﻠﻮﺭﻳﺪﺍ‪،‬‬
‫ﺍﻻﻗﺘﺒﺎﺱ‬
‫ﺍﻟﻮﻻﻳﺎﺕﺍﻟﻤﺘﺤﺪﺓ‪2،‬ﻣﻌﻬﺪ ﺟﻮﻥ ﺟﻨﺎﺑﺮ ﻷﺑﺤﺎﺙ ﺍﻟﻌﻠﻮﻡ‪ ،‬ﺑﺎﻟﺘﻴﻤﻮﺭ‪ ،‬ﻣﺎﺭﻳﻼﻧﺪ‪ ،‬ﺍﻟﻮﻻﻳﺎﺕ ﺍﻟﻤﺘﺤﺪﺓ‬
‫‪.‬ﺍﻟﻨﺒﺎﺗﺎﺕﺿﺪ ﺍﻟﺴﺮﻃﺎﻥ‪ :‬ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻌﺸﺒﻲ ﺍﻟﻤﻌﺰﺯ‬
‫ﻟﻠﻤﻨﺎﻋﺔ‪:‬ﻟﻴﺲ ﻣﻦ ﺍﻟﻨﺒﺎﺕ‪ ،‬ﻭﻟﻜﻦ ﻓﻲ ﺍﻟﻨﺒﺎﺕ‪.‬‬
‫ﺍﻟﻤﻔﺎﻫﻴﻢﺍﻷﺳﺎﺳﻴﺔ ﻭﺍﻟﻤﻘﺪﻣﺔ ﻭﺍﻟﻤﻮﺍﺭﺩ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ‬
‫ﻻﻛﺘﺸﺎﻑﺍﻟﻤﻮﺍﺩ ﺍﻟﻤﺴﺎﻋﺪﺓ ﻟﻠﻘﺎﺡ (‪KFA )2023‬‬
‫‪E، Barnes A، Badisa R، Council S، Soliman‬‬
‫‪Mazzio‬‬
‫ﺇﻥﻭﺟﻮﺩ ﻣﺠﺘﻤﻌﺎﺕ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ )‪ (MOCs‬ﺍﻟﻤﻜﻮﻧﺔ ﻣﻦ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ ﻭﺍﻟﻔﻄﺮﻳﺎﺕ ﻭﺍﻟﻌﺘﺎﺋﻖ‬
‫ﻭﺍﻟﻄﺤﺎﻟﺐﻭﺍﻷﻭﺍﻟﻲ ﻭﺍﻟﻔﻴﺮﻭﺳﺎﺕ ﻭﻣﺎ ﺷﺎﺑﻪ ﺫﻟﻚ‪ ،‬ﻣﻮﺟﻮﺩ ﻓﻲ ﻛﻞ ﻣﻜﺎﻥ ﻓﻲ ﺟﻤﻴﻊ ﺍﻷﻧﺴﺠﺔ ﺍﻟﺤﻴﺔ‪ ،‬ﺑﻤﺎ‬ ‫ﺃﻣﺎﻡ‪.‬ﺃﻭﻧﻜﻮﻝ‪ .13:1180084.‬ﺩﻭﻯ‪:‬‬
‫ﻓﻲﺫﻟﻚ ﺍﻟﻨﺒﺎﺕ ﻭﺍﻟﺤﻴﻮﺍﻥ‪ .‬ﺗﻠﻌﺐ ‪ MOCs‬ﺩﻭﺭﺍً ﻣﻬﻤﺎً ﻓﻲ ﺇﻧﺸﺎء ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻄﺮﻳﺔ ﻭﺍﻟﻤﻜﺘﺴﺒﺔ‪ ،‬ﻭﺑﺎﻟﺘﺎﻟﻲ‬ ‫‪fonc.2023.1180084/10.3389‬‬
‫ﺍﻟﺘﺄﺛﻴﺮﻋﻠﻰ ﺍﻟﻘﺎﺑﻠﻴﺔ ﻭﺍﻟﻤﻘﺎﻭﻣﺔ ﻟﻸﻣﺮﺍﺽ‪ .‬ﻭﻗﺪ ﻋﺰﺯ ﻫﺬﺍ ﺍﻟﻔﻬﻢ ﺍﻟﺘﻘﺪﻡ ﺍﻟﻜﺒﻴﺮ ﻓﻲ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻟﻤﺠﺎﻻﺕ‬ ‫ﺣﻘﻮﻕﺍﻟﻨﺸﺮ‬
‫© ‪ 2023‬ﻣﺎﺯﻳﻮ‪ ،‬ﺑﺎﺭﻧﺰ‪ ،‬ﺑﺎﺩﻳﺴﺎ‪ ،‬ﻛﺎﻭﻧﺴﻴﻞ ﻭﺳﻠﻴﻤﺎﻥ‪ .‬ﻫﺬﻩ‬
‫ﻣﺜﻞﺍﻟﺰﺭﺍﻋﺔ‪ ،‬ﻭﻋﻠﻮﻡ‪/‬ﺳﻼﻣﺔ ﺍﻷﻏﺬﻳﺔ‪ ،‬ﻭﺗﻄﻮﻳﺮ ﺍﻟﻠﻘﺎﺣﺎﺕ‪/‬ﺍﻟﻤﻮﺍﺩ ﺍﻟﻤﺴﺎﻋﺪﺓ‪ ،‬ﺍﻟﺘﻲ ﺗﻌﺘﻤﺪ ﻋﻠﻰ ﺇﺩﺍﺭﺓ‬ ‫ﻣﻘﺎﻟﺔﻣﻔﺘﻮﺣﺔ ﺍﻟﻮﺻﻮﻝ ﻭﻣﻮﺯﻋﺔ ﺑﻤﻮﺟﺐ ﺷﺮﻭﻁﺭﺧﺼﺔ‬
‫ﻣﺴﺒﺒﺎﺕﺍﻷﻣﺮﺍﺽ ‪ MOC‬ﺍﻟﻤﻌﻄﻠﺔ ﻭﺍﻟﻤﻀﻌﻔﺔ‪ .‬ﺗﺸﻴﺮ ﺍﻷﺩﻟﺔ ﺍﻟﺘﺎﺭﻳﺨﻴﺔ ﺍﻟﺘﻲ ﻳﻌﻮﺩ ﺗﺎﺭﻳﺨﻬﺎ ﺇﻟﻰ ﺍﻟﻘﺮﻥ‬ ‫ﺍﻟﻤﺸﺎﻉﺍﻹﺑﺪﺍﻋﻲ )‪.(CC BY‬ﻳﺴُﻤﺢ ﺑﺎﺳﺘﺨﺪﺍﻡ ﺃﻭ ﺗﻮﺯﻳﻊ ﺃﻭ‬
‫ﺍﻟﺘﺎﺳﻊﻋﺸﺮ‪ ،‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺗﻘﺎﺭﻳﺮ ﺍﻟﺪﻛﺎﺗﺮﺓ ﺑﻮﺵ ﻭﻛﻮﻟﻲ ﻭﻓﻴﻠﻴﺴﻦ‪ ،‬ﺇﻟﻰ ﺃﻥ ﺍﻟﻌﺪﻭﻯ ﺍﻟﺤﻤﻮﻳﺔ ﺍﻟﺤﺎﺩﺓ‬ ‫ﺇﻋﺎﺩﺓﺇﻧﺘﺎﺝ ﻓﻲ ﻣﻨﺘﺪﻳﺎﺕ ﺃﺧﺮﻯ‪ ،‬ﺑﺸﺮﻁ ﺃﻥ ﻳﻨُﺴﺐ ﺍﻟﻔﻀﻞ‬
‫ﺇﻟﻰﺍﻟﻤﺆﻟﻒ )ﺍﻟﻤﺆﻟﻔﻴﻦ( ﺍﻷﺻﻠﻴﻴﻦ ﻭﻣﺎﻟﻚ )ﻣﺎﻟﻜﻲ( ﺣﻘﻮﻕ‬
‫ﺍﺳﺘﺠﺎﺑﺔﻟـ "ﻣﻴﻜﺮﻭﺑﺎﺕ ﻣﻌﻴﻨﺔ" ﻳﻤﻜﻦ ﺃﻥ ﺗﺆﺩﻱ ﺇﻟﻰ ﺷﻔﺎء ﺍﻟﻮﺭﻡ ﺗﻠﻘﺎﺋﻴﺎً ﻟﺪﻯ ﺍﻟﺒﺸﺮ‪ .‬ﺃﺩﻯ ﻫﺬﺍ ﺍﻻﻛﺘﺸﺎﻑ‬ ‫ﺍﻟﻄﺒﻊﻭﺍﻟﻨﺸﺮ ﻭﺃﻥ ﻳﺴُﺘﺸﻬﺪ ﺑﺎﻟﻤﻨﺸﻮﺭ ﺍﻷﺻﻠﻲ ﻓﻲ ﻫﺬﻩ‬
‫ﺇﻟﻰﺍﻹﺩﺍﺭﺓ ﺍﻟﻬﺎﺩﻓﺔ ﻟﻨﻔﺲ ﺍﻟﺴﻼﻻﺕ ﺍﻟﻤﻮﻫﻨﺔ‪ ،‬ﺍﻟﻤﻌﺮﻭﻓﺔ ﺑﺎﺳﻢ "ﺳﻢ ﻛﻮﻟﻲ"‪ ،‬ﻣﻤﺎ ﻳﻤﺜﻞ ﺑﺪﺍﻳﺔ ﺃﻭﻝ ﻋﻼﺝ‬ ‫ﺍﻟﻤﺠﻠﺔ‪،‬ﻭﻓﻘﺎً ﻟﻠﻤﻤﺎﺭﺳﺎﺕ ﺍﻷﻛﺎﺩﻳﻤﻴﺔ ﺍﻟﻤﻘﺒﻮﻟﺔ‪ .‬ﻻ ﻳﺴُﻤﺢ‬
‫ﺑﺎﺳﺘﺨﺪﺍﻡﺃﻭ ﺗﻮﺯﻳﻊ ﺃﻭ ﺇﻋﺎﺩﺓ ﺇﻧﺘﺎﺝ ﻣﺎ ﻻ ﻳﺘﻮﺍﻓﻖ ﻣﻊ ﻫﺬﻩ‬
‫ﻣﻨﺎﻋﻲﻟﻠﻮﺭﻡ ﻳﻌﺘﻤﺪ ﻋﻠﻰ ﺍﻟﻨﻤﻂ ﺍﻟﺠﺰﻳﺌﻲ ﺍﻟﻤﻴﻜﺮﻭﺑﻲ )ﺍﻟﻤﻤﺮﺽ( )‪ MAMPs‬ﺃﻭ ‪ ،(PAMPs‬ﻭﺍﻟﺬﻱ ﺗﻢ‬
‫ﺍﻟﺸﺮﻭﻁ‪.‬‬
‫ﺍﺳﺘﺨﺪﺍﻣﻪﺳﺮﻳﺮﻳﺎً ﻷﻛﺜﺮ ﻣﻦ ﺃﺭﺑﻌﺔ ﻋﻘﻮﺩ‪ .‬ﻭﺍﻟﻴﻮﻡ‪ ،‬ﻳﺘﻢ ﺍﺳﺘﻬﻼﻙ ﻧﻔﺲ ﻫﺬﻩ ﺍﻟـ ‪ MAMPs‬ﺷﻔﻮﻳﺎ ﻣﻦ ﻗﺒﻞ‬
‫ﺍﻟﻤﻠﻴﺎﺭﺍﺕﻣﻦ ﺍﻟﻤﺴﺘﻬﻠﻜﻴﻦ ﻓﻲ ﺟﻤﻴﻊ ﺃﻧﺤﺎء ﺍﻟﻌﺎﻟﻢ‪ ،‬ﻣﻦ ﺧﻼﻝ ﻭﺳﺎﺋﻞ "ﻣﺤﺪﺩﺓ" )ﺍﻟﻤﻜﻤﻼﺕ ﺍﻟﻌﺸﺒﻴﺔ‬
‫ﺍﻟﻤﻌﺰﺯﺓﻟﻠﻤﻨﺎﻋﺔ( ﺑﺎﻋﺘﺒﺎﺭﻫﺎ ﺣﺎﻣﻼﺕ ﻟﻠﻤﺮﻛﺒﺎﺕ ﺍﻟﻌﻀﻮﻳﺔ ﺍﻟﻤﺘﻌﺪﺩﺓ ﺍﻟﻌﻀﻮﻳﺔ ﻋﺎﻟﻴﺔ ﺍﻟﺘﺮﻛﻴﺰ ﺍﻟﻤﺘﺮﺍﻛﻤﺔ ﻓﻲ‬
‫ﺍﻟﺠﺬﻭﺭ‪،‬ﻭﺍﻟﻠﺤﺎء‪ ،‬ﻭﺍﻟﻘﺸﺮﻳﺎﺕ‪ ،‬ﻭﺍﻟﻄﺤﺎﻟﺐ ﺍﻟﺒﺤﺮﻳﺔ‪ ،‬ﻭﺍﻟﺒﺬﻭﺭ‪ .‬ﺗﻔﺮﺽ ﺟﻤﻌﻴﺔ ﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﻌﺸﺒﻴﺔ ﺍﻷﻣﺮﻳﻜﻴﺔ‬
‫)‪ (AHPA‬ﺗﻘﻠﻴﻞ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﻓﻲ ﻣﻌﺎﻟﺠﺔ ﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﻨﺒﺎﺗﻴﺔ ﻭﻟﻜﻨﻬﺎ ﻻ ﺗﺘﻄﻠﺐ ﺇﺯﺍﻟﺔ ﺍﻟﺤﻄﺎﻡ ﺍﻟﻤﻴﻜﺮﻭﺑﻲ‬
‫ﺍﻟﻤﻴﺖﺍﻟﻤﺤﻤﻞ ﺑـ ‪ ،MAMP‬ﻭﺍﻟﺬﻱ ﻧﺒﺘﻠﻌﻪ‪ .‬ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ‪ ،‬ﻓﻲ ﺣﻴﻦ ﺭﻛﺰﺕ ﺍﻷﺑﺤﺎﺙ ﺍﻟﺤﺎﻟﻴﺔ ﻋﻠﻰ ﺩﻭﺭ‬
‫ﺍﻟﻤﻮﺍﺩﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﻓﻲ ﺗﻌﺪﻳﻞ ﺍﻟﻤﻨﺎﻋﺔ‪ ،‬ﻓﺈﻥ ﺧﺼﺎﺋﺺ ﺗﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻌﻠﻴﺔ ﻗﺪ ﺗﻜﻤﻦ ﺑﺪﻻ ً‬
‫ﻣﻦﺫﻟﻚ ﻓﻘﻂ ﻓﻲ ﺍﻟﻜﺘﻠﺔ ﺍﻟﺤﻴﻮﻳﺔ ﺍﻟﻤﺤﻤﻠﺔ ﺑـ ‪ MOC MAMP‬ﺍﻟﺨﺎﺻﺔ ﺑﺎﻟﻨﺒﺎﺕ‪ .‬ﻫﺬﺍ ﺍﻟﺘﺄﻛﻴﺪ ﻣﻨﻄﻘﻲ‪ ،‬ﻣﻊ‬
‫ﺍﻷﺧﺬﻓﻲ ﺍﻻﻋﺘﺒﺎﺭ ﺃﻥ ﺍﻟﺤﻮﺍﺗﻢ ﺍﻟﻤﺴﺘﻀﺪﻳﺔ ﺍﻟﻤﺜﻴﺮﺓ ﻟﻠﻤﻨﺎﻋﺔ‪ ،‬ﻭﻟﻴﺲ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ‪ ،‬ﻣﻌﺮﻭﻓﺔ‬
‫ﺑﺄﻧﻬﺎﺗﺤﻔﺰ ﺍﻻﺳﺘﺠﺎﺑﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ‪ .‬ﺗﺴﺘﻜﺸﻒ ﻫﺬﻩ ﺍﻟﻤﺮﺍﺟﻌﺔ ﻣﺠﺎﻻً ﺑﺤﺜﻴﺎً ﻣﻬﻤﻼً ﻓﻴﻤﺎ ﻳﺘﻌﻠﻖ ﺑﺘﺄﺛﻴﺮﺍﺕ‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡﺍﻟﻌﺸﺒﻲ ﻋﻠﻰ ﺗﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ ‪ -‬ﻭﻫﻮ ﻭﺟﻮﺩ ﺗﺪﻋﻤﻪ ﺑﺸﻜﻞ ﻏﻴﺮ ﻣﺒﺎﺷﺮ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﻣﺠﺎﻻﺕ‬
‫ﺍﻟﺪﺭﺍﺳﺔﺍﻟﻄﺮﻓﻴﺔ ﻭﻳﻄﺮﺡ ﺳﺆﺍﻻً ﺃﺳﺎﺳﻴﺎً‪ :‬ﻧﻈﺮﺍً ﻷﻥ ﺳﻼﻣﺔ ﺍﻷﻏﺬﻳﺔ ﺗﺮﻛﺰ ﻋﻠﻰ‬
‫‪frontiersin.org‬‬ ‫‪01‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪10.3389/fonc.2023.1180084‬‬ ‫ﻣﺎﺯﻳﻮﻭﺁﺧﺮﻭﻥ‪.‬‬
‫ﺍﻟﻘﻀﺎءﻋﻠﻰ ﻣﺴﺒﺒﺎﺕ ﺍﻷﻣﺮﺍﺽ ﺍﻟﻀﺎﺭﺓ ﻭﻋﻠﻮﻡ ﺍﻟﻤﺤﺎﺻﻴﻞ ﺗﻌﺘﺮﻑ ﺑﻮﺟﻮﺩ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﺍﻟﻨﺒﺎﺗﻴﺔ‪ ،‬ﻣﺎ ﻫﻲ‬
‫ﻋﻠﻰﻭﺟﻪ ﺍﻟﺘﺤﺪﻳﺪ ﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻨﺎﺟﻤﺔ ﻋﻦ ﺗﻨﺎﻭﻝ ‪ MAMPs‬ﺫﺍﺕ ﺍﻟﺘﺮﻛﻴﺐ ﺍﻟﻬﻴﻜﻠﻲ ﺍﻟﻤﺘﻨﻮﻉ‬
‫ﻭﺍﻟﺘﺮﻛﻴﺰ‪،‬ﻭﺃﻳﻦ ﻳﺘﻢ ﺗﻮﺯﻳﻌﻬﺎ ﻓﻲ ﻧﺒﺎﺗﺎﺗﻨﺎ؟ ﺳﻨﻨﺎﻗﺶ ﻣﻮﺿﻮﻉ ‪ MAMPs‬ﺍﻟﻤﺮﻛﺰﺓ ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ ﻛﺰﺧﺎﺭﻑ‬
‫ﺣﻤﻀﻴﺔﻭﻣﺴﺘﻘﺮﺓ ﺣﺮﺍﺭﻳﺎ ًﻣﻮﺟﻮﺩﺓ ﻓﻲ ﺃﻋﺸﺎﺏ ﻣﺤﺪﺩﺓ ﻭﻛﻴﻒ ﻳﻤﻜﻦ ﺃﻥ ﺗﻨﺸﻂ ﻣﺴﺘﻘﺒﻼﺕ ﺍﻟﺘﻌﺮﻑ ﻋﻠﻰ‬
‫ﺍﻷﻧﻤﺎﻁﺍﻟﻤﺸﺎﺑﻬﺔ )‪ (PPRs‬ﻓﻲ ﺍﻷﻧﺴﺠﺔ ﺍﻟﻠﻤﻔﺎﻭﻳﺔ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻷﻣﻌﺎء ﺍﻟﻌﻠﻮﻳﺔ )‪ ،(GALT‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺑﻘﻊ‬
‫ﺑﺎﻳﺮﻭﺍﻟﺼﻔﻴﺤﺔ ﺍﻟﻤﺨﺼﻮﺻﺔ‪ ،‬ﻣﻦ ﺃﺟﻞ ﺗﻌﺰﻳﺰ ﻋﻴﺎﺭ ﺍﻷﺟﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ‪ ،‬ﻭﺧﻼﻳﺎ ‪ +CD8‬ﻭ‪ ،CD4+ T‬ﻭﻧﺸﺎﻁ‬
‫‪ ،NK‬ﻭﺗﻜﻮﻥ ﺍﻟﺪﻡ‪ ،‬ﻭﺗﺴﻬﻴﻞ ﺍﻧﺘﻘﺎﻝ ﺍﻟﻨﻤﻂ ﺍﻟﻈﺎﻫﺮﻱ ﻟﻠﺒﻼﻋﻢ ‪ M2‬ﺇﻟﻰ ‪ M1‬ﺑﻄﺮﻳﻘﺔ ﻣﻤﺎﺛﻠﺔ ﻟﻠﻘﺎﺣﺎﺕ‪ .‬ﻳﻤﻜﻦ‬
‫ﻟﻬﺬﻩﺍﻟﻤﻌﺮﻓﺔ ﺍﻟﺠﺪﻳﺪﺓ ﺃﻥ ﺗﻤﻬﺪ ﺍﻟﻄﺮﻳﻖ ﻟﺘﻄﻮﻳﺮ ﻋﻼﺟﺎﺕ ‪ MOC‬ﺍﻟﻤﺰﺭﻭﻋﺔ ﺑﺎﻟﻤﻔﺎﻋﻼﺕ ﺍﻟﺤﻴﻮﻳﺔ‪/‬ﺍﻟﻤﻌﻄﻠﺔ‬
‫ﺑﺎﻟﺤﺮﺍﺭﺓﻟﺘﻌﺰﻳﺰ ﻣﻨﺎﻋﺔ ﺍﻹﻧﺴﺎﻥ ﺿﺪ ﺍﻟﻌﺪﻭﻯ ﻭﺗﺤﺴﻴﻦ ﻣﺮﺍﻗﺒﺔ ﺍﻷﻭﺭﺍﻡ‪.‬‬
‫ﺍﻟﻜﻠﻤﺎﺕﺍﻟﺪﺍﻟﺔ‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡﺍﻟﺼﺎﻟﺢ ﻟﻸﻛﻞ‪ ،‬ﺍﻟﺤﺸﺮﺍﺕ ﻛﺄﺩﻭﻳﺔ‪ ،‬ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻌﺸﺒﻲ‪ ،‬ﺗﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ‪ ،‬ﺍﻟﻠﻘﺎﺡ ﺍﻟﺼﺎﻟﺢ ﻟﻸﻛﻞ‪ ،‬ﺍﻟﻌﻼﺟﺎﺕ‬
‫ﺍﻟﻤﻨﺎﻋﻴﺔ‪،‬ﺍﻟﺴﺮﻃﺎﻥ‪ ،‬ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻨﺒﺎﺗﻲ‬
‫ﺧﺎﻓﻀﺎﺕﺍﻟﺤﺮﺍﺭﺓ )ﺃﺳﻴﺘﺎﻣﻴﻨﻮﻓﻴﻦ( )‪ .(15‬ﻻ ﺗﺰﺍﻝ ﺍﻟﻌﺪﻭﻯ‪ ،‬ﺳﻮﺍء ﺑﻌﺪ ﺍﻟﻌﻤﻠﻴﺔ‬ ‫‪1‬ﺍﻟﻤﻘﺪﻣﺔ‬

‫ﺍﻟﺠﺮﺍﺣﻴﺔﺃﻭ ﻏﻴﺮﻫﺎ‪ ،‬ﻫﻲ ﺍﻟﺴﺒﺐ ﺍﻟﺮﺋﻴﺴﻲ ﻟﻠﻮﻓﺎﺓ ﺑﻴﻦ ﻣﺮﺿﻰ ﺍﻟﺴﺮﻃﺎﻥ )‪19-16‬‬
‫(‪ .‬ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ‪ ،‬ﻛﺎﻥ ﻻﺳﺘﺨﺪﺍﻡ ﺍﻟﻌﻘﺎﻗﻴﺮ ﺍﻻﺻﻄﻨﺎﻋﻴﺔ ﻋﻠﻰ ﻧﻄﺎﻕ ﻭﺍﺳﻊ‬ ‫ﻣﺠﺘﻤﻌﺎﺕﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ )‪ ،(MOCs‬ﺍﻟﺘﻲ ﺗﺸﻤﻞ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ‬
‫ﺗﺄﺛﻴﺮﺳﻠﺒﻲ ﺗﺮﺍﻛﻤﻲ ﻋﻠﻰ ﺍﻟﺬﻛﺎء ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﺒﺸﺮﻱ ﻓﻲ ﺍﻟﻤﺠﺘﻤﻌﺎﺕ ﺍﻟﻤﺘﺤﻀﺮﺓ‪.‬‬ ‫ﻭﺍﻟﻔﻄﺮﻳﺎﺕﻭﺍﻟﻌﺘﺎﺋﻖ ﻭﺍﻟﻄﺤﺎﻟﺐ ﻭﺍﻷﻭﺍﻟﻲ ﻭﺍﻟﻔﻴﺮﻭﺳﺎﺕ‪ ،‬ﻭﺍﻟﺘﻲ ﻳﺸﺎﺭ ﺇﻟﻴﻬﺎ ﻏﺎﻟﺒﺎً‬
‫ﻳﻌﺘﻤﺪﺟﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﺒﺸﺮﻱ ﻋﻠﻰ ﻗﺪﺭﺗﻪ ﻋﻠﻰ ﺟﻤﻊ ﻣﻜﺘﺒﺔ ﻣﻦ ﺍﻟﺒﻴﺎﻧﺎﺕ ﺣﻮﻝ‬ ‫ﺑﺎﻟﻌﺎﻣﻴﺔﺑﺎﺳﻢ "ﺍﻟﺒﻖ"‪ ،‬ﺗﺸﻜﻞ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻄﺮﻳﺔ ﻭﺍﻟﻤﻜﺘﺴﺒﺔ ﻓﻲ ﺟﻤﻴﻊ ﺍﻷﻧﻈﻤﺔ‬
‫ﻣﺴﺒﺒﺎﺕﺍﻷﻣﺮﺍﺽ ﺍﻷﺟﻨﺒﻴﺔ‪ ،‬ﻣﻤﺎ ﻳﺴﻤﺢ ﻟﻪ ﺑﺎﻟﻘﻀﺎء ﻋﻠﻰ ﺍﻟﺘﻬﺪﻳﺪﺍﺕ ﺍﻟﻤﻌﺮﻭﻓﺔ‬ ‫ﺍﻟﺤﻴﺔ‪،‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺍﻟﻨﺒﺎﺗﺎﺕ ﻭﺍﻟﺒﺸﺮ‪ ،‬ﻭﺣﺘﻰ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺨﺒﻴﺜﺔ‪ .‬ﻛﻞ ﻣﻨﻬﺎ‬
‫ﺑﺴﺮﻋﺔ‪.‬ﻏﺎﻟﺒﺎً ﻣﺎ ﻳﺘﻀﻤﻦ ﺍﻟﺘﻔﺎﻋﻞ ﺍﻷﻭﻟﻲ ﺣﻼً ﺳﺮﻳﻌﺎً ﻟﻠﻌﺪﻭﻯ ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﺤﻤﻰ‬ ‫ﻳﺴﺘﻀﻴﻒﻣﻴﻜﺮﻭﺑﻴﻮﻣﺎً ﻓﺮﻳﺪﺍً‪ .‬ﺇﻥ ﺍﻟﺪﻭﺭ ﺳﺮﻳﻊ ﺍﻟﺘﻄﻮﺭ ﺍﻟﺬﻱ ﺗﻠﻌﺒﻪ ‪ MOCs‬ﻓﻲ‬
‫ﻭﺍﻟﺪﻓﺎﻉﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻘﻮﻱ‪.‬‬ ‫ﻋﻼﺝﺍﻟﺴﺮﻃﺎﻥ‪ ،‬ﻣﺪﻓﻮﻋﺎً ﺑﺎﻟﺘﻘﺪﻡ ﻓﻲ ﻋﻠﻢ ﺍﻟﻤﻴﺘﺎﺟﻴﻨﻮﻣﻴﺎﺕ‪ ،‬ﻟﻪ ﺟﺬﻭﺭ ﺗﺎﺭﻳﺨﻴﺔ‬
‫ﺗﻌﻮﺩﺇﻟﻰ ﺃﻭﺍﺧﺮ ﺍﻟﻘﺮﻥ ﺍﻟﺘﺎﺳﻊ ﻋﺸﺮ‪ .‬ﻻﺣﻆ ﺍﻷﻃﺒﺎء‪ ،‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺑﻮﺵ‪ ،‬ﻭﻛﻮﻟﻲ‪،‬‬
‫ﺇﻥﺍﻟﻤﻴﻮﻝ ﺍﻟﺤﺪﻳﺜﺔ ﻧﺤﻮ ﺍﻟﺮﺍﺣﺔ ﻋﻠﻰ ﺗﺤﻤﻞ ﺍﻟﻤﺮﺽ‪ ،‬ﻭﺍﻹﻓﺮﺍﻁ ﻓﻲ‬ ‫ﻭﻓﻴﻬﻠﻴﺰﻥ‪،‬ﺃﻥ ﻣﺮﺿﻰ ﺍﻟﺴﺮﻃﺎﻥ ﻳﺨﻀﻌﻮﻥ ﻟﻤﻐﻔﺮﺓ ﺗﻠﻘﺎﺋﻴﺔ ﻣﻠﺤﻮﻇﺔ ﺑﻌﺪ‬
‫ﺍﺳﺘﺨﺪﺍﻡﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ‪ ،‬ﻭﺧﺎﻓﻀﺎﺕ ﺍﻟﺤﺮﺍﺭﺓ )ﺗﺎﻳﻠﻴﻨﻮﻝ(‪ ،‬ﻭﻣﺴﻜﻨﺎﺕ‬ ‫ﺍﻻﻟﺘﻬﺎﺑﺎﺕﺍﻟﺤﻤﻮﻳﺔ ﺍﻟﺤﺎﺩﺓ )‪ 40-38‬ﺩﺭﺟﺔ ﻣﺌﻮﻳﺔ( ﺍﻟﻨﺎﺟﻤﺔ ﻋﻦ ﺍﻟﻤﻜﻮﺭﺍﺕ‬
‫ﺍﻷﻟﻢ‪،‬ﺃﺩﺕ ﺇﻟﻰ ﺇﺿﻌﺎﻑ ﺍﻟﺬﻛﺎء ﺍﻟﻤﻨﺎﻋﻲ‪ .‬ﻭﻣﻤﺎ ﻳﺰﻳﺪ ﺍﻟﻄﻴﻦ ﺑﻠﺔ‪ ،‬ﺃﻥ ﺍﻟﻨﻈﺎﻡ‬ ‫ﺍﻟﻌﻘﺪﻳﺔﺍﻟﻤﻘﻴﺤﺔ )‪ .(2,1‬ﺃﻟﻬﻤﺖ ﻫﺬﻩ ﺍﻟﻤﻼﺣﻈﺎﺕ ﺍﻟﺘﻌﺎﻭﻥ ﻭﺍﻟﻤﺤﺎﻭﻻﺕ‬
‫ﺍﻟﻐﺬﺍﺋﻲﺍﻟﺴﻴﺊ ﻭﺍﻟﻀﻐﻂ ﺍﻻﺟﺘﻤﺎﻋﻲ ﺍﻟﻤﻨﺘﺸﺮ‪ ،‬ﻳﺴﺎﻫﻤﺎﻥ ﻓﻲ ﺍﻧﺘﺸﺎﺭ ﺧﻠﻞ‬ ‫ﺍﻟﻤﺘﻌﻤﺪﺓﻟﻌﻼﺝ ﻣﺮﺿﻰ ﺍﻟﺴﺮﻃﺎﻥ ﺑﺎﺳﺘﺨﺪﺍﻡ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺠﺬﻋﻴﺔ ﺍﻟﻌﻀﻮﻳﺔ ﺍﻟﺤﻴﺔ‪،‬‬
‫ﺍﻟﺘﻌﺮﻕﻓﻲ ﺍﻟﻘﻨﺎﺓ ﺍﻟﻬﻀﻤﻴﺔ ﻭﺧﻠﻞ ﻓﻲ ﺟﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻤﻀﻴﻒ )ﺗﺄﺛﻴﺮﺍﺕ ﻗﺎﺑﻠﺔ‬ ‫ﻣﻤﺎﺃﺩﻯ ﻓﻲ ﺑﻌﺾ ﺍﻷﺣﻴﺎﻥ ﺇﻟﻰ ﺍﻹﻧﺘﺎﻥ ﺍﻟﻘﺎﺗﻞ‪ .‬ﺗﻀﻤﻦ ﺍﻟﻨﻬﺞ ﺍﻟﻨﺎﺟﺢ ﺍﺳﺘﺨﺪﺍﻡ‬
‫ﻟﻠﺘﺤﻮﻳﻞ(ﻓﻲ ﺍﻟﺮﺣﻢﻣﻦ ﺍﻷﻡ ﺇﻟﻰ ﺍﻟﻄﻔﻞ()‪ .(21,20‬ﻭﺗﺆﺩﻱ "ﻓﺮﺿﻴﺔ ﺍﻟﻨﻈﺎﻓﺔ"‪،‬‬ ‫ﺍﻟﻤﻜﻮﺭﺍﺕﺍﻟﻌﻘﺪﻳﺔ ﺍﻟﻤﻘﻴﺤﺔ ﺍﻟﻤﻮﻫﻨﺔ )ﺇﻳﺠﺎﺑﻴﺔ ﺍﻟﺠﺮﺍﻡ( ﻭﺍﻟﺴﺮﺍﺗﻴﺔ ﺍﻟﺬﺍﺑﻠﺔ )ﺳﻠﺒﻴﺔ‬
‫ﺍﻟﺘﻲﺗﻔﺘﺮﺽ ﺃﻥ ﺍﻟﺤﺪ ﺍﻷﺩﻧﻰ ﻣﻦ ﺍﻟﺘﻌﺮﺽ ﻟﻠﻤﻴﻜﺮﻭﺑﺎﺕ ﻓﻲ ﺍﻟﺤﻴﺎﺓ ﺍﻟﻤﺒﻜﺮﺓ‬ ‫ﺍﻟﺠﺮﺍﻡ(‪ ،‬ﻣﻤﺎ ﻳﺸﻜﻞ ﺃﻭﻝ ﻋﻼﺝ ﻣﻨﺎﻋﻲ ﻟﻠﻘﺎﺡ ﺍﻟﻮﺭﻡ ﺫﻭ ﺍﻟﻨﻤﻂ ﺍﻟﺠﺰﻳﺌﻲ ﺍﻟﻤﺮﺗﺒﻂ‬
‫ﻳﺆﺩﻱﺇﻟﻰ ﺧﻠﻞ ﺍﻟﻌﺴﺮ ﺍﻟﺤﻴﻮﻱ‪ ،‬ﺇﻟﻰ ﺗﻔﺎﻗﻢ ﺍﻟﻤﺸﻜﻠﺔ‪ .‬ﻭﻗﺪ ﺗﻢ ﺭﺑﻂ ﻫﺬﺍ ﺍﻟﻮﺿﻊ‬ ‫ﺑﺎﻟﻤﻴﻜﺮﻭﺑﺎﺕ)‪ ،(MAMP‬ﻭﺍﻟﺬﻱ ﻳﺘﻜﻮﻥ ﻣﻦ ﻣﺴﺘﻘﺒﻼﺕ ﺗﺸﺒﻪ ﺍﻟﺮﻗﻢ )‪TLRs 2،4‬‬
‫ﺑﺎﻻﺿﻄﺮﺍﺑﺎﺕﺍﻟﻮﺑﺎﺋﻴﺔ ﻏﻴﺮ ﺍﻟﻤﻌﺪﻳﺔ ﻭﺍﻟﺴﺮﻃﺎﻧﺎﺕ ﺍﻟﺒﺸﺮﻳﺔ )‪ .(24-22‬ﺇﻥ‬ ‫(‪ ( .‬ﻣﻨﺒﻬﺎﺕ ﺍﻟﺒﻜﺘﻴﺮﻳﺔ ‪ LPS‬ﺍﻟﺬﻳﻔﺎﻥ ﺍﻟﺪﺍﺧﻠﻲ‪/‬ﺍﻟﺒﺒﺘﻴﺪﻭﻏﻠﻴﻜﺎﻥ )‪ .(3‬ﺃﺩﻯ ﺍﻟﻌﻼﺝ‬
‫ﺍﻻﻫﺘﻤﺎﻡﺑﺎﻟﺼﺮﻑ ﺍﻟﺼﺤﻲ ﻭﺍﻟﺮﺍﺣﺔ ﻳﺆﺩﻱ ﺇﻟﻰ ﺿﻤﻮﺭ ﺍﻟﺬﻛﺎء ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﺒﺸﺮﻱ‪.‬‬ ‫ﺍﻟﻤﻨﺎﻋﻲﻟﻠﻮﺭﻡ ﻛﻮﻟﻲ ﺇﻟﻰ ﻣﻐﻔﺮﺓ ﻋﻼﺟﻴﺔ ﻓﻲ ﺣﻮﺍﻟﻲ ‪ ٪50‬ﻣﻦ ﺳﺮﻃﺎﻧﺎﺕ ﺍﻷﺩﻳﻢ‬
‫ﻭﻧﺘﻴﺠﺔﻟﺬﻟﻚ‪ ،‬ﻫﻨﺎﻙ ﺍﺭﺗﻔﺎﻉ ﻭﺑﺎﺋﻲ ﻓﻲ ﺣﺎﻻﺕ ﺍﻟﻌﺪﻭﻯ ﺍﻟﻤﺰﻣﻨﺔ‪/‬ﺍﻻﻟﺘﻬﺎﺑﺎﺕ ﺍﻟﺘﻲ‬ ‫ﺍﻟﻤﺘﻮﺳﻂﺍﻟﺠﻨﻴﻨﻴﺔ )ﺍﻟﺴﺎﺭﻛﻮﻣﺎ‪ ،‬ﺳﺮﻃﺎﻥ ﺍﻟﻐﺪﺩ ﺍﻟﻠﻴﻤﻔﺎﻭﻳﺔ‪ ،‬ﺳﺮﻃﺎﻥ ﺍﻟﺪﻡ‪،‬‬
‫ﺗﺨﻠﻖ"ﺇﺭﻫﺎﻕ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ" ﺍﻟﻤﻘﺎﻭﻣﺔ ﻟﻠﺤﺮﺍﺭﺓ ﻭﺣﺎﻟﺔ ﻣﻦ ﻛﺒﺖ ﺍﻟﻤﻨﺎﻋﺔ‪ ،‬ﻣﻤﺎ‬ ‫ﺍﻟﻜﻠﻰ‪،‬ﺍﻟﻤﺒﻴﺾ‪ ،‬ﻭﻣﺎ ﺇﻟﻰ ﺫﻟﻚ( ﻷﻛﺜﺮ ﻣﻦ ‪ 40‬ﻋﺎﻣﺎً )‪ .(4‬ﻭﻣﻊ ﺫﻟﻚ‪ ،‬ﻓﻘﺪ ﺗﻢ‬
‫ﻳﺆﺩﻱﺇﻟﻰ ﺯﻳﺎﺩﺓ ﺍﻟﺘﻌﺮﺽ ﻟﻤﺨﺘﻠﻒ ﺃﻧﻮﺍﻉ ﺍﻟﺴﺮﻃﺎﻥ )‪ .(29-25‬ﻋﻠﻰ ﺍﻟﻌﻜﺲ ﻣﻦ‬ ‫ﺍﺳﺘﺒﺪﺍﻝﻫﺬﺍ ﺍﻟﻨﻬﺞ ﻓﻲ ﻧﻬﺎﻳﺔ ﺍﻟﻤﻄﺎﻑ ﺑﺎﻟﺘﻘﺪﻡ ﻓﻲ ﺍﻹﺷﻌﺎﻉ ﻭﺍﻟﺠﺮﺍﺣﺔ ﻭﺍﻟﻌﻼﺝ‬
‫ﺫﻟﻚ‪،‬ﻓﺈﻥ ﺗﻌﺰﻳﺰ ﺍﻟﺬﻛﺎء ﺍﻟﻤﻨﺎﻋﻲ ﻣﻦ ﺧﻼﻝ ﺍﻟﺘﻌﺮﺽ ﺍﻟﺼﺎﺭﻡ ﻟﻠﺨﻼﻳﺎ ﺍﻟﺠﺬﻋﻴﺔ‬ ‫ﺍﻟﻜﻴﻤﻴﺎﺋﻲﺍﻟﻤﺜﺒﻂ ﻟﻠﻤﻨﺎﻋﺔ‪ ،‬ﻭﺍﻟﺬﻱ ﻫﻴﻤﻦ ﻋﻠﻰ ﻣﺠﺎﻝ ﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ ﻟﻌﺪﺓ ﻋﻘﻮﺩ )‪5‬‬
‫ﺍﻟﻌﻀﻮﻳﺔﻳﻮﻓﺮ ﺍﻻﺳﺘﻬﺪﺍﻑ ﺍﻟﺘﻔﺎﻋﻠﻲ ﺍﻟﺮﻭﺗﻴﻨﻲ ﺍﻟﻼﺯﻡ ﻟﺘﺪﻣﻴﺮ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺨﺒﻴﺜﺔ‬ ‫‪.(6,‬‬
‫ﺍﻟﻤﻀﻴﻔﺔﺫﺍﺗﻴﺎً ﻭﺍﻟﺘﻲ ﺗﺤﺘﻮﻱ ﻋﻠﻰ ﻣﺴﺘﻀﺪﺍﺕ ﻣﺸﺎﺑﻬﺔ ﻣﺮﺗﺒﻄﺔ ﺑﺎﻟﻮﺭﻡ )‪(TAAs‬‬
‫ﺑﻄﺮﻳﻘﺔﺃﻗﺮﺏ ﺇﻟﻰ ﺍﻻﺳﺘﺠﺎﺑﺔ ﻟﻠﻌﺪﻭﻯ )‪.(30‬‬
‫ﻫﻨﺎﻙﺗﺠﺪﺩ ﺍﻻﻫﺘﻤﺎﻡ ﺑﺎﻟﻌﻼﺟﺎﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻸﻭﺭﺍﻡ ﻟﺘﺤﻘﻴﻖ ﻧﻔﺲ ﺍﻟﻬﺪﻭء‬

‫ﻳﺘﺠﻠﻰﻛﺒﺖ ﺍﻟﻤﻨﺎﻋﺔ ﻓﻲ ﺻﻮﺭﺓ ﻓﻘﺪﺍﻥ ﺍﻟﻤﺮﺍﻗﺒﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻠﻮﺭﻡ‪ ،‬ﻭﺍﻟﺘﻲ ﺗﻌﺪ‬ ‫ﺍﻟﺬﻱﺍﺗﺒﻌﻪ ﻛﻮﻟﻲ ﻓﻲ ﺍﻟﺒﺪﺍﻳﺔ ﻣﻨﺬ ﺃﻛﺜﺮ ﻣﻦ ﻗﺮﻥ ﻣﻦ ﺍﻟﺰﻣﺎﻥ )‪ .(8,7,5‬ﻭﻣﻊ ﺫﻟﻚ‪،‬‬
‫ﺑﻮﺍﺑﺔﺍﻟﺘﺤﻜﻢ ﻟﺠﻤﻴﻊ ﺃﻧﻮﺍﻉ ﺍﻟﺴﺮﻃﺎﻥ ﺍﻟﺒﺸﺮﻳﺔ ﻟﺘﻨﺸﺄ ﻭﺗﺘﻄﻮﺭ ﻭﺗﺰﺩﻫﺮ )‪.(34-31‬‬ ‫ﻳﺠﺐﺃﻥ ﺗﺘﻐﻠﺐ ﻫﺬﻩ ﺍﻟﻌﻼﺟﺎﺕ ﺍﻵﻥ ﻋﻠﻰ ﻛﺒﺖ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﺬﻱ ﺗﻔﺮﺿﻪ‬
‫ﺑﺎﻹﺿﺎﻓﺔﺇﻟﻰ ﺫﻟﻚ‪ ،‬ﻳﺆﺩﻱ ﻛﺒﺖ ﺍﻟﻤﻨﺎﻋﺔ ﺇﻟﻰ ﺯﻳﺎﺩﺓ ﻇﻬﻮﺭ ﺍﻟﻮﺭﻡ ﻋﻨﺪ ﺍﻟﺘﻌﺮﺽ‬ ‫ﺍﻟﻌﻼﺟﺎﺕﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﻭﻣﺴﻜﻨﺎﺕ ﺍﻷﻟﻢ ﺍﻟﺴﺎﺋﺪﺓ )ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﻣﻀﺎﺩﺍﺕ‬
‫ﻟﻠﻤﻮﺍﺩﺍﻟﺒﻴﺌﻴﺔ ﺍﻟﻤﺴﺮﻃﻨﺔ )ﻣﺜﻞ ﺍﻟﻤﻠﻮﺛﺎﺕ ﻭﺍﻷﺑﺨﺮﺓ‪/‬ﺍﻟﻐﺒﺎﺭ ﺍﻟﻤﻬﻨﻲ ﻭﺍﻷﺷﻌﺔ‬ ‫ﺍﻷﻭﺭﺍﻡﺍﻟﺨﻠﻮﻳﺔ‪ ،‬ﻭﺍﻟﻤﻮﺍﺩ ﺍﻷﻓﻴﻮﻧﻴﺔ‪ ،‬ﻭﺍﻟﻜﻮﺭﺗﻴﻜﻮﺳﺘﻴﺮﻭﻳﺪﺍﺕ(‪ ،(14-9.‬ﺍﻟﺘﻲ ﺗﺪﻣﺮ‬
‫ﻓﻮﻕﺍﻟﺒﻨﻔﺴﺠﻴﺔ ﺍﻟﻤﺆﻳﻨﺔ )‪ ((35‬ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﺍﻟﻤﺴﺮﻃﻨﺔ )‪) ،(37,36‬ﺡ ﺑﻴﻠﻮﺭﻱ(‪،‬‬ ‫ﺗﻜﻮﻥﺍﻟﺪﻡ )ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﻗﻠﺔ ﺍﻟﻜﺮﻳﺎﺕ‪ ،‬ﻗﻠﺔ ﺍﻟﻌﺪﻻﺕ(‪ ،‬ﻭﺗﺆﺩﻱ ﺇﻟﻰ ﺯﻳﺎﺩﺓ‬
‫ﺍﻟﻄﻔﻴﻠﻴﺎﺕ)ﻳﺎ ﻓﻴﻔﺮﻳﻦ‪ ،‬ﺳﻲ ﺳﻴﻨﻴﻨﺴﻴﺲ‪،‬ﻭﺍﻟﻬﻴﻤﺎﺗﻮﺑﻴﻮﻡ(‬ ‫ﺧﻄﺮﺍﻹﺻﺎﺑﺔ ﺑﺎﻟﻌﺪﻭﻯ‪ ،‬ﻭﺍﻟﺘﻲ ﺗﺘﻔﺎﻗﻢ ﺃﻛﺜﺮ ﺑﺎﺳﺘﺨﺪﺍﻡ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ‬
‫ﺍﻟﻤﺜﺒﻄﺔﻟﻠﻤﻨﺎﻋﺔ‪ ،‬ﻭ‬

‫ﻭﺍﻟﺘﺮﻛﻴﺒﺎﺕﻭﺍﻟﻤﻌﺎﺩﻥ(‪ ،‬ﻭﺍﻟﻄﺒﻴﻌﺔ ﺍﻟﻠﻤﺴﻴﺔ ﻟﻠﻨﺒﺎﺕ )ﻣﺜﻞ ﺍﻟﺠﻴﻨﺎﺕ(‪ ،‬ﻭﺗﻐﻴﺮ‬ ‫ﺍﻟﻔﻴﺮﻭﺳﺎﺕ)ﺇﺑﺸﺘﺎﻳﻦ‪-‬ﺑﺎﺭ‪ ،‬ﺍﻟﻮﺭﻡ ﺍﻟﺤﻠﻴﻤﻲ ﺍﻟﺒﺸﺮﻱ‪ ،‬ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺪ ‪،B، C‬‬
‫‪ MOCs‬ﺃﺛﻨﺎء ﺍﻟﻨﻀﺞ ﻋﻨﺪ ﺍﻟﺤﺼﺎﺩ‪ ،‬ﻭﺍﻟﺘﻔﺎﻋﻼﺕ ﺍﻟﻤﻌﻘﺪﺓ ﺃﺛﻨﺎء ﺍﻟﻨﻤﻮ‪ ،‬ﻣﻦ ﺑﻴﻦ‬ ‫ﺍﻟﻬﺮﺑﺲﺍﻟﺒﺸﺮﻱ ﻣﻦ ﺍﻟﻨﻮﻉ ‪ ،8‬ﻭﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﻠﻤﻔﺎﻭﻳﺔ ﺍﻟﺒﺸﺮﻳﺔ ﻣﻦ ﺍﻟﻨﻮﻉ ‪) (1‬‬
‫ﺃﺷﻴﺎءﺃﺧﺮﻯ‪ .‬ﺗﺤﺘﻮﻱ ﺟﻤﻴﻊ ﺍﻷﻋﺸﺎﺏ ﻭﺍﻟﺘﻮﺍﺑﻞ ﺍﻟﻄﺒﻴﺔ ﻋﻠﻰ ‪ ،MOCs‬ﺣﻴﺚ‬ ‫‪ .(38‬ﻭﺗﺘﻄﻠﺐ ﻫﺬﻩ ﺍﻟﻌﻮﺍﻣﻞ ﺍﺳﺘﻜﺸﺎﻑ ﻃﺮﻕ ﺟﺪﻳﺪﺓ ﻟﺘﻌﺰﻳﺰ ﻗﺪﺭﺓ ﺍﻟﺠﻬﺎﺯ‬
‫ﻟﻮﺍﺋﺢﺳﻼﻣﺔ ﺍﻷﻏﺬﻳﺔ ﻣﻦ ﻗﺒﻞ ﺟﻤﻌﻴﺔ ﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﻌﺸﺒﻴﺔ ﺍﻷﻣﺮﻳﻜﻴﺔ )‪(AHPA‬‬ ‫ﺍﻟﻤﻨﺎﻋﻲﻋﻠﻰ ﻣﻜﺎﻓﺤﺔ ﺍﻟﺴﺮﻃﺎﻧﺎﺕ ﺍﻟﺒﺸﺮﻳﺔ‪.‬‬
‫ﻭﻣﺆﺳﺴﺔﺍﻟﻌﻠﻮﻡ ﺍﻟﻮﻃﻨﻴﺔ ‪ /‬ﺍﻟﻤﻌﻬﺪ ﺍﻟﻮﻃﻨﻲ ﺍﻷﻣﺮﻳﻜﻲ ﻟﻠﻤﻌﺎﻳﻴﺮ )‪(NSF / ANSI‬‬
‫)‪ (47-44‬ﺗﺘﻄﻠﺐ ﺍﻟﺤﺪ ﻣﻦ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﻭﺍﺧﺘﺒﺎﺭ ﻃﺮﻑ ﺛﺎﻟﺚ ﻟﺘﺤﺪﻳﺪ ‪ (1‬ﻋﺪﻡ‬
‫ﻭﺟﻮﺩﻣﺴﺒﺒﺎﺕ ﺍﻷﻣﺮﺍﺽ ﻭﺍﻟﺴﻤﻮﻡ ﺍﻟﻔﻄﺮﻳﺔ ﺍﻟﻘﺎﺑﻠﺔ ﻟﻠﺤﻴﺎﺓ‪ (2 ،‬ﺍﻟﻌﺎﺋﺪ ﺍﻟﻌﺘﺒﻲ‬ ‫‪2‬ﺍﻟﻄﺐ ﺍﻟﻨﺒﺎﺗﻲ‪:‬‬
‫ﺍﻟﻤﺘﺒﻘﻲﻣﻦ ﺍﻟﻘﻮﻟﻮﻧﻴﺎﺕ ﺍﻟﺤﻴﺔ ﻏﻴﺮ ﺍﻟﻤﺴﺒﺒﺔ ﻟﻸﻣﺮﺍﺽ‪ ،‬ﻭﻋﺪﺩ ﺍﻟﺼﻔﺎﺋﺢ‬ ‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡﺍﻟﻨﺒﺎﺗﻲ‬
‫ﺍﻟﻬﻮﺍﺋﻴﺔ‪،‬ﻭﺇﺟﻤﺎﻟﻲ ﺍﻟﺨﻤﻴﺮﺓ ﻭﺍﻟﻌﻔﻦ ﺍﻟﻤﺒﻠﻎ ﻋﻨﻬﺎ ﻛﻮﺣﺪﺍﺕ ﺗﺸﻜﻴﻞ ﻣﺴﺘﻌﻤﺮﺓ‬
‫)‪ / (CFU‬ﺯ )‪ .(49-44‬ﻭﻣﻊ ﺫﻟﻚ‪ ،‬ﻓﺈﻥ ﻓﻬﻤﻨﺎ ﻟﻠﻤﻴﻜﺮﻭﺑﺎﺕ ﺍﻟﻨﺒﺎﺗﻴﺔ ﺍﻟﺘﻲ ﺗﻌﻤﻞ‬ ‫ﻳﺘﻢﺗﻌﺰﻳﺰ ﺍﻟﻤﺮﻭﻧﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻣﻦ ﺧﻼﻝ ﺇﺩﺧﺎﻝ ﻣﺴﺘﻀﺪﺍﺕ ‪ ،MOC‬ﻭﻫﻮ‬
‫ﻋﻠﻰﺗﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ‪ ،‬ﻭﻛﻴﻒ ﻳﺆﺛﺮ ﺃﺛﺮﻫﺎ ﺍﻟﻤﺘﺒﻘﻲ ﻣﻦ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ‪ MAMPs/‬ﻋﻠﻰ‬ ‫ﻣﺒﺪﺃﺃﺳﺎﺳﻲ ﻟﻠﻘﺎﺣﺎﺕ )‪ .(43-39‬ﻭﻣﻊ ﺫﻟﻚ‪ ،‬ﺍﻋﺘﺒﺎﺭﺍً ﻣﻦ ﺍﻟﻴﻮﻡ‪ ،‬ﻫﻨﺎﻙ ﺃﺑﺤﺎﺙ‬
‫ﺍﻟﺼﺤﺔ‪،‬ﻣﻦ ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﻤﺴﺒﺒﺔ ﻟﻸﻣﺮﺍﺽ ﺇﻟﻰ ﻏﻴﺮ ﺍﻟﻤﺴﺒﺒﺔ ﻟﻸﻣﺮﺍﺽ‪ ،‬ﻻ ﻳﺰﺍﻝ‬ ‫ﻫﺰﻳﻠﺔﻓﻲ ﺩﺭﺍﺳﺔ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﺍﻟﻨﺒﺎﺗﻴﺔ ﺍﻟﻤﻌﻄﻠﺔ‪/‬ﺍﻟﻤﻀﻌﻔﺔ ﻓﻲ ﺃﺩﻭﻳﺘﻨﺎ ﺍﻟﻨﺒﺎﺗﻴﺔ‬
‫ﻣﺤﺪﻭﺩﺍً‪.‬ﻳﻤﻜﻦ ﺃﻥ ﺗﻌﻤﻞ ‪ MAMPs‬ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ‪ ،‬ﻭﺍﻟﺘﻲ ﻏﺎﻟﺒﺎً ﻣﺎ ﺗﻜﻮﻥ‬ ‫ﺍﻟﺘﻲﺗﺤﺘﻮﻱ ﻋﻠﻰ ‪ MOCs‬ﺍﻟﺨﺎﺹ ﺑﻤﻨﺘﺞ ﻣﻌﻴﻦ )ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﻣﺴﺒﺒﺎﺕ‬
‫ﺣﻤﻀﻴﺔﻭﻣﺴﺘﻘﺮﺓ ﺣﺮﺍﺭﻳﺎ‪ ً،‬ﻋﻠﻰ ﻣﺴﺘﻘﺒﻼﺕ ﺍﻟﺘﻌﺮﻑ ﻋﻠﻰ ﺍﻷﻧﻤﺎﻁ )‪ (PRRs‬ﻓﻲ‬ ‫ﺍﻷﻣﺮﺍﺽﺍﻟﻔﺘﺎﻛﺔ( ﻭﻛﻴﻔﻴﺔ ﺗﺄﺛﻴﺮﻫﺎ ﻋﻠﻰ ﻣﻨﺎﻋﺔ ﺍﻹﻧﺴﺎﻥ‪ .‬ﻳﺘﻢ ﺗﺪﻣﻴﺮ ‪MOCs‬‬
‫ﺍﻷﻧﺴﺠﺔﺍﻟﻠﻤﻔﺎﻭﻳﺔ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻷﻣﻌﺎء ﺍﻟﻌﻠﻮﻳﺔ )‪ ،(GALT‬ﻭﺑﻘﻊ ﺑﺎﻳﺮ‪ ،‬ﻭﺍﻟﺼﻔﻴﺤﺔ‬ ‫ﺍﻟﺨﺎﺻﺔﺑﺎﻟﻨﺒﺎﺗﺎﺕ ﺃﺛﻨﺎء ﺗﻘﻨﻴﺎﺕ ﻣﻌﺎﻟﺠﺔ ﺍﻷﻏﺬﻳﺔ ﻣﺜﻞ ﺍﻟﻤﻌﻮﺟﺔ ﻭﺍﻟﺒﺴﺘﺮﺓ‪ .‬ﻭﻣﻊ‬
‫ﺍﻟﻤﺨﺼﻮﺻﺔ‪،‬ﻣﻤﺎ ﻳﺆﺛﺮ ﻋﻠﻰ ﺃﺟﻬﺰﺓ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻄﺮﻳﺔ ﻭﺍﻟﻤﻜﺘﺴﺒﺔ‪.(50,47-44.‬‬ ‫ﺫﻟﻚ‪،‬ﻻ ﺗﺘﺮﻙ ﺟﻤﻴﻊ ‪ MOCs‬ﺃﺛﺮﺍً ﻣﻦ ﺍﻷﻧﻤﺎﻁ ﺍﻟﺠﺰﻳﺌﻴﺔ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ‬
‫ﻭﻣﻊﺫﻟﻚ‪ ،‬ﻋﻠﻰ ﺍﻟﺮﻏﻢ ﻣﻦ ﺍﻧﺘﺸﺎﺭﻫﺎ ﻓﻲ ﺍﻷﻃﻌﻤﺔ‪ ،‬ﻓﺈﻥ ﻣﻌﻈﻢ ﺍﻟﺪﺭﺍﺳﺎﺕ ﺣﻮﻝ "‬ ‫ﺍﻟﻤﺜﻴﺮﺓﻟﻠﻤﻨﺎﻋﺔ )‪ ،(MAMPs‬ﻭﻳﺨﺘﻠﻒ ﺍﻧﺘﺸﺎﺭﻫﺎ ﻓﻲ ﻛﻞ ﻣﻜﺎﻥ‪ ،‬ﻭﻫﻲ ﺍﻟﻘﻀﺎﻳﺎ‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡﺍﻟﻨﺒﺎﺗﻲ ﺍﻟﺼﺎﻟﺢ ﻟﻸﻛﻞ" ﺗﺮﻛﺰ ﻋﻠﻰ ﺗﺤﺪﻳﺪ ﺗﺼﻨﻴﻒ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ‬ ‫ﺍﻟﺘﻲﻧﻨﺎﻗﺸﻬﺎ ﺃﺩﻧﺎﻩ‪ .‬ﺇﻥ ‪ MAMPs‬ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ ﻭﺍﻟﻤﺤﻔﺰﺓ ﻟﻠﻤﻨﺎﻋﺔ ﻫﻲ‬
‫ﺍﻟﺪﻗﻴﻘﺔﺍﻟﻤﻮﺟﻮﺩﺓ‪ ،‬ﻣﻊ ﺍﻟﻘﻠﻴﻞ ﻣﻦ ﺍﻻﻫﺘﻤﺎﻡ ﻵﺛﺎﺭﻫﺎ ﺍﻟﺼﺤﻴﺔ ﺍﻟﻤﺤﺘﻤﻠﺔ )‪58-51‬‬ ‫ﻣﺴﺘﻮﺩﻋﺎﺕﻃﺒﻴﻌﻴﺔ ﻣﺮﻛﺰﺓ ﻟﻠﻤﻨﺸﻄﺎﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺩﺍﺧﻞ ﻋﺎﻟﻢ ﺍﻟﻨﺒﺎﺕ‪.‬ﺷﻜﻞ ‪1‬‬
‫(‪.‬‬ ‫ﺗﺘﻮﺍﺟﺪ‪ MOCs‬ﺩﺍﺋﻤﺎً ﻛﻌﻨﺎﺻﺮ ﺗﺤﻜﻢ ﻓﻲ ﺻﺤﺔ ﺍﻟﻨﺒﺎﺕ ﻭﻧﻤﻮﻩ ﻭﻧﻀﺠﻪ ﻭﺍﻟﺘﺤﻜﻢ‬
‫ﺍﻟﺒﻴﺌﻲﺣﻴﺚ ﺗﺆﺛﺮ ﻋﻮﺍﻣﻞ ﻋﺪﻳﺪﺓ ﻋﻠﻰ ﺍﻟﺘﻨﻮﻉ ﻭﺍﻟﺘﺮﻛﻴﺰ‪ .‬ﻭﺗﺸﻤﻞ ﻫﺬﻩ ﺍﻟﺨﺼﺎﺋﺺ‬
‫ﻟﻘﺪﺍﺳﺘﻬﻠﻚ ﺍﻟﺒﺸﺮ ﺍﻷﺩﻭﻳﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﻭﺍﻟﻤﺮﻛﺒﺎﺕ ﺍﻟﻌﻀﻮﻳﺔ ‪MOCs‬‬ ‫ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔﺍﻟﻨﺒﺎﺗﻴﺔ ﻟﻠﻨﺒﺎﺕ‪/‬ﺟﺰء ﻣﻨﻪ )ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﺧﺼﺎﺋﺺ ﺍﻟﻤﻀﺎﺩﺍﺕ‬
‫ﺍﻟﻤﻮﺟﻮﺩﺓﻓﻴﻬﺎ ﻣﻨﺬ ﺁﻻﻑ ﺍﻟﺴﻨﻴﻦ‪ ،‬ﻭﻧﺴﺒﻮﺍ ﺍﻟﻔﻮﺍﺋﺪ ﺍﻟﺼﺤﻴﺔ ﻓﻘﻂ ﺇﻟﻰ ﺍﻟﻨﺒﺎﺕ‬ ‫ﺍﻟﺤﻴﻮﻳﺔﻭﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻔﻄﺮﻳﺎﺕ(‪ ،‬ﻭﻣﻮﻗﻌﻪ ﻭﺟﺰء ﻣﻨﻪ )ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪،‬‬
‫ﻭﺍﻟﻤﻮﺍﺩﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﺍﻟﻤﻜﻮﻧﺔ ﻟﻪ‪ .‬ﻭﻣﻊ ﺫﻟﻚ‪ ،‬ﻓﻘﺪ ﺍﻗﺘﺮﺡ ﻋﺪﺩ ﺻﻐﻴﺮ ﻣﻦ‬ ‫ﺍﻟﺴﻴﻘﺎﻥ‪/‬ﺍﻷﻭﺭﺍﻕ ﺍﻟﻤﻮﺟﻮﺩﺓ ﻓﻮﻕ ﺍﻷﺭﺽ ﺍﻟﻤﻌﺮﺿﺔ ﻷﺷﻌﺔ ﺍﻟﺸﻤﺲ ﺍﻟﻤﻌﻘﻤﺔ‬
‫ﻓﺮﻕﺍﻟﺒﺤﺚ ﺃﻥ ﺍﻟﻔﻮﺍﺋﺪ ﺍﻟﺼﺤﻴﺔ ﻟﺒﻌﺾ ﺍﻷﻋﺸﺎﺏ ﻗﺪ ﺗﺮﺟﻊ ﺑﺪﻻ ًﻣﻦ ﺫﻟﻚ ﺇﻟﻰ‬ ‫ﺑﺎﻷﺷﻌﺔﻓﻮﻕ ﺍﻟﺒﻨﻔﺴﺠﻴﺔ ﻭﻏﺴﻞ ﻣﻴﺎﻩ ﺍﻷﻣﻄﺎﺭ‪ ،‬ﺃﻭ ﺍﻷﺟﺰﺍء ﺍﻟﻤﻮﺟﻮﺩﺓ ﺗﺤﺖ‬
‫ﻛﺘﻠﺘﻬﺎﺍﻟﺤﻴﻮﻳﺔ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ ﺍﻟﻤﻌﻄﻠﺔ ﺑﻌﺪ ﻓﺼﻞ ‪ MAMPs‬ﺍﻟﻨﺸﻄﺔ ﺑﻴﻮﻟﻮﺟﻴﺎً ﻋﻦ‬ ‫ﺍﻟﺴﻄﺢﺍﻟﻤﻌﺮﺿﺔ ﻟﻐﺎﺯﺍﺕ ﻣﺨﺘﻠﻔﺔ‪.‬‬
‫ﺍﻟﻨﺒﺎﺕﻧﻔﺴﻪ‪.‬‬
‫ﺷﻜﻞ‪1‬‬
‫ﺍﻟﻜﺎﺋﻨﺎﺕﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻫﻲ ﻣﺠﺘﻤﻌﺎﺕ ﻣﺘﻨﻮﻋﺔ )‪ (MOCs‬ﻣﻦ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ ﻭﺍﻟﻔﻴﺮﻭﺳﺎﺕ ﻭﺍﻟﻔﻄﺮﻳﺎﺕ ﻭﺍﻷﻭﺍﻟﻲ ﻭﻣﺎ ﺇﻟﻰ ﺫﻟﻚ‪ ،‬ﻭﻫﻲ ﻣﻨﺘﺸﺮﺓ ﻓﻲ ﻛﻞ ﻣﻜﺎﻥ ﻓﻲ ﺍﻟﻄﺒﻴﻌﺔ‪ .‬ﺗﺘﻮﺍﺟﺪ ‪ MOCs‬ﺩﺍﺋﻤﺎً ﺩﺍﺧﻞ ﺃﻏﻨﻰ‬
‫ﺍﻟﺨﺰﺍﻧﺎﺕﺑﺎﻟﺠﺬﻭﺭ ﻭﺍﻟﺒﺬﻭﺭ ﻭﺍﻟﻄﺤﺎﻟﺐ ﺍﻟﺒﺤﺮﻳﺔ‪ .‬ﺗﻨﺘﻬﻲ ﻫﺬﻩ ‪ MOCs‬ﻓﻲ ﻃﻌﺎﻣﻨﺎ ﻭﻣﻴﺎﻫﻨﺎ ﻭﺃﺩﻭﻳﺘﻨﺎ ﺍﻟﻨﺒﺎﺗﻴﺔ‪ .‬ﺗﺨﻀﻊ ﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﻨﺒﺎﺗﻴﺔ ﻟﻠﺘﻌﻘﻴﻢ ﺑﻌﺪ ﺍﻟﺤﺼﺎﺩ ﻟﻀﻤﺎﻥ ﺳﻼﻣﺔ ﺍﻟﻐﺬﺍء‪ ،‬ﺣﻴﺚ ﺗﺒﻘﻰ ‪) MOCS‬‬
‫ﺍﻟﻤﻌﻄﻠﺔ(‪ .‬ﺗﺤﺘﻮﻱ ﻫﺬﻩ ‪ MOCS‬ﻋﻠﻰ ﻧﺴﺒﺔ ﻋﺎﻟﻴﺔ ﻣﻦ ﺍﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﻤﺤﺪﺩﺓ ﺍﻟﺘﻲ ﻻ ﺗﺤﺘﺎﺝ ﺇﻟﻰ ﻭﺻﻔﺔ ﻃﺒﻴﺔ‪ ،‬ﻭﺍﻟﻘﻠﻴﻞ ﻣﻨﻬﺎ ﻏﻨﻲ ﺑـ ‪ MAMPs‬ﻣﻦ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ ﺳﺎﻟﺒﺔ ﺍﻟﺠﺮﺍﻡ‪ .‬ﺗﻢ ﺍﺳﺘﻬﻼﻙ ‪ MAMPs‬ﺍﻟﻤﻨﺸﻄﺔ ﻟـ‬
‫‪ TLR4‬ﻋﻦ ﻏﻴﺮ ﻗﺼﺪ ﻵﻻﻑ ﺍﻟﺴﻨﻴﻦ‪ ،‬ﻣﻤﺎ ﻳﻤﻜﻦ ﺃﻥ ﻳﻌﺰﺯ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻄﺮﻳﺔ ﻭﺍﻟﻤﻜﺘﺴﺒﺔ‪ ،‬ﻓﻲ ﺣﻴﻦ ﺭﻛﺰﺕ ﺍﻟﺠﻬﻮﺩ ﺍﻟﺒﺤﺜﻴﺔ ﻓﻲ ﺍﻟﻐﺎﻟﺐ ﻋﻠﻰ ﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﺍﻟﻌﻼﺟﻴﺔ ﻟﻠﻤﻜﻮﻧﺎﺕ ﺍﻟﻨﺒﺎﺗﻴﺔ‪/‬ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ‪ .‬ﻧﻈﺮﺍً‬
‫ﻷﻥﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻨﺒﺎﺗﻲ ﻳﻌﺪ ﻣﻜﻮﻧﺎً ﻓﺮﻳﺪﺍً ﺩﺍﺧﻞ‪/‬ﻭﻟﻜﻦ ﻟﻴﺲ ﺩﺍﺧﻞ ﺍﻟﻨﺒﺎﺕ ‪ -‬ﻳﻤﻜﻦ ﺯﺭﺍﻋﺔ ‪ MOCS‬ﻓﻲ ﻣﻔﺎﻋﻞ ﺣﻴﻮﻱ‪/‬ﻗﺒﻞ ﺍﻟﺘﻌﻄﻴﻞ ﻭﺗﻘﻴﻴﻢ ﺗﺄﺛﻴﺮﻩ ﻋﻠﻰ ﺻﺤﺔ ﺍﻹﻧﺴﺎﻥ‪ .‬ﺗﻢ ﺇﻧﺸﺎﺅﻫﺎ ﺑﺎﺳﺘﺨﺪﺍﻡ‬
‫‪.BioRender.com‬‬

‫ﻭﻗﺪﺗﻢ ﺍﺳﺘﻐﻼﻝ ﻫﺬﻩ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﻟﻌﺪﺓ ﻗﺮﻭﻥ ﻟﻠﺤﻔﺎﻅ ﻋﻠﻰ‬ ‫)‪ .(41-39‬ﺗﺘﻮﺍﻓﻖ ﻫﺬﻩ ﺍﻟﻨﻈﺮﻳﺔ ﻣﻊ ﺍﻟﻤﺠﺎﻝ ﺍﻷﻭﺳﻊ ﻟﻌﻠﻢ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ‬
‫ﺍﻻﻟﺘﻬﺎﺑﺎﺕﻭﻋﻼﺟﻬﺎ‪ .‬ﻭﺍﻟﻴﻮﻡ‪ ،‬ﻻ ﻳﺰﺍﻝ ﺍﻟﺘﺮﻛﻴﺰ ﺍﻟﺴﺎﺋﺪ ﻋﻠﻰ ﺍﻷﺩﻭﻳﺔ ﺍﻟﻄﺒﻴﻌﻴﺔ‬ ‫ﻭﺍﻟﻤﻨﻄﻖﺍﻟﺒﺴﻴﻂ ﺍﻟﻘﺎﺋﻞ ﺑﺄﻥ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﻲ ﻳﺴﺘﺠﻴﺐ ﺑﻘﻮﺓ ﻟﻴﺲ ﻟﻠﻤﻮﺍﺩ‬
‫ﺍﻟﻤﻀﺎﺩﺓﻟﻠﺴﺮﻃﺎﻥ ﻣﻨﺼﺒﺎً ﻋﻠﻰ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ‪ .‬ﺗﺜﺒﺖ ﺁﻻﻑ‬ ‫ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔﺍﻟﻨﺒﺎﺗﻴﺔ ﺃﻭ ﺍﻷﺩﻭﻳﺔ ﻭﻟﻜﻦ ﻟﻮﺟﻮﺩ ﺣﻄﺎﻡ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ‬
‫ﺍﻟﺪﺭﺍﺳﺎﺕﺍﺳﺘﺨﺪﺍﻡ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﻓﻲ ﻣﻌﺎﻟﺠﺔ ﻣﺴﺎﺭﺍﺕ ﺍﻹﺷﺎﺭﺍﺕ‬ ‫ﺍﻟﻤﺴﺘﻀﺪﻳﺔﺍﻷﺟﻨﺒﻴﺔ )‪ ،(MAMPs‬ﻭﻫﻮ ﺃﺳﺎﺱ ﺗﻄﻮﻳﺮ ﺍﻟﻠﻘﺎﺡ ﻭﺍﻟﻤﻮﺍﺩ‬
‫ﺍﻟﺨﻠﻮﻳﺔﻣﺜﻞ ﻣﻮﺕ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻤﺒﺮﻣﺞ )‪ ،(Bcl-2/Bax‬ﻭﻧﺴﺦ ﺍﻟﺠﻴﻦ ﺍﻟﻮﺭﻣﻲ‪،‬‬ ‫ﺍﻟﻤﺴﺎﻋﺪﺓ‪.‬ﺍﻛﺘﺸﻒ ﻋﺪﺩ ﻗﻠﻴﻞ ﻣﻦ ﻓﺮﻕ ﺍﻟﺒﺤﺚ ﺃﻥ ﻣﻨﺒﻬﺎﺕ ‪PRR TLR4‬‬
‫ﻭﺗﺤﺮﻳﺾﺍﻟﺠﻴﻨﺎﺕ‪ ،‬ﻭﺗﻌﺒﻴﺮ‪/‬ﻧﺸﺎﻁ ﺍﻹﻧﺰﻳﻢ )ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﺍﻟﺘﻮﺑﻮﻳﺰﻭﻣﻴﺮﺍﺯ‪،‬‬ ‫‪ MOC-MAMP‬ﻣﺴﺆﻭﻟﺔ ﻋﻦ ﺗﺄﺛﻴﺮﺍﺕ ﺗﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ ﻓﻲ ﺍﻷﻋﺸﺎﺏ ﺍﻟﺘﺎﻟﻴﺔ‪:‬‬
‫ﻭﺇﻧﺰﻳﻤﺎﺕﺍﻷﻛﺴﺪﺓ ﺍﻟﺤﻠﻘﻴﺔ‪ ،‬ﻭﺍﻟﺒﺮﻭﺗﻴﻨﺎﺕ ﺍﻟﻤﻌﺪﻧﻴﺔ ﺍﻟﻤﺼﻔﻮﻓﻴﺔ(‪ ،‬ﻭﺗﻨﻈﻴﻢ ﺩﻭﺭﺓ‬ ‫ﺍﻟﺠﻮﺯﺍﻷﺳﻮﺩ‪ ،‬ﺟﺬﺭ ﺇﺷﻨﺴﺎ‪ ،‬ﺟﺬﺭ ﺍﻟﺠﻴﻨﺴﻨﻎ‪ ،‬ﺑﺬﻭﺭ ﺍﻟﺒﺮﺳﻴﻢ )‪ (59‬ﺟﺬﺭ ﺍﻟﻘﺘﺎﺩ )‪60‬‬
‫ﺍﻟﺨﻠﻴﺔ‪،‬ﻭﺗﻌﺪﻳﻞ ﺍﻹﺷﺎﺭﺍﺕ‪ .‬ﺍﻷﻧﻈﻤﺔ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻨﻤﻮ ﺍﻟﺴﺮﻳﻊ ﻟﻠﻮﺭﻡ )ﻋﻠﻰ ﺳﺒﻴﻞ‬ ‫‪ ،(61,‬ﺟﺬﻭﺭ ﺣﺸﻴﺸﺔ ﺍﻟﻤﻼﻙ )‪ ، (62‬ﻭﺍﻟﻘﻤﺢ‪ ،‬ﻭﻫﻮ ﺍﻷﺧﻴﺮ ﺍﻟﺬﻱ ﻳﻘﺪﻡ ﻣﻔﻬﻮﻡ‬
‫ﺍﻟﻤﺜﺎﻝ‪،‬ﻣﺴﺎﺭ ‪ ،(MAPK/ERK، PI3K/AKT/ mTORC1‬ﺃﻭ ﻟﺘﻨﺸﻴﻂ ﺁﻟﻴﺎﺕ‬ ‫‪ LPS‬ﺍﻟﺼﺎﻟﺢ ﻟﻸﻛﻞ ﺍﻟﻤﻮﺟﻮﺩ ﻓﻲ ﺍﻟﻘﻤﺢ ﻣﻦﺗﻜﺘﻼﺕ ﺑﺎﻧﺘﻮﻳﺎ ﺑﺎﻋﺘﺒﺎﺭﻩ "ﺳﻢ ﻛﻮﻟﻴﺰ‬
‫ﺇﺻﻼﺡﺍﻟﺤﻤﺾ ﺍﻟﻨﻮﻭﻱ )‪ .(85-80‬ﻭﻟﻮﺣﻆ ﺗﺮﻛﻴﺰ ﻣﻤﺎﺛﻞ ﻋﻠﻰ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ‬ ‫ﻏﻴﺮﺳﺎﻡ ﻓﻲ ﺍﻟﻌﺼﺮ ﺍﻟﺤﺪﻳﺚ" ﺑﻘﺪﺭﺓ ﻻ ﺣﺪﻭﺩ ﻟﻬﺎ ﻋﻨﺪ ﺗﻨﺎﻭﻟﻪ ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ )‬
‫ﻓﻲﺍﻷﺑﺤﺎﺙ ﺍﻟﺘﻲ ﺗﺴﺘﻜﺸﻒ ﺍﻟﺘﻔﺎﻋﻞ ﺑﻴﻦ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﻭﺍﻟﺴﺮﻃﺎﻥ‪ ،‬ﻣﻊ ﺍﻟﺘﺮﻛﻴﺰ‬ ‫‪ .(66-63‬ﻳﺪﻋﻢ ﺑﺤﺜﻨﺎ ﺍﻷﺧﻴﺮ ﻧﺘﺎﺋﺞ ﻛﻞ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺎﺕ‪ ،‬ﻣﻤﺎ ﻳﺸﻴﺮ ﺇﻟﻰ ﺃﻥ‬
‫ﺑﺸﻜﻞﺧﺎﺹ ﻋﻠﻰ ﺍﻟﻤﺴﺘﻘﻠﺒﺎﺕ ﺍﻟﺜﺎﻧﻮﻳﺔ ﺍﻟﺘﻲ ﺗﻨﺘﺠﻬﺎ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ‪.‬‬ ‫ﺧﺼﺎﺋﺺﺗﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ ﻟﻴﺴﺖ ﻣﻦ ﺍﻟﻨﺒﺎﺕ‪ ،‬ﺑﻞ ﺗﻌﺰﻯ ﺇﻟﻰ ﺍﻟﻜﺘﻠﺔ ﺍﻟﺤﻴﻮﻳﺔ‬
‫ﺍﻷﻛﺘﻴﻨﻮﺑﺎﻛﺘﺮﻳﺎﻭﺍﻟﻌﻘﺪﻳﺔ ﺍﻟﻨﻴﺎﺑﺔ‪ .‬ﺗﺸﻜﻞ ﻫﺬﻩ ﺍﻟﻤﺴﺘﻘﻠﺒﺎﺕ‪ ،‬ﻭﺍﻟﺘﻲ ﺗﺸﻤﻞ‬ ‫‪ ،MAMP MOC‬ﺑﻴﻨﻤﺎ ﻧﻘﻮﻡ ﺍﻵﻥ ﺑﺘﻮﺳﻴﻊ ﻫﺬﻩ ﺍﻟﻘﺎﺋﻤﺔ ﻟﺘﺸﻤﻞ ‪ 65‬ﻣﻦ ﺃﺻﻞ‬
‫ﺍﻟﺒﻮﻟﻴﻔﻴﻨﻮﻝ‪،‬ﻭﺍﻹﻧﺪﻭﻟﻮﻛﺮﺑﺎﺯﻭﻝ‪ ،‬ﻭﺍﻷﻧﺜﺮﺍﺳﻴﻜﻠﻴﻦ‪ ،‬ﻭﺍﻟﻤﺮﻛﺒﺎﺕ ﺍﻟﻤﻬﻠﺠﻨﺔ‪،‬‬ ‫‪2000‬ﻣﻨﺘﺞ ﺗﻘﺮﻳﺒﺎً ﻣﻦ ‪ OTC‬ﺗﻢ ﺍﺧﺘﺒﺎﺭﻫﺎ ﻭﺍﻟﺘﻲ ﺗﺤﺘﻮﻱ ﻋﻠﻰ ‪ .TLR4‬ﻣﻨﺒﻬﺎﺕ‬
‫ﻭﺍﻟﺒﻮﻟﻴﻜﻴﺘﻴﺪﺍﺕ‪،‬ﻭﺍﻷﻧﺜﺮﺍﺳﻴﻨﺎﺕ‪ ،‬ﻭﺍﻟﻘﻠﻮﻳﺪﺍﺕ‪ ،‬ﺍﻷﺳﺎﺱ ﻷﺩﻭﻳﺔ ﺍﻟﻌﻼﺝ‬ ‫‪) PRR‬ﻓﻲ ﺍﻧﺘﻈﺎﺭ ﺍﻟﻨﺸﺮ‪ ،‬ﻣﺎﺯﻳﻮ ﻭﺁﺧﺮﻭﻥ‪ .2023 ،‬ﻣﺠﻠﺔ ﺍﻷﻃﻌﻤﺔ ﺍﻟﻮﻇﻴﻔﻴﺔ (‪.‬‬
‫ﺍﻟﻜﻴﻤﻴﺎﺋﻲﺍﻟﺘﻘﻠﻴﺪﻳﺔ ﻣﺜﻞ ﺩﻭﻛﺴﻮﺭﻭﺑﻴﺴﻴﻦ‪ ،‬ﻭﻣﻴﺜﺮﺍﻣﺎﻳﺴﻴﻦ‪ ،‬ﻭﻣﻴﺘﻮﻣﻴﺴﻴﻦ‬
‫ﺳﻲ‪.(86.‬‬
‫ﻓﻲﺣﻴﻦ ﺃﻥ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﻳﻤﻜﻦ ﺃﻥ ﺗﻤﻨﻊ ﺍﻟﺴﺮﻃﺎﻥ ﻋﻦ ﻃﺮﻳﻖ‬
‫ﺗﺨﻔﻴﻒﺍﻻﻟﺘﻬﺎﺏ ﺍﻟﻤﺰﻣﻦ ﺍﻟﺬﻱ ﻳﺴﺒﺐ ﺍﻟﺴﺮﻃﺎﻥ )‪ ، (87,27‬ﺗﺘﻄﻠﺐ ﺇﺩﺍﺭﺓ‬ ‫ﺗﺘﻮﺍﻓﻖﻧﺘﺎﺋﺞ ﺑﺤﺜﻨﺎ ﺑﺸﻜﻞ ﻣﺒﺎﺷﺮ ﻣﻊ ﺍﻟﺪﺭﺍﺳﺎﺕ ﺍﻟﺒﻴﺌﻴﺔ ﺍﻟﺘﻲ ﺗﺸﻴﺮ ﺇﻟﻰ‬
‫ﺍﻟﺴﺮﻃﺎﻥﺍﻟﻤﻮﺟﻮﺩ ﺑﺎﻟﻔﻌﻞ ﺗﻌﺰﻳﺰﺍً ﻣﻨﺎﻋﻴﺎً ﻗﻮﻳﺎً ﻭﺣﺎﺩﺍً‪ ،‬ﻣﻤﺎ ﻳﺴﺘﻠﺰﻡ ﺍﺳﺘﺠﺎﺑﺔ‬ ‫ﻭﺟﻮﺩﻣﻴﻜﺮﻭﺑﺎﺕ ﺟﺬﻣﻮﺭ ﻣﻤﺎﺛﻠﺔ ﻣﺪﻣﺠﺔ ﻓﻲ ﺍﻟﺘﺮﺑﺔ )‪) (67‬ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪،‬‬
‫ﻣﺆﻳﺪﺓﻟﻼﻟﺘﻬﺎﺑﺎﺕ‪.‬‬ ‫ﺇﺷﻨﺴﺎ‪،‬ﻧﺒﺎﺕ ﺍﻟﻘﺮﺍﺹ ﺍﻟﻼﺫﻉ‪ ،‬ﺍﻷﺭﻗﻄﻴﻮﻥ ﻭﻣﺎ ﺇﻟﻰ ﺫﻟﻚ( ﻭﺗﺮﻛﻴﺰﺍﺕ ﻋﺎﻟﻴﺔ ﻣﻦ‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕﺳﺎﻟﺒﺔ ﺍﻟﺠﺮﺍﻡ ﻭﺍﻷﻏﺸﻴﺔ ﺍﻟﺤﻴﻮﻳﺔ ﻓﻲ ﻋﺸﺐ ﺍﻟﺒﺤﺮ ﺍﻟﺼﺎﻟﺢ ﻟﻸﻛﻞ‬
‫ﻭﺍﻟﻨﺒﺎﺗﺎﺕﺍﻟﺒﺤﺮﻳﺔ ﺍﻷﺧﺮﻯ‪ ،‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚﺍﻟﻤﻜﻮﺭﺍﺕ ﺍﻟﺤﺒﻴﺒﻴﺔ ﺃﻧﺘﺎﺭﻛﺘﻴﻜﺎ‪ ،‬ﻫﻴﻠﻴﺎ‬
‫ﻓﻲﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ‬ ‫ﺑﺎﻟﻨﻴﻮﻟﻴﻨﺴﻴﺲ)ﺟﺎﻣﺎﺑﺮﻭﺗﻴﻮﺑﺎﻛﺘﺮﻳﺎ( ﺍﻟﻌﺼﻮﺍﻧﻴﺎﺕ ﻭﺍﻷﻟﻔﺎ ﺑﺮﻭﺗﻴﻮﺑﺎﻛﺘﺮﻳﺎ‪،‬ﻫﺬﻩ ﺑﻤﺎ‬
‫ﻟﻠﻮﺭﻡ‪2.2 MAMPS‬‬ ‫ﻓﻲﺫﻟﻚﻓﻮﻗﺲ ﺣﻮﻳﺼﻠﻲ‪) N. leutkeana ،‬ﺍﻟﻤﺜﺎﻧﺔ(‪،‬ﺹ‪ .‬ﺳﻜﻮﻟﻴﺮﻱ )ﺗﺼﻔﺢ‬
‫ﺍﻟﻌﺸﺐ(‪،‬ﻻﻣﻴﻨﺎﺭﻳﺎ ﺳﻴﺘﺸﻴﻠﻲ )ﻋﺸﺐ ﺍﻟﺒﺤﺮ(ﻛﻮﻧﺪﺭﻭﺱ ﻛﺮﻳﺴﺒﻮﺱ )ﺍﻟﻄﺤﻠﺐ‬
‫ﺇﻥﺍﻟﻘﺪﺭﺓ ﻋﻠﻰ ﺗﻌﺰﻳﺰ ﺟﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﺔ ﻟﻠﺘﻐﻠﺐ ﻋﻠﻰ ﺍﻟﻮﺭﻡ ﺍﻟﺒﺸﺮﻱ ﻭﺗﺪﻣﻴﺮﻩ‬ ‫ﺍﻻﻳﺮﻟﻨﺪﻱ(‪،‬ﻻﻣﻴﻨﺎﺭﻳﺎ ﺃﻭﻛﺮﻭﻟﻴﻮﻛﺎ )ﻋﺸﺐ ﺍﻟﺒﺤﺮ ‪ /‬ﺍﻷﻋﺸﺎﺏ ﺍﻟﺒﺤﺮﻳﺔ ﺍﻟﺒﻨﻴﺔ(‪،‬‬
‫ﺗﺸﻜﻞﺍﻷﺳﺎﺱ ﻻﺧﺘﺮﺍﻗﺎﺕ ﺍﻟﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ‪ .‬ﺗﺸﺘﺮﻙ ﺟﻤﻴﻊ‬ ‫ﺑﺎﻟﻤﺎﺭﻳﺎﺭﺍﺣﺔ ﺍﻟﻴﺪ )ﺩﻭﻟﺴﻲ(‪ ،‬ﺍﻟﺦ )‪.(69,68‬‬
‫ﺍﻟﻌﻼﺟﺎﺕﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻠﻮﺭﻡ ﻓﻲ ﻫﺪﻑ ﻣﺸﺘﺮﻙ‪" :‬ﺗﻌﺰﻳﺰ" ﺃﻭ "ﺗﻨﺸﻴﻂ" ﺃﻭ "ﺇﻋﺎﺩﺓ‬
‫ﺇﻳﻘﺎﻅ" ﺍﻟﺠﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﻀﻴﻒ ﺍﻟﺨﺎﻣﻞ ﺍﻟﺬﻱ ﻳﺘﻢ ﺇﺧﻀﺎﻋﻪ ﺑﻮﺍﺳﻄﺔ ﺍﻟﺤﺎﺟﺰ‬ ‫ﻭﻓﻘﺎًﻟﺒﺤﺜﻨﺎ‪ ،‬ﻓﺈﻥ ﻣﺎ ﻳﻘﺮﺏ ﻣﻦ ‪ %98‬ﻣﻦ ﺍﻷﻋﺸﺎﺏ ﻭﺍﻟﻔﻮﺍﻛﻪ ﻭﺍﻟﺨﻀﺮﻭﺍﺕ‬
‫ﺍﻟﻤﺜﺒﻂﻟﻠﻤﻨﺎﻋﺔ ﻟﻠﻮﺭﻡ ﻻﺳﺘﻌﺎﺩﺓ ﺍﻟﺴﻴﻄﺮﺓ ﻋﻠﻰ ﺍﻵﻟﻴﺎﺕ ﺍﻟﻘﺎﺩﺭﺓ ﻋﻠﻰ ﺗﺪﻣﻴﺮ‬ ‫ﻻﺗﺤﺘﻮﻱ ﻋﻠﻰ ﻣﻨﺒﻬﺎﺕ ﺍﻟﻤﺴﺘﻘﺒﻼﺕ ﺍﻟﻨﺸﻄﺔ ﺑﻴﻮﻟﻮﺟﻴﺎً )‪ ،(TLR4‬ﻣﻤﺎ ﻳﺸﻴﺮ‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﺨﺒﻴﺜﺔ )‪ ;(8,7,5‬ﻭﻫﺬﺍ ﻳﺘﻄﻠﺐ ﺍﺳﺘﺠﺎﺑﺔ ﻣﺆﻳﺪﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ )ﻣﻌﺰﺯﺓ‬ ‫ﺇﻟﻰﺃﻥ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻣﺎﺕ ﺍﻟﻤﻌﺪﻟﺔ ﻟﻠﻤﻨﺎﻋﺔ ﻓﻲ ﺍﻟﻨﺒﺎﺗﺎﺕ ﻭﺍﻷﻋﺸﺎﺏ ﻟﻴﺴﺖ‬
‫ﻟﻠﻤﻨﺎﻋﺔ(‪ ،‬ﻭﻟﻴﺲ ﺍﺳﺘﺠﺎﺑﺔ ﻣﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ‪ .‬ﻟﻘﺪ ﺍﺳﺘﻜﺸﻔﺖ ﺍﻟﻌﻼﺟﺎﺕ )‬ ‫ﻣﻨﺘﺸﺮﺓﻓﻲ ﻛﻞ ﻣﻜﺎﻥ ﻭﻟﻜﻨﻬﺎ ﺗﻨﺘﺞ ﺑﺪﻻ ًﻣﻦ ﺫﻟﻚ ﻣﻦ ﻗﻮﻯ ﻃﺒﻴﻌﻴﺔ ﺗﺸﺠﻊ‬
‫ﺍﻟﻤﺸﺎﺑﻬﺔﻟـ ‪ (Coley‬ﺣﺘﻰ ﺍﻵﻥ ﻣﺰﻳﺠﺎً ﻣﻦ ﺍﺭﺗﻔﺎﻉ ﺍﻟﺤﺮﺍﺭﺓ ﺍﻻﺻﻄﻨﺎﻋﻲ )ﺍﻟﺤﻤﻰ(‬ ‫ﺗﺮﺍﻛﻤﻬﻢ‪.‬‬
‫‪ ±‬ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﺍﻟﻤﻌﻄﻠﺔ ﺍﻟﺘﻲ ﺗﺤﺘﻮﻱ ﻋﻠﻰ ‪ MAMPS‬ﺍﻟﻘﻮﻳﺔ )‪(89,88,6‬‬
‫ﻟﻘﺎﺣﺎﺕ‪ ، (91,90) MAMP‬ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﺍﻟﺨﺎﺭﺟﻴﺔ )‪ ،(IL-2، 15‬ﺇﻧﺘﺮﻓﻴﺮﻭﻥ‬
‫ﺃﻟﻔﺎ)‪IFN‬ﺃ(ﺃﻭ ﻋﺎﻣﻞ ﺗﺤﻔﻴﺰ ﻣﺴﺘﻌﻤﺮﺍﺕ ﺍﻟﺒﻼﻋﻢ ﺍﻟﻤﺤﺒﺒﺔ )‪ ،(GM-CSF‬ﻋﻼﺟﺎﺕ‬ ‫‪2.1‬ﺗﺤﻮﻳﻞ ﻧﻘﺎﻁ ﺍﻟﺘﺮﻛﻴﺰ ﺍﻟﺒﺤﺜﻴﺔ‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﺘﺎﺋﻴﺔ ﺑﺎﻟﺘﺒﻨﻲ ﻣﻊ ﺍﻻﺳﺘﻬﺪﺍﻑ ﺍﻟﻤﺒﺎﺷﺮ ﻟـ )ﺍﻟﻤﺴﺘﻀﺪﺍﺕ ﺍﻟﻤﺮﺗﺒﻄﺔ‬
‫ﺑﺎﻟﻮﺭﻡ)‪ / (TAA‬ﺍﻟﻤﺴﺘﻀﺪﺍﺕ ﺍﻟﺨﺎﺻﺔ ﺑﺎﻟﻮﺭﻡ )‪ ((TSA‬ﻭﻣﺜﺒﻄﺎﺕ ﻧﻘﺎﻁ‬ ‫ﺗﻢﺗﻮﺟﻴﻪ ﺃﺑﺤﺎﺙ ﻣﻬﻤﺔ ﻧﺤﻮ ﻣﻮﺿﻮﻋﺎﺕ ﻫﺎﻣﺸﻴﺔ‪ ،‬ﻏﺎﻟﺒﺎً ﻣﺎ ﺗﺘﺠﺎﻫﻞ‬
‫ﺍﻟﺘﻔﺘﻴﺶﺍﻟﺘﻲ ﺗﺰﻳﻞ ‪ /‬ﺃﻧﻈﻤﺔ ﺍﻟﻜﺒﺢ )‪ ،(mAb‬ﺇﻳﺒﻴﻠﻴﻤﻮﻣﺎﺏ ‪ ،‬ﻧﻴﻔﻮﻟﻮﻣﺎﺏ‪،‬‬ ‫ﺍﻟﺠﺎﻧﺐﺍﻟﻤﺤﺘﻤﻞ ﻟﻠﺼﺤﺔ ﺍﻟﺒﺸﺮﻳﺔ ﺍﻟﻤﺘﻤﺜﻞ ﻓﻲ ﺗﻨﺎﻭﻝ ‪ MOCs‬ﺍﻟﻤﻌﻄﻠﺔ‪ .‬ﻭﻣﻊ‬
‫ﺑﻴﻤﺒﺮﻭﻟﻴﺰﻭﻣﺎﺏ‪،‬ﻭﻣﺎ ﺇﻟﻰ ﺫﻟﻚ( )‪ (95-92‬ﺃﻭ ﻟﻘﺎﺣﺎﺕ ﺍﻟﻮﺭﻡ ﺍﻟﺬﺍﺗﻴﺔ‪/‬ﺍﻟﺨﻴﻔﻴﺔ‬ ‫ﺫﻟﻚ‪،‬ﻓﺈﻥ ﺍﻟﻤﻔﻬﻮﻡ ﺍﻟﻘﺎﺋﻞ ﺑﺄﻥ ﺗﻨﺎﻭﻝ "ﺍﻟﺤﺸﺮﺍﺕ ﺍﻟﻤﻴﺘﺔ" ﻳﻤﻜﻦ ﺃﻥ ﻳﺆﺛﺮ ﻋﻠﻰ‬
‫ﺍﻟﻤﺠﻬﺰﺓﺑﻤﻮﺍﺩ ﻣﺴﺎﻋﺪﺓ ﺑﻜﺘﻴﺮﻳﺔ ﻣﻨﺎﻋﻴﺔ ﻗﻮﻳﺔ ﻭﺳﻴﺘﻮﻛﻴﻨﺎﺕ ﺗﻘﺪﻳﺮﻳﺔ )‪.(96‬‬ ‫ﺻﺤﺔﺍﻹﻧﺴﺎﻥ ﻳﻜﺘﺴﺐ ﻗﺒﻮﻻً ﺗﺪﺭﻳﺠﻴﺎً‪ ،‬ﻛﻤﺎ ﺭﺃﻳﻨﺎ ﻓﻲ ﺍﻟﻤﺠﺎﻻﺕ ﺍﻟﻨﺎﺷﺌﺔ‬
‫ﻟﻠﺒﺮﻭﺑﻴﻮﺗﻴﻚ)ﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚ ﺍﻟﻤﻌﻄﻠﺔ( )‪ (72 -70‬ﺗﻄﻮﻳﺮ ﺍﻟﻠﻘﺎﺣﺎﺕ ﻋﻦ ﻃﺮﻳﻖ‬
‫ﺍﻟﻔﻢ)‪ (74,73‬ﻭﺑﻔﻬﻢ ﺃﻛﺒﺮ ﻓﻴﻤﺎ ﻳﺘﻌﻠﻖ ﺑﺘﺸﺮﻳﺢ ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻷﻣﻌﺎء ﺍﻟﺒﺸﺮﻳﺔ ﻭ‬
‫‪ PRRs‬ﺍﻟﺨﺎﺻﺔ ﺑﻪ )‪ .(75,50,47-44‬ﻋﻠﻰ ﺍﻟﺮﻏﻢ ﻣﻦ ﺫﻟﻚ‪ ،‬ﻓﺈﻥ ﻣﻌﻈﻢ ﺍﻷﻋﻤﺎﻝ‬
‫ﺍﻟﺘﻲﺗﻢ ﺗﻨﻔﻴﺬﻫﺎ ﻋﻠﻰ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﺒﺸﺮﻱ ﺣﺘﻰ ﺍﻵﻥ ﺭﻛﺰﺕ ﻋﻠﻰ "ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ‬
‫ﻗﺪﺗﻔﻌﻞ ‪ MAMPS‬ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ ﻣﻦ ﺍﻟﻨﺎﺣﻴﺘﻴﻦ ﺍﻟﺪﻭﺍﺋﻴﺔ ﻭﺍﻟﻤﻴﻜﺎﻧﻴﻜﻴﺔ‬ ‫ﺍﻟﺤﻲ" )ﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚ‪ ،‬ﻭﺍﻟﺒﺮﻳﺒﺎﻳﻮﺗﻜﺲ‪ ،‬ﻭﺛﻘﺎﻓﺎﺕ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ(‬
‫ﺍﻟﺸﻲءﻧﻔﺴﻪ‪ ،‬ﺣﻴﺚ ﺗﺘﻤﺘﻊ ﺑﺈﻣﻜﺎﻧﻴﺔ ﺍﻟﻮﺻﻮﻝ ﺍﻟﻤﺒﺎﺷﺮ ﺇﻟﻰ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﻲ ﻣﻦ‬ ‫ﺑﺎﻋﺘﺒﺎﺭﻫﺎﻣﺘﻜﺎﻓﻠﺔ‪/‬ﻣﻤﺮﺿﺔ )‪ .(79-76‬ﻭﻓﻲ ﺍﻟﻮﻗﺖ ﻧﻔﺴﻪ‪ ،‬ﺗﺴﺘﻤﺮ ﺍﻷﺑﺤﺎﺙ‬
‫ﺧﻼﻝﺍﻟﻐﺸﺎء ﺍﻟﻤﺨﺎﻃﻲ ﻟﻸﻣﻌﺎء‪ .‬ﻳﻤﻜﻦ ﻟﻠﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ ﺍﻟﻌﻠﻮﻱ ﺍﻟﺘﻘﺎﻁ )ﻋﻦ‬ ‫ﺍﻟﻌﻼﺟﻴﺔﻓﻲ ﻃﺐ ﺍﻟﻨﺒﺎﺕ ﻓﻲ ﺍﻟﺘﺮﻛﻴﺰ ﻋﻠﻰ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ‬
‫ﻃﺮﻳﻖﺍﻟﻤﻴﻮﺳﻴﻦ( ﻭﺗﺤﺪﻳﺪ ﻭﺍﻻﺳﺘﺠﺎﺑﺔ ﻭﺑﻨﺎء ﻗﺎﻋﺪﺓ ﺑﻴﺎﻧﺎﺕ ﻣﻨﺎﻋﺔ ﻣﻜﺘﺴﺒﺔ‬ ‫ﺑﺪﻻ ًﻣﻦ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻤﻌﻄﻞ ﻓﻲ ﺍﻟﻨﺒﺎﺕ‪ .‬ﺗﺤﺘﻮﻱ ﺍﻟﻨﺒﺎﺗﺎﺕ ﻋﻠﻰ ﻣﺠﻤﻮﻋﺔ‬
‫ﻟﻠﻤﺴﺘﻀﺪﺍﺕﺍﻷﺟﻨﺒﻴﺔ ﻣﻊ ﺗﻮﻓﻴﺮ ﻣﺴﺎﺣﺔ ﺳﻄﺤﻴﺔ ﺗﺒﻠﻎ ‪ 15‬ﺿﻌﻒ ﻣﺴﺎﺣﺔ‬ ‫ﻣﺘﻨﻮﻋﺔﻣﻦ "ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ" ﻣﺜﻞ ﺍﻟﻔﻼﻓﻮﻧﻮﻳﺪ‪ ،‬ﺍﻟﻔﻴﻨﻮﻝ‪،‬‬
‫ﺍﻷﻣﻌﺎءﺍﻟﻐﻠﻴﻈﺔ )‪ .(97‬ﻳﺤﺘﻮﻱ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ ﺍﻟﻌﻠﻮﻱ ﺃﻳﻀﺎً ﻋﻠﻰ ﻭﻓﺮﺓ ﻣﻦ‬ ‫ﺍﻟﻘﻠﻮﻳﺪﺍﺕ‪،‬ﺍﻟﺠﻠﻴﻜﻮﺳﻴﺪﺍﺕ‪ ،‬ﺍﻟﻘﺸﻮﺭ‪ ،‬ﻭ ﺗﺮﺍﻳﺘﻴﺮﺑﻴﻨﻮﻳﺪﺍﺕ‪ ،‬ﻭﺍﻟﺘﻲ ﺗﻈﻬﺮ‬
‫‪ ،GALT-/LP PRRs‬ﻓﻲ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻤﻌﻮﻳﺔ ﻭﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻈﻬﺎﺭﻳﺔ )ﺍﻟﻌﺪﻻﺕ‪ ،‬ﺍﻟﺒﻼﻋﻢ‬ ‫ﻣﺠﻤﻮﻋﺔﻭﺍﺳﻌﺔ ﻣﻦ ﺍﻟﺨﺼﺎﺋﺺ ﺍﻟﻮﻗﺎﺋﻴﺔ‪ ،‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ‪،‬‬
‫‪/‬ﺍﻟﺨﻼﻳﺎ ﺍﻟﻮﺣﻴﺪﺓ‪ ،‬ﺍﻟﺨﻼﻳﺎ ﺍﻟﺠﺬﻋﻴﺔ‪ ،‬ﺍﻟﺨﻼﻳﺎ ﺍﻟﺒﺪﻳﻨﺔ‪ ،‬ﺍﻟﺨﻼﻳﺎ ﺍﻟﻠﻴﻤﻔﺎﻭﻳﺔ ‪ T‬ﻭ‪،(B‬‬ ‫ﻣﺴﻜﻦ‪،‬ﺧﺎﻓﺾ ﻟﻠﺤﺮﺍﺭﺓ‪ ،‬ﻣﻀﺎﺩ ﻟﻠﻤﻼﺭﻳﺎ‪ ،‬ﻣﻀﺎﺩ ﻟﻠﺠﺮﺍﺛﻴﻢ‪ ،‬ﻣﻀﺎﺩ ﺍﻷﻭﺍﻟﻲ‪،‬‬
‫ﻭﺳﻄﺢﺇﺷﺎﺭﺍﺕ ﻣﺘﻜﺎﻣﻞ ﻟﻠﻐﺎﻳﺔ ﻳﺘﻢ ﺍﻟﺘﺼﺮﻑ ﻋﻠﻴﻪ ﺑﺴﻬﻮﻟﺔ ﺑﻮﺍﺳﻄﺔ ‪MAMPS‬‬ ‫ﻣﻀﺎﺩﻟﻸﻛﺴﺪﺓ‪ ،‬ﺗﺄﺛﻴﺮﺍﺕ ﻣﻀﺎﺩﺓ ﻟﻠﻔﻄﺮﻳﺎﺕ ﻭﻣﻀﺎﺩﺓ ﻟﻠﻔﻴﺮﻭﺳﺎﺕ )‪ .(80‬ﻋﻦ‬
‫ﻋﻠﻰ‪ - .C‬ﺍﻟﻤﺴﺘﻘﺒﻼﺕ ﺍﻟﺸﺒﻴﻬﺔ ﺑﺎﻟﻠﻴﻜﺘﻴﻦ )‪(CLRs‬‬ ‫ﻏﻴﺮﻗﺼﺪ‪ ،‬ﻗﺪﺭﺍﺕ ﻣﻀﺎﺩﺍﺕ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ‬

‫ﺗﺘﻔﺮﻉﺍﻟﺨﻼﻳﺎ ﺇﻟﻰ ﺍﻷﻭﻋﻴﺔ ﺍﻟﻠﻤﻔﺎﻭﻳﺔ ﺍﻟﺠﻬﺎﺯﻳﺔ )‪ (125-123,75‬ﺍﺳﺘﺤﻀﺎﺭ‬ ‫) (‪ Toll-like )TLRs‬ﻭﻣﺴﺘﻘﺒﻼﺕ (‪ )NOD( )NLRs‬ﻭﻣﺴﺘﻘﺒﻼﺕ ﺗﺸﺒﻪ ﻣﺠﺎﻝ ﺍﺣﺘﻜﺎﺭ‬
‫ﺍﻟﺘﻮﺳﻊﺍﻟﻨﺴﻴﻠﻲ ﻟﻠﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ )‪ .(128-126‬ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ‪ ،‬ﻗﺪ ﻳﺪﺧﻞ ﺗﻨﺎﻭﻝ‬ ‫ﺍﻟﻘﻠﺔﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻨﻴﻮﻛﻠﻴﻮﺗﻴﺪﺍﺕ (‪ Mcl‬ﻭ ‪ Mincle‬ﻭ ‪ .(98)Dectins‬ﺃﻣﺎ ﺑﺎﻟﻨﺴﺒﺔ‬
‫‪ MAMPS‬ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ‪ ،‬ﻣﺜﻞ ‪ ،LPS‬ﺇﻟﻰ ﺍﻟﺪﻭﺭﺓ ﺍﻟﺪﻣﻮﻳﺔ ﻣﻦ ﺧﻼﻝ‬ ‫ﻟﻠﻤﺴﺘﻘﺒﻼﺕ‪ ،TLRs‬ﻓﻬﻲ ﻣﻮﺟﻮﺩﺓ ﻓﻲ ﺍﻟﻀﻔﻴﺮﺓ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﻌﻮﻳﺔ ﻋﻠﻰ ﺃﻱ ﻣﻦ ﺃﺳﻄﺢ‬
‫ﺍﻣﺘﺼﺎﺹﺍﻟﺪﻫﻮﻥ ﺃﻭ ﺍﻟﻜﻴﻠﻮﻣﻜﺮﻭﻧﺎﺕ ﺑﻮﺍﺳﻄﺔ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻈﻬﺎﺭﻳﺔ ﺍﻟﻤﻌﻮﻳﺔ )‪(50‬‬ ‫ﺍﻟﺨﻼﻳﺎ)‪ (TLR1، 2، 4، 5، 6‬ﺃﻭ‪/‬ﻓﻲ )ﺍﻹﻧﺪﻭﺳﻮﻣﺎﺕ ‪ .(100,99) (TLR3، 7، 8، 9‬ﺗﺸﺘﻤﻞ‬
‫ﺇﺛﺎﺭﺓﺍﺳﺘﺠﺎﺑﺔ ﺟﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻄﺮﻳﺔ ﻭﺍﻟﻤﻜﺘﺴﺒﺔ ﻛﻤﺎ ﻫﻮ ﻣﻮﺿﺢ ﻓﻲ ﺍﻟﺜﺪﻳﻴﺎﺕ )‬ ‫‪ MAMPS‬ﺍﻟﻤﻌﺮﻭﻓﺔ ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ ﻭﺍﻟﺘﻲ ﻣﻦ ﺷﺄﻧﻬﺎ ﺗﻨﺸﻴﻂ ﻫﺬﻩ ﺍﻟﻌﻨﺎﺻﺮ ﻋﻠﻰ ‪LPS‬‬
‫‪.(75‬‬ ‫ﺍﻟﺒﻜﺘﻴﺮﻳﺔﺍﻟﻐﺬﺍﺋﻴﺔ‪ ،‬ﻭﺍﻟﺒﺮﻭﺗﻴﻨﺎﺕ ﺍﻟﺪﻫﻨﻴﺔ‪ ،‬ﻭﺍﻟﺰﻳﻤﻮﺯﺍﻥ‪ ،‬ﻭﺍﻟﺒﺎﻳﺠﻠﻴﻜﺎﻥ‪ ،‬ﻭﺍﻟﺒﺒﺘﻴﺪﺍﺕ ﺍﻟﺪﻫﻨﻴﺔ‬
‫ﺍﻟﻤﺆﺳﻴﻠﺔ‪،‬ﻭﺣﻤﺾ ﺍﻟﺪﻫﻦ ﺍﻟﺪﻫﻨﻲ‪ ،‬ﻭﺍﻟﺒﺒﺘﻴﺪﻭﻏﻠﻴﻜﺎﻥ‪ ،‬ﻭﺍﻟﻤﻮﺩﻳﻮﻟﻴﻦ‪ ،‬ﻭﺍﻟﺤﻤﺾ ﺍﻟﻨﻮﻭﻱ‬
‫ﺍﻟﺮﻳﺒﻮﺯﻱﺍﻟﻤﺰﺩﻭﺝ ﻣﻦ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ‪ ،‬ﻭﺍﻟﺠﻠﻴﻜﻮﻟﻴﺒﻴﺪﺍﺕ‪ ،‬ﻭﺍﻟﻔﻴﺒﺮﻳﻨﻮﺟﻴﻦ‪/‬ﺍﻟﻔﺒﺮﻭﻧﻜﺘﻴﻦ‪،‬‬
‫‪2.3‬ﻫﻞ ﻣﻨﺒﻬﺎﺕ ‪PRR-TLR4‬‬ ‫ﻭﺑﺮﻭﺗﻴﻨﺎﺕﺍﻟﺼﺪﻣﺔ ﺍﻟﺤﺮﺍﺭﻳﺔ‪ ،‬ﻭﺣﻤﺾ ﺍﻟﺒﻮﻟﻴﻚ‪ ،‬ﻭﺍﻟﺴﻮﻁ )‪ ssRNA ، ( .(TLR5‬ﻣﻦ ﺃﺻﻞ‬
‫ﺍﻟﺼﺎﻟﺤﺔﻟﻸﻛﻞ ﺳﻤﻮﻡ ﺩﺍﺧﻠﻴﺔ؟‬ ‫ﻣﻴﻜﺮﻭﺑﻲﻭﺍﻟﺤﻤﺾ ﺍﻟﻨﻮﻭﻱ ﺍﻟﻐﻨﻲ ﺑـ ‪ CpG‬ﻏﻴﺮ ﺍﻟﻤﻴﺜﻴﻞ )‪.(104-101‬‬
‫ﻓﻘﻂﻓﻲ ﺣﺎﻟﺔ ﻣﻨﺒﻬﺎﺕ ‪ TLR‬ﻭﺣﺪﻫﺎ‪ ،‬ﻓﻬﻲ ﻣﻮﺟﻮﺩﺓ ﻋﻠﻰ ﻧﻄﺎﻕ ﻭﺍﺳﻊ ﻓﻲ‬
‫ﻫﻞﻧﻘﺘﺮﺡ ﺃﻥ ﺍﻟﺬﻳﻔﺎﻥ ﺍﻟﺪﺍﺧﻠﻲ ﺍﻟﺼﺎﻟﺢ ﻟﻸﻛﻞ ﻳﻤﻜﻦ ﺃﻥ ﻳﻐﻴﺮ ﺍﻟﻤﻨﺎﻋﺔ؟‬ ‫ﺃﻃﻌﻤﺘﻨﺎﻭﻟﻘﺎﺣﺎﺗﻨﺎ ﻛﻤﻮﺍﺩ ﻣﺴﺎﻋﺪﺓ‪ ،‬ﻛﻮﻧﻬﺎ ﻣﺆﻳﺪﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ‪ ،‬ﻣﻊ ﺍﻟﻘﺪﺭﺓ ﻋﻠﻰ‬
‫ﻧﻌﻢ‪،‬ﻟﻘﺪ ﺗﻢ ﺗﻄﺒﻴﻖ ﻣﻤﺎﺭﺳﺔ ﺍﺳﺘﻬﻼﻙ ﺍﻟﺴﻤﻮﻡ ﺍﻟﺪﺍﺧﻠﻴﺔ ﻣﻨﺬ ﻣﺌﺎﺕ ‪ -‬ﺁﻻﻑ‬ ‫ﺗﻌﺰﻳﺰﻋﻴﺎﺭ ﺍﻷﺟﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ‪ ،‬ﻭﺧﻼﻳﺎ ‪ +CD8‬ﻭ‪ ،CD4+ T‬ﻭﻣﺴﺘﻮﻳﺎﺕ‬
‫ﺍﻟﺴﻨﻴﻦ‪،‬ﻗﺒﻞ ﺍﻛﺘﺸﺎﻑ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﻓﻲ ﺍﻟﻄﺐ ﺍﻟﺜﻘﺎﻓﻲ‪ ،‬ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‬ ‫ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ)‪.(-IL-12، TNF‬ﺃ‪،‬ﺍﻹﻧﺘﺮﻓﻴﺮﻭﻥ‪-‬ﺯ‪،‬ﺇﻧﺘﺮﻓﻴﺮﻭﻥ ‪ 6‬ﻭﺍﻟﻨﻮﻉ ﺍﻷﻭﻝ‬
‫ﺳﺒﻴﺮﻭﻟﻴﻨﺎﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ‪ ،‬ﻭﺍﻟﻜﻠﻮﺭﻳﻼ‪ ،‬ﻭﺍﻟﻄﺤﺎﻟﺐ ﺍﻟﺒﺤﺮﻳﺔ‪ ،‬ﻭﻋﺸﺐ ﺍﻟﺒﺤﺮ‪.‬‬ ‫ﺇﻧﺘﺮﻓﻴﺮﻭﻥ(‪ ،‬ﻛﻴﻤﻮﻛﻴﻨﺎﺕ )ﺑﺮﻭﺗﻴﻦ ﺟﺎﺫﺏ ﻛﻴﻤﻴﺎﺋﻲ ﻭﺣﻴﺪ ﺍﻟﺨﻠﻴﺔ ‪-1/ CCL2) 1-‬‬
‫ﻫﻨﺎﻙﺍﺭﺗﺒﺎﻙ ﻫﺎﺋﻞ ﻳﺤﻴﻂ ﺑﻤﺼﻄﻠﺢ "ﺍﻟﺬﻳﻔﺎﻥ ﺍﻟﺪﺍﺧﻠﻲ" ﻷﻧﻪ ﺗﺴﻤﻴﺔ ﺧﺎﻃﺌﺔ‪.‬‬ ‫‪ ،(MCP‬ﺑﺮﻭﺗﻴﻨﺎﺕ ﺍﻟﺘﻬﺎﺑﺎﺕ ﺍﻟﺒﻼﻋﻢ )‪-MIP‬ﺃ‪-1/‬ﺏ(‪ NF-‬ﻣﻦ ﺧﻼﻝ ﺍﻟﺘﻨﺸﻴﻂ‬
‫ﻣﺼﻄﻠﺢ"ﺍﻟﺴﻤﻮﻡ ﺍﻟﺪﺍﺧﻠﻴﺔ" ﺍﻟﻴﻮﻡ ﻫﻮ ﻣﺼﻄﻠﺢ ﻣﻔﺘﻮﺡ ﻭﻏﺎﻣﺾ ﻟﻮﺻﻔﻪﺍﻟﺠﻤﻴﻊ‬ ‫ﺍﻟﻨﺴﺨﻲﻟـ (‪ )IRAK، MAPK‬ﻭﻣﺴﺎﺭﺍﺕ ﺍﻹﺷﺎﺭﺍﺕ ﺫﺍﺕ ﺍﻟﺼﻠﺔ ‪، IL-1R(،‬‬
‫ﺟﺪﺍﺭﺍﻟﺨﻠﻴﺔ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ ﺳﺎﻟﺒﺔ ﺍﻟﺠﺮﺍﻡ ‪ LPS‬ﻣﻊ ﺍﻟﺪﻫﻦ ‪" A‬ﺍﻟﺴﻢ" ﺟﻤﻴﻌﻬﺎ ﺣﻴﺔ‬ ‫‪MyD88‬ﻙﺏ ﻭ‪ .(43,42) AP-1‬ﺗﺸﻤﻞ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻤﺴﺎﻋﺪﺓ ‪PRR TLR‬‬
‫ﺃﻭﻣﻴﺘﺔ‪ ،‬ﻭﺟﻤﻴﻌﻬﺎ ﻣﺴﺒﺒﺔ ﻟﻸﻣﺮﺍﺽ ﺃﻭ ﻏﻴﺮ ﻣﻤﺮﺿﺔ‪ ،‬ﻭﺷﺎﻣﻠﺔ ﻟﻜﻞ ﻧﻮﻉ ﻣﻦ‬ ‫ﺍﻟﻤﺴﺘﺨﺪﻣﺔﻓﻲ ﺍﻟﻠﻘﺎﺣﺎﺕ ﻣﻨﺒﻬﺎﺕ ((‪oligodeoxynucleotides )ODN‬‬
‫ﺃﻧﻮﺍﻉﺍﻟﺘﺒﺎﻳﻦ ﺍﻟﺘﺼﻨﻴﻔﻲ ﻭﺗﻌﺪﺩ ﺍﻟﺴﻜﺎﺭﻳﺪ ﻓﻲ ﺟﺪﺍﺭ ﺍﻟﺨﻠﻴﺔ‪ .‬ﻣﺼﻄﻠﺢ ﺍﻟﺴﻤﻮﻡ‬ ‫‪ - TLR9 )CpG‬ﻟﻘﺎﺡ ﻓﻴﺮﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺪ ‪B Heplisav-B، MGN1703‬‬
‫ﺍﻟﺪﺍﺧﻠﻴﺔﻫﻮ ﺃﺣﺪ ﺍﻟﻤﺼﻄﻠﺤﺎﺕ ﺍﻟﻤﺴﺘﺨﺪﻣﺔ ﻟﻮﺻﻒ ﺍﻟﻌﺪﻭﻯ ﺍﻟﻘﺎﺗﻠﺔ )ﺍﻹﻧﺘﺎﻥ(‬ ‫ﻟﻠﻘﺎﺣﺎﺕﺍﻟﺴﺮﻃﺎﻥ؛ ‪) TLR3‬ﻣﺸﺘﻘﺎﺕ ‪®poly-IC/ICLC )Ampligen‬‬
‫ﻣﻊﻓﺸﻞ ﺍﻷﻋﻀﺎء ﺍﻟﻤﺘﻌﺪﺩﺓ ﻭﺍﻟﻤﻮﺕ‪ ،‬ﻟﻠﻤﻨﺘﺠﺎﺕ ﺍﻟﺼﺤﻴﺔ ﺍﻟﺘﻲ ﺗﺒﺎﻉ ﺑﺪﻭﻥ‬ ‫ﻫﻴﻠﺘﻮﻧﻮﻝ®(( ﻟﻠﻘﺎﺣﺎﺕ ﺍﻟﺴﺮﻃﺎﻥ ﻭﻓﻴﺮﻭﺱ ﻧﻘﺺ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﺒﺸﺮﻳﺔ‪) TLR4 ،‬‬
‫ﻭﺻﻔﺔﻃﺒﻴﺔ ﻭﺍﻟﺘﻲ ﻳﺘﻨﺎﻭﻟﻬﺎ ﻣﻠﻴﺎﺭﺍﺕ ﺍﻟﻤﺴﺘﻬﻠﻜﻴﻦ ﻓﻲ ﺟﻤﻴﻊ ﺃﻧﺤﺎء ﺍﻟﻌﺎﻟﻢ ﻛﻞ‬ ‫ﻧﺎﻫﺾﻣﺸﺘﻖ ﻟﻠﺪﻫﻮﻥ ﺃﺣﺎﺩﻳﺔ ﺍﻟﻔﻮﺳﻔﻮﺭﻳﻞ ‪ ،AS04‬ﻟـ ‪) Cervarix‬ﻓﻴﺮﻭﺱ‬
‫ﻳﻮﻡ‪،‬ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﻛﻤﺎ ﺫﻛﺮﻧﺎ ﺳﺎﺑﻘﺎً‪LPS :‬ﺍﻟﻤﻔﺼﻠﻴﺎﺕ ﺑﻼﺗﻨﺴﻴﺲ )‬ ‫ﺍﻟﻮﺭﻡﺍﻟﺤﻠﻴﻤﻲ ﺍﻟﺒﺸﺮﻱ ﺍﻟﺒﺸﺮﻱ(‪ Shingrix®Hep B )Fendrix/‬ﻟﻠﻘﺎﺡ‬
‫ﺳﺒﻴﺮﻭﻟﻴﻨﺎ(‪ .‬ﺍﻟﺴﻤﻮﻡ ﺍﻟﺪﺍﺧﻠﻴﺔ ﻫﻲ ﻓﻲ ﻛﺜﻴﺮ ﻣﻦ ﺍﻟﺤﺎﻻﺕ ﻣﻌُﺪﻻِّﺕ ﻣﻨﺎﻋﻴﺔ‬ ‫ﺍﻟﻬﺮﺑﺲﺍﻟﻨﻄﺎﻗﻲ ‪ )®(، AS01‬ﺭﻳﺴﻴﻜﻮﻳﻤﻮﺩ )ﺇﻳﻤﻴﺪﺍﺯﻭﻛﻮﻳﻨﻮﻟﻴﻦ( ﺍﻟﻤﺴﺘﺨﺪﻡ ﻣﻊ‬
‫ﺩﺍﺧﻠﻴﺔ)ﻭﻟﻴﺴﺖ ﺳﻤﻮﻣﺎً( ﻭﻟﻬﺎ ﺁﺛﺎﺭ ﻣﻔﻴﺪﺓ ﺗﺒﺮﺭ ﺍﺳﺘﺨﺪﺍﻣﻬﺎ ﻛﻠﻘﺎﺣﺎﺕ ﻣﻀﺎﺩﺓ‬ ‫ﻟﻘﺎﺣﺎﺕﺍﻟﺴﺮﻃﺎﻥ) ‪ TLR7‬ﺃﻭ (‪ entolimod‬ﺃﻭ ‪ Mobilan‬ﻣﺸﺘﻘﺎﺕ ﻓﻼﺟﻴﻠﻴﻦ‬
‫ﻟﻠﺴﺮﻃﺎﻥﻗﺎﺋﻤﺔ ﻋﻠﻰ ﺍﻟﺒﺒﺘﻴﺪ )‪ .(101‬ﺗﻈﻬﺮ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻟﺪﺭﺍﺳﺎﺕ ﺃﻥ ﺍﻟﺬﻳﻔﺎﻥ‬ ‫ﻣﺜﻞ) ‪ TLR 5‬ﻟﻠﻘﺎﺣﺎﺕ ﺍﻷﻧﻔﻠﻮﻧﺰﺍ(‪ ،‬ﺃﻭ ﻣﻨﺒﻬﺎﺕ ‪، glucopyranosyl Lipid A‬‬
‫ﺍﻟﺪﺍﺧﻠﻲﻓﻲ ﻧﻤﺎﺫﺝ ﺍﻟﺴﺮﻃﺎﻥ ﺫﺍﺕ ﺍﻟﻜﻔﺎءﺓ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻳﻤﻜﻦ ﺃﻥ ﻳﻌﻜﺲ ﺍﻵﺛﺎﺭ‬ ‫‪.(42‬‬
‫ﺍﻟﺴﻠﺒﻴﺔﻟﻠﻌﻼﺝ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ ﻭﻳﻘﻠﺺ‪/‬ﻓﻲ ﺑﻌﺾ ﺍﻷﺣﻴﺎﻥ ﻳﺴﺘﺄﺻﻞ ﺍﻷﻭﺭﺍﻡ‬ ‫ﻓﻲﺣﻴﻦ ﺃﻥ ﺍﻟﺤﺸﺮﺍﺕ ﺍﻟﻤﻴﺘﺔ ﻓﻲ ﺍﻷﺩﻭﻳﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﻟﺪﻳﻨﺎ ﻟﻢ ﻳﺘﻢ‬
‫ﺍﻟﺒﺸﺮﻳﺔﺑﻄﺮﻳﻘﺔ ﻛﻤﺎ ﻭﺻﻔﻬﺎ ﻛﻮﻟﻲ )‪ (138-129‬ﻣﻊ ﺍﻟﻘﺪﺭﺓ ﻋﻠﻰ ﺗﻌﺰﻳﺰ ﻧﺸﺎﻁ‬ ‫ﺍﺳﺘﻜﺸﺎﻓﻬﺎﺑﻌﺪ ﺑﻜﻤﻴﺎﺕ ﻛﺒﻴﺮﺓ‪ ،‬ﻓﺈﻥ ﺍﻟﺠﺰﻳﺌﺎﺕ ﺍﻟﻔﻄﺮﻳﺔ ﺗﺨﻀﻊ ﻷﺑﺤﺎﺙ‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﻘﺎﺗﻠﺔ ﺍﻟﻄﺒﻴﻌﻴﺔ ﻭﺗﻨﺸﻴﻂ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺒﻠﻌﻤﻴﺔ ﻭﺗﺤﻔﻴﺰ ﺗﻜﻮﻥ ﺍﻟﺪﻡ ﻓﻲ‬ ‫ﺷﺎﻣﻠﺔ‪،‬ﻛﻤﺎ ﻫﻮ ﺍﻟﺤﺎﻝ ﻓﻲ ﺟﺰء ﺍﻟﺒﺒﺘﻴﺪ ﺯﻳﻤﻮﺳﺎﻥ؛ ﺍﻟﻤﻌﺮﻭﻑ ﺃﻳﻀﺎ ﺑﺎﺳﻢﺏ‪-‬‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﻠﻴﻤﻔﺎﻭﻳﺔ )‪ .(155-139‬ﻭﺇﺫﺍ ﻛﺎﻧﺖ ﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ ﺍﻟﻤﺤﻤﻠﺔ‬ ‫ﺟﻠﻮﻛﺎﻥﻣﺸﺘﻖ ﻣﻦﻓﻄﺮﻳﺎﺕ ﺍﻟﺴﻜﻴﺮﺍء )‪ .(112 -105‬ﻋﻨﺪ ﺗﻨﺎﻭﻟﻪ ﻋﻦ ﻃﺮﻳﻖ‬
‫ﺑـ‪ MAMP‬ﺗﺸﺒﻪ ﺳﻢ ﻛﻮﻟﻲ )‪ ، (156‬ﺛﻢ ﺍﻟﻠﻴﻴﻔﺎﺕ ﺍﻟﻄﻮﻟﻴﺔ ﺍﻟﻤﺘﺠﺎﻭﺭﺓ )‪ (157‬ﻫﻢ‬ ‫ﺍﻟﻔﻢ‪،‬ﺏ‪-‬ﻳﻘﻮﻡ ﺍﻟﺠﻠﻮﻛﺎﻥ ﺑﺘﻨﺸﻴﻂ )ﺍﻟﺨﻼﻳﺎ ‪ ،/(M‬ﻭﺑﻘﻊ ﺑﺎﻳﺮ ﻭﺗﻌﺰﻳﺰ ﺍﻟﺬﻛﺎء‬
‫ﺃﻳﻀﺎًﻣﻦ ﺍﻟﻤﺤﺘﻤﻞ ﺟﺪﺍً ﺃﻥ ﻳﺜﻴﺮﻭﺍ ﺗﻨﺸﻴﻂ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺒﺎﺋﻴﺔ ﺍﻟﻤﺘﺴﺒﺒﺔ ﻓﻲ‬ ‫ﺍﻟﻤﻜﺘﺴﺐﺍﻟﻔﻄﺮﻱ ﻭﺍﻟﻨﻈﺎﻣﻲ )‪ .(109 -107‬ﺁﻟﻴﺔ ﺍﻟﻌﻤﻞ ﻫﺬﻩ ﻟﻬﺎ ﻋﻼﻗﺔ ﻣﺒﺎﺷﺮﺓ‬
‫ﺍﻟﺘﺴﺒﺐﻓﻲ ﺍﻟﺘﺴﺒﺐ )‪ (158‬ﺍﻟﺘﺄﺛﻴﺮ ﻋﻠﻰ ﺍﻟﻨﻈﺎﻡ ﺍﻟﺘﻜﻤﻴﻠﻲ )‪ ، (156‬ﺗﺤﻔﻴﺰ‬ ‫ﺑﺎﻟﻌﻼﺟﺎﺕﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻠﻮﺭﻡ ﻧﻈﺮﺍً ﻷﻧﻬﺎ ﻳﻤﻜﻦ ﺃﻥ ﺗﺜﻴﺮ ﺍﺳﺘﺠﺎﺑﺎﺕ ﺣﺎﺩﺓ ﺗﻌﺰﺯ ‪(1‬‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﺒﻠﻌﻤﻴﺔ ﻟﺘﺤﻠﻞ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺴﺮﻃﺎﻧﻴﺔ )‪ (159‬ﻭﻣﻨﺢ ﺟﻤﻴﻊ ﺍﻟﻔﻮﺍﺋﺪ ﺍﻟﻤﻌﺮﻭﻓﺔ‬ ‫ﺍﺳﺘﻘﻄﺎﺏﺍﻟﻨﻤﻂ ﺍﻟﻈﺎﻫﺮﻱ ﻟﻠﺒﻼﻋﻢ ﻓﻲ ﺍﻟﺒﻼﻋﻢ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻮﺭﻡ )‪ (TAMs‬ﺇﻟﻰ‬
‫ﻟﻤﺤﻔﺰﺍﺕ‪ LPS/TLR4‬ﻭﺍﺳﺘﺨﺪﺍﻣﻬﺎ ﻓﻲ ﺍﻷﺩﻭﻳﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ ﻋﻨﺪ‬ ‫ﺍﻟﺒﻼﻋﻢﺍﻟﻤﻘﺎﺗﻠﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻮﺭﻡ ‪ (2 ، (111,110) M1‬ﺗﻘﻠﻴﻞ ﺣﻤﻞ ﻣﺜﺒﻄﺎﺕ‬
‫ﺗﻨﺎﻭﻟﻬﺎﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ )‪.(66,65,63‬‬ ‫ﻣﻨﺎﻋﺔﺍﻟﻮﺭﻡ ﻣﺜﻞ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻜﺎﺑﺘﺔ ﺍﻟﻤﺸﺘﻘﺔ ﻣﻦ ﺍﻟﻨﺨﺎﻉ ﺍﻟﺸﻮﻛﻲ )‪ (MDSC‬ﺃﻭ‬
‫‪ (3 (112) Tregs‬ﺯﻳﺎﺩﺓ ﺗﻨﺸﻴﻂ ﺧﻼﻳﺎ ‪ CD4)+(، CD8)+( T‬ﻭ‪-IL-2 IFN‬ﺯ‬
‫ﺗﻢﺇﺛﺒﺎﺕ ﻫﺬﺍ ﺍﻟﻤﻔﻬﻮﻡ ﺑﺸﻜﻞ ﺃﻛﺒﺮ ﻣﻦ ﺧﻼﻝ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻟﺪﺭﺍﺳﺎﺕ ﺍﻟﺘﻲ‬ ‫ﺇﺟﺎﺑﺔ)‪ (4 (113‬ﺯﻳﺎﺩﺓ ﺗﻜﻮﻥ ﺍﻟﺪﻡ )‪ (106‬ﺍﻟﻨﻀﺞ ﺍﻟﺴﺮﻳﻊ ﻟﻠﻌﺪﻻﺕ ﻭﺍﻟﺒﻼﻋﻢ‬
‫ﺃﺟﺮﻳﺖﻋﻠﻰ ﺍﻟﺤﻴﻮﺍﻧﺎﺕ ﻭﺍﻟﺒﺸﺮ ﻭﺍﻟﺘﻲ ﺃﻇﻬﺮﺕ ﺃﻥ ﺍﻟﺘﻌﺮﺽ ﻟـ ‪ LPS‬ﻓﻲ ﺍﻟﺤﻴﺎﺓ‬ ‫ﻭﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔ ﻭﺍﻟﺨﻼﻳﺎ ﺍﻟﻘﺎﺗﻠﺔ ﺍﻟﻄﺒﻴﻌﻴﺔ )‪/Dectin/ TLR‬ﺍﻟﻤﺴﺘﻘﺒﻞ‬
‫ﺍﻟﻤﺒﻜﺮﺓﻳﻤﻜﻦ ﺃﻥ ﻳﺤﻔﺰ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﺠﻬﺎﺯﻳﺔ‪ ،‬ﻭﻳﺮﺗﺒﻂ ﻋﻜﺴﻴﺎً ﺑﺤﺪﻭﺙ ﺣﻤﻰ‬ ‫ﺍﻟﻤﻜﻤﻞ‪ (115,114) (CD11b CD18 ،(CR3) 3‬ﻭ ‪ (5‬ﺑﺪء ﺍﺳﺘﻬﺪﺍﻑ ﺍﻟﺨﻼﻳﺎ‬
‫ﺍﻟﻘﺶ‪،‬ﻭﺍﻟﺮﺑﻮ ﺍﻟﺘﺄﺗﺒﻲ‪ ،‬ﻭﺍﻟﺤﺴﺎﺳﻴﺔ ﺍﻟﺘﺄﺗﺒﻴﺔ )‪ .(160‬ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ‪ ،‬ﺗﻢ ﺗﺤﺪﻳﺪ‬ ‫ﺍﻟﺴﺮﻃﺎﻧﻴﺔﺑﺎﺳﺘﺨﺪﺍﻡ ‪ iC3b‬ﻣﻦ ﺃﺟﻞ ﺍﻟﺒﻠﻌﻤﺔ ﻭﺇﺯﺍﻟﺔ ﺍﻟﺘﺤﺒﺐ )‪,114,107,106‬‬
‫‪ ،LPS‬ﻭﻫﻮ ﺫﻳﻔﺎﻥ ﺩﺍﺧﻠﻲ ﻗﻴﺎﺳﻲ‪ ،‬ﺑﺎﻋﺘﺒﺎﺭﻩ ﻣﻨﺒﻬﺎً ﺣﻴﻮﻳﺎً ﻟﺠﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﺔ )‪.(161‬‬ ‫‪ ، (116‬ﻣﺮﺗﺒﻂ ﺑﺎﻧﺨﻔﺎﺽ ﻋﺐء ﺍﻟﻮﺭﻡ ﻓﻲ ﺍﻟﺜﺪﻳﻴﺎﺕ )‪-117,115,114,105‬‬
‫ﻋﻠﻰﻭﺟﻪ ﺍﻟﺘﺤﺪﻳﺪ‪ ،‬ﺛﺒﺖ ﺃﻥ ‪ LPS‬ﺍﻟﻤﺸﺘﻖ ﻣﻦ ﺍﻹﺷﺮﻳﻜﻴﺔ ﺍﻟﻘﻮﻟﻮﻧﻴﺔ ﻳﺜﻴﺮ‬ ‫‪.(119‬‬
‫ﺍﺳﺘﺠﺎﺑﺔﻣﻨﺎﻋﻴﺔ ﻗﻮﻳﺔ ﻋﺒﺮ ﺇﺷﺎﺭﺍﺕ ‪TLR4‬؛ ﻭﻫﺬﺍ ﺑﺪﻭﺭﻩ ﻳﺆﺩﻱ ﺇﻟﻰ ﺇﻃﻼﻕ‬
‫ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕﺍﻟﻤﺆﻳﺪﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ‪ ،‬ﻣﻤﺎ ﻳﺆﺩﻱ ﺇﻟﻰ ﺗﻌﺰﻳﺰ ﺍﻻﺳﺘﺠﺎﺑﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ )‬
‫‪ .(162‬ﺃﻇﻬﺮﺕ ﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﺘﻲ ﺗﺴﺘﻔﻴﺪ ﻣﻦ ‪ LPS‬ﻧﺘﺎﺋﺞ ﻭﺍﻋﺪﺓ ﻓﻲ‬ ‫ﺇﻥﺍﺳﺘﺨﺪﺍﻡ ﻣﻌﺰﺯﺍﺕ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ ﻣﺜﻞ ﺍﻟﺰﻳﻤﻮﺳﺎﻥ ﻳﻤﻜﻦ ﺃﻥ‬
‫ﺍﻟﺪﺭﺍﺳﺎﺕﻗﺒﻞ ﺍﻟﺴﺮﻳﺮﻳﺔ ﻭﺍﻟﺴﺮﻳﺮﻳﺔ‪ .‬ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﺗﻢ ﺍﺳﺘﺨﺪﺍﻡ ‪) MPL‬‬ ‫ﻳﺆﺩﻱﺇﻟﻰ ﺗﻀﺎﻓﺮ ﻓﻌﺎﻟﻴﺔ ﻣﺜﺒﻄﺎﺕ ﻧﻘﺎﻁ ﺍﻟﺘﻔﺘﻴﺶ‪ ،‬ﺣﻴﺚ ﻳﺆﺩﻱ ﺭﻓﻊ ﺍﻟﻘﺪﻡ ﻋﻦ‬
‫ﺍﻟﺪﻫﻮﻥﺍﻷﺣﺎﺩﻱ ﺍﻟﻔﻮﺳﻔﻮﺭﻳﻞ ‪ ،(A‬ﻭﻫﻮ ﺃﺣﺪ ﻣﺸﺘﻘﺎﺕ ‪ ،LPS‬ﺑﻨﺠﺎﺡ ﻛﻤﺴﺎﻋﺪ‬ ‫ﺍﻟﺤﺎﺟﺰﺍﻟﻤﺜﺒﻂ ﻟﻠﻤﻨﺎﻋﺔ ﻟﻠﻮﺭﻡ )ﻣﺜﺒﻄﺎﺕ ﻧﻘﺎﻁ ﺍﻟﺘﻔﺘﻴﺶ ﺍﻟﻤﻨﺎﻋﻴﺔ( ﺟﻨﺒﺎً ﺇﻟﻰ‬
‫ﻓﻲﺍﻟﻠﻘﺎﺣﺎﺕ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ )‪ .(163 ,162‬ﻋﻠﻰ ﺍﻟﺮﻏﻢ ﻣﻦ ﻫﺬﻩ‬ ‫ﺟﻨﺐﻣﻊ ﺍﻟﻘﺪﻡ ﺍﻟﺜﺎﻧﻴﺔ ﻋﻠﻰ ﺗﺴﺮﻳﻊ "ﺗﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ" ﺇﻟﻰ ﺗﻮﻓﻴﺮ ﻣﻴﺰﺓ ﻋﻼﺟﻴﺔ‪) .‬‬
‫ﺍﻟﺘﻄﻮﺭﺍﺕ‪،‬ﻓﺈﻥ ﺇﻣﻜﺎﻧﺎﺕ ﺍﻟﺤﺸﺮﺍﺕ ﺍﻟﻤﻴﺘﺔ‪ ،‬ﻭﺧﺎﺻﺔ ﺳﻤﻮﻣﻬﺎ ﺍﻟﺪﺍﺧﻠﻴﺔ‪ ،‬ﻓﻲ‬ ‫‪ )121,120,115‬ﻭﺍﻟﺘﻲ ﺗﻨﺘﻘﻞ ﺑﻌﺪ ﺫﻟﻚ ﺇﻟﻰ ﺍﻟﻌﻘﺪﺓ ﺍﻟﻠﻴﻤﻔﺎﻭﻳﺔ ﺍﻟﻤﺴﺎﺭﻳﻘﻴﺔ ‪،‬‬
‫ﺍﻟﻌﻼﺟﺎﺕﻭﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻻ ﺗﺰﺍﻝ ﻏﻴﺮ ﻣﺴﺘﻜﺸﻔﺔ ﺇﻟﻰ ﺣﺪ ﻛﺒﻴﺮ‪ .‬ﻛﺎﻥ‬ ‫(‪ )APCs‬ﺇﻟﻰ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻤﻤﺜﻠﺔ ﻟﻠﻤﺴﺘﻀﺪ ‪ M‬ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ )ﺍﻟﺰﻳﻤﻮﺟﻴﻦ ﺃﻭ ﻏﻴﺮﻩ‬
‫ﺍﻟﻌﺎﺋﻖﺍﻷﺳﺎﺳﻲ ﻫﻮ ﺍﻟﺘﺼﻮﺭ ﺍﻟﺘﻘﻠﻴﺪﻱ ﻟﻠﺴﻤﻮﻡ ﺍﻟﺪﺍﺧﻠﻴﺔ ﻛﻤﻮﺍﺩ ﺿﺎﺭﺓ ﻣﺮﺗﺒﻄﺔ‬ ‫( ﺍﻟﺘﻲ ﺗﺼﻞ ﺇﻟﻰ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ ﻣﻦ ﺷﺄﻧﻬﺎ ﺃﻥ ﺗﺜﻴﺮ ﻧﻘﻞ ﺑﻴﺎﻧﺎﺕ ﻣﺴﺘﻀﺪﺍﺕ‬
‫ﺑﺄﻣﺮﺍﺽﻣﺜﻞ ﺍﻹﻧﺘﺎﻥ‪ .‬ﻭﻟﺬﻟﻚ‪ ،‬ﻓﺈﻥ ﺇﻣﻜﺎﻧﺎﺕ ﺍﻟﺒﻖ ﺍﻟﻤﻴﺖ ﻓﻲ ﺍﻟﻌﻼﺟﺎﺕ ﻭ‬ ‫ﺍﻟﻌﺪﻭﻣﻦ ﺧﻼﻝ ﺍﻟﺨﻼﻳﺎ ‪ (122(. MAMPS‬ﺍﻟﻤﺼﺎﺣﺒﺔ ﻟﻠﺼﻔﻴﺤﺔ ﺍﻟﻤﺨﺼﻮﺻﺔ‬
‫‪ APC‬ﺍﻟﺸﺠﻴﺮﻱ‬

‫ﺍﻧﺨﻔﺎﺽﻓﻲ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻜﺎﺑﺘﺔ ﺍﻟﻤﺸﺘﻘﺔ ﻣﻦ ﺍﻟﻨﺨﺎﻉ ﺍﻟﺸﻮﻛﻲ‪ ،‬ﻭﺍﻟﺨﻼﻳﺎ ‪،Tregs‬‬ ‫ﺍﻟﻌﻼﺝﺍﻟﻤﻨﺎﻋﻲ ﻳﺘﻄﻠﺐ ﺍﻟﻤﺰﻳﺪ ﻣﻦ ﺍﻻﺳﺘﻜﺸﺎﻑ‪ .‬ﻳﺠﺐ ﺃﻥ ﺗﺮﻛﺰ ﺍﻟﺪﺭﺍﺳﺎﺕ‬
‫ﻭﺍﻟﺘﻲﺗﺴﺎﻫﻢ ﺟﻤﻴﻌﻬﺎ ﻓﻲ ﺗﻘﻠﻴﻞ ﻋﺐء ﺍﻟﻮﺭﻡ )‪ .(188-186‬ﺗﺮﺗﺒﻂ ﻫﺬﻩ‬ ‫ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔﻋﻠﻰ ﻛﺸﻒ ﺁﻟﻴﺎﺕ ﺗﻌﺪﻳﻞ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻤﺤﺪﺩﺓ ﻟﻠﺴﻤﻮﻡ ﺍﻟﺪﺍﺧﻠﻴﺔ‬
‫ﺍﻻﺳﺘﺠﺎﺑﺎﺕﺃﻳﻀﺎً ﺑﺸﻜﻞ ﻣﺒﺎﺷﺮ ﺑﺎﻟﻤﺮﺣﻞ ﺍﻟﻮﻇﻴﻔﻲ ﻻﺳﺘﺠﺎﺑﺔ ﻣﺤﻮﻝ ﻣﺴﺘﻘﺒﻞ‬ ‫ﻭﺍﻟﻤﻜﻮﻧﺎﺕﺍﻷﺧﺮﻯ ﻟﻠﺤﺸﺮﺍﺕ ﺍﻟﻤﻴﺘﺔ ﻭﺗﻄﺒﻴﻘﺎﺗﻬﺎ ﺍﻟﻤﺤﺘﻤﻠﺔ ﻓﻲ ﻋﻼﺝ ﺃﻣﺮﺍﺽ‬
‫‪ .(190,189,133) TLR4/ Myd88‬ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﺗﻈﻬﺮ ﺍﻟﻔﺌﺮﺍﻥ ‪TLR4‬‬ ‫ﻣﺜﻞﺍﻟﺴﺮﻃﺎﻥ‪ .‬ﻭﻣﻊ ﺍﻟﺘﻘﺪﻡ ﺍﻟﺘﻜﻨﻮﻟﻮﺟﻲ ﻭﻓﻬﻢ ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻷﻣﻌﺎء‪ ،‬ﻓﺈﻥ‬
‫‪ −/−‬ﻧﻤﻮﺍً ﺳﺮﻳﻌﺎً ﻟﻠﻮﺭﻡ ﺑﻌﺪ ﺍﻟﺘﻠﻘﻴﺢ )‪ (191‬ﻭﺍﻟﺬﻱ ﻳﺘﻮﺍﻓﻖ ﻣﻊ ﺍﻟﻨﻘﺺ ﻓﻲ ﺧﻼﻳﺎ‬ ‫ﺍﺣﺘﻤﺎﻝﺍﻻﺳﺘﻔﺎﺩﺓ ﻣﻦ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ ﺍﻟﻤﻴﺘﺔ ﻓﻲ ﺍﻟﻌﻼﺟﺎﺕ ﺃﻣﺮ ﻭﺍﻋﺪ‪.‬‬
‫‪ CD8 + CD4 + T‬ﻭﺍﻟﺨﻼﻳﺎ ‪ NK‬ﺍﻟﻤﻨﺸﻄﺔ )‪.(192,42‬‬
‫ﻻﺗﺰﺍﻝ ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﺘﻲ ﺗﺤﺎﻓﻆ ﻋﻠﻰ ﺍﻟﻨﻤﻂ ﺍﻟﻈﺎﻫﺮﻱ ‪ M2‬ﻣﺤﻞ ﻧﻘﺎﺵ‪،‬‬

‫ﻭﻟﻜﻦﻳﻘﺎﻝ ﺇﻧﻬﺎ ﺗﻨﻄﻮﻱ ﻋﻠﻰ ﺍﻟﺘﻌﺮﺽ ﺍﻟﻤﺴﺘﻤﺮ ﻟﻠﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﺍﻟﻤﻨﻄﻠﻘﺔ ﻣﻦ‬ ‫‪3‬ﻣﻨﺒﻬﺎﺕ ‪ LPS/TRL4‬ﻭﻧﻤﺎﺫﺝ‬
‫ﺍﻟﺴﺪﻯ‪/‬ﺍﻟﻮﺭﻡ ﻧﻔﺴﻪ‪ ،‬ﻣﺜﻞ ﻋﺎﻣﻞ ﺍﻟﻤﺴﺘﻘﺒﻞ ‪ E‬ﺍﻟﻘﻤﻌﻲ‪ ،‬ﺍﻟﻬﻴﺎﻟﻮﺭﻭﻧﺎﻥ )‪-193‬‬ ‫ﺍﻟﺴﺮﻃﺎﻥ‬
‫‪ (196‬ﺃﻭ ﻫﻴﻤﻨﺔ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ ﺳﺎﻟﺒﺔ ﺍﻟﺠﺮﺍﻡ ﻓﻲ "ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻮﺭﻡ"‪ ،‬ﻛﻤﺎ ﻳﻈﻬﺮ ﻓﻲ‬
‫ﺳﺮﻃﺎﻥﺍﻷﻗﻨﻴﺔ ﺍﻟﺒﻨﻜﺮﻳﺎﺳﻲ ﺍﻟﻤﻘﺎﻭﻡ ﻟﻠﺠﻴﻤﺴﻴﺘﺎﺑﻴﻦ )‪ .(197‬ﺍﻻﺳﺘﺨﺪﺍﻡ‬ ‫ﺇﺫﺍﻛﺎﻥ ﺇﻋﻄﺎء ‪ LPS‬ﺳﺎﻟﺐ ﺍﻟﺠﺮﺍﻡ )ﻏﻴﺮ ﻣﺤﺪﺩ ﺍﻟﺴﻼﻟﺔ( ﻳﻤﻜﻦ ﺃﻥ ﻳﻘﻠﻞ ﻣﻦ‬
‫ﺍﻟﻌﻼﺟﻲﺍﻟﻤﺴﺘﻘﺒﻠﻲ ﻟﻤﻨﺒﻬﺎﺕ ‪ LPS/TLR4‬ﻳﻤﻜﻦ ﺃﻥ ﻳﻌﺰﺯ ﻓﻌﺎﻟﻴﺔ ﻣﺜﺒﻄﺎﺕ‬ ‫ﻋﺐءﺍﻟﻮﺭﻡ‪ ،‬ﻓﻠﻤﺎﺫﺍ ﺗﻜﻮﻥ ﺍﻷﺩﺑﻴﺎﺕ ﻣﻠﻴﺌﺔ ﺑﺎﻟﺘﻨﺎﻗﺾ؟ ﺗﺒﺪﻭ ﻫﺬﻩ ﺍﻟﺘﻘﺎﺭﻳﺮ‬
‫ﻧﻘﺎﻁﺍﻟﺘﻔﺘﻴﺶ ﺍﻟﻤﻨﺎﻋﻴﺔ )‪ ، (201-198) (ICIs‬ﺯﻳﺎﺩﺓ ﻓﻌﺎﻟﻴﺔ ﺍﻷﺟﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ‬ ‫ﺍﻟﻤﺘﻀﺎﺭﺑﺔﻣﺘﺴﻘﺔ ﻋﻨﺪ ﺗﻨﻈﻴﻤﻬﺎ ﺣﺴﺐ ﻧﻮﻉ ﺍﻟﻨﻤﻮﺫﺝ ﻭﻃﺮﻳﻖ ﺍﻹﺩﺍﺭﺓ‪ .‬ﻋﻠﻰ‬
‫ﻭﺣﻴﺪﺓﺍﻟﻨﺴﻴﻠﺔ )‪) (MAbs‬ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﺗﺮﺍﺳﺘﻮﺯﻭﻣﺎﺏ( )‪ (202‬ﻭﺗﻌﺰﻳﺰ‬ ‫ﺳﺒﻴﻞﺍﻟﻤﺜﺎﻝ‪ ،‬ﻳﺘﻢ ﺍﻹﺑﻼﻍ ﺑﺎﺳﺘﻤﺮﺍﺭ ﻋﻦ ﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﺍﻟﻤﺆﻳﺪﺓ ﻟﻠﻮﺭﻡ ﻟـ ‪ LPS‬ﻓﻲ‬
‫ﻓﻌﺎﻟﻴﺔﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻘﺎﺋﻤﺔ ﻋﻠﻰ ﺍﻟﺒﻼﺗﻴﻦ ﻭﺍﻟﺘﺎﻛﺴﻮﻝ )‪ .(203‬ﺍﻋﺘﺒﺎﺭﺍً‬ ‫ﺍﻟﻨﻤﺎﺫﺝﺍﻟﺤﻴﻮﺍﻧﻴﺔ )ﺍﻟﺘﻲ ﺗﻌﺎﻧﻲ ﻣﻦ ﻧﻘﺺ ﺍﻟﻤﻨﺎﻋﺔ(‪ ،‬ﺃﻭ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺴﺮﻃﺎﻧﻴﺔ‬
‫ﻣﻦﺍﻵﻥ‪ ،‬ﻳﺘﻢ ﺍﺳﺘﺨﺪﺍﻡ ﻣﻨﺒﻬﺎﺕ ‪ TLR4‬ﺑﺸﻜﻞ ﺃﺳﺎﺳﻲ ﻛﻤﻮﺍﺩ ﻣﺴﺎﻋﺪﺓ ﻓﻲ‬ ‫ﺍﻟﻤﻌﺰﻭﻟﺔ‪.‬ﻓﻲ ﺍﻟﻤﺨﺘﺒﺮ )ﺑﺪﻭﻥ ﺯﺭﺍﻋﺔ ﻣﻨﺎﻋﻴﺔ( ﺃﻭ ﻣﻦ ﺧﻼﻝ ﺍﻓﺘﺮﺍﺿﺎﺕ ﻣﺮﺳﻮﻣﺔ‬
‫ﻟﻘﺎﺣﺎﺕﺍﻷﻭﺭﺍﻡ )‪ (207-204‬ﻭﻓﻲ ﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻮﺭﻡ ﺑﺎﻟﺘﺒﻨﻲ )‬ ‫ﻋﻠﻰﻣﺴﺘﻮﻳﺎﺕ ﺗﻌﺒﻴﺮ ﺃﻛﺒﺮ ﻟـ ‪ TLR4‬ﺍﻟﻤﺒُﻠﻎ ﻋﻨﻬﺎ ﻓﻲ ﺍﻟﺴﺮﻃﺎﻥ ﻣﻘﺎﺑﻞ ﺍﻷﻧﺴﺠﺔ‬
‫‪ (208‬ﻭﻛﺬﻟﻚ ﻓﻲ ﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻤﻌﺘﻤﺪﺓ ﻋﻠﻰ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺠﺬﻋﻴﺔ ﺍﻟﺨﺎﺻﺔ‬ ‫ﺍﻟﻤﺠﺎﻭﺭﺓﺍﻟﺼﺤﻴﺔ )‪ .(175-164‬ﻭﻣﻊ ﺫﻟﻚ‪ ،‬ﻳﺘﻢ ﺍﻹﺑﻼﻍ ﺑﺎﺳﺘﻤﺮﺍﺭ ﻋﻦ ﺍﻟﺘﺄﺛﻴﺮﺍﺕ‬
‫ﺑﻤﺴﺘﻀﺪﺍﺕﺍﻟﻮﺭﻡ )‪.(209‬‬ ‫ﺍﻟﻤﻀﺎﺩﺓﻟﻠﻮﺭﻡ ﻟﻤﻨﺒﻬﺎﺕ ‪ LPS/TLR4‬ﻓﻲ ﺍﻟﺤﻴﻮﺍﻧﺎﺕ ﺫﺍﺕ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻜﺎﻣﻠﺔ‪،‬‬
‫ﻭﺗﻈﻬﺮﺍﻷﻏﻠﺒﻴﺔ ﻭﻗﺘﺎً ﺃﻃﻮﻝ ﻟﻠﺒﻘﺎء ﻋﻠﻰ ﻗﻴﺪ ﺍﻟﺤﻴﺎﺓ‪ ،‬ﻭﻣﻐﻔﺮﺓ ﻋﻼﺟﻴﺔ ﻓﻲ ﻧﺴﺒﺔ‬
‫ﻛﺒﻴﺮﺓﻣﻦ ﻣﺠﻤﻮﻋﺎﺕ ﺍﻻﺧﺘﺒﺎﺭ ﺍﻟﻤﺸﺎﺑﻬﺔ ﻟﺴﻤﻮﻡ ﻛﻮﻟﻲ‪ ،‬ﻭﺗﻘﻠﻴﻞ ﺍﻵﺛﺎﺭ ﺍﻟﻀﺎﺭﺓ‬
‫ﻟﻠﻌﻼﺝﺍﻟﻜﻴﻤﻴﺎﺋﻲ ﻭﺍﻹﺷﻌﺎﻉ‪ .‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺍﻟﻤﻘﺎﻭﻣﺔ )‪، (178-176,133-130‬‬
‫‪3.2‬ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻮﺭﻡ‪ :‬ﺣﺎﺟﺰ ﻣﺜﺒﻂ ﻟﻠﻤﻨﺎﻋﺔ‬ ‫ﻭﺗﺰﺩﺍﺩﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﻋﻨﺪ ﺩﻣﺠﻬﺎ ﻣﻊ ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻮﺭﻡ )ﻣﺜﻞ ‪) (G-CSF‬‬
‫‪ .(134‬ﺇﺩﺍﺭﺓ ‪ ،LPS‬ﻋﻨﺪ ﺣﻘﻨﻬﺎ ﻣﺒﺎﺷﺮﺓ ﻓﻲ ﺍﻷﻭﺭﺍﻡ )ﻧﻤﺎﺫﺝ ﺫﺍﺕ ﻛﻔﺎءﺓ ﻣﻨﺎﻋﻴﺔ(‬
‫‪-‬ﺗﺆﺩﻱ ﺇﻟﻰ ﺗﻬﺮﻳﺐ ﻛﻤﻴﺎﺕ ﻛﺒﻴﺮﺓ ﻣﻦ ﺍﻟﺒﻼﻋﻢ ﻭﺍﻟﻌﺪﻻﺕ )‪ (135‬ﻣﻤﺎ ﻳﺸﻴﺮ ﺇﻟﻰ‬
‫ﻟﻘﺪﺟﻠﺐ ﺍﻛﺘﺸﺎﻑ ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻮﺭﻡ ﺗﺤﺪﻳﺎﺕ ﻛﺒﻴﺮﺓ ﻟﻸﺳﺎﺱ ﺍﻟﻤﻔﺎﻫﻴﻤﻲ‬ ‫ﺍﻧﺤﺪﺍﺭﺍﻟﻮﺭﻡ ﺍﻟﻜﺎﻣﻞ ﻭﺍﻟﻜﺎﻣﻞ ﺗﻘﺮﻳﺒﺎً )‪ .(137,136‬ﻓﻲ ﺍﻟﺒﺸﺮ‪ ،‬ﺗﻨﺎﻭﻝ ‪ LPS‬ﻋﻦ‬
‫ﻟﻠﻘﺎﺣﺎﺕﺍﻟﻮﺭﻡ‪ .‬ﻳﺨﻠﻖ ﻫﺬﺍ ﺍﻻﻛﺘﺸﺎﻑ ﻧﻤﻮﺫﺟﺎً ﺃﻗﺮﺏ ﺇﻟﻰ ﻣﻨﺰﻝ ﺩﺍﺧﻞ ﻣﻨﺰﻝ‪.‬‬ ‫ﻃﺮﻳﻖﺍﻟﻔﻢ ﻣﻦ ﺍﻟﻘﻤﺢ )ﺗﻜﺘﻼﺕ ﺑﺎﻧﺘﻮﻳﺎ(ﻳﻈُﻬﺮ ﺍﻟﺘﻌﺎﻓﻲ ﻭﺍﻟﺸﻔﺎء ﻟﺪﻯ ‪ %62‬ﻣﻦ‬
‫ﻳﻤﺜﻞﺍﻟﻤﻨﺰﻝ ﺍﻷﻛﺒﺮ ﺩﻭﺭ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﺒﺸﺮﻱ ﻓﻲ ﺗﻨﻈﻴﻢ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﺠﻬﺎﺯﻳﺔ‪،‬‬ ‫ﻣﺮﺿﻰﺍﻟﺴﺮﻃﺎﻥ )‪ ،(138‬ﻓﻲ ﺣﻴﻦ ﺃﻥ ﺍﻟﻤﺼﺎﺩﺭ ﺍﻷﺧﺮﻯ )ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪،‬‬
‫ﺑﻴﻨﻤﺎﻳﺮﻣﺰ ﺍﻟﻤﻨﺰﻝ ﺍﻷﺻﻐﺮ ﺇﻟﻰ ﺩﻭﺭ ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻮﺭﻡ ﻓﻲ ﺍﻟﺘﺤﻜﻢ ﻓﻲ ﺑﻴﺌﺘﻪ‬ ‫‪LPS‬ﺃﻟﻴﺴﺘﻴﺒﺲ ﺷﺎﻫﻲ(ﻳﻤﻜﻦ ﺃﻥ ﻳﺤﻘﻖ ﺍﻧﺨﻔﺎﺿﺎً ﻓﻲ ﺍﻵﺛﺎﺭ ﺍﻟﺠﺎﻧﺒﻴﺔ ﺍﻟﻤﺮﺗﺒﻄﺔ‬
‫ﺍﻟﻤﺤﻠﻴﺔ‪.‬ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻤﻀﻴﻒ‪ ،‬ﺍﻟﺬﻱ ﻳﺴﺘﻌﻤﺮ ﺇﻟﻰ ﺣﺪ ﻛﺒﻴﺮ ﺍﻷﻧﺴﺠﺔ‬ ‫ﺑﺎﻟﻌﻼﺝﺍﻹﺷﻌﺎﻋﻲ‪/‬ﺍﻟﻜﻴﻤﻴﺎﺋﻲ )‪.(129‬‬
‫ﺍﻟﻤﺨﺎﻃﻴﺔﻟﻠﺘﺠﻮﻳﻒ ﺍﻟﻔﻤﻮﻱ ‪ /‬ﺍﻷﻧﻔﻲ ﻭﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ ﻭﺍﻟﻤﻬﺒﻞ ﻭﺍﻟﺠﻬﺎﺯ‬
‫ﺍﻟﺒﻮﻟﻲﺍﻟﺘﻨﺎﺳﻠﻲ )‪ ،(210,97‬ﺣﺴﺎﺱ ﻟﻠﻌﻮﺍﻣﻞ ﺍﻟﺒﻴﺌﻴﺔ )ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪،‬‬
‫ﺍﻷﺩﻭﻳﺔ‪،‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ ﻭﺍﻟﻌﻼﺝ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ‪ ،‬ﺍﻟﺒﺮﻳﺒﺎﻳﻮﺗﻜﺲ‪،‬‬
‫ﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚ‪،‬ﺍﻟﻜﺤﻮﻝ‪ ،‬ﺍﻟﻨﻈﺎﻡ ﺍﻟﻐﺬﺍﺋﻲ‪ ،‬ﺍﻟﺸﻴﺨﻮﺧﺔ ﺑﺴﺒﺐ ﺍﻹﺟﻬﺎﺩ‪ ،‬ﻭﻣﻤﺎﺭﺳﺔ‬
‫ﺍﻟﺮﻳﺎﺿﺔ( )‪.(213-211‬‬
‫‪3.1‬ﻣﻨﺒﻬﺎﺕ ‪ :LPS/TLR4‬ﺁﻟﻴﺔ ﺍﻟﻌﻤﻞ‬
‫ﻋﻨﺪﻣﺎﺗﺘﻔﻮﻕ ﺍﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﻤﺴﺒﺒﺔ ﻟﻸﻣﺮﺍﺽ ﻋﻠﻰ ﺍﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﻄﺒﻴﻌﻴﺔ‪ ،‬ﻛﻤﺎ‬

‫ﻫﻮﻣﻮﺛﻖ ﻓﻲ ﺁﻻﻑ ﺍﻟﺪﺭﺍﺳﺎﺕ ]ﺍﻟﺘﻲ ﺗﺸﻴﺮ ﺇﻟﻰ ﺍﻟﺘﻐﻴﺮﺍﺕ ﻓﻲ ﺗﻜﻮﻳﻦ‬ ‫ﺗﻈﻞﺍﻵﻟﻴﺔ ﺍﻟﺘﻲ ﻳﻌﻤﻞ ﺑﻬﺎ ‪ LPS‬ﻋﻠﻰ ﺗﻘﻠﻴﻞ ﺣﺠﻢ ﺍﻟﻮﺭﻡ ﻣﻮﺿﻮﻋﺎً ﻟﻠﺒﺤﺚ‬
‫ﺍﻟﻤﺠﺘﻤﻌﺎﺕﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ ﻓﻲ ﺍﻷﻧﺴﺠﺔ ﺍﻟﺨﺒﻴﺜﺔ ﻣﻘﺎﺑﻞ ﺍﻷﻧﺴﺠﺔ ﺍﻟﺴﻠﻴﻤﺔ ﻏﻴﺮ‬ ‫ﺍﻟﻤﺴﺘﻤﺮ‪،‬ﻭﻟﻜﻦ ﻳﻌُﺘﻘﺪ ﻋﻤﻮﻣﺎً ﺃﻧﻬﺎ ﻣﺮﺗﺒﻄﺔ ﺑﺸﻜﻞ ﻭﺛﻴﻖ ﺑﺪﻭﺭﻫﺎ ﺍﻟﺤﺎﺳﻢ ﻓﻲ‬
‫ﺍﻟﺨﺒﻴﺜﺔ[‪ ،‬ﻓﺈﻥ ﺫﻟﻚ ﻳﺰﻳﺪ ﻣﻦ ﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑﺎﻟﺴﺮﻃﺎﻥ )‪ .(216-214,76‬ﻳﻤﻜﻦ‬ ‫ﺗﻨﻈﻴﻢﺍﻟﺨﻼﻳﺎ ﺍﻟﺒﻠﻌﻤﻴﺔ‪ .‬ﺗﺘﻮﺳﻂ ﻋﺪﺓ ﺧﻄﻮﺍﺕ ﺗﺄﺛﻴﺮﺍﺗﻪ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻮﺭﻡ‪(1 :‬‬
‫ﻟﻠﻨﺒﺎﺗﺎﺕﺍﻟﻤﺴﺒﺒﺔ ﻟﻸﻣﺮﺍﺽ ﺍﻟﺘﻲ ﺗﺴﺎﻫﻢ ﻓﻲ ﺍﻹﺻﺎﺑﺔ ﺑﺎﻟﺴﺮﻃﺎﻥ ﺃﻥ ﺗﻨﺘﺸﺮ‬ ‫ﻳﺮﺗﺒﻂ‪ LPS‬ﺃﻭﻻ ًﺑـ ‪ LPS‬ﻭﻳﺮﺗﺒﻂ ﺃﻭﻻ ًﺑﺎﻟﺒﺮﻭﺗﻴﻦ‪/‬ﺍﻟﻤﺤﺴﺲ ‪،(2 (179) CD14‬‬
‫ﻣﺤﻠﻴﺎً)ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﻣﻦ ﺍﻟﻤﻬﺒﻞ ﺇﻟﻰ ﻋﻨﻖ ﺍﻟﺮﺣﻢ(‪ (217‬ﺃﻭ ﻣﻦ ﺍﻟﺠﻬﺎﺯ‬ ‫ﻛﻼﻫﻤﺎﻳﺮﺗﺒﻂ ﺑﻌﺪ ﺫﻟﻚ ﺑﻤﺠﻤﻊ ‪ (3 ، (180) TLR4/MD-2‬ﺍﻟﺬﻱ ﻳﻄﻠﻖ ﺇﺷﺎﺭﺓ‬
‫ﺍﻟﺘﻨﻔﺴﻲﺇﻟﻰ ﺍﻟﺮﺋﺘﻴﻦ )‪ ((218‬ﺃﻭ ﺑﺸﻜﻞ ﺃﻗﺼﻰ ﻣﺜﻞ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ ﺍﻟﺘﻲ ﺗﻨﺸﺄ ﻓﻲ‬ ‫‪ (MyD88،4‬ﻭﻳﺆﺩﻱ ﺇﻟﻰ ﺍﺳﺘﺠﺎﺑﺔ ‪ IFN‬ﻣﻦ ﺍﻟﻨﻮﻉ ‪ ،1‬ﻭ‪ NF-kappaB‬ﻭﺗﻔﻌﻴﻞ‬
‫ﺗﺠﻮﻳﻒﺍﻟﻔﻢ )ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪.‬ﺯ‪ ،.‬ﺑﻮﺭﻓﻴﺮﻭﻣﻮﻧﺎﺱ ﺍﻟﻠﺜﺔ‪ ،‬ﺗﺎﻧﻴﺮﻳﻼ ﻓﻮﺭﺳﻴﺜﻴﺎ‪،‬‬ ‫‪ TAMs‬ﻓﻲ ‪ ،TME‬ﻭﺑﺎﻟﺘﺎﻟﻲ ﺗﺸﻐﻴﻞ ﺍﻟﻨﻤﻂ ﺍﻟﻈﺎﻫﺮﻱ ﻟﻠﻤﻘﺎﺗﻞ ﺍﻟﻤﻀﺎﺩ‬
‫ﻓﻴﻠﻮﻧﻴﻼﺑﺎﺭﻓﻮﻻ‪ ،‬ﻑ‪ .‬ﻧﻮﻛﻠﻴﺎﺗﻮﻡ‪ ،‬ﺑﺎﺭﻓﻴﻤﻮﻧﺎﺱ ﻣﻴﻜﺮﺍ‪،‬ﺍﻟﺦ(‪ ،‬ﺗﻢ ﺍﻟﻌﺜﻮﺭ ﻋﻠﻰ‬ ‫ﻟﻠﺴﺮﻃﺎﻥ‪) M1‬ﺍﻟﻤﺆﻳﺪ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ‪ ،‬ﻭﺍﻟﻤﻀﺎﺩ ﻟﻠﺴﺮﻃﺎﻥ(‪- .‬ﺍﻟﻮﺭﻡ( ﻭﺍﻟﺘﻐﻠﺐ ﻋﻠﻰ‬
‫ﺍﺭﺗﺒﺎﻃﻬﺎﺑﺴﺮﻃﺎﻥ ﺍﻟﻤﺮﻱء )‪ ،(219‬ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ‪ /‬ﺍﻟﻘﻮﻟﻮﻥ )‪(220‬‬ ‫‪) M2‬ﺍﻟﻨﻤﻂ ﺍﻟﻈﺎﻫﺮﻱ ﺍﻟﻤﻀﺎﺩ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ ﺍﻟﻤﺆﻳﺪ ﻟﻸﻭﺭﺍﻡ( )‪.(182,181,7‬‬
‫ﺍﻟﺒﻨﻜﺮﻳﺎﺱ)‪ (221‬ﻭﺍﻟﻜﺒﺪ )‪ .(87‬ﺑﻤﺠﺮﺩ ﺇﻧﺸﺎء ﺍﻟﺴﺮﻃﺎﻥ‪ ،‬ﻳﻤﻜﻦ ﻟﻠﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ‬ ‫ﺍﻟﺸﻜﻞ‪2‬ﻓﻲ ﺍﻟﺤﻴﻮﺍﻧﺎﺕ ﺫﺍﺕ ﺍﻟﻜﻔﺎءﺓ ﺍﻟﻤﻨﺎﻋﻴﺔ‪ ،‬ﻳﺮﺗﺒﻂ ﺍﻻﻧﺘﻘﺎﻝ ﻣﻦ ﺍﻟﻨﻤﻂ‬
‫ﺍﻟﺪﻗﻴﻘﺔﺃﻥ ﺗﺘﺴﻠﻞ ﺇﻟﻰ ﺍﻟﺒﻴﺌﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻟﻠﻮﺭﻡ )‪ ،(TME‬ﻭﺗﻌﻤﻞ ﺑﺸﻜﻞ ﺗﺂﺯﺭﻱ ﻣﻊ‬ ‫ﺍﻟﻈﺎﻫﺮﻱ‪ M2‬ﺇﻟﻰ ‪ M1 TAM‬ﺑﺈﻋﺎﺩﺓ ﺇﻳﻘﺎﻅ ﺍﻻﺳﺘﺠﺎﺑﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﺘﻜﻴﻔﻴﺔ‬
‫ﻣﺠﻤﻮﻋﺎﺕﺍﻟﻜﺮﻳﺎﺕ ﺍﻟﺒﻴﺾ ﺍﻟﻔﺮﻋﻴﺔ ﺍﻟﻤﺮﺷﺤّﺔ ﻟﻠﻮﺭﻡ )‪(LSPs‬؛ ﺍﻟﺒﻼﻋﻢ ﺍﻟﻤﺮﺗﺒﻄﺔ‬ ‫ﻟﻠﻤﻀﻴﻒﻋﺒﺮ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﺘﻲ ﺗﺘﻌﺮﻑ ﻋﻠﻰ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺨﺒﻴﺜﺔ‪ .‬ﻭﻣﻊ ﺫﻟﻚ‪ ،‬ﻻ‬
‫ﺑﺎﻟﻮﺭﻡ)‪ ،(TAMs‬ﺍﻟﻌﺪﻻﺕ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻮﺭﻡ )‪ ،(TANs‬ﺍﻟﺨﻼﻳﺎ ﺍﻟﻜﺎﺑﺘﺔ ﺍﻟﻤﺸﺘﻘﺔ‬ ‫ﺗﺰﺍﻝﺁﻟﻴﺎﺕ ﻫﺬﺍ ﺍﻟﺘﺤﻮﻝ ﻏﻴﺮ ﻣﻔﻬﻮﻣﺔ ﺑﺸﻜﻞ ﺟﻴﺪ )‪ .(186-183,101‬ﺗﺘﺰﺍﻣﻦ‬
‫ﻣﻦﺍﻟﻨﺨﺎﻉ ﺍﻟﺸﻮﻛﻲ )‪CD4+CD25+Foxp3 ،(MDSCs‬‬ ‫ﺍﻷﻧﻤﺎﻁﺍﻟﻈﺎﻫﺮﻳﺔ ﻟـ ‪ M1 TAM‬ﻣﻊ ﺯﻳﺎﺩﺓ ﺗﻨﺸﻴﻂ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﺴﺎﻣﺔ ﻟﻠﺨﻼﻳﺎ‬
‫‪ (+)CD4‬ﻭ‪ ،(+)CD8‬ﻭﺍﻟﺨﻼﻳﺎ ﺍﻟﻘﺎﺗﻠﺔ ﺍﻟﻄﺒﻴﻌﻴﺔ‪ ،‬ﻭﺍﺭﺗﻔﺎﻉ ‪،IFN-gamma‬‬
‫) ﺗﺨﻠﻖ ﺣﺎﺟﺰﺍً ﻗﻮﻳﺎً ﻭﻗﻮﻳﺎً ﻟﻠﻤﻨﺎﻋﺔ ‪.(223,222,87,37+ Tregs‬‬

‫ﺍﻟﺸﻜﻞ‪2‬‬
‫(‪ )NF-‬ﺍﻟﻤﻨﺸﻄَّﺔ ‪ B‬ﻓﻲ ﺍﻟﻤﺠﺎﻝ ﺍﻟﻌﺼﺎﺭﻱ ﺍﻟﺨﻠﻮﻱ‪ ،‬ﻭﻳﻨﺸﻂ ﺇﺷﺎﺭﺍﺕ ﺑﺮﻭﺗﻴﻦ ﻛﻴﻨﺎﺯ ﺍﻟﻤﻨﺸﻂ ﻟﻠﻤﻴﺘﻮﺟﻴﻦ ﻻﺳﺘﻨﺒﺎﻁ ﺇﺯﺍﺣﺔ ﻣﺤُﺴﻦِّ ﺳﻠﺴﻠﺔ ﺍﻟﻌﺎﻣﻞ ﺍﻟﻨﻮﻭﻱ ﻛﺎﺑﺎ ﺍﻟﺨﻔﻴﻒ ﻟﻠﺨﻼﻳﺎ ‪ MyD88‬؛ ﻳﺆﺩﻱ ﺇﻟﻰ ﺗﺠﻨﻴﺪ‬
‫‪ M1‬ﺗﻨﺸﻴﻂ ﺍﻟﻨﻤﻂ ﺍﻟﻈﺎﻫﺮﻱ ﻟﻤﺜﺒﻂ ﺍﻟﻮﺭﻡ ‪LPS TLR4‬ﻙ(‪ )IFN-‬ﺍﺳﺘﺠﺎﺑﺔ ﻣﺆﻳﺪﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ ‪ )CCL2، CCL6، CCL12، CXCL10، CXCL11، CXCL12، CXCL13(،‬ﻭﺗﻨﻈﻴﻢ ﻣﺠﻤﻮﻋﺔ ﻣﻦ ﺍﻟﺠﻴﻨﺎﺕ‬
‫ﺍﻟﻤﺸﺎﺭﻛﺔﻓﻲ ﺗﺠﻨﻴﺪ ﺍﻟﻜﺮﻳﺎﺕ ﺍﻟﺒﻴﺾ (‪B‬ﺯ‪ ،‬ﺗﻨﻒ –ﺃ‪ IFN-،‬ﺃﻭ ﺇﻧﺘﺮﻓﻴﺮﻭﻥ ﻣﻦ ﺍﻟﻨﻮﻉ ﺍﻷﻭﻝ ‪IL-6‬ﺃﻭ ﺍﻹﻧﺘﺮﻓﻴﺮﻭﻥ‪-‬ﺏ(‪،‬ﺗﺤﺮﻳﺾ ‪ iNOS‬ﻭﺇﻧﺘﺎﺝ ‪ [(42)].NO2‬ﺗﻢ ﺇﻧﺸﺎﺅﻫﺎ ﺑﺎﺳﺘﺨﺪﺍﻡ‪BioRender.com‬‬
‫ﺍﻷﻓﺮﺍﺩ‪،‬ﻋﻠﻰ ﻣﺴﺘﻮﻯ ﺍﻟﻌﺎﻟﻢ‪ ،‬ﺍﻟﺬﻳﻦ ﻳﺴﺘﻬﻠﻜﻮﻥ ﺍﻟﻤﻜﻤﻼﺕ ﺍﻟﻐﺬﺍﺋﻴﺔ ﺍﻟﻴﻮﻣﻴﺔ‬ ‫ﻳﻤﻜﻦﺍﻟﺘﻐﻠﺐ ﻋﻠﻰ ﺍﻟﺤﺎﺟﺰ ﺍﻟﻤﺜﺒﻂ ﻟﻠﻤﻨﺎﻋﺔ ﺍﻟﺬﻱ ﻳﺤﻴﻂ ﺑﺎﻷﻭﺭﺍﻡ ﺇﻣﺎ ﻋﻦ‬
‫ﺍﻟﺘﻲﺗﺤﺘﻮﻱ ﻋﻠﻰ ﺍﻟﺨﻤﻴﺮﺓ ﺍﻟﻔﻄﺮﻳﺔ )ﺏ‪-‬ﺟﻠﻮﻛﺎﻥ( ‪ /‬ﻣﻨﺒﻬﺎﺕ ‪MAMP TLR‬‬ ‫ﻃﺮﻳﻖﺍﻟﺘﺪﻣﻴﺮ ﺍﻟﻜﺎﻣﻞ ﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻮﺭﻡ‪ ،‬ﻭﺍﻟﺬﻱ ﻳﻤﻜﻦ ﺃﻥ ﻳﺴﺘﻌﻴﺪ ﺍﻟﻜﻔﺎءﺓ‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ‪.‬ﻫﻨﺎﻙ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻟﻨﺘﺎﺋﺞ ﺍﻟﺮﺋﻴﺴﻴﺔ ﺍﻟﻤﻌﻘﻮﻟﺔ ﻟﻼﺳﺘﺨﺪﺍﻡ ﺍﻟﻴﻮﻣﻲ‬ ‫ﺍﻟﻤﻨﺎﻋﻴﺔ‪،‬ﻭﻳﻘﻠﻞ ﻣﻦ ﻣﺜﺒﻄﺎﺕ ﺍﻟﻤﻨﺎﻋﺔ )‪ ،(MDSCs‬ﻭﻳﻌﺰﺯ ﻭﻇﻴﻔﺔ ‪/CD8+ T‬‬
‫ﺍﻟﻤﺘﻜﺮﺭ‪ (1:‬ﺇﻧﺸﺎء ﺍﻟﺘﺤﻤﻞ ﺍﻟﺒﻴﻮﻟﻮﺟﻲ‪ ،‬ﻭﺍﻟﺬﻱ ﻳﻤﻜﻦ ﺃﻥ ﻳﻮﻓﺮ ﺍﻟﻤﺮﻭﻧﺔ ﺗﺠﺎﻩ‬ ‫‪ CD4+‬ﻣﻦ ﺍﻟﻨﻮﻉ ‪ (221) Th1‬ﺃﻭ ﺗﻌﺰﻳﺰ ﺟﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﺔ )ﺑﺎﺳﺘﺨﺪﺍﻡ ﺍﻟﻌﻼﺟﺎﺕ‬
‫ﺍﻟﺤﺴﺎﺳﻴﺔ)ﻋﻠﻰ ﺳﺒﻴﻞ ﺍﻟﻤﺜﺎﻝ‪ ،‬ﺣﺒﻮﺏ ﺍﻟﻠﻘﺎﺡ( )‪ ،(227‬ﺍﻷﻛﺰﻳﻤﺎ )‪ (228‬ﺃﻭ‬ ‫ﺍﻟﻤﻨﺎﻋﻴﺔ(‪ ،‬ﻋﻠﻰ ﻏﺮﺍﺭ ﻟﻘﺎﺡ ‪ MAMP‬ﺍﻷﺻﻠﻲ ﻣﻦ ﻛﻮﻟﻲ‪ ،‬ﻭﻟﻜﻦ ﻣﻊ ﺧﺼﻮﺻﻴﺔ‬
‫ﻫﺸﺎﺷﺔﺍﻟﻌﻈﺎﻡ )‪ (229‬ﻭﺍﻟﻌﺪﻭﻯ ﻭﺍﻟﺴﺮﻃﺎﻥ )‪ (231 ,230‬ﺃﻭ ‪ (2‬ﺍﻟﺘﻬﺎﺏ ﻣﺰﻣﻦ )‬ ‫ﺃﻛﺒﺮ)‪.(224,90‬‬
‫‪ (233,232‬ﻣﻤﺎ ﻳﺆﺩﻱ ﺇﻟﻰ ﺍﺳﺘﻨﻔﺎﺩ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﻤﻘﺎﻭﻣﺔ ﻟﻠﺤﺮﺍﺭﺓ‪ ،‬ﻭﺗﻨﻈﻴﻢ‬
‫ﻣﺤﻮﺭ)‪ ،(PD-L1)/(PD-1‬ﻭ‪ MDSCs‬ﻭﺗﻌﺰﻳﺰ ﻗﺪﺭﺓ ﺗﻜﻮﻳﻦ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺴﺮﻃﺎﻧﻴﺔ‬
‫ﺑﻮﺳﺎﻃﺔ)‪235,234,27,26‬ﻫﺬﺍ ﻳﺜﻴﺮ ﺳﺆﺍﻻً ﻣﻬﻤﺎً‪ :‬ﻫﻞ ﻳﻤﻜﻦ ﺃﻥ ﻳﺆﺩﻱ ﺗﻨﺎﻭﻝ‬
‫ﺍﻷﻋﺸﺎﺏﺍﻟﻐﻨﻴﺔ ﺑـ ‪ MAMP‬ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ ﺑﺸﻜﻞ ﻣﺘﻜﺮﺭ ﻣﺜﻞ ﻃﺤﺎﻟﺐ ﺍﻟﺒﺤﺮ ‪/‬‬ ‫ﻭﺍﻻﻟﺘﻬﺎﺏﺍﻟﻤﺰﻣﻦ ‪4 MAMPS‬‬
‫ﻋﺸﺐﺍﻟﺒﺤﺮ ﻭﺍﻟﺠﺬﻭﺭ ﺇﻟﻰ ﻛﺒﺖ ﺍﻟﻤﻨﺎﻋﺔ ﺑﺴﺒﺐ ﺍﻻﻟﺘﻬﺎﺏ ﺍﻟﻤﺰﻣﻦ‪ ،‬ﻭﻛﻼﻫﻤﺎ‬
‫ﻳﻤﻜﻦﺃﻥ ﻳﺆﺩﻱ ﺇﻟﻰ ﺍﻹﺻﺎﺑﺔ ﺑﺴﺮﻃﺎﻧﺎﺕ ﺑﺸﺮﻳﺔ؟ ﻓﻲ ﻫﺬﺍ ﺍﻟﺴﻴﺎﻕ‪ ،‬ﻗﺪ ﻳﻜﻮﻥ‬ ‫ﻫﻨﺎﻙﺳﻼﺡ ﺫﻭ ﺣﺪﻳﻦ ﻣﺤﺘﻤﻞ ﻳﺘﻀﻤﻦ ﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﺍﻟﺒﻴﻮﻟﻮﺟﻴﺔ ﻟﻤﻨﺒﻬﺎﺕ‬
‫ﻣﻦﺍﻟﻤﺴﺘﺤﺴﻦ ﺗﺸﺠﻴﻊ ﺗﻨﺎﻭﻝ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ‬ ‫‪ ،LPS/TLR‬ﻭﺍﻟﺘﻲ ﻣﻦ ﻧﺎﺣﻴﺔ ﻗﺪ ﺗﻌﺰﺯ ﺍﻻﺳﺘﺠﺎﺑﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ‪ ،‬ﻭﻣﻦ ﻧﺎﺣﻴﺔ ﺃﺧﺮﻯ‬
‫ﻟﺘﻘﻠﻴﻞﺧﻄﺮ ﺍﻹﺻﺎﺑﺔ ﺑﺎﻟﺴﺮﻃﺎﻥ )‪ .(236,28‬ﻋﻠﻰ ﺍﻟﻨﻘﻴﺾ ﻣﻦ ﺫﻟﻚ‪ ،‬ﻳﻤﻜﻦ‬ ‫ﺗﺴﺘﺨﺪﻡﻓﻲ ﺍﻟﻨﻤﺎﺫﺝ ﺍﻟﺘﺠﺮﻳﺒﻴﺔ ﻟﻺﺻﺎﺑﺔ ﺍﻟﺘﺄﻛﺴﺪﻳﺔ ﺍﻻﻟﺘﻬﺎﺑﻴﺔ‪ .‬ﺑﺸﻜﻞ ﻋﺎﻡ‪ ،‬ﻳﻌﺪ‬
‫ﺭﺑﻂﺗﺤﻔﻴﺰ ‪ TLR-4‬ﺍﻟﻤﺘﻜﺮﺭ ﺑﺎﻟﻌﺪﻭﻯ ﺍﻟﻤﺰﻣﻨﺔ ﻭﺍﻟﺤﺎﻻﺕ ﺍﻻﻟﺘﻬﺎﺑﻴﺔ ﻭﻗﺪ ﻳﻜﻮﻥ‬ ‫ﺗﻨﺎﻭﻝ‪ LPS‬ﺍﻟﻤﺘﻜﺮﺭ ﻓﻲ ﺍﻟﺤﻴﻮﺍﻧﺎﺕ ﻧﻤﻮﺫﺟﺎً ﺛﺎﺑﺘﺎً ﻟﻺﺻﺎﺑﺔ ﺍﻻﻟﺘﻬﺎﺑﻴﺔ ﻟﺘﻘﻴﻴﻢ‬
‫ﻣﻮﺍﻧﻌﺎًﻟﻸﻓﺮﺍﺩ ﺍﻟﺬﻳﻦ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﺃﻣﺮﺍﺽ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﺬﺍﺗﻴﺔ )‪ .(237‬ﻫﺬﻩ ﻫﻲ‬ ‫ﻗﻴﻤﺔﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ )‪ .(226,225‬ﺗﻌﺪ ﺩﺭﺍﺳﺔ ﺍﻟﺘﻨﺎﻗﺾ ﺑﻴﻦ‬
‫ﺍﻟﻘﻀﺎﻳﺎﺍﻟﻤﻠﺤﺔ ﺍﻟﺘﻲ ﺗﺘﻄﻠﺐ ﻣﺰﻳﺪﺍ ﻣﻦ ﺍﻟﺘﺤﻘﻴﻖ ﻣﻦ ﺃﺟﻞ ﺍﻟﻮﺿﻮﺡ‪.‬‬ ‫ﺗﺤﻔﻴﺰﺍﻟﻤﻨﺎﻋﺔ ﻭﺍﻻﻟﺘﻬﺎﺏ ﺍﻟﻤﺰﻣﻦ ﻣﺠﺎﻻً ﺑﺤﺜﻴﺎً ﺿﺮﻭﺭﻳﺎً ﻧﻈﺮﺍً ﻟﻠﻌﺪﺩ ﺍﻟﻜﺒﻴﺮ ﻣﻦ‬

‫ﻗﺪﺭﺓ‪ MOCs‬ﻋﻠﻰ ﺗﻌﺰﻳﺰ ﺍﻟﺪﻓﺎﻉ ﺍﻟﺒﺸﺮﻱ ﺿﺪ ﻣﺴﺒﺒﺎﺕ ﺍﻷﻣﺮﺍﺽ ﻭﺗﺤﺴﻴﻦ‬ ‫‪.5‬ﺍﻟﺨﻼﺻﺔ‬

‫ﻣﺮﺍﻗﺒﺔﺍﻷﻭﺭﺍﻡ‪.‬‬
‫ﺗﺒﺤﺚﻫﺬﻩ ﺍﻟﻤﺮﺍﺟﻌﺔ ﻓﻲ ﺇﻣﻜﺎﻧﺎﺕ ﺍﻟﻤﺮﻛﺒﺎﺕ ﺍﻟﻌﻀﻮﻳﺔ ﺍﻟﺜﺎﺑﺘﺔ ﺍﻟﻤﻌﻄﻠﺔ‬
‫ﻟﻠﺤﺮﺍﺭﺓ‪،‬ﺧﺎﺻﺔ ﻓﻲ ﺍﻟﻨﺒﺎﺗﺎﺕ‪ ،‬ﻟﺘﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ ﻭﺗﺤﺴﻴﻦ ﻧﺘﺎﺋﺞ ﺍﻟﻤﺮﺽ‪.‬‬
‫ﺍﻟﻜﺎﺗﺐﺍﻻﺷﺘﺮﺍﻛﺎﺕ‬ ‫ﺍﻷﻋﺸﺎﺏﺍﻟﻤﺤﺪﺩﺓ ﺍﻟﻤﻌﺰﺯﺓ ﻟﻠﻤﻨﺎﻋﺔ ﻭﻓﻴﺮﺓ ﺑﺎﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﺍﻟﻤﻴﺘﺔ‪ ،‬ﻣﻤﺎ ﻳﺤﻤﻞ‬
‫ﺃﻫﻤﻴﺔﻛﺒﻴﺮﺓ ﻓﻲ ﻣﺴﺎﻋﻲ ﺍﻛﺘﺸﺎﻑ ﺍﻷﺩﻭﻳﺔ ﻟﺘﻄﻮﻳﺮ ﻋﻼﺟﺎﺕ ﻣﻨﺎﻋﻴﺔ ﻟﻠﻮﺭﻡ ﻋﻦ‬
‫ﻟﻘﺪﻗﺪﻡ ﺟﻤﻴﻊ ﺍﻟﻤﺆﻟﻔﻴﻦ ﺍﻟﻤﺪﺭﺟﻴﻦ ﻣﺴﺎﻫﻤﺔ ﻛﺒﻴﺮﺓ ﻭﻣﺒﺎﺷﺮﺓ ﻭﻓﻜﺮﻳﺔ ﻓﻲ‬ ‫ﻃﺮﻳﻖﺍﻟﻔﻢ ﺻﺎﻟﺤﺔ ﻟﻸﻛﻞ‪ .‬ﻳﺠﺐ ﺃﻥ ﺗﺴﺘﻜﺸﻒ ﺍﻷﺑﺤﺎﺙ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ ﺍﻟﻔﺮﺿﻴﺔ‬
‫ﺍﻟﻌﻤﻞ‪،‬ﻭﻭﺍﻓﻘﻮﺍ ﻋﻠﻰ ﻧﺸﺮﻩ‪.‬‬ ‫ﺍﻟﻤﺜﻴﺮﺓﻟﻼﻫﺘﻤﺎﻡ ﻭﻫﻲ ﺃﻥ ﺍﻟﻔﻮﺍﺋﺪ ﺍﻟﺼﺤﻴﺔ ﻟﺒﻌﺾ ﺍﻷﻋﺸﺎﺏ ﻗﺪ ﺗﻜﻮﻥ ﺑﺴﺒﺐ‬
‫ﻛﺘﻠﺘﻬﺎﺍﻟﺤﻴﻮﻳﺔ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ ﺍﻟﻤﻌﻄﻠﺔ ﻭﻟﻴﺲ ﺑﺴﺒﺐ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ‬
‫ﺍﻟﻤﻮﺟﻮﺩﺓﻓﻲ ﺍﻟﻨﺒﺎﺕ؛ ﻭﻫﺬﺍ ﻟﻦ ﻳﺘﻮﺍﻓﻖ ﻓﻘﻂ ﻣﻊ ﺍﻟﻤﺠﺎﻝ ﺍﻷﻭﺳﻊ ﻟﻌﻠﻢ‬
‫ﺍﻟﺘﻤﻮﻳﻞ‬ ‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ‪،‬ﻭﻟﻜﻦ ﺃﻳﻀﺎً ﻣﻊ ﺍﻟﻤﻨﻄﻖ ﺍﻟﺒﺴﻴﻂ ﺍﻟﻤﺘﻤﺜﻞ ﻓﻲ ﺃﻥ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻤﻨﺎﻋﻲ‬
‫ﻳﺘﻔﺎﻋﻞﻣﻊ ﺣﻄﺎﻡ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﺍﻟﻤﺴﺘﻀﺪﻳﺔ ﺍﻷﺟﻨﺒﻴﺔ )‪،(MAMPs‬‬
‫ﺗﻢﺩﻋﻢ ﻫﺬﺍ ﺍﻟﻤﺸﺮﻭﻉ ﻣﻦ ﺧﻼﻝ ﺍﻟﻤﻨﺤﺔ ﺍﻟﺒﺤﺜﻴﺔ ﻟﻤﺮﻛﺰ ‪ FAMU‬ﻟﻠﺘﻔﺎﻭﺗﺎﺕ‬ ‫ﻭﻫﻮﺍﻷﺳﺎﺱ ﻟﺘﻄﻮﻳﺮ ﺍﻟﻠﻘﺎﺡ ﻭﺍﻟﻤﻮﺍﺩ ﺍﻟﻤﺴﺎﻋﺪﺓ‪ .‬ﻭﻋﻠﻰ ﺍﻟﺮﻏﻢ ﻣﻦ ﻣﻌﺮﻓﺘﻨﺎ‬
‫ﺍﻟﺼﺤﻴﺔ‪ RCMI 5U54MD007582،‬ﻣﻦ ﺍﻟﻤﻌﺎﻫﺪ ﺍﻟﻮﻃﻨﻴﺔ ﻟﻠﺼﺤﺔ‪.‬‬ ‫ﺍﻟﻤﺘﺰﺍﻳﺪﺓ‪،‬ﻻ ﺗﺰﺍﻝ ﻫﻨﺎﻙ ﻓﺠﻮﺍﺕ ﻛﺒﻴﺮﺓ ﻳﺘﻌﻴﻦ ﻋﻠﻴﻨﺎ ﺍﻛﺘﺸﺎﻓﻬﺎ‪ .‬ﻋﻠﻰ ﺳﺒﻴﻞ‬
‫ﺍﻟﻤﺜﺎﻝ‪،‬ﺍﻷﺑﺤﺎﺙ ﺍﻟﺤﺎﻟﻴﺔ ﺍﻟﺘﻲ ﺗﺮﻛﺰ ﻓﻲ ﺍﻟﻤﻘﺎﻡ ﺍﻷﻭﻝ ﻋﻠﻰ ﻓﻬﺮﺳﺔ ﺍﻟﻜﺎﺋﻨﺎﺕ‬
‫ﺍﻟﺤﻴﺔﺍﻟﺪﻗﻴﻘﺔ ﻓﻲ "ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ ﺃﻭ ﺍﻟﻄﺒﻴﺔ"‪ ،‬ﻏﺎﻟﺒﺎ ﻣﺎ‬
‫ﺗﻀﺎﺭﺏﺍﻟﻤﺼﺎﻟﺢ‬ ‫ﺗﻜﻮﻥﺩﻭﻥ ﺍﻟﻨﻈﺮ ﻓﻲ ﺍﻵﺛﺎﺭ ﺍﻟﺼﺤﻴﺔ ﺍﻟﻤﺤﺘﻤﻠﺔ‪ .‬ﻓﻲ ﺣﻴﻦ ﺃﻧﻨﺎ ﻧﻔﻬﻢ ﺃﻱ‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕﺍﻟﻨﺒﺎﺗﻴﺔ ﺍﻟﺘﻲ ﺗﻨﺠﻮ ﻣﻦ ﻟﻮﺍﺋﺢ ﺳﻼﻣﺔ ﺍﻷﻏﺬﻳﺔ‪ ،‬ﻓﺈﻧﻨﺎ ﺑﺤﺎﺟﺔ ﺇﻟﻰ‬
‫ﻳﻌﻠﻦﺍﻟﻤﺆﻟﻔﻮﻥ ﺃﻥ ﺍﻟﺒﺤﺚ ﺗﻢ ﺇﺟﺮﺍﺅﻩ ﻓﻲ ﻏﻴﺎﺏ ﺃﻱ ﻋﻼﻗﺎﺕ ﺗﺠﺎﺭﻳﺔ ﺃﻭ‬ ‫ﻣﻌﺮﻓﺔﺷﺎﻣﻠﺔ ﻋﻦ ‪ MAMPS‬ﻣﻦ ‪ MOCS‬ﺍﻟﻤﻌﻄﻠﺔ ﻭﺇﻣﻜﺎﻧﺎﺗﻬﺎ ﻓﻲ ﺗﻌﺰﻳﺰ‬
‫ﻣﺎﻟﻴﺔﻳﻤﻜﻦ ﺗﻔﺴﻴﺮﻫﺎ ﻋﻠﻰ ﺃﻧﻬﺎ ﺗﻀﺎﺭﺏ ﻣﺤﺘﻤﻞ ﻓﻲ ﺍﻟﻤﺼﺎﻟﺢ‪.‬‬ ‫ﺍﻟﻤﻨﺎﻋﺔ‪،‬ﺑﻤﺎ ﻓﻲ ﺫﻟﻚ ﺍﻟﺘﺮﻛﻴﺰﺍﺕ ﻭﺍﻟﺘﺼﻨﻴﻒ‪ ،‬ﻣﻦ ﻣﺴﺒﺒﺎﺕ ﺍﻷﻣﺮﺍﺽ ﺇﻟﻰ ﻏﻴﺮ‬
‫ﻣﺴﺒﺒﺔﻟﻸﻣﺮﺍﺽ‪.‬‬
‫ﻳﻤﻜﻦﺃﻥ ﻳﻜﻮﻥ ﻟﻬﺬﺍ ﺍﻟﺘﺤﻮﻝ ﺍﻟﻨﻤﻮﺫﺟﻲ ﺍﻟﻤﺤﺘﻤﻞ ﺁﺛﺎﺭ ﻛﺒﻴﺮﺓ ﻋﻠﻰ ﻓﻬﻤﻨﺎ‬
‫ﻣﻼﺣﻈﺔﺍﻟﻨﺎﺷﺮ‬ ‫ﻟﻠﺼﺤﺔﺍﻟﻨﺒﺎﺗﻴﺔ ﻭﻟﺘﻄﻮﻳﺮ ﺃﺳﺎﻟﻴﺐ ﻋﻼﺟﻴﺔ ﺟﺪﻳﺪﺓ‪ .‬ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻚ‪ ،‬ﻓﺈﻥ‬
‫ﺍﻟﺨﻠﻔﻴﺔﺍﻟﺘﺎﺭﻳﺨﻴﺔ ﻟﺘﺄﺛﻴﺮ ‪ MOCs‬ﻋﻠﻰ ﺍﻟﻤﻨﺎﻋﺔ‪ ،‬ﻛﻤﺎ ﻳﺘﻀﺢ ﻣﻦ ﺣﺎﻻﺕ ﻣﻐﻔﺮﺓ‬
‫ﺟﻤﻴﻊﺍﻟﻤﻄﺎﻟﺒﺎﺕ ﺍﻟﻮﺍﺭﺩﺓ ﻓﻲ ﻫﺬﻩ ﺍﻟﻤﻘﺎﻟﺔ ﺗﺨﺺ ﺍﻟﻤﺆﻟﻔﻴﻦ ﻓﻘﻂ ﻭﻻ ﺗﻤﺜﻞ‬ ‫ﺍﻟﻮﺭﻡﺍﻟﺘﻠﻘﺎﺋﻲ ﺑﺴﺒﺐ ﺃﻣﺮﺍﺽ ﺍﻟﺤﻤﻰ ﺍﻟﺤﺎﺩﺓ‪ ،‬ﺗﻀﻊ ﺍﻷﺳﺎﺱ ﻟﻠﺘﺤﻘﻴﻖ ﻓﻲ‬
‫ﺑﺎﻟﻀﺮﻭﺭﺓﺍﺩﻋﺎءﺍﺕ ﺍﻟﻤﻨﻈﻤﺎﺕ ﺍﻟﺘﺎﺑﻌﺔ ﻟﻬﻢ‪ ،‬ﺃﻭ ﺍﺩﻋﺎءﺍﺕ ﺍﻟﻨﺎﺷﺮ ﻭﺍﻟﻤﺤﺮﺭﻳﻦ‬ ‫ﺍﻹﻣﻜﺎﻧﺎﺕﺍﻟﻌﻼﺟﻴﺔ ﻟـ ‪ MOCs‬ﻓﻲ ﺍﻟﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ ﻟﻠﺴﺮﻃﺎﻥ‪ .‬ﻭﻫﺬﺍ ﻟﺪﻳﻪ ﺍﻟﻘﺪﺭﺓ‬
‫ﻭﺍﻟﻤﺮﺍﺟﻌﻴﻦ‪.‬ﺃﻱ ﻣﻨﺘﺞ ﻗﺪ ﻳﺘﻢ ﺗﻘﻴﻴﻤﻪ ﻓﻲ ﻫﺬﻩ ﺍﻟﻤﻘﺎﻟﺔ‪ ،‬ﺃﻭ ﻣﻄﺎﻟﺒﺔ ﻗﺪ ﺗﻘﺪﻣﻬﺎ‬ ‫ﻋﻠﻰﺗﺤﻮﻳﻞ ﻧﻬﺠﻨﺎ ﻓﻲ ﺍﻟﻮﻗﺎﻳﺔ ﻣﻦ ﺍﻷﻣﺮﺍﺽ ﻭﻋﻼﺟﻬﺎ‪ ،‬ﻭﺧﺎﺻﺔ ﻋﻦ ﻃﺮﻳﻖ‬
‫ﺍﻟﺸﺮﻛﺔﺍﻟﻤﺼﻨﻌﺔ ﻟﻪ‪ ،‬ﻏﻴﺮ ﻣﻀﻤﻮﻥ ﺃﻭ ﻣﻌﺘﻤﺪ ﻣﻦ ﻗﺒﻞ ﺍﻟﻨﺎﺷﺮ‪.‬‬ ‫ﺍﻻﺳﺘﺨﺪﺍﻡ‬
‫ﻣﺮﺍﺟﻊ‬
‫‪.12‬ﺟﻮﺩﻣﺎﻥ ﺁﺭ ﺇﺱ‪ ،‬ﺟﻮﻧﺴﻮﻥ ﺩﻱ ﺑﻲ‪ ،‬ﺑﺎﻟﻜﻮ ﺟﻲ ﺇﻡ‪ .‬ﺍﻟﻜﻮﺭﺗﻴﻜﻮﺳﺘﻴﺮﻭﻳﺪﺍﺕ ﻭﺍﻟﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ‬ ‫‪.‬ﻣﺴﺒﺒﺎﺕﺍﻷﻣﺮﺍﺽ ﻭﺍﻟﻮﺭﻡ ﺍﻟﺪﺑﻘﻲ‪ :‬ﺗﺎﺭﻳﺦ ﻣﻦ ﺍﻻﻛﺘﺸﺎﻓﺎﺕ ﻏﻴﺮ ﺍﻟﻤﺘﻮﻗﻌﺔ ﺍﻟﺘﻲ ﺗﺒﺸﺮ ﺑﻌﻼﺝ ﺟﺪﻳﺪ ‪N.‬‬
‫ﻟﻠﺴﺮﻃﺎﻥ‪.‬ﺍﻟﺪﻗﺔ ﺍﻟﺴﺮﻳﺮﻳﺔ ﻟﻠﺴﺮﻃﺎﻥ )‪ .(2023‬ﺩﻭﻯ‪10.1158/1078-0432.CCR-22-3181:‬‬ ‫‪1. Shah AH، Jusue-Torres I، Ivan ME، Komotar RJ، Kasahara‬ﻧﻴﻮﺭﻭﺳﻮﺭﺝ ﻱ )‪(2018‬‬
‫‪.‬ﻛﺒﺖﺍﻟﻤﻨﺎﻋﺔ ﻓﻲ ﺍﻟﻔﺘﺮﺓ ﺍﻟﻤﺤﻴﻄﺔ ﺑﺎﻟﺠﺮﺍﺣﺔ ﻟﺪﻯ ﻣﺮﺿﻰ ﺍﻟﺴﺮﻃﺎﻥ ‪SA، Santiago-Palma J، Ahmad S.‬‬
‫‪ .46–1139:(4)128‬ﺩﻭﻯ‪10.3171/2016.12.JNS162123:‬‬
‫‪ )13. Vallejo R، Hord ED، Barna‬ﺇﻧﻔﻴﺮﻭﻥ ﺑﺎﺛﻮﻝ ﺗﻮﻛﺴﻴﻜﻮﻝ ﺃﻭﻧﻜﻮﻝ ‪ .46–139:(2) 22 (2003J‬ﺩﻭﻯ‪:‬‬ ‫‪.2‬ﻛﻮﻟﻲ ﺩﺑﻠﻴﻮ ﺑﻲ‪ .‬ﺛﺎﻧﻴﺎ‪ .‬ﺍﻟﻤﺴﺎﻫﻤﺔ ﻓﻲ ﻣﻌﺮﻓﺔ ﺍﻟﺴﺎﺭﻛﻮﻣﺎ‪.‬ﺁﻥ ﺳﻮﺭﺝ )‪14 (1891‬‬
‫‪10.1615/JEnvPathToxOncol.v22.i2.70‬‬ ‫)‪.199-220:(3‬‬
‫‪.14‬ﺗﺎﻧﺞ ﺇﺱ‪ ،‬ﺷﻴﺮﻳﺮ ﺇﻡ ﺇﻥ‪ ،‬ﺟﺮﻳﺐ ﺳﻲ‪ ،‬ﻓﺎﻳﺲ ﺗﻲ‪ ،‬ﺟﻮﺳﺘﻞ ﺇﻡ‪ ،‬ﻓﺮﺍﻧﻚ ﺇﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺘﻤﺘﻊ ﻋﻘﺎﺭ‬ ‫‪.3‬ﻓﺎﺗﺸﻴﻠﻲ ﺇﻱ‪ ،‬ﺇﻳﺠﻴﺮﻣﻮﻧﺖ ﺃ‪ ،‬ﺳﻮﺗﻴﺲ ﻓﺮﻳﺪﻣﺎﻥ ﺳﻲ‪ ،‬ﺟﺎﻟﻮﻥ ﺟﻲ‪ ،‬ﺯﻳﺘﻔﻮﺟﻴﻞ ﺇﻝ‪ ،‬ﻛﺮﻭﻣﺮ ﺟﻲ‪،‬‬
‫ﺑﺎﻛﻠﻴﺘﺎﻛﺴﻴﻞﺍﻟﻤﻀﺎﺩ ﻟﻸﻭﺭﺍﻡ ﺑﺨﺼﺎﺋﺺ ﻣﺜﺒﻄﺔ ﻟﻠﻤﻨﺎﻋﺔ ﻳﻤﻜﻦ ﺃﻥ ﺗﻌﺰﺯ ﺑﺸﻜﻞ ﻓﻌﺎﻝ ﺑﻘﺎء ﺍﻟﻄﻌﻢ‬ ‫ﻭﺁﺧﺮﻭﻥ‪.‬ﻣﺮﺍﻗﺒﺔ ﺍﻟﻤﺤﺎﻛﻤﺔ‪ :‬ﻣﻨﺒﻬﺎﺕ ﺍﻟﻤﺴﺘﻘﺒﻼﺕ ﺍﻟﺸﺒﻴﻬﺔ ﻟﻌﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ‪.‬ﻋﻠﻢ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻷﻭﺭﺍﻡ ‪:‬ﺩﻭﻯ‬
‫ﺍﻟﺨﻴﻔﻲﻓﻲ ﻧﻤﻮﺫﺝ ﺯﺭﻉ ﻗﻠﺐ ﺍﻟﻔﺌﺮﺍﻥ‪.‬ﺯﺭﻉ )‪ .23–216:(2) 73 (2002‬ﺩﻭﻯ‪:‬‬ ‫‪10.4161/onci.25238)2013( 2)8(:e25238.‬‬
‫‪10.1097/00007890-200201270-00011‬‬ ‫‪.4‬ﻫﻮﺑﻮﻫﻢ ﻳﻮ‪ .‬ﺍﻟﺤﻤﻰ ﻭﺍﻟﺴﺮﻃﺎﻥ ﻓﻲ ﺍﻟﻤﻨﻈﻮﺭ‪.‬ﺍﻟﺴﺮﻃﺎﻥ ‪(2001) Immunol Immunother‬‬
‫‪.15‬ﺟﻮﺳﺘﻴﺰ ﻓﻴﻼﻧﺖ ‪ ،AA‬ﺯﻳﺘﻮ ﺑﻴﺈﻡ‪ .‬ﺍﻟﻌﺪﻻﺕ‪ .‬ﻓﻲ‪:‬ﺳﺘﺎﺗﺒﻴﺮﻟﺰ‪.‬ﺟﺰﻳﺮﺓ ﺍﻟﻜﻨﺰ )ﻓﻠﻮﺭﻳﺪﺍ )‪.(2023‬‬ ‫‪ .6–391:(8)50‬ﺩﻭﻯ‪10.1007/s002620100216:‬‬
‫‪.‬ﺍﻟﻤﻠﻒﺍﻟﺒﻜﺘﻴﺮﻱ ﻭﺃﻧﻤﺎﻁ ﺍﻟﺤﺴﺎﺳﻴﺔ ﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﻟﺪﻯ ﻣﺮﺿﻰ ﺍﻟﺴﺮﻃﺎﻥ ‪، Belay G، Tigabu A.‬‬ ‫‪.5‬ﻣﻜﺎﺭﺛﻲ ﺇﻱ ﺇﻑ‪ ،‬ﺁﻳﻮﺍ ﺃﻭﺭﺛﻮﺏ ﺟﻴﻪ‪ .‬ﺳﻤﻮﻡ ﻭﻳﻠﻴﺎﻡ ﺏ‪ .‬ﻛﻮﻟﻲ ﻭﻋﻼﺝ ﺍﻷﻭﺭﺍﻡ ﺍﻟﻠﺤﻤﻴﺔ ﻓﻲ ﺍﻟﻌﻈﺎﻡ‬
‫‪16. WorkuM‬ﺑﻠﻮﺱ ﻭﺍﺣﺪ )‪:‬ﺩﻭﻯ ‪10.1371/journal.pone.02669192022( 17)4(:e0266919.‬‬ ‫ﻭﺍﻷﻧﺴﺠﺔﺍﻟﺮﺧﻮﺓ‪.8–26:154 (2006) .‬‬
‫‪.‬ﺍﻟﻌﻼﺝﺍﻟﻮﻗﺎﺋﻲ ﺍﻟﻤﻀﺎﺩ ﻟﻠﻔﻄﺮﻳﺎﺕ ﻣﻘﺎﺑﻞ ﺍﻟﻌﻼﺝ ﺍﻟﺘﺠﺮﻳﺒﻲ ﺍﻟﻤﻀﺎﺩ ﻟﻠﻔﻄﺮﻳﺎﺕ ﻟﻘﻠﺔ ﺍﻟﻌﺪﻻﺕ‬ ‫‪.‬ﻭﺗﺮﺍﺟﻊﺍﻟﻮﺭﻡ‪ :‬ﻣﻜﺎﻥ ﻓﻲ ﺍﻟﺘﺎﺭﻳﺦ ﺃﻭ ﻓﻲ ﺍﻟﻤﺴﺘﻘﺒﻞ ‪JP، van Netten C. Dr William coley‬‬
‫ﺍﻟﺤﻤﻮﻳﺔﻟﺪﻯ ﺍﻷﺷﺨﺎﺹ ﺍﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﺴﺮﻃﺎﻥ ‪H، Makuuchi Y، Tochitani K، Watanabe N.‬‬ ‫‪6. Hoption Cann SA، van Netten‬ﺍﻟﺪﺭﺍﺳﺎﺕ ﺍﻟﻌﻠﻴﺎ ﻣﻴﺪ ‪ .80–672:(938)79 (2003) J‬ﺩﻭﻯ‪:‬‬
‫‪17. Uneno Y، Imura‬ﻣﺮﺍﺟﻌﺔ ﻧﻈﺎﻡ ﻗﺎﻋﺪﺓ ﺑﻴﺎﻧﺎﺕ ﻛﻮﻛﺮﻳﻦ )‪2022( 11)11(:CD013604.‬‬ ‫‪10.1093/postgradmedj/79.938.672‬‬
‫‪.18‬ﺭﺍﻭ ﺇﻝ‪ ،‬ﺗﺸﺎﻧﻎ ﻙ‪ ،‬ﻟﻮﻩ ﺇﺗﺶ‪ ،‬ﻫﻲ ﺇﺱ‪ ،‬ﻟﻲ ﻭﺍﻱ‪ ،‬ﻟﻴﻮ ﺳﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻗﺪﺭﺓ ﺍﻟﻌﻼﻣﺎﺕ ﺍﻻﻟﺘﻬﺎﺑﻴﺔ‬ ‫‪.7‬ﺩﺭﻭﺱ ‪ Orange M، Reuter U، Hobohm U. Coley‬ﺍﻟﺘﻲ ﺗﻢ ﺗﺬﻛﺮﻫﺎ‪ :‬ﺯﻳﺎﺩﺓ ﻋﻼﺝ ﺍﻟﻬﺪﺍﻝ‪.‬‬
‫ﻋﻠﻰﺍﻟﺘﻌﺮﻑ ﻋﻠﻰ ﺍﻟﻌﺪﻭﻯ ﻟﺪﻯ ﻣﺮﺿﻰ ﺍﻟﺴﺮﻃﺎﻥ ﺍﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﺤﻤﻰ ﻋﻨﺪ ﺍﻟﺪﺧﻮﻝ‪.‬ﺍﻟﺪﻗﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ )‬ ‫ﺍﻟﺘﻜﺎﻣﻞﻣﻊ ﺍﻟﺴﺮﻃﺎﻥ )‪ .502-11:(4)15 (2016‬ﺩﻭﻯ‪10.1177/1534735416649916:‬‬
‫‪ .667-77:(5)70 (2022‬ﺩﻭﻯ‪10.1007/s12026-022-09299-4:‬‬ ‫‪.8‬ﻛﻮﻝ ﺩﺑﻠﻴﻮ ﺇﺗﺶ‪ .‬ﺍﻻﻧﺤﺪﺍﺭ ﺍﻟﺘﻠﻘﺎﺋﻲ ﻟﻠﺴﺮﻃﺎﻥ ﻭﺃﻫﻤﻴﺔ ﺍﻟﻌﺜﻮﺭ ﻋﻠﻰ ﺳﺒﺒﻪ‪.‬ﻣﻌﻬﺪ ﺍﻟﺴﺮﻃﺎﻥ ﺍﻟﻮﻃﻨﻲ )‬
‫‪.19‬ﻭﺍﻧﻎ ﻭﻭ‪ ،‬ﻭﻭ ﺇﻝ‪ ،‬ﻟﻮ ﺩﺑﻠﻴﻮ‪ ،‬ﺗﺸﻦ ﺩﺑﻠﻴﻮ‪ ،‬ﻳﺎﻥ ﺩﺑﻠﻴﻮ‪ ،‬ﺗﺸﻲ ﺳﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﺰﻳﺪ ﻋﺪﻳﺪﺍﺕ ﺍﻟﺴﻜﺎﺭﻳﺪ‬ ‫‪.5-9 :44 (1976‬‬
‫ﺍﻟﺪﻫﻨﻴﺔﻣﻦ ﺧﻄﺮ ﺗﻜﺮﺍﺭ ﺍﻹﺻﺎﺑﺔ ﺑﺴﺮﻃﺎﻥ ﺍﻟﻘﻮﻟﻮﻥ ﻭﺍﻟﻤﺴﺘﻘﻴﻢ ﻭﺍﻻﻧﺒﺜﺎﺙ ﺑﺴﺒﺐ ﺗﺤﺮﻳﺾ ﻣﺼﺎﺋﺪ‬ ‫‪.9‬ﺑﻴﺮﺗﺎﻏﻠﻴﺎ ﻓﻲ‪ ،‬ﻣﻮﺭﻳﻠﻲ ﺁﻡ‪ ،‬ﺳﻮﻟﻴﻨﺎﺱ ﺳﻲ‪ ،‬ﺃﻳﻴﻠﻮ ﺇﻡ ﺇﻡ‪ ،‬ﻣﺎﻧﻮﻧﺘﺎ ﺇﺱ‪ ،‬ﺩﻳﻨﺎﺭﻭ ﺇﻥ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬
‫ﺍﻟﻌﺪﻻﺕﺧﺎﺭﺝ ﺍﻟﺨﻠﻴﺔ ﺑﻌﺪ ﺍﻻﺳﺘﺌﺼﺎﻝ ﺍﻟﻌﻼﺟﻲ‪ ).‬ﺍﻟﺴﺮﻃﺎﻥ ﺍﻟﺪﻗﺔ ﻛﻠﻴﻦ ﺃﻭﻧﻜﻮﻝ ‪(2021J‬‬ ‫ﺍﻻﻟﺘﻬﺎﺑﺎﺕﻓﻲ ﻣﺮﺿﻰ ﺳﺮﻃﺎﻥ ﺍﻟﺮﺋﺔ ﺍﻟﺬﻳﻦ ﻳﺨﻀﻌﻮﻥ ﻟﻠﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ ﻭﺍﻟﻌﻼﺝ ﺍﻟﻤﻮﺟﻪ‪ :‬ﻧﻈﺮﺓ ﻋﺎﻣﺔ ﻋﻠﻰ‬
‫‪ .19–2609:(9)147‬ﺩﻭﻯ‪10.1007/s00432-021-03682-8:‬‬ ‫ﺍﻟﺴﻴﻨﺎﺭﻳﻮﺍﻟﺤﺎﻟﻲ‪.‬ﻛﺮﻳﺖ ﺭﻳﻒ ﺃﻭﻧﻜﻮﻝ ﻫﻴﻤﺎﺗﻮﻝ )‪ .184:103954 (2023‬ﺩﻭﻯ‪:‬‬
‫‪.20‬ﻭﻭﻛﺮ ﺁﺭ ﺩﺑﻠﻴﻮ‪ ،‬ﻛﻠﻴﻤﻨﺘﻲ ﺟﻲ ﺳﻲ‪ ،‬ﺑﻴﺘﺮ ﺍﻷﻭﻝ‪ ،‬ﻟﻮﺱ ﺁﺭ ﺟﻲ ﺇﻑ‪ .‬ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻷﻣﻌﺎء ﻗﺒﻞ ﺍﻟﻮﻻﺩﺓ‪ :‬ﻫﻞ‬ ‫‪10.1016/j.critrevonc.2023.103954‬‬
‫ﻧﺤﻦﻣﺴﺘﻌﻤﺮﻭﻥ ﺑﺎﻟﺒﻜﺘﻴﺮﻳﺎ ﻓﻲ ﺍﻟﺮﺣﻢ؟ﻃﺒﻴﺐ ﺃﻃﻔﺎﻝ )‪ 12 (2017‬ﻣﻠﺤﻖ ‪) 1‬ﻣﻠﺤﻖ ‪ .17–3 :(1‬ﺩﻭﻯ‪:‬‬ ‫‪.‬ﻭﺣﻤﺾﺍﻟﻤﻴﻜﻮﻓﻴﻨﻮﻟﻴﻚ ﻳﻌﺰﺯﻭﻥ ﺑﺸﻜﻞ ﻣﺒﺎﺷﺮ ﺗﻜﺎﺛﺮ ﻓﻴﺮﻭﺱ ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﺪ ﺏ ﻭﺍﻟﺘﻌﺒﻴﺮ ﻋﻨﻪ ﻓﻲ ﺍﻟﻤﺨﺘﺒﺮ ‪،‬‬
‫‪10.1111/ijpo.12217‬‬ ‫‪Ruan J، Sun S، Cheng X، Han P، Zhang Y، Sun D. Mitomycin، 5-fluorouracil، leflunomide‬‬
‫‪.21‬ﺟﺮﻳﻜﻮ ﺟﻲ ﺟﻲ‪ ،‬ﺟﺎﻭ ﻭﺍﻱ‪ ،‬ﺟﺎﻭ ﺇﺗﺶ‪ ،‬ﻟﻴﻮ ﻭﺍﻱ‪ ،‬ﺃﺗﻮﻭﺩ ﺑﻲ ﻛﻴﻪ‪ .‬ﻳﺆﺩﻱ ﺗﻨﺎﻭﻝ ﺍﻟﻤﻮﺍﺩ ﺍﻷﻓﻴﻮﻧﻴﺔ ﻗﺒﻞ‬ ‫‪10.‬ﻓﻴﺮﻭﻝ ﺟﻲ )‪ .89:(1)17 (2020‬ﺩﻭﻯ‪10.1186/s12985-020-01339-5:‬‬
‫ﺍﻟﻮﻻﺩﺓﺇﻟﻰ ﺣﺪﻭﺙ ﺗﻐﻴﻴﺮﺍﺕ ﻣﺸﺘﺮﻛﺔ ﻓﻲ ﻣﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻷﻣﻌﺎء ﻟﻸﻡ ﻭﺍﻟﺬﺭﻳﺔ‪ :‬ﺗﺤﻠﻴﻞ ﺃﻭﻟﻲ‪.‬ﺗﻌﺎﻃﻲ‬ ‫‪.‬ﺍﻟﺘﻄﻮﺭﺍﺕﺍﻟﺤﺪﻳﺜﺔ ﻓﻲ ﺍﻟﻮﺻﻔﺎﺕ ﺍﻟﻄﺒﻴﺔ ﺍﻷﻓﻴﻮﻧﻴﺔ ﻟﻸﻟﻢ ﺍﻟﻤﺰﻣﻦ ﻏﻴﺮ ﺍﻟﺴﺮﻃﺎﻧﻲ ‪11. Snidvongs S، Mehta V.‬‬
‫ﺍﻟﻤﺨﺪﺭﺍﺕﻭﺍﻟﻜﺤﻮﻝ )‪ .227:108914 (2021‬ﺩﻭﻯ‪10.1016/j.drugalcdep.2021.108914:‬‬ ‫ﺍﻟﺪﺭﺍﺳﺎﺕﺍﻟﻌﻠﻴﺎ ﻣﻴﺪ ‪ .72–66:(1036)88 (2012) J‬ﺩﻭﻯ‪10.1136/pgmj.2010.112045:‬‬

‫ﺍﻷﺳﻮﺍﻕﻓﻲ ﺟﻨﻮﺏ ﻏﺮﺏ ﺃﻟﻤﺎﻧﻴﺎ‪.‬ﺍﻷﻣﺮﺍﺽ ﺍﻟﻤﻨﻘﻮﻟﺔ ﺑﺎﻟﻐﺬﺍء )‪ .75–269:(4)16 (2019‬ﺩﻭﻯ‪:‬‬ ‫‪.22‬ﺃﻟﻔﺎﺭﻳﺰ ﺟﻴﻪ‪ ،‬ﻓﺮﻧﺎﻧﺪﻳﺰ ﺭﻳﺎﻝ ﺟﻲ ﺇﻡ‪ ،‬ﻏﻮﺍﺭﻧﺮ ﺇﻑ‪ ،‬ﻏﻴﻤﻮﻧﺪ ﺇﻡ‪ ،‬ﺭﻭﺩﺭﻳﻐﻴﺰ ﺟﻲ ﺇﻡ‪ ،‬ﺳﺎﻳﻨﺰ ﺩﻱ ﺑﻴﺒﺎﻭﻥ‬
‫‪10.1089/fpd.2018.2541‬‬ ‫ﺇﻡ‪،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻣﻴﻜﺮﻭﺑﺎﺕ ﺍﻷﻣﻌﺎء ﻭﺍﻟﺼﺤﺔ‪.‬ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ ﺍﻟﻜﺒﺪﻱ )‪ .35 –519:(7)44 (2021‬ﺩﻭﻯ‪:‬‬
‫‪.‬ﺗﻨﺎﻭﻝﻋﺪﻳﺪﺍﺕ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻴﺔ ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ ﻟﻠﻮﻗﺎﻳﺔ ﻣﻦ ﺍﻷﻣﺮﺍﺽ ﺍﻟﻤﺨﺘﻠﻔﺔ‪ :‬ﺍﻟﻔﺎﺋﺪﺓ ﻭﺍﻟﻔﺎﺋﺪﺓ‬ ‫‪10.1016/j.gastre.2021.01.002‬‬
‫‪50. Inagawa H، Kohchi C، Soma G.‬ﺍﻟﺪﻗﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ )‪.6–2431:(7) 31 (2011‬‬ ‫‪.23‬ﺑﻴﺮﻛﻴﻦ ﺇﻡ ﺁﺭ‪ ،‬ﺳﺘﺮﺍﺷﺎﻥ ﺩﻱ ﺑﻲ‪ .‬ﻓﺮﺿﻴﺔ ﺍﻟﻨﻈﺎﻓﺔ ﻟﻠﺤﺴﺎﺳﻴﺔ – ﺍﻟﺤﻤﻞ ﻭﺍﻟﺘﻄﻮﺭ‪.‬ﺍﻟﺤﺴﺎﺳﻴﺔ‬
‫ﺍﻷﻣﺎﻣﻴﺔ)‪ .3:1051368 (2022‬ﺩﻭﻯ‪10.3389/falgy.2022.1051368:‬‬
‫‪.51‬ﺳﻮﺗﻮ‪-‬ﺟﻴﺮﻭﻥ ﺇﻡ ﺟﻲ‪ ،‬ﻛﻴﻢ ﺟﻲ ﺇﻥ‪ ،‬ﺷﻮﺕ ﺇﻱ‪ ،‬ﺗﻬﻤﻴﻦ ﺳﻲ‪ ،‬ﺇﻳﺸﻮﻱ ﺗﻲ‪ ،‬ﻣﻴﻨﺴﺮ ﺗﻲ ﺟﻴﻪ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬ ‫‪.‬ﺍﻻﻓﺘﺘﺎﺣﻴﺔ‪:‬ﺍﻵﺛﺎﺭ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻔﺮﺿﻴﺔ ﺍﻟﻨﻈﺎﻓﺔ ‪24. Pfefferle PI، Postigo I، Garn H.‬ﺍﻟﺠﺒﻬﺔ‬
‫ﻳﻤﺜﻞﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻨﺒﺎﺗﻲ ﺍﻟﺼﺎﻟﺢ ﻟﻸﻛﻞ ﻣﺴﺘﻮﺩﻋﺎً ﺟﻴﻨﻴﺎً ﻣﺘﻨﻮﻋﺎً ﻳﺘﻤﺘﻊ ﺑﺈﻣﻜﺎﻧﺎﺕ ﻭﻇﻴﻔﻴﺔ ﻓﻲ ﺍﻟﻤﻀﻴﻒ‬ ‫ﺍﻟﻤﻨﺎﻋﻴﺔ)‪ .12:732127 (2021‬ﺩﻭﻯ‪10.3389/fimmu.2021.732127:‬‬
‫ﺍﻟﺒﺸﺮﻱ‪.‬ﻣﻨﺪﻭﺏ ﺍﻟﻌﻠﻮﻡ )‪ .24017:(1)11 (2021‬ﺩﻭﻯ‪10.1038/s41598-021-03334-4:‬‬
‫‪.25‬ﻭﻳﺮﻱ ﺇﻱ ﺟﻴﻪ‪ .‬ﺍﺳﺘﻨﻔﺎﺩ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ‪.‬ﻧﺎﺕ ﺇﻳﻤﻮﻧﻮﻝ )‪ .9–492:(6)12 (2011‬ﺩﻭﻯ‪/10.1038:‬ﻧﻲ‪2035.‬‬
‫‪.‬ﻳﺆﺛﺮﺍﻟﺘﺪﺟﻴﻦ ﻋﻠﻰ ﺗﻜﻮﻳﻦ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻓﻲ ﺑﺬﻭﺭ ﺍﻟﺤﺒﻮﺏ ﻭﺗﻨﻮﻋﻬﺎ ﻭﺗﻮﺍﺟﺪﻫﺎ ﺍﻟﻤﺸﺘﺮﻙ‬
‫‪52. Abdlaeva Y، Manirajan Ambika B، Honermeier B، Schnell S، Cardinale M.‬‬ ‫‪.26‬ﻟﻴﻮ ﺳﻲ ﺇﺗﺶ‪ ،‬ﺗﺸﻦ ﺯﻱ‪ ،‬ﺗﺸﻦ ﻛﻴﻪ‪ ،‬ﻟﻴﺎﻭ ﺇﻑ ﺗﻲ‪ ،‬ﺗﺸﻮﻧﻎ ﺳﻲ‪ ،‬ﻟﻴﻮ ﺇﻛﺲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻻﻟﺘﻬﺎﺏ‬
‫) ‪ .86–31:75 (2021J Adv Res‬ﺩﻭﻯ‪10.1016/j.jare.2020.12.008:‬‬ ‫ﺍﻟﻤﺰﻣﻦﺍﻟﻨﺎﺗﺞ ﻋﻦ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻳﻌﺰﺯ ﺳﺮﻃﺎﻥ ﺍﻟﺮﺋﺔ ﺍﻟﻨﺎﺗﺞ ﻋﻦ ﻣﺎﺩﺓ ﻣﺴﺮﻃﻨﺔ ﺍﻟﺘﺒﻎ ﻭﻳﺤﺪﺩ‬
‫‪.53‬ﻫﻴﻐﻴﻨﺰ ﺩ‪ ،‬ﺑﺎﻝ ﺳﻲ‪ ،‬ﺳﻠﻴﻤﺎﻥ ﺁﻱ ﺇﻡ‪ ،‬ﺟﻴﺎ ﺳﻲ‪ ،‬ﺯﻳﺮﻭﻳﺦ ﺗﻲ‪ ،‬ﺩﻭﺩ ﺇﺱ ﺇﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﻄﺒﻴﻖ ﺍﻟﺘﺴﻠﺴﻞ‬ ‫ﻓﻌﺎﻟﻴﺔﺍﻟﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ‪.‬ﺩﻗﺔ ﺍﻟﺴﺮﻃﺎﻥ )‪ .144-57:(1)81 (2021‬ﺩﻭﻯ‪:‬‬
‫ﺍﻟﺤﺮﺍﺭﻱﻋﺎﻟﻲ ﺍﻹﻧﺘﺎﺟﻴﺔ ﻓﻲ ﺗﺤﻠﻴﻞ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻟﻠﺴﻠﻊ ﺍﻟﻐﺬﺍﺋﻴﺔ ﺍﻟﻤﺸﺘﺮﺍﺓ ﻣﻦ ﻣﻨﺎﻓﺬ ﺍﻟﺒﻴﻊ ﺑﺎﻟﺘﺠﺰﺋﺔ‬ ‫‪10.1158/0008-5472.CAN-20-1994‬‬
‫ﺍﻟﺼﻐﻴﺮﺓﻭﺍﻟﻜﺒﻴﺮﺓ ﻓﻲ ﻣﻨﻄﻘﺔ ﺣﻀﺮﻳﺔ ﺑﺎﻟﻮﻻﻳﺎﺕ ﺍﻟﻤﺘﺤﺪﺓ ‪ -‬ﺩﺭﺍﺳﺔ ﺗﺠﺮﻳﺒﻴﺔ‪ .‬ﺍﻟﻐﺬﺍء ﺍﻟﺪﻗﺔ ﻛﺜﺎﻓﺔ ﺍﻟﻌﻤﻠﻴﺎﺕ )‬
‫‪.27‬ﺩﻱ ﻣﻲ‪ ،‬ﻛﺎﻫﻜﻮﻧﻴﻦ ﺑﻲ‪ ،‬ﻟﻴﻮ ﺳﻲ ﺇﺗﺶ‪ ،‬ﺩﻱ ﻭﺍﻱ ﺑﻲ‪ .‬ﺳﺮﻃﺎﻥ ﺍﻟﺮﺋﺔ ﺍﻟﻨﺎﺟﻢ ﻋﻦ ‪ NNK‬ﻭ ‪.LPS‬‬
‫‪ .29-40 :105 (2018‬ﺩﻭﻯ‪10.1016/j.foodres.2017.10.057:‬‬
‫ﻃﺮﻕﺍﻟﺨﻠﻴﺔ ﺑﻴﻮﻝ )‪ .85–163:175 (2021‬ﺩﻭﻯ‪10.1016/bs.mcb.2021.01.002:‬‬
‫‪.‬ﻓﺤﺺﺍﻟﻤﺠﺘﻤﻌﺎﺕ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﺨﺲ ﺍﻟﻬﻨﺪﻱ ﺃﺛﻨﺎء ﻣﻌﺎﻟﺠﺔ ﻣﺎ ﺑﻌﺪ ﺍﻟﺤﺼﺎﺩ ﻋﻠﻰ‬ ‫‪.28‬ﺗﺸﻦ ﺳﻲ ﻭﺍﻱ‪ ،‬ﻛﺎﻭ ﺳﻲ ﺇﻝ‪ ،‬ﻟﻴﻮ ﺳﻲ ﺇﻡ‪ .‬ﺍﻟﻮﻗﺎﻳﺔ ﻣﻦ ﺍﻟﺴﺮﻃﺎﻥ ﻭﻣﻀﺎﺩﺍﺕ ﺍﻻﻟﺘﻬﺎﺏ ﻭﻣﻀﺎﺩﺍﺕ‬
‫ﺍﻟﻤﺴﺘﻮﻯﺍﻟﺼﻨﺎﻋﻲ ‪Frohling A، Rademacher A، Rumpold B، Klocke M، Schluter O.‬‬ ‫ﺍﻷﻛﺴﺪﺓﻟﻠﻤﻮﺍﺩ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﻨﺒﺎﺗﻴﺔ ﺍﻟﻨﺸﻄﺔ ﺑﻴﻮﻟﻮﺟﻴﺎً ﻭﺍﻟﺘﻲ ﺗﺴﺘﻬﺪﻑ ﻣﺴﺎﺭ ﺇﺷﺎﺭﺍﺕ ‪.TLR4‬ﺇﻧﺖ ‪ J‬ﻣﻮﻝ ﺍﻟﻌﻠﻮﻡ )‬
‫‪54.‬ﻫﻴﻠﻴﻮﻥ )‪:‬ﺩﻭﻯ ‪10.1016/j.heliyon.2018.e006712018( 4)7(:e00671.‬‬ ‫‪ .1-17:(9)19 (2018‬ﺩﻭﻯ‪10.3390/ijms19092729:‬‬
‫‪.55‬ﻫﻮﻧﻎ ﺇﺱ‪ ،‬ﻳﻮﺍﻥ ﺇﻛﺲ‪ ،‬ﻳﺎﻧﻎ ﺟﻴﻪ‪ ،‬ﻳﺎﻧﻎ ﻭﺍﻱ‪ ،‬ﺟﻲ ﻓﻲ ﺇﺗﺶ‪ ،‬ﻟﻲ ﺁﺭ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻜﺸﻒ ﺍﺧﺘﻴﺎﺭ‬ ‫‪.‬ﺍﻻﻟﺘﻬﺎﺏﺍﻟﻤﺰﻣﻦ ﺗﺠﺎﻩ ﺍﻹﺻﺎﺑﺔ ﺑﺎﻟﺴﺮﻃﺎﻥ‪ :‬ﻣﺮﺍﺟﻌﺔ ﻣﻨﻬﺠﻴﺔ ﻭﺗﺤﻠﻴﻞ ﺗﻠﻮﻱ ﻟﻠﺪﺭﺍﺳﺎﺕ ﺍﻟﻮﺑﺎﺋﻴﺔ ‪I.‬‬
‫ﻣﺠﺘﻤﻌﺎﺕﺍﻟﺠﺬﻭﺭ ﻣﻦ ﻣﺤﺎﺻﻴﻞ ﺍﻟﺪﻭﺭﺓ ﺍﻟﻤﺘﻨﻮﻋﺔ ﻋﻦ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻷﺳﺎﺳﻲ ﺍﻟﻔﺮﻳﺪ ﺍﻟﻤﺮﺗﺒﻂ ﺑﺎﻧﺨﻔﺎﺽ‬ ‫‪29. Michels N، van Aart C، Morisse J، Mullee A، Huybrechts‬ﻛﺮﻳﺖ ﺭﻳﻒ ﺃﻭﻧﻜﻮﻝ‬
‫ﻣﺮﺽﺫﺑﻮﻝ ﻓﻴﻮﺯﺍﺭﻳﻮﻡ ﺍﻟﻤﻮﺯ‪.‬ﻧﻴﻮ ﻓﻴﺘﻮﻝ )‪ .(2023‬ﺩﻭﻯ‪10.1111/nph.18816:‬‬ ‫ﻫﻴﻤﺎﺗﻮﻝ)‪ .157:103177 (2021‬ﺩﻭﻯ‪10.1016/ j.critrevonc.2020.103177:‬‬
‫‪.56‬ﻧﺎﻛﺎﻳﺎﺳﻮ ﺇﻡ‪ ،‬ﺗﺎﻛﺎﻣﺎﺗﺴﻮ ﻙ‪ ،‬ﻳﺎﺯﺍﻛﻲ ﻙ‪ ،‬ﺳﻮﺟﻴﺎﻣﺎ ﺃ‪ .‬ﻧﺒﺎﺗﺎﺕ ﺍﻷﻳﺾ ﺍﻟﻤﺘﺨﺼﺼﺔ ﻓﻲ ﺟﺬﻭﺭ‬
‫ﺍﻟﻄﻤﺎﻃﻢ‪:‬ﺍﻹﻓﺮﺍﺯ ﻭﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﻋﻠﻰ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ‪.‬ﺍﻟﺘﻜﻨﻮﻟﻮﺟﻴﺎ ﺍﻟﺤﻴﻮﻳﺔ ﺍﻟﺤﻴﻮﻳﺔ )‪(1)87 (2022‬‬ ‫‪.‬ﺗﺄﺛﻴﺮﺍﻟﺘﻘﻠﻴﺪ ﺍﻟﺠﺰﻳﺌﻲ ﺍﻟﻤﺴﺘﻀﺪﻱ ﻋﻠﻰ ﺍﻻﺳﺘﺠﺎﺑﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻠﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ ‪L.‬‬
‫‪.13-20:‬ﺩﻭﻯ‪/10.1093:‬ﺑﺐ‪zbac181/‬‬ ‫‪30. Tagliamonte M، Buonaguro‬ﺃﻭﻧﻜﻮﻝ ﺃﻣﺎﻣﻲ )‪ .12:1009247 (2022‬ﺩﻭﻯ‪:‬‬
‫‪.57‬ﺃﺟﺎﺭﻭﺳﻲ ﺇﻡ ﺳﻲ ﺇﻥ‪ ،‬ﺑﻴﺮﻳﺮﺍ ﺃﻭ ﺟﻲ‪ ،‬ﺑﻴﻤﻴﻨﺘﻴﻞ ﺇﻑ ﺇﻱ‪ ،‬ﺃﺯﻳﻔﻴﺪﻭ ﺳﻲ ﺇﻑ‪ ،‬ﺩﺍ ﺳﻴﻠﻔﺎ ﻓﻲ ﺑﻲ‪.‬‬ ‫‪10.3389/fonc.2022.1009247‬‬
‫ﻣﻴﻜﺮﻭﺑﻴﻮﻡﺍﻟﺬﺭﺓ ﺍﻟﻤﻌﺎﺩ ﺗﺮﻃﻴﺒﻬﺎ ﻭﺣﺒﻮﺏ ﺍﻟﺬﺭﺓ ﺍﻟﺮﻓﻴﻌﺔ ﺍﻟﻤﻌﺎﻟﺠﺔ ﺑﺎﻟﻠﻘﺎﺣﺎﺕ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ ﻓﻲ ﻓﺘﺮﺍﺕ‬ ‫‪.31‬ﺭﺍﻣﺎ ﺍﻷﻭﻝ‪ ،‬ﻏﺮﻳﻨﻴﻮ ﺟﻲ ﺇﻡ‪ .‬ﺍﻟﻮﺭﻡ ﺍﻟﺨﺒﻴﺚ ﺑﻌﺪ ﺯﺭﻉ ﺍﻟﻜﻠﻰ‪ :‬ﺩﻭﺭ ﻛﺒﺖ ﺍﻟﻤﻨﺎﻋﺔ‪.‬ﻧﺎﺕ ﺭﻳﻒ ﻧﻴﻔﺮﻭﻝ )‬
‫ﺗﺨﻤﻴﺮﻣﺨﺘﻠﻔﺔ‪.‬ﻣﻨﺪﻭﺏ ﺍﻟﻌﻠﻮﻡ )‪ .16864:(1)12 (2022‬ﺩﻭﻯ‪10.1038/s41598-022- 21461-4:‬‬ ‫‪ .9–511:(9)6 (2010‬ﺩﻭﻯ‪10.1038/nrneph.2010.102:‬‬
‫‪.32‬ﻓﻴﺎﻝ ﺗﻲ‪ ،‬ﺩﻳﺴﻜﻮﺗﻴﺲ ﺟﻲ‪ .‬ﺍﻷﺩﻭﻳﺔ ﺍﻟﻤﺜﺒﻄﺔ ﻟﻠﻤﻨﺎﻋﺔ ﻭﺍﻟﺴﺮﻃﺎﻥ‪.‬ﻋﻠﻢ ﺍﻟﺴﻤﻮﻡ )‪185 (2003‬‬
‫‪.‬ﺍﻟﻌﻮﺩﺓﺇﻟﻰ ﺍﻟﺠﺬﻭﺭ‪ :‬ﺗﺤﺪﻳﺪ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻷﺳﺎﺳﻲ ﻟﻠﺬﺭﺓ ﺍﻟﺒﻴﻀﺎء ﺛﻨﺎﺋﻴﺔ ﺍﻟﻠﻮﻥ ﻓﻲ ﺗﺮﺑﺔ ﺍﻟﺤﻘﻮﻝ‬ ‫)‪ .229-40 :(3‬ﺩﻭﻯ‪10.1016/S0300-483X)02(00612-1:‬‬
‫ﺍﻟﺰﺭﺍﻋﻴﺔﻣﻦ ﻣﺮﻛﺰ ﺍﻟﻤﻨﺸﺄ ‪S، Shimels M، Tessema T، Raaijmakers JM، Dini-Andreote F.‬‬
‫‪58. Abera‬ﻓﻴﻤﺲ ﻣﻴﻜﺮﻭﺑﻴﻮﻝ ﺇﻳﻜﻮﻝ )‪ .(12)98 (2022‬ﺩﻭﻯ‪/10.1093:‬ﻓﻴﻤﺴﻴﻚ‪/‬ﻓﻴﺎﻙ‪136‬‬ ‫‪.33‬ﺑﻨﺴﻠﻔﺎﻧﻴﺎ ‪ .I‬ﺍﻷﻭﺭﺍﻡ ﺍﻟﺜﺎﻧﻮﻳﺔ ﻧﺘﻴﺠﺔ ﻟﺰﺭﺍﻋﺔ ﺍﻷﻋﻀﺎء ﻭﻋﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ‪.‬ﻛﺸﻒ ﺍﻟﺴﺮﻃﺎﻥ ﺍﻟﺴﺎﺑﻖ )‬
‫‪.39-57:(1-6)12 (1988‬‬
‫‪.59‬ﺑﻮﺝ ﺇﻥ ﺩﻱ‪ ،‬ﺗﺎﻣﺘﺎ ﺇﺗﺶ‪ ،‬ﺑﺎﻻﺷﺎﻧﺪﺭﺍﻥ ﺑﻲ‪ ،‬ﻭﻭ ﺇﻛﺲ‪ ،‬ﻫﻮﻳﻞ ﺟﻴﻪ‪ ،‬ﺩﺍﻳﺎﻥ ﺇﻑ ﺇﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻏﺎﻟﺒﻴﺔ‬
‫ﺗﻨﺸﻴﻂﺍﻟﺒﻼﻋﻢ ﻓﻲ ﺍﻟﻤﺨﺘﺒﺮ ﺍﻟﺬﻱ ﺗﻈﻬﺮﻩ ﻣﺴﺘﺨﻠﺼﺎﺕ ﺑﻌﺾ ﺍﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﻤﻌﺰﺯﺓ ﻟﻠﻤﻨﺎﻋﺔ ﻳﺮﺟﻊ ﺇﻟﻰ‬ ‫‪[.‬ﺍﻷﺩﻭﻳﺔ ﺍﻟﻤﺜﺒﻄﺔ ﻟﻠﻤﻨﺎﻋﺔ ‪ -‬ﻛﻴﻒ ﺗﻌﻤﻞ ﻭﺁﺛﺎﺭﻫﺎ ﺍﻟﺠﺎﻧﺒﻴﺔ ﻭﺗﻔﺎﻋﻼﺗﻬﺎ] ‪F, Ackermann D.‬‬
‫ﺍﻟﺒﺮﻭﺗﻴﻨﺎﺕﺍﻟﺪﻫﻨﻴﺔ ﺍﻟﺒﻜﺘﻴﺮﻳﺔ ﻭﺍﻟﺴﻜﺮﻳﺎﺕ ﺍﻟﺪﻫﻨﻴﺔ‪.‬ﺇﻧﺖ ﺇﻣﻮﻧﻮﻓﺎﺭﻣﺎﻛﻮﻝ )‪.32–1023:(7)8 (2008‬‬ ‫‪34. Stucker‬ﻫﻨﺎﻙ ﺃﻭﻣﺶ )‪ .679-86:(12)68 (2011‬ﺩﻭﻯ‪10.1024/0040- 5930/a000230:‬‬
‫ﺩﻭﻯ‪10.1016/j.intimp.2008.03.007:‬‬
‫‪.‬ﺩﻭﺭﺍﻟﻤﻜﻮﻧﺎﺕ ﺍﻟﺒﻜﺘﻴﺮﻳﺔ ﺍﻟﺪﺍﺧﻠﻴﺔ ‪ /‬ﺍﻟﻨﺒﺘﺔ ﻓﻲ ﻧﺸﺎﻁ ﺍﻟﺘﺤﻔﻴﺰ ﺍﻟﻤﻨﺎﻋﻲ ﻟﻠﻐﺸﺎء ﺍﻟﻨﺒﺎﺗﻲ ﺍﻟﻘﺘﺎﺩ ‪J.‬‬ ‫‪.35‬ﺷﻴﻠﺮ ﺟﻲ ﺗﻲ‪ ،‬ﻟﻮﻱ ﺩ‪ .‬ﺁﻓﺎﻕ ﺍﻟﻮﻗﺎﻳﺔ ﻣﻦ ﺍﻟﺴﺮﻃﺎﻥ ﺑﺎﻟﻠﻘﺎﺣﺎﺕ ﺍﻟﻮﻗﺎﺋﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻤﻴﻜﺮﻭﺑﺎﺕ‪.‬‬
‫‪60. Koehler H، Puchalski K، Ruiz G، Jacobs B، Langland‬ﻳﻴﻞ ﺟﻲ ﺑﻴﻮﻝ ﻣﻴﺪ )‪(2020‬‬ ‫ﺍﻟﻤﻴﻜﺮﻭﺏﺍﻟﻤﻀﻴﻒ ﻟﻠﺨﻠﻴﺔ )‪ .(2022‬ﺩﻭﻯ‪10.1016/j.chom.2022.10.016:‬‬
‫‪.50–239:(2)93‬‬ ‫‪.36‬ﻳﻮ ﺇﻝ‪ ،‬ﺗﺸﻮ ﺟﻲ‪ ،‬ﺷﻴﻦ ﺯﻱ‪ ،‬ﻫﻮﻙ ﺟﻲ ﺇﺱ‪ ،‬ﻧﺎ ﺇﻑ‪ ،‬ﺗﺎﻧﻎ ﺟﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﺗﺠﺎﻫﺎﺕ ﺟﺪﻳﺪﺓ ﻟﻌﻠﻢ ﺍﻷﻭﺭﺍﻡ‬
‫‪.61‬ﺩﻳﻨﺰﻟﺮ ﻛﻮﺍﻻﻟﻤﺒﻮﺭ‪ ،‬ﻭﻭﺗﺮﺯ ﺁﺭ‪ ،‬ﺟﺎﻛﻮﺑﺲ ﺑﻲ ﺇﻝ‪ ،‬ﺭﻭﺗﺸﻮﻥ ﻭﺍﻱ‪ ،‬ﻻﻧﺠﻼﻧﺪ ﺟﻮ‪ .‬ﺗﻨﻈﻴﻢ ﺍﻟﺘﻌﺒﻴﺮ‬ ‫ﺍﻟﺪﻗﻴﻖ‪:‬ﺗﻌﻤﻴﻢ ﺍﻟﺤﻤﺾ ﺍﻟﻨﻮﻭﻱ ﺍﻟﻤﻴﻜﺮﻭﺑﻲ ﺍﻟﻨﺎﺷﺊ ﻓﻲ ﻣﻨﺎﻃﻖ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﺴﺮﻃﺎﻧﻴﺔ‪.‬ﺑﺮﻳﺴﻴﺲ ﻛﻠﻴﻦ ﻣﻴﺪ )‬
‫ﺍﻟﺠﻴﻨﻲﺍﻻﻟﺘﻬﺎﺑﻲ ﻓﻲ ‪ PBMCs‬ﺑﻮﺍﺳﻄﺔ ﻧﺒﺎﺗﺎﺕ ﺍﻟﺘﺤﻔﻴﺰ ﺍﻟﻤﻨﺎﻋﻲ‪.‬ﺑﻠﻮﺱ ﻭﺍﺣﺪ )‪:‬ﺩﻭﻯ ‪( 5)9(:e12561.‬‬ ‫‪:‬ﺩﻭﻯ‪10.1093/pcmedi/pbac0052022( 5)1(:pbac005.‬‬
‫‪10.1371/journal.pone.00125612010‬‬ ‫‪.37‬ﺳﻴﻠﻲ ﻛﻴﻪ ﺩﻱ‪ ،‬ﻣﻮﺭﺟﺎﻥ ﺇﻳﻪ ﺩﻱ‪ ،‬ﻫﺎﺟﻨﺸﺘﺎﻳﻦ ﺇﻝ ﺩﻱ‪ ،‬ﻓﻠﻮﺭﻱ ﺟﻲ ﺇﻡ‪ ،‬ﺳﻤﻮﻝ ﺟﻲ ﺇﻡ‪ .‬ﺗﻮﺭﻁ‬
‫‪.62‬ﻣﻮﻧﺘﻴﻨﻴﻐﺮﻭ ﺩ‪ ،‬ﻛﺎﻟﺒﺎﻧﺎ ﻙ‪ ،‬ﻛﺮﻳﺴﻴﺎﻥ ﺳﻲ‪ ،‬ﺷﺎﺭﻣﺎ ﺃ‪ ،‬ﺗﺎﻛﺎﻭﻛﺎ ﺃ‪ ،‬ﺇﻳﺎﻛﻮﻓﻴﺪﻭ ﺇﻡ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﻜﺸﻒ‬ ‫ﺍﻟﺒﻜﺘﻴﺮﻳﺎﻓﻲ ﺗﻄﻮﺭ ﻭﺭﻡ ﺧﺒﻴﺚ ﻣﻦ ﺃﻭﺭﺍﻡ ﺍﻟﻘﻮﻟﻮﻥ ﻭﺍﻟﻤﺴﺘﻘﻴﻢ‪.‬ﺍﻟﺴﺮﻃﺎﻥ )ﺑﺎﺯﻝ( )‪ .(4)14 (2022‬ﺩﻭﻯ‪:‬‬
‫ﻋﻦ"ﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚ ﺍﻟﻌﺸﺒﻲ" ﺍﻟﻤﺤﺘﻤﻞ ﻓﻲ ‪ juzen-taiho-to‬ﻣﻦ ﺧﻼﻝ ﺩﺭﺍﺳﺔ ﺍﻟﻤﺠﻤﻮﻋﺎﺕ ﺍﻟﺒﻜﺘﻴﺮﻳﺔ‬ ‫‪/10.3390‬ﺍﻟﺴﺮﻃﺎﻥ‪14041019‬‬
‫ﺍﻟﻤﺮﺗﺒﻄﺔﺑﻬﺎ‪.‬ﺑﻴﻮﺭﺝ ﻣﻴﺪ ﻛﻴﻢ ﻟﻴﺖ )‪ .9–466:(3)25 (2015‬ﺩﻭﻯ‪:‬‬ ‫‪.38‬ﻫﻴﺪﻣﺎﻥ ﺩﺑﻠﻴﻮ‪ .‬ﻣﺎ ﺍﻟﺠﺪﻳﺪ ﻓﻲ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺨﺒﻴﺜﺔ ﻓﻲ ﺍﺿﻄﺮﺍﺑﺎﺕ ﻧﻘﺺ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻤﻜﺘﺴﺐ؟‬
‫‪10.1016/j.bmcl.2014.12.036‬‬ ‫ﻣﻤﺎﺭﺳﺔﺍﻟﺪﻗﺔ ﺑﺎﺛﻮﻝ )‪ .930-4:(6)185 (1989‬ﺩﻭﻯ‪10.1016/S0344-0338)89(80300-0:‬‬
‫‪.63‬ﻧﻴﺸﻴﺰﺍﻭﺍ ﺗﻲ‪ ،‬ﺇﻳﻨﺎﺟﺎﻭﺍ ﺇﺗﺶ‪ ،‬ﺃﻭﺷﻴﻤﺎ ﺇﺗﺶ‪ ،‬ﺃﻭﻛﻮﺗﻮﻣﻲ ﺗﻲ‪ ،‬ﺗﺴﻮﻛﻴﻮﻛﺎ ﺩﻱ‪ ،‬ﺇﻳﺠﻮﺗﺸﻲ ﺇﻡ‪،‬‬ ‫‪.39‬ﻛﻮﻣﺎﺭ ﺍﻟﺨﺎﻣﺲ‪ ،‬ﺑﺎﺭﻳﺖ ﺟﻲ‪ .‬ﺍﻟﻤﺴﺘﻘﺒﻼﺕ ﺍﻟﻤﺸﺎﺑﻬﺔ )‪ (TLRs‬ﻓﻲ ﺍﻟﺼﺤﺔ ﻭﺍﻟﻤﺮﺽ‪ :‬ﻧﻈﺮﺓ ﻋﺎﻣﺔ‪.‬‬
‫ﻭﺁﺧﺮﻭﻥ‪.‬ﺍﻟﺘﻮﺍﺯﻥ ﻛﻤﺎ ﻳﻨﻈﻤﻪ ﺍﻟﺒﻼﻋﻢ ﺍﻟﻤﻨﺸﻂ‪ .‬ﺃﻧﺎ‪ .‬ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ )‪ (LPS‬ﻣﻦ ﺩﻗﻴﻖ ﺍﻟﻘﻤﺢ‪:‬‬ ‫ﻫﺎﻧﺪﺏﺇﻛﺴﺐ ﻓﺎﺭﻣﺎﻛﻮﻝ )‪ .1-21 :276 (2022‬ﺩﻭﻯ‪568_2021_10.1007/164:‬‬
‫ﺍﻟﻌﺰﻝﻭﺍﻟﺘﻨﻘﻴﺔ ﻭﺑﻌﺾ ﺍﻷﻧﺸﻄﺔ ﺍﻟﺒﻴﻮﻟﻮﺟﻴﺔ‪.‬ﻛﻴﻢ ﻓﺎﺭﻡ ﺑﻮﻝ )ﻃﻮﻛﻴﻮ( )‪ .83–479:(2)40 (1992‬ﺩﻭﻯ‪:‬‬
‫‪ PAMP.‬ﺍﻵﻟﻴﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻭﺍﻟﺘﻄﺒﻴﻖ ﺍﻟﺴﺮﻳﺮﻱ ﻟﻤﺴﺎﻋﺪﺍﺕ ‪40. Yan Y، Yao D، Li X.‬ﺍﻻﻛﺘﺸﺎﻑ‬
‫‪10.1248/cpb.40.479‬‬
‫ﺍﻷﺧﻴﺮﻟﻸﺩﻭﻳﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ )‪ .43–30:(1)16 (2021‬ﺩﻭﻯ‪:‬‬
‫‪.‬ﺇﻥﺗﻨﺎﻭﻝ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ ﺃﻭ ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﺠﻠﺪ ﺫﻭ ﺍﻟﺤﺠﻢ ﺍﻟﺠﺰﻳﺌﻲ ﺍﻟﺼﻐﻴﺮ‬ ‫‪10.2174/1574892816666210201114712‬‬
‫ﻗﺪﻳﻌﺎﻟﺞ ﺍﻟﻌﺪﻳﺪ ﻣﻦ ﺍﻷﻣﺮﺍﺽ ﺍﻟﻤﺴﺘﻌﺼﻴﺔ‪ :‬ﻧﺴﺨﺔ ﺟﺪﻳﺪﺓ ﻣﻦ ﺳﻤﻮﻡ ﻛﻮﻟﻲ ‪Mizuno D، Soma G.‬‬
‫‪.‬ﺍﺳﺘﻜﺸﺎﻑﻣﻨﺒﻬﺎﺕ ﻣﺴﺘﻘﺒﻼﺕ ﺍﻟﺘﻌﺮﻑ ﻋﻠﻰ ﺍﻷﻧﻤﺎﻁ ﻛﻤﻮﺍﺩ ﻣﺴﺎﻋﺪﺓ ﻣﺮﺷﺤﺔ ‪، Kawasaki T، Kawai T.‬‬
‫‪64.‬ﻣﻮﻝ ﺑﻴﻮﺗﺮ )‪.166-9:(4)4 (1992‬‬
‫‪41. Ong GH، Lian BSX‬ﺍﻟﺨﻠﻴﺔ ﺍﻷﻣﺎﻣﻴﺔ ﺗﺼﻴﺐ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻝ )‪ .11:745016 (2021‬ﺩﻭﻯ‪:‬‬
‫‪.‬ﻛﻤﻨﺸﻂﻟﻠﺒﻼﻋﻢ ‪ LPS‬ﻓﺎﺋﺪﺓ ﻭﺳﻼﻣﺔ ﻣﺴﺘﺨﻠﺺ ﺍﻟﺪﻗﻴﻖ ﺍﻟﻤﺨﻤﺮ ﺍﻟﻤﻌﺘﻤﺪ ﻋﻠﻰ ‪C، Soma G.‬‬ ‫‪10.3389/fcimb.2021.745016‬‬
‫‪65. Taniguchi Y، Yoshioka N، Nishizawa T، Inagawa H، Kohchi‬ﺍﻟﺪﻗﺔ ﺍﻟﻤﻀﺎﺩﺓ‬
‫‪.‬ﻛﻤﻮﺍﺩﻣﺴﺎﻋﺪﺓ ﻟﻠﻘﺎﺣﺎﺕ ﺗﺴﺘﻬﺪﻑ ﺍﻟﺴﺮﻃﺎﻥ ﻭﺍﻷﻣﺮﺍﺽ ﺍﻟﻤﻌﺪﻳﺔ ‪ TLR‬ﻣﻨﺒﻬﺎﺕ ‪S، Milicic A.‬‬
‫ﻟﻠﺴﺮﻃﺎﻥ)‪.64–859:(3)29 (2009‬‬
‫‪42. Luchner M، Reinke‬ﺍﻟﻤﺴﺘﺤﻀﺮﺍﺕ ﺍﻟﺼﻴﺪﻻﻧﻴﺔ )‪ .(2)13 (2021‬ﺩﻭﻯ‪/10.3390:‬‬
‫‪.‬ﻟﻠﺮﻋﺎﻳﺔﺍﻟﺼﺤﻴﺔ ﺑﻨﺎء ًﻋﻠﻰ ﻧﻈﺮﻳﺔ ﺷﺒﻜﺔ ﺍﻟﺒﻼﻋﻢ (‪ )IP-PA1‬ﺗﻄﺒﻴﻘﺎﺕ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ‬ ‫ﺻﻴﺪﻟﺔ‪13020142‬‬
‫ﺍﻟﻤﺸﺘﻖﻣﻦ ﺗﻜﺘﻼﺕ ﺍﻟﺒﺎﻧﺘﻮﻳﺎ ‪Inagawa H، Nishizawa T، Yamaguchi T، Nagai S، Soma G.‬‬
‫‪.‬ﺍﻻﻓﺘﺘﺎﺣﻴﺔ‪:‬ﻣﺴﺘﻘﺒﻼﺕ ﺍﻟﺘﻌﺮﻑ ﻋﻠﻰ ﺍﻷﻧﻤﺎﻁ ﻋﻨﺪ ﺍﻟﺤﺪﻳﺚ ﺍﻟﻤﺘﺒﺎﺩﻝ ﺑﻴﻦ ﺃﺟﻬﺰﺓ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻄﺮﻳﺔ‬
‫‪66. Kohchi C،‬ﺟﻲ ﺑﻴﻮﺳﻲ ﺑﻴﻮﻧﺞ )‪ .96–485:(6)102 (2006‬ﺩﻭﻯ‪10.1263/jbb.102.485:‬‬
‫ﻭﺍﻟﺘﻜﻴﻔﻴﺔﻭﺍﻵﺛﺎﺭ ﺍﻟﻤﺘﺮﺗﺒﺔ ﻋﻠﻰ ﺗﻄﻮﻳﺮ ﺍﻟﻠﻘﺎﺣﺎﺕ ‪43. Rossi O، Mastroeni P.‬ﺍﻟﺨﻠﻴﺔ ﺍﻷﻣﺎﻣﻴﺔ‬
‫ﺗﺼﻴﺐﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻝ )‪ .12:1088029 (2022‬ﺩﻭﻯ‪10.3389/ fcimb.2022.1088029:‬‬
‫‪.67‬ﻻﻛﺸﻤﺎﻧﺎﻥ ﻑ‪ ،‬ﺭﺍﻱ ﺑﻲ‪ ،‬ﻛﺮﺍﻓﻦ ﺩﻳﻨﺎﺭ ﻛﻮﻳﺘﻲ‪ .‬ﺑﺮﻭﺗﻮﻛﻮﻻﺕ ﺃﺧﺬ ﻋﻴﻨﺎﺕ ﺭﻳﺰﻭﺳﻔﻴﺮ ﻹﻋﺪﺍﺩ ﻣﻜﺘﺒﺔ‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ)‪ (16S/18S/ITS rRNA‬ﻭﺇﺛﺮﺍﺋﻬﺎ ﻟﻌﺰﻝ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﺍﻟﺘﻲ ﺗﻌﺰﺯ ﺗﺤﻤﻞ ﺍﻟﺠﻔﺎﻑ‪.‬ﻃﺮﻕ ﻣﻮﻝ‬
‫‪.44‬ﺷﻲ ﻭﺍﻱ ﺟﻲ‪ ،‬ﺗﺸﻮ ﺳﻲ ﺇﻡ‪ ،‬ﻟﻲ ﺩﻱ ﺇﺗﺶ‪ ،‬ﺷﻲ ﺯﻱ‪ ،‬ﺟﻮ ﻛﻴﻮ‪ ،‬ﺗﺸﻦ ﻭﺍﻱ ﺩﺑﻠﻴﻮ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺁﻓﺎﻕ ﺟﺪﻳﺪﺓ‬
‫ﺑﻴﻮﻝ)‪ .62–1631:349 (2017‬ﺩﻭﻯ‪23_10.1007/978-1-4939-7136-7:‬‬
‫ﻓﻲﺳﻼﻣﺔ ﺍﻷﻏﺬﻳﺔ ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻟﻮﺟﻴﺔ‪ :‬ﺍﻟﺘﻌﻄﻴﻞ ﺍﻟﺪﻳﻨﺎﻣﻴﻜﻲ ﺍﻟﻀﻮﺋﻲ ﻓﺎﺋﻖ ﺍﻟﻜﻔﺎءﺓ ﺍﺳﺘﻨﺎﺩﺍً ﺇﻟﻰ ﻣﺸﺘﻖ ﺣﻤﺾ‬
‫ﺍﻟﻐﺎﻟﻴﻚﻭﺿﻮء ﺍﻷﺷﻌﺔ ﻓﻮﻕ ﺍﻟﺒﻨﻔﺴﺠﻴﺔ ﻭﺗﻄﺒﻴﻘﻪ ﻣﻊ ﺃﻟﻴﺎﻑ ﻧﺎﻧﻮﻳﺔ ﺩﻛﺴﺘﺮﻳﻦ ﺣﻠﻘﻴﺔ ﻣﻐﺰﻭﻟﺔ ﻛﻬﺮﺑﺎﺋﻴﺎً‪.‬ﻱ ﺍﻟﺰﺭﺍﻋﻴﺔ‬
‫‪.68‬ﻣﻴﺮﺍﻧﺪﺍ ﻙ‪ ،‬ﻭﻳﺠﻴﻞ ﺑﻲ ﺇﻝ‪ ،‬ﻓﻮﻏﺎﺭﺗﻲ ﺇﻱ ﺳﻲ‪ ،‬ﻓﻴﺴﻴﻠﻲ ﺁﻱ ﺇﻳﻪ‪ ،‬ﺟﻴﺒﻠﻴﻦ ﺇﻳﻪ ﺇﻱ‪ ،‬ﺇﺭﻳﻦ ﺁﻡ‪،‬‬ ‫ﻟﻠﻜﻴﻤﺎﻭﻳﺎﺕﺍﻟﻐﺬﺍﺋﻴﺔ )‪ .74–14961:(49)69 (2021‬ﺩﻭﻯ‪10.1021/acs.jafc.1c04827:‬‬
‫ﻭﺁﺧﺮﻭﻥ‪.‬ﺍﻟﺘﻨﻮﻉ ﻭﺍﻟﻘﺪﺭﺓ ﺍﻟﻮﻇﻴﻔﻴﺔ ﻟﻠﻤﻴﻜﺮﻭﺑﺎﺕ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﻜﺒﻴﺮﺓ ﺍﻟﺴﺎﺣﻠﻴﺔ‪ .‬ﺍﻡ ﺳﻴﺴﺘﻤﺰ )‬
‫‪.45‬ﺷﻮﻟﺘﺲ ﻛﺎ‪ ،‬ﻟﻮﻱ ﻙ‪ ،‬ﻭﺍﻟﺘﺮﺯ ﺟﻲ ﺩﺑﻠﻴﻮ‪ ،‬ﺳﻮﺑﺴﻲ ﺇﻡ ﺩﻱ‪ ،‬ﻟﻴﻨﺪﻥ ﻛﻴﻪ ﺟﻲ‪ ،‬ﻛﺎﺯﺍﻧﻮﻓﺎ ﺇﻝ ﺇﻡ‪ .‬ﻣﻘﺎﺭﻧﺔ‬
‫‪:‬ﺩﻭﻯ‪10.1128/msystems.00592-222022(:e0059222.‬‬
‫ﺍﻟﺜﻨﺎﺋﻴﺎﺕﺍﻟﺒﺎﻋﺜﺔ ﻟﻠﻀﻮء ﻓﻮﻕ ﺍﻟﺒﻨﻔﺴﺠﻲ ﻭﻣﺼﺎﺑﻴﺢ ﺍﻟﻘﻮﺱ ﺍﻟﺰﺋﺒﻘﻲ ﻣﻨﺨﻔﺾ ﺍﻟﻀﻐﻂ ﻟﺘﻄﻬﻴﺮ ﺍﻟﻤﻴﺎﻩ‪.‬‬
‫‪.69‬ﻭﻳﺠﻴﻞ ﺑﻲ ﺇﻝ‪ ،‬ﻓﻴﺴﺘﺮ ﻛﺎﻟﻴﻔﻮﺭﻧﻴﺎ‪ .‬ﻳﺸﻜﻞ ﺍﺳﺘﻘﻼﺏ ﺍﻷﻛﺴﺠﻴﻦ ﺗﺴﻮﻳﺔ ﻣﻴﻜﺮﻭﺑﻴﺔ ﻋﻠﻰ ﺷﻔﺮﺍﺕ‬ ‫ﺗﻜﻨﻮﻟﻮﺟﻴﺎﺍﻟﺒﻴﺌﺔ )‪ .2183-8:(17)37 (2016‬ﺩﻭﻯ‪09593330.2016.1144798 /10.1080:‬‬
‫ﻋﺸﺐﺍﻟﺒﺤﺮ ﺍﻟﻀﻮﺋﻲ ﻣﻘﺎﺭﻧﺔ ﻣﻊ ﺭﻛﺎﺋﺰ ﻋﺸﺐ ﺍﻟﺒﺤﺮ ﺍﻻﺻﻄﻨﺎﻋﻲ‪.‬ﻣﻤﺜﻞ ﺍﻟﺒﻴﺌﺔ ﻣﻴﻜﺮﻭﺑﻴﻮﻝ )‪(2021‬‬
‫‪ .84–176:(2)13‬ﺩﻭﻯ‪10.1111/1758-2229.12923:‬‬ ‫‪.‬ﻣﺨﺎﻃﺮﺟﻴﻨﺎﺕ ﻣﻘﺎﻭﻣﺔ ﺍﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻮﻳﺔ ﻭﻣﻘﺎﻭﻣﺔ ﻣﻀﺎﺩﺍﺕ ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﻓﻲ ﻇﻞ ﺍﻟﺘﻄﻬﻴﺮ‬
‫‪.‬ﺍﻟﺨﺼﺎﺋﺺﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻠﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﺑﺮﻭﺑﻴﻮﺗﻴﻚ ﺑﻤﺎ ﻳﺘﺠﺎﻭﺯ ﻗﺪﺭﺗﻬﺎ ﻋﻠﻰ ﺍﻟﺒﻘﺎء )‬ ‫ﺑﺎﻟﻜﻠﻮﺭﻣﻊ ﻣﺨﺎﻭﻑ ﺗﺘﻌﻠﻖ ﺑﺎﻟﺼﺤﺔ ﺍﻟﻌﺎﻣﺔ ‪46. Ma L، Yang H، Guan L، Liu X، Zhang T.‬‬
‫ﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚﺍﻟﺸﺒﺢ‪ :‬ﺍﻗﺘﺮﺍﺡ ﻣﻔﻬﻮﻡ ﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚ( ‪70. Taverniti V، Guglielmetti S.‬ﺍﻟﺠﻴﻨﺎﺕ ﻧﻮﺗﺮ )‬ ‫ﺍﻟﺒﻴﺌﺔﺍﻟﺪﻭﻟﻴﺔ )‪ .158:106978 (2022‬ﺩﻭﻯ‪10.1016/j.envint.2021.106978:‬‬
‫‪ .74–261:(3)6 (2011‬ﺩﻭﻯ‪10.1007/s12263-011-0218-x:‬‬ ‫‪.47‬ﺟﻴﻔﺮﻱ ﻳﻮ‪ ،‬ﺧﺎﻥ ﺃ‪ ،‬ﻟﻴﻢ ﻭﺍﻱ ﺳﻲ‪ ،‬ﻟﻲ ﻛﻲ ﺇﺱ‪ ،‬ﻟﻴﻮ ﻛﻴﻪ ﺑﻲ‪ ،‬ﻛﺴﺎﺏ ﻭﺍﻱ ﺩﺑﻠﻴﻮ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻣﺮﺍﺟﻌﺔ ﻣﻨﻬﺠﻴﺔ ﻟﺜﺎﻧﻲ‬
‫‪.‬ﻣﺮﺍﺟﻌﺔﻟﻸﺩﻟﺔ ﺍﻟﺤﺎﻟﻴﺔ ﻭﺍﻻﺗﺠﺎﻫﺎﺕ ﺍﻟﻨﺎﺷﺌﺔ ‪-Mendoza A. Postbiotics and paraprobiotics:‬‬ ‫ﺃﻛﺴﻴﺪﺍﻟﻜﻠﻮﺭ ﻛﻤﻄﻬﺮ‪.‬ﺟﻲ ﻣﻴﺪ ﻻﻳﻒ )‪ .8–313:(3)15 (2022‬ﺩﻭﻯ‪10.25122/jml-2021-0180:‬‬
‫‪71. Vallejo-Cordoba B، Castro-Lopez C، Garcia HS، Gonzalez-Cordova AF، Hernandez‬‬ ‫‪.‬ﺍﻟﻜﺸﻒﻋﻦ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ ﺍﻟﻌﺼﻮﻳﺔ ﺍﻟﺸﻤﻌﻴﺔ ﺍﻟﻤﻔﺘﺮﺿﺔ ﺍﻟﻤﺴﺒﺒﺔ ﻟﻠﺴﻤﻮﻡ ﺍﻟﻤﻌﻮﻳﺔ ﻭﻣﻨﺘﺠﻲ‬
‫ﺃﺩﻑﻓﻮﺩ ﻧﻮﺗﺮ ﺭﻳﺲ )‪ .34–1 :94 (2020‬ﺩﻭﻯ‪10.1016/bs.afnr.2020.06.001:‬‬ ‫ﺍﻟﺴﻴﺮﻳﻮﻟﻴﺪﻓﻲ ﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﻐﺬﺍﺋﻴﺔ ﻭﺍﻟﻤﻜﻮﻧﺎﺕ ‪Jovanovic J، Tretiak S، Begyn K، Rajkovic A.‬‬
‫‪.‬ﺍﻟﻤﻜﻮﻧﺎﺕﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ ﺍﻟﻤﻬﻤﻠﺔ ﻟﺘﺮﻛﻴﺒﺎﺕ ﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚ ﺍﻟﺘﺠﺎﺭﻳﺔ ‪W، Arioli S، Guglielmetti S.‬‬ ‫‪48.‬ﺍﻟﺴﻤﻮﻡ )ﺑﺎﺯﻝ( )‪ .(4)14 (2022‬ﺩﻭﻯ‪/10.3390:‬ﺳﻤﻮﻡ‪14040289‬‬
‫‪72. Fiore‬ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺪﻗﻴﻘﺔ )‪ .(8)8 (2020‬ﺩﻭﻯ‪ /10.3390:‬ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ‪8081177‬‬ ‫ﺍﻟﺘﻠﻮﺙﺍﻟﻤﻴﻜﺮﻭﺑﻲ ﻟﺴﻠﻄﺎﺕ ﺍﻟﺨﻀﺎﺭ ﺍﻟﻄﺎﺯﺟﺔ ﻭﺍﻷﻋﺸﺎﺏ ﺍﻟﻤﻨﺘﺠﺔ ﻋﻀﻮﻳﺎً ﻭﺗﻘﻠﻴﺪﻳﺎً ﻣﻦ ﻣﺘﺎﺟﺮ‬
‫ﺍﻟﺘﺠﺰﺋﺔ ‪49. Becker B, Stoll D, Schulz P, Kulling S, Huch M.‬‬

‫‪.100‬ﺟﺎﻟﻮﺯﻱ ﺇﻝ‪ ،‬ﻓﺎﺗﺸﻴﻠﻲ ﺇﻱ‪ ،‬ﺇﻳﺠﻴﺮﻣﻮﻧﺖ ﺃ‪ ،‬ﻓﺮﻳﺪﻣﺎﻥ ﺩﺑﻠﻴﻮ ﺇﺗﺶ‪ ،‬ﺟﺎﻟﻮﻥ ﺟﻲ‪ ،‬ﺳﺎﻭﺗﺲ ﻓﺮﻳﺪﻣﺎﻥ‬ ‫‪.73‬ﺃﻛﺘﺮ ﺇﺱ‪ ،‬ﺑﺎﺭﻙ ﺟﻴﻪ ﺇﺗﺶ‪ ،‬ﺟﻮﻧﻎ ﻫﻮﻧﺞ ﻛﻮﻧﺞ‪ .‬ﺍﻟﻔﻮﺍﺋﺪ ﺍﻟﻤﺤﺘﻤﻠﺔ ﻟﺘﻌﺰﻳﺰ ﺍﻟﺼﺤﺔ ﻣﻦ‬
‫ﺝ‪،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﻤﺮﺍﻗﺒﺔ ﺍﻟﺘﺠﺮﻳﺒﻴﺔ‪ :‬ﻣﻨﺒﻬﺎﺕ ﺍﻟﻤﺴﺘﻘﺒﻼﺕ ﺍﻟﺘﺠﺮﻳﺒﻴﺔ ﻟﻌﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ‪ .‬ﻋﻠﻢ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻷﻭﺭﺍﻡ )‬ ‫ﺍﻟﺒﺎﺭﺍﺑﺮﻭﺑﻴﻮﺗﻴﻚ‪،‬ﻭﺧﻼﻳﺎ ﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚ ﺍﻟﻤﻌﻄﻠﺔ‪.‬ﺟﻲ ﻣﻴﻜﺮﻭﺑﻴﻮﻝ ﺑﻴﻮﺗﻜﻨﻮﻝ )‪.81 –477:(4)30 (2020‬‬
‫‪ .699-716:(5)1 (2012‬ﺩﻭﻯ‪10.4161/onci.20696:‬‬ ‫ﺩﻭﻯ‪10.4014/jmb.1911.11019:‬‬
‫‪.‬ﻭﺩﻭﺭﻫﺎﻓﻲ ﺍﻟﺘﺴﺮﻃﻦ ﻭﺍﻟﻌﻼﺝ ﺍﻟﻤﻀﺎﺩ ﻟﻠﻮﺭﻡ ‪ Toll-like‬ﻣﺴﺘﻘﺒﻼﺕ ‪-Maranda E، Robak T.‬‬ ‫‪.‬ﻟﻠﻮﻟﺪﺍﻥﺍﻟﻤﺒﺘﺴﺮﻳﻦ‪ ،‬ﺍﻟﺤﺪﻭﺩ ﺍﻟﺘﺎﻟﻴﺔ ‪Deshpande G، Athalye-Jape G، Patole S. Para-probiotics‬‬
‫‪101. Wolska A، Lech‬ﺧﻠﻴﺔ ﻣﻮﻝ ﺑﻴﻮﻝ ﻟﻴﺖ )‪ .72–248:(2)14 (2009‬ﺩﻭﻯ‪:‬‬ ‫‪74.‬ﺍﻟﻌﻨﺎﺻﺮ ﺍﻟﻐﺬﺍﺋﻴﺔ )‪ .(7)10 (2018‬ﺩﻭﻯ‪10.3390/nu10070871:‬‬
‫‪10.2478/s11658-008-0048-z‬‬ ‫‪.75‬ﺇﻗﺒﺎﻝ ﺇﺱ‪ ،‬ﺯﻳﺒﻴﻠﻲ ﻛﻴﻮ‪ ،‬ﻣﺎﻧﺴﻤﺎﻥ ﺩﺍ‪ ،‬ﺩﺍﻥ ﺇﺱ ﺇﻡ‪ ،‬ﺃﻣﻴﺘﺎﺝ ﺑﻲ ﺇﻥ‪ .‬ﺍﻹﺩﺍﺭﺓ ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ ﻟـ ‪LPS‬‬
‫‪.‬ﻛﻤﻀﺨﻢﻓﻄﺮﻱ ﻟﻠﻌﺪﻭﻯ ﻭﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﺬﺍﺗﻴﺔ ﻭﺍﻟﺴﺮﻃﺎﻥ (ﻛﺎﻟﺒﺮﻭﺗﻜﺘﻴﻦ) ‪ S100A8 / S100A9‬ﺍﻟﺪﺍﺧﻠﻴﺔ‬ ‫ﻭﺣﻤﺾﺍﻟﺪﻫﻦ ﺍﻟﺪﻫﻨﻲ ﺍﻟﻤﺘﻔﺎﻋﻞ ﻗﺒﻞ ﺍﻟﻮﻻﺩﺓ ﻣﻦ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻄﺮﻳﺔ ﻭﺍﻟﺨﻠﻄﻴﺔ ﻓﻲ ﺃﺑﻘﺎﺭ ﺍﻷﻟﺒﺎﻥ‬
‫‪4‬ﻧﺎﻫﺾ ‪ Toll-like‬ﻣﺴﺘﻘﺒﻼﺕ ‪Ehrchen JM، Sunderkotter C، Foell D، Vogl T، Roth J.‬‬ ‫ﺍﻟﻤﺤﻴﻄﺔﺑﺎﻟﻮﻻﺩﺓ‪.‬ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻔﻄﺮﻳﺔ )‪ .390-400:(4)20 (2014‬ﺩﻭﻯ‪:‬‬
‫‪102.‬ﺟﻲ ﻟﻴﻮﻛﻮﻙ ﺑﻴﻮﻝ )‪ .557-66:(3)86 (2009‬ﺩﻭﻯ‪10.1189/jlb.1008647:‬‬ ‫‪10.1177/1753425913496125‬‬
‫‪.‬ﺍﻟﺨﻂﻓﻲ ﻧﻤﻮﺫﺝ ﺍﻟﻔﺄﺭﺓ ‪ MB49‬ﻋﻠﻰ ﺧﻠﻴﺔ ﺳﺮﻃﺎﻥ ﺍﻟﻤﺜﺎﻧﺔ ‪ LPS‬ﻭ ‪Unmethylated CpG‬‬ ‫‪.‬ﻓﻲﺳﺮﻃﺎﻥ ﺍﻟﺪﻡ ﺍﻟﺤﺎﺩ‪ :‬ﺍﻷﺩﻟﺔ ﺍﻟﺤﺎﻟﻴﺔ ﻭﺍﻻﺗﺠﺎﻫﺎﺕ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ ‪Y، Zhou C، Zhang A. Microbiota‬‬
‫‪:‬ﻭﻣﻨﺒﻬﺎﺕﺍﻟﻤﺴﺘﻘﺒﻼﺕ ﺍﻟﻤﺸﺎﺑﻬﺔ ‪ OX40‬ﺁﺛﺎﺭ ﻣﺰﻳﺞ ﻣﻦ ﺍﻷﺟﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﺃﺣﺎﺩﻳﺔ ﺍﻟﻨﺴﻴﻠﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟـ‬ ‫‪76. Zhou‬ﺍﻟﺠﺒﻬﺔ ﻣﻴﻜﺮﻭﺑﻴﻮﻝ )‪ .13:1045497 (2022‬ﺩﻭﻯ‪10.3389/fmicb.2022.1045497:‬‬
‫‪103. Gulyas D، Kovacs G، Jankovics I، Meszaros L، Lorincz M، Denes B.‬ﺑﻠﻮﺱ ﻭﺍﺣﺪ‬ ‫‪.‬ﺍﻟﺘﺄﺛﻴﺮﺍﺕﺍﻟﻤﺤﺘﻤﻠﺔ ﻟﻠﺒﺮﻳﺒﺎﻳﻮﺗﻜﺲ ﻭﺍﻟﺒﺮﻭﺑﻴﻮﺗﻴﻚ ﻋﻠﻰ ﺍﻟﻮﻗﺎﻳﺔ ﻣﻦ ﺍﻟﺴﺮﻃﺎﻥ ‪ 77. Samanta S.‬ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﻤﻀﺎﺩﺓ‬
‫)‪:‬ﺩﻭﻯ ‪10.1371/journal.pone.02708022022( 17)7(:e0270802.‬‬ ‫ﻟﻠﺴﺮﻃﺎﻥﻣﻴﺪ ﻛﻴﻢ )‪ .28–605:(4)22 (2022‬ﺩﻭﻯ‪10.2174/1871520621999201210220442:‬‬
‫‪.‬ﺍﻷﻧﺸﻄﺔﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻌﺪﻭﻯ ﻭﺍﻷﻭﺭﺍﻡ ﻟﻠﺒﻴﺘﺎﺟﻠﻮﻛﺎﻥ ‪104. Vetvicka V، Vetvickova J.‬ﺍﻟﺪﻗﺔ‬ ‫‪.78‬ﺳﻌﻴﺪ ﻡ‪ ،‬ﺷﻌﻴﺐ ﺃ‪ ،‬ﻛﺎﻧﺪﻳﻤﺎﻻ ﺭ‪ ،‬ﺟﺎﻓﻴﺪ ﺱ‪ ،‬ﺍﻟﻤﻄﺮﻭﺩﻱ ﺃ‪ ،‬ﻏﻮﺑﺘﺎ ﺭ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﻌﻼﺟﺎﺕ ﺍﻟﻘﺎﺋﻤﺔ‬
‫ﺍﻟﻤﻀﺎﺩﺓﻟﻠﺴﺮﻃﺎﻥ )‪ .45–3139:(6)40 (2020‬ﺩﻭﻯ‪/10.21873:‬ﺃﻧﺘﻴﻜﺎﻧﺮﻳﺲ‪14295.‬‬ ‫ﻋﻠﻰﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕ ﻟﺴﺮﻃﺎﻥ ﺍﻟﻘﻮﻟﻮﻥ ﻭﺍﻟﻤﺴﺘﻘﻴﻢ‪ :‬ﺍﻟﻤﺰﺍﻳﺎ ﻭﺍﻟﻘﻴﻮﺩ‪.‬ﺳﺮﻃﺎﻥ ﺍﻟﺴﺎﺋﻞ ﺍﻟﻤﻨﻮﻱ ﺑﻴﻮﻝ )‪(2022‬‬
‫‪.‬ﻣﻨﺸﻂﻣﻨﺎﻋﻲ‪ ،‬ﺩﻭﺍء ﻣﺴﺎﻋﺪ‪ ،‬ﻣﺤﺘﻤﻞ ‪105. Vetvicka V. Glucan -‬ﺍﻟﻌﺎﻟﻢ ‪ J‬ﻛﻠﻴﻦ ﺃﻭﻧﻜﻮﻝ )‪(2011‬‬ ‫‪)86‬ﺍﻟﺠﺰء ‪ .65–652:(3‬ﺩﻭﻯ‪10.1016/j.semcancer.2021.05.018:‬‬
‫‪ .9–115:(2)2‬ﺩﻭﻯ‪10.5306/wjco.v2.i2.115:‬‬ ‫‪.‬ﺍﻷﻣﻌﺎءﺍﻟﺪﻗﻴﻘﺔ‪ :‬ﻗﻄﻌﺔ ﺟﺪﻳﺪﺓ ﻓﻲ ﻓﻬﻢ ﺗﺴﺮﻃﻦ ﺍﻟﻜﺒﺪ ‪L، Zeng S، Lei Y، Yang S، Tang B.‬‬
‫‪.‬ﺑﻴﺘﺎﺟﻠﻮﻛﺎﻥ ﺍﻟﻤﺸﺘﻖ ﻣﻦ ﺍﻟﺨﻤﻴﺮﺓ ﻓﻲ ﺍﻟﺴﺮﻃﺎﻥ‪ :‬ﺍﺳﺘﺨﺪﺍﻣﺎﺕ ﺟﺪﻳﺪﺓ ﻟﻠﻌﻼﺝ ﺍﻟﺘﻘﻠﻴﺪﻱ ‪R، Yan J.‬‬ ‫‪79. Zhou A، Tang‬ﺍﻟﺴﺮﻃﺎﻥ ﻟﻴﺖ )‪ .22–15 :474 (2020‬ﺩﻭﻯ‪/ j.canlet.2020.01.002:‬‬
‫‪106. Geller A، Shrestha‬ﺇﻧﺖ ‪ J‬ﻣﻮﻝ ﺍﻟﻌﻠﻮﻡ )‪ .(15)20 (2019‬ﺩﻭﻯ‪10.3390/ijms20153618:‬‬ ‫‪10.1016‬‬
‫‪.‬ﺍﻷﺟﺴﺎﻡﺍﻟﻤﻀﺎﺩﺓ ﻭﺣﻴﺪﺓ ﺍﻟﻨﺴﻴﻠﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻮﺭﻡ ﺑﺎﻟﺘﺰﺍﻣﻦ ﻣﻊ ﺑﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ‪ :‬ﻋﻼﺝ ﻣﻨﺎﻋﻲ ﺟﺪﻳﺪ‬ ‫‪.80‬ﺻﺪﻳﻘﻲ ‪ ،AJ‬ﺟﺎﻫﺎﻥ ‪ ،S‬ﺳﻴﻨﻎ ‪ ،R‬ﺳﺎﻛﺴﻴﻨﺎ ‪ ،J‬ﺃﺷﺮﻑ ‪ ،SA‬ﺧﺎﻥ ‪ ،A‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﻨﺒﺎﺗﺎﺕ ﻓﻲ ﺍﻛﺘﺸﺎﻑ‬
‫ﻣﻀﺎﺩﻟﻠﺴﺮﻃﺎﻥ ‪107. Xiang D، Sharma VR، Freter CE، Yan J.‬ﻛﻮﺭ ﻣﻴﺪ ﻛﻴﻢ )‪(2012‬‬ ‫ﺍﻷﺩﻭﻳﺔﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ‪ :‬ﻣﻦ ﺍﻵﻟﻴﺔ ﺍﻟﺠﺰﻳﺌﻴﺔ ﺇﻟﻰ ﺍﻟﻮﻗﺎﻳﺔ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ‪.‬ﺑﻴﻮﻣﻴﺪ ﺍﻟﺪﻗﺔ ﻛﺜﺎﻓﺔ ﺍﻟﻌﻤﻠﻴﺎﺕ )‪(2022‬‬
‫‪ .305–4298:(25)19‬ﺩﻭﻯ‪10.2174/092986712802884303:‬‬ ‫‪.2022:5425485‬ﺩﻭﻯ‪10.1155/2022/5425485:‬‬
‫‪.108‬ﻟﻲ ﺑﻲ‪ ،‬ﻛﺎﻱ ﻭﺍﻱ‪ ،‬ﺗﺸﻲ ﺳﻲ‪ ،‬ﻫﺎﻧﺴﻦ ﺁﺭ‪ ،‬ﺩﻳﻨﻎ ﺳﻲ‪ ،‬ﻣﻴﺘﺸﻞ ﺗﻲ ﺳﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﻌﻤﻞ ﺟﺴﻴﻤﺎﺕ ﺑﻴﺘﺎ‬ ‫‪.81‬ﺷﻴﺎ ﻭﺍﻱ‪ ،‬ﻟﻴﺎﻥ ﺇﺱ‪ ،‬ﺧﻮﻱ ﺑﻲ ﺇﻥ‪ ،‬ﻳﻮﻥ ﺇﺗﺶ ﺟﻴﻪ‪ ،‬ﺟﻮ ﻳﻲ‪ ،‬ﺗﺸﺎﻱ ﻛﻮ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻤﻨﻊ ‪Chrysin‬‬
‫ﺟﻠﻮﻛﺎﻥﺍﻟﺘﻲ ﻳﺘﻢ ﺗﻨﺎﻭﻟﻬﺎ ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ ﻋﻠﻰ ﺗﻌﺪﻳﻞ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺠﺬﻋﻴﺔ ﺍﻟﺘﻲ ﺗﻠﺘﻘﻂ ﺍﻟﻮﺭﻡ ﻭﺗﺤﺴﻦ ﺍﺳﺘﺠﺎﺑﺎﺕ‬ ‫ﺗﻌﺒﻴﺮ‪ MMP-9‬ﺍﻟﻨﺎﺟﻢ ﻋﻦ ﻣﺮﻭﺝ ﺍﻟﻮﺭﻡ ﻋﻦ ﻃﺮﻳﻖ ﻣﻨﻊ ‪ AP-1‬ﻋﻦ ﻃﺮﻳﻖ ﻗﻤﻊ ﻣﺴﺎﺭﺍﺕ ‪ ERK‬ﻭ‪ JNK‬ﻓﻲ‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻮﺭﻡ ﻓﻲ ﺍﻟﺴﺮﻃﺎﻥ‪.‬ﺍﻟﺪﻗﺔ ﺍﻟﺴﺮﻳﺮﻳﺔ ﻟﻠﺴﺮﻃﺎﻥ )‪ .64–5153:(21)16 (2010‬ﺩﻭﻯ‪:‬‬ ‫ﺧﻼﻳﺎﺳﺮﻃﺎﻥ ﺍﻟﻤﻌﺪﺓ‪.‬ﺑﻠﻮﺱ ﻭﺍﺣﺪ )‪:‬ﺩﻭﻯ ‪/ Journal.pone.01240072015( 10)4(:e0124007.‬‬
‫‪10.1158/1078-0432.CCR-10-0820‬‬ ‫‪10.1371‬‬
‫‪.109‬ﻟﻴﻮ ﺇﻡ‪ ،‬ﻟﻮﻩ ﺇﻑ‪ ،‬ﺩﻳﻨﻎ ﺳﻲ‪ ،‬ﺍﻟﺒﻴﺘﻮﻧﻲ ﺇﺱ‪ ،‬ﻫﻮ ﺇﻛﺲ‪ ،‬ﻣﺎ ﻭﺍﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺆﺩﻱ ﺗﻨﺸﻴﻂ ‪-1‬‬ ‫‪.82‬ﺑﺎﺭﻙ ﺳﻲ‪ ،‬ﻟﻲ ﺩﺑﻠﻴﻮ ﺇﺱ‪ ،‬ﺟﻮ ﺳﻲ‪ ،‬ﻧﺎﺟﺎﺑﺎﻥ ﺇﻳﻪ‪ ،‬ﻫﺎﻥ ﺇﻡ ﺇﺗﺶ‪ ،‬ﻫﻮﻧﻎ ﺇﺱ ﺇﺗﺶ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻣﻮﺭﻳﻦ‪ ،‬ﻭﻫﻮ ﻓﻼﻓﻮﻧﻮﻳﺪ‬
‫‪ Dectin‬ﺑﻮﺍﺳﻄﺔ ﻣﻨﺘﺞ ﻃﺒﻴﻌﻲ ﺑﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ ﺇﻟﻰ ﺗﺤﻮﻳﻞ ﺍﻟﺒﻼﻋﻢ ﺍﻟﻤﺜﺒﻄﺔ ﻟﻠﻤﻨﺎﻋﺔ ﺇﻟﻰ ﻧﻤﻂ ﻇﺎﻫﺮﻱ‬ ‫ﻣﻦ‪ ،Moraceae‬ﻳﺤﺚ ﻋﻠﻰ ﻣﻮﺕ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻤﺒﺮﻣﺞ ﻋﻦ ﻃﺮﻳﻖ ﺗﺤﻔﻴﺰ ﺍﻟﺒﺮﻭﺗﻴﻦ ﺍﻟﺴﻴﺊ ﻓﻲ ﺧﻼﻳﺎ ﺳﺮﻃﺎﻥ ﺍﻟﺪﻡ ﺍﻟﺒﺸﺮﻳﺔ‪.‬‬
‫ﻳﺸﺒﻪ‪.M1‬ﻱ ﺇﻣﻮﻧﻮﻝ )‪ .5055-65:(10)195 (2015‬ﺩﻭﻯ‪/10.4049:‬ﺟﻴﻤﻮﻧﻮﻝ‪1501158.‬‬ ‫ﺇﻧﺖ‪ J‬ﻣﻮﻝ ﺍﻟﻌﻠﻮﻡ )‪ .59–645:(1)16 (2014‬ﺩﻭﻯ‪10.3390/ijms16010645:‬‬
‫‪.110‬ﺷﻴﻦ ﻭﺍﻱ‪ ،‬ﺟﻲ ﺇﺗﺶ‪ ،‬ﺗﺸﻮ ﺇﻱ‪ ،‬ﺭﻭﻩ ﻛﻲ ﺑﻲ‪ ،‬ﻳﻮ ﺟﻲ‪ ،‬ﺑﺎﺭﻙ ﺩﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﺄﺛﻴﺮ ﺗﻌﺰﻳﺰ ﺍﻟﻤﻨﺎﻋﺔ ﻟﻠﺒﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ‬ ‫‪.‬ﻭﺑﻴﻮﻟﻮﺟﻴﺎﺍﻟﺴﺮﻃﺎﻥ‪ :‬ﺗﺮﻛﻴﺰ ﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﺍﻟﺘﻨﻈﻴﻤﻴﺔ ﻓﻲ ﻣﺴﺎﺭﺍﺕ ﺍﻹﺷﺎﺭﺍﺕ ﺍﻟﻤﺨﺘﻠﻔﺔ ‪D. Curcumin‬‬
‫ﺍﻟﻘﺎﺑﻞﻟﻠﺬﻭﺑﺎﻥ ﻓﻲ ﺍﻟﻤﺎء ﻭﺍﻟﻤﺸﺘﻖ ﻣﻦ ﺍﻟﺘﺤﻠﻞ ﺍﻟﻤﺎﺋﻲ ﺍﻷﻧﺰﻳﻤﻲ ﻟﺠﻠﻮﻛﺎﻥ ﺍﻟﺨﻤﻴﺮﺓ‪.‬ﻣﻨﺪﻭﺏ ﺍﻟﻜﻴﻤﻴﺎء ﺍﻟﺤﻴﻮﻳﺔ ﻭﺍﻟﻔﻴﺰﻳﺎء‬ ‫‪83. Bhatia M، Bhalerao M، Cruz-Martins N، Kumar‬ﻓﻴﺘﻮﺛﺮ ﺍﻟﺪﻗﺔ )‪(9)35 (2021‬‬
‫ﺍﻟﺤﻴﻮﻳﺔ)‪ .30:101256 (2022‬ﺩﻭﻯ‪10.1016/j.bbrep.2022.101256:‬‬ ‫‪.4913-29:‬ﺩﻭﻯ‪10.1002/ptr.7121:‬‬
‫‪.111‬ﺍﻟﺒﻴﺘﻮﻧﻲ ﺇﺱ ﺇﺗﺶ‪ ،‬ﺩﻳﻨﺞ ﺳﻲ‪ ،‬ﻟﻴﻮ ﺇﻡ‪ ،‬ﻫﻮ ﺇﻛﺲ‪ ،‬ﻟﻮﻩ ﺇﻑ‪ ،‬ﻛﻠﻮﻛﺮ ﺟﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻌﻤﻞ ﻋﻼﺝ‬ ‫‪.‬ﺗﻘﻴﻴﻢﺍﻹﻣﻜﺎﻧﺎﺕ ﺍﻟﻌﻼﺟﻴﺔ ﺍﻟﺨﺎﺻﺔ ﺑﺎﻟﻬﺪﻑ ﻟﻠﻤﺮﻛﺒﺎﺕ ﺍﻟﻌﺸﺒﻴﺔ ﻟﻌﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ ‪I، Samant M.‬‬
‫ﺑﻴﺘﺎﺟﻠﻮﻛﺎﻥ ﺍﻟﺠﺰﻳﺌﻲ ﺍﻟﻤﺸﺘﻖ ﻣﻦ ﺍﻟﺨﻤﻴﺮﺓ ﻋﻠﻰ ﺗﺨﺮﻳﺐ ﻗﻤﻊ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻜﺎﺑﺘﺔ ﺍﻟﻤﺸﺘﻘﺔ ﻣﻦ ﺍﻟﻨﺨﺎﻉ‬ ‫‪84. Upreti S، Pandey SC، Bisht‬ﺍﻟﻐﻮﺍﺻﻴﻦ ﻣﻮﻝ )‪ .35–1823:(3)26 (2022‬ﺩﻭﻯ‪:‬‬
‫ﺍﻟﺸﻮﻛﻲ)‪ (MDSC‬ﻋﻦ ﻃﺮﻳﻖ ﺗﺤﻔﻴﺰ ﻣﻮﺕ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻤﺒﺮﻣﺞ ﻣﺘﻌﺪﺩ ﺍﻷﺷﻜﺎﻝ ﺍﻟﻨﻮﻯ ﻭﺗﻤﺎﻳﺰ ‪MDSC‬‬ ‫‪10.1007/s11030-021-10271-x‬‬
‫ﺃﺣﺎﺩﻱﺍﻟﺨﻠﻴﺔ ﺇﻟﻰ ‪ APC‬ﻓﻲ ﺍﻟﺴﺮﻃﺎﻥ‪.‬ﻱ ﺇﻣﻮﻧﻮﻝ )‪ .80–2167:(5)196 (2016‬ﺩﻭﻯ‪/10.4049:‬‬ ‫‪.‬ﺍﻟﺘﺤﺪﻳﺎﺕﺍﻟﻤﺤﺘﻤﻠﺔ ﻟﺒﺮﺍءﺍﺕ ﺍﻻﺧﺘﺮﺍﻉ ﻭﺍﻟﺘﺠﺎﺭﺏ ﺍﻟﺴﺮﻳﺮﻳﺔ ﻟﻠﻤﺮﻛﺒﺎﺕ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ ﻣﻦ‬
‫ﺟﻴﻤﻮﻧﻮﻝ‪1501853.‬‬ ‫ﺍﻟﻤﻨﺘﺠﺎﺕﺍﻟﻄﺒﻴﻌﻴﺔ‪ :‬ﻣﺮﺍﺟﻌﺔ ﻣﺘﻤﺎﺳﻜﺔ ‪A، Mandal AK، Kumar M، Dwivedi K، Singh D.‬‬
‫‪.112‬ﺩﻳﻨﻎ ﺟﻲ‪ ،‬ﻓﻨﻎ ﺗﻲ‪ ،‬ﻧﻴﻨﻎ ﻭﺍﻱ‪ ،‬ﻟﻲ ﺩﺑﻠﻴﻮ‪ ،‬ﻭﻭ ﻛﻴﻮ‪ ،‬ﺗﺸﻴﺎﻥ ﻛﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻌﺰﺯ ﺑﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ ﺍﺳﺘﺠﺎﺑﺎﺕ‬ ‫‪85. Sahoo‬ﺍﻛﺘﺸﺎﻑ ﺃﺣﺪﺙ ﺍﻷﺩﻭﻳﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ )‪ . (2022‬ﺩﻭﻯ ‪/10.2174:‬‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﻠﻤﻔﺎﻭﻳﺔ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﺴﺎﻣﺔ ﻟﻠﺨﻼﻳﺎ ﻋﻦ ﻃﺮﻳﻖ ﺗﻨﺸﻴﻂ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺠﺬﻋﻴﺔ ﺍﻟﻤﺸﺘﻘﺔ ﻣﻦ ﺍﻟﺨﻼﻳﺎ ﺍﻷﺣﺎﺩﻳﺔ‬ ‫‪1574892818666221104113703‬‬
‫ﺍﻟﺒﺸﺮﻳﺔﻋﺒﺮ ﻣﺴﺎﺭ ‪.PI3K / AKT‬ﻫﻮﻡ ﺇﻣﻮﻧﻮﻝ )‪ .146-54:(2-3)76 (2015‬ﺩﻭﻯ‪/ j.humimm.2015.01.009:‬‬
‫‪.‬ﺍﻟﻤﺴﺘﻘﻠﺒﺎﺕﺍﻟﻤﻴﻜﺮﻭﺑﻴﺔ ﺍﻟﻨﺸﻄﺔ ﺑﻴﻮﻟﻮﺟﻴﺎً ﻓﻲ ﻋﻼﺟﺎﺕ ﺍﻟﺴﺮﻃﺎﻥ‪ :‬ﺍﻟﺘﻌﺪﻳﻦ‪ ،‬ﻭﺇﻋﺎﺩﺓ ﺍﻻﺳﺘﺨﺪﺍﻡ‪،‬‬
‫‪10.1016‬‬
‫ﻭﺃﻫﺪﺍﻓﻬﺎﺍﻟﺠﺰﻳﺌﻴﺔ ‪86. Pattnaik S، Imchen M، Kumavath R، Prasad R، Busi S.‬‬
‫‪.113‬ﺳﻮ ﻭﺍﻱ‪ ،‬ﺗﺸﻦ ﺇﻝ‪ ،‬ﻳﺎﻧﻎ ﺇﻑ‪ ،‬ﺗﺸﻴﻮﻧﻎ ﺑﻲ ﺳﻲ ﻛﻴﻪ‪ .‬ﻧﻈﺎﻡ ﺗﻮﺻﻴﻞ ﺍﻟﺪﻭﺍء ﺍﻟﻤﻌﺘﻤﺪ ﻋﻠﻰ ﺑﻴﺘﺎ‪-‬ﺩ‪-‬‬ ‫ﻣﻴﻜﺮﻭﺑﻴﻮﻝﺍﻟﻌﻤﻠﺔ )‪ .300:(10)79 (2022‬ﺩﻭﻯ‪10.1007/s00284-022-02990-7:‬‬
‫ﺟﻠﻮﻛﺎﻥﻭﺗﻄﺒﻴﻘﻪ ﺍﻟﻤﺤﺘﻤﻞ ﻓﻲ ﺍﺳﺘﻬﺪﺍﻑ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺒﻠﻌﻤﻴﺔ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻮﺭﻡ‪.‬ﻛﺮﺑﻮﻫﻴﺪﺭﺍﺕ ﺑﻮﻟﻴﻢ )‪(2021‬‬ ‫‪.‬ﺍﻟﺤﻤﻰﻭﺣﺪﻭﺙ ﺍﻟﺴﺮﻃﺎﻥ ﻭﺍﻟﻬﺠﻮﻉ ﺍﻟﺘﻠﻘﺎﺋﻲ ‪R، Jonas WB، Knogler W، Stenzinger W.‬‬
‫‪.253:117258‬ﺩﻭﻯ‪10.1016/j.carbpol.2020.117258:‬‬ ‫‪87. Kleef‬ﺗﻌﺪﻳﻞ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻟﻌﺼﺒﻴﺔ )‪ .55-64:(2)9 (2001‬ﺩﻭﻯ‪10.1159/000049008:‬‬
‫‪.114‬ﺗﺸﺎﻥ ﺁﺵ‪ ،‬ﻛﺎﻧﻐﺎﺱ ﺗﻮ‪ ،‬ﺗﺸﻴﻮ ﺇﻛﺲ‪ ،‬ﺃﻭﻫﻠﻴﻚ ﺇﻡ ﺗﻲ‪ ،‬ﻓﻮﻟﺘﻮﻥ ﺁﺭ ﺑﻲ‪ ،‬ﺃﻭﺗﻮﺳﻮﻥ ﺇﻥ ﺁﺭ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻌﺰﺯ‬
‫‪ Imprime PGG‬ﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻮﺭﻡ ﻟﻸﺟﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﻻﺳﺘﻬﺪﺍﻑ ﺍﻟﻮﺭﻡ ﻭﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺘﻜﻮﻳﻦ ﺍﻟﻮﻋﺎﺋﻲ‬
‫‪.‬ﺍﺳﺘﻬﺪﻑﺍﺭﺗﻔﺎﻉ ﺍﻟﺤﺮﺍﺭﺓ ﺑﺎﻟﻘﺮﺏ ﻣﻦ ﺍﻷﺷﻌﺔ ﺗﺤﺖ ﺍﻟﺤﻤﺮﺍء ﻣﻊ ﺍﻟﺘﺤﻔﻴﺰ ﺍﻟﻤﻨﺎﻋﻲ ﻟﺘﺤﺴﻴﻦ ﺍﻟﻔﻌﺎﻟﻴﺔ‬
‫ﻭﺍﻷﺟﺴﺎﻡﺍﻟﻤﻀﺎﺩﺓ ﻟﻨﻘﺎﻁ ﺍﻟﺘﻔﺘﻴﺶ ﺍﻟﻤﻨﺎﻋﻴﺔ‪.‬ﺃﻭﻧﻜﻮﻝ ﺃﻣﺎﻣﻲ )‪ .12:869078 (2022‬ﺩﻭﻯ‪:‬‬
‫ﺍﻟﻌﻼﺟﻴﺔﻓﻲ ﻋﻼﺝ ﺳﺮﻃﺎﻥ ﺍﻟﻐﺪﺓ ﺍﻟﺪﺭﻗﻴﺔ ‪88. Zhou L، Zhang M، Fu Q، Li J، Sun H.‬‬
‫‪10.3389/fonc.2022.869078‬‬
‫ﺃﻭﻧﻜﻮﺗﺎﺭﻏﺖ)‪ .90–6878:(6)7 (2016‬ﺩﻭﻯ‪10.18632/oncotarget.6901:‬‬
‫‪.‬ﺁﺛﺎﺭﺑﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ ﻋﻠﻰ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺠﺬﻋﻴﺔ ﻭﺁﺛﺎﺭﻫﺎ ﻋﻠﻰ ﻋﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ ‪115. Albeituni SH، Yan J.‬‬ ‫‪.89‬ﺳﻠﻴﻤﺎﻧﻲ ﻥ‪ ،‬ﺟﻮﺍﺩﻱ ﻡ‪.‬ﻡ‪ .‬ﺍﻵﻓﺎﻕ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ ﻟﻌﻼﺟﺎﺕ ﺍﻟﺴﺮﻃﺎﻥ ﺑﻮﺳﺎﻃﺔ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ‪ :‬ﻣﺤﻨﺔ ﺃﻡ‬
‫ﺍﻟﻌﻮﺍﻣﻞﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ ﻣﻴﺪ ﻛﻴﻢ )‪ .98–689:(5)13 (2013‬ﺩﻭﻯ‪/1871520611313050003:‬‬ ‫ﻓﺮﺻﺔ؟ﺍﻟﻤﻴﻜﺮﻭﺏ ﺍﻟﻤﺮﺿﻲ )‪ .172:105795 (2022‬ﺩﻭﻯ‪10.1016/ j.micpath.2022.105795:‬‬
‫‪10.2174‬‬
‫‪.116‬ﺗﻘﻮﻱ ﻡ‪ ،‬ﻣﺮﺗﺰ ﺇ‪ ،‬ﺧﺴﺮﻭﻱ ﺃ‪ ،‬ﻓﺎﻫﻴﺪﻱ ﺝ‪ ،‬ﻓﻮﻟﻜﺮﺗﺲ ﺝ‪ ،‬ﻓﺎﺭﺍﻫﺮﺍﻡ ﻡ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺨﻔﻒ ﺯﻳﻤﻮﺳﺎﻥ‬ ‫‪.‬ﺧﻴﺎﺭﺍﺕﺍﻟﻌﻼﺝ ﺍﻟﻨﺎﺷﺌﺔ ﻟﺴﺮﻃﺎﻥ ﺍﻟﻤﺜﺎﻧﺔ ﻏﻴﺮ ﺍﻟﻐﺎﺯﻱ ﻏﻴﺮ ﺍﻟﻤﺴﺘﺠﻴﺐ ﻟﻠﻌﻀﻼﺕ ‪، Ory J، Saad F.‬‬
‫ﺗﻄﻮﺭﻧﻤﻮ ﺳﺮﻃﺎﻥ ﺍﻟﺠﻠﺪ‪ ،‬ﻭﻳﺰﻳﺪ ﻣﻦ ﺗﻜﺎﺛﺮ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻄﺤﺎﻟﻴﺔ ﻭﻳﺤﻔﺰ ﺗﻌﺒﻴﺮ ‪ TLR-2/4‬ﻭ‪ TNF-alpha‬ﻓﻲ‬ ‫‪90. Kokorovic A‬ﺩﻋﻢ ﺍﻟﺮﺃﻱ ﺍﻟﻌﺎﻡ ﺑﺎﻟﻌﻤﻠﺔ ﺍﻟﻤﻠﻄﻔﺔ )‪ .53–48:(1)16 (2022‬ﺩﻭﻯ‪:‬‬
‫ﺍﻟﻔﺌﺮﺍﻥ‪.‬ﺍﻟﺘﻬﺎﺏ ﻱ )ﻟﻮﻧﺪ( )‪ .15 (20185‬ﺩﻭﻱ‪:‬ﺫ‪10.1186/s12950-018-0182-‬‬ ‫‪10.1097/SPC.0000000000000587‬‬
‫‪.91‬ﺟﺎﺭﺳﻴﺎ ﻣﺎﺭﺗﻴﻨﻴﺰ ﺇﻱ‪ ،‬ﺳﻤﻴﺚ ﺇﻡ‪ ،‬ﺑﻮﻛﻲ ﺇﻳﻪ‪ ،‬ﺃﺭﺍﻧﺪﺍ ﺇﻑ‪ ،‬ﺩﻱ ﻻ ﺑﻴﻨﺎ ﺇﻑ ﺇﻳﻪ‪ ،‬ﺇﻳﻔﺎﺭﺯ ﺇﻳﻪ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬
‫‪.117‬ﺟﻴﻠﺮ ﺇﻳﻪ ﺇﻱ‪ ،‬ﺷﺮﻳﺴﺘﺎ ﺁﺭ‪ ،‬ﻭﻭﺳﺘﻲ ﺇﻡ ﺁﺭ‪ ،‬ﺟﻮﻭ ﺇﺗﺶ‪ ،‬ﻫﻮ ﺇﻛﺲ‪ ،‬ﺩﻳﻨﻎ ﺳﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﺤﺮﻳﺾ‬ ‫ﻣﺮﺍﻗﺒﺔﺍﻟﺘﺠﺮﺑﺔ‪ :‬ﺍﻟﺘﺤﻔﻴﺰ ﺍﻟﻤﻨﺎﻋﻲ ﺑﺎﺳﺘﺨﺪﺍﻡ ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﺍﻟﻤﺆﺗﻠﻔﺔ ﻟﻌﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ‪ .‬ﻋﻠﻢ ﺍﻟﻤﻨﺎﻋﺔ‬
‫ﺍﻟﻤﻨﺎﻋﺔﺍﻟﻤﺪﺭﺑﺔ ﺍﻟﻤﺤﻴﻄﻴﺔ ﻓﻲ ﺍﻟﺒﻨﻜﺮﻳﺎﺱ ﻳﺤﻔﺰ ﺍﻟﻨﺸﺎﻁ ﺍﻟﻤﻀﺎﺩ ﻟﻠﻮﺭﻡ ﻟﻠﺴﻴﻄﺮﺓ ﻋﻠﻰ ﺗﻄﻮﺭ ﺳﺮﻃﺎﻥ‬ ‫ﺍﻷﻭﺭﺍﻡ)‪:‬ﺩﻭﻯ ‪10.1080/2162402X.2018.14339822018( 7)6(:e1433982.‬‬
‫ﺍﻟﺒﻨﻜﺮﻳﺎﺱ‪.‬ﻧﺎﺕ ﻛﻮﻣﻮﻥ )‪ .759:(1)13 (2022‬ﺩﻭﻯ‪10.1038/s41467- 022-28407-4:‬‬
‫‪.92‬ﻣﺎﻳﻮﺭﺍﻧﻮ ﺑﻲ ﺇﻳﻪ‪ ،‬ﻣﺎﻳﻮﺭﺍﻧﻮ ﺇﻡ ﺇﻑ ﺑﻲ‪ ،‬ﺳﻴﺎﺭﺩﻳﻠﻮ ﺩﻱ‪ ،‬ﻣﺎﺟﻠﻴﻮﻧﻲ ﺇﻳﻪ‪ ،‬ﺃﻭﺭﺩﻳﺘﻮﺭﺍ ﺇﻡ‪ ،‬ﻟﻮﺭﻭﺳﻮ‬
‫ﺩ‪،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻣﺎ ﻭﺭﺍء ﺍﻟﺒﻼﺗﻴﻦ‪ ICIs ،‬ﻓﻲ ﺳﺮﻃﺎﻥ ﻋﻨﻖ ﺍﻟﺮﺣﻢ ﺍﻟﻨﻘﻴﻠﻲ‪ :‬ﻣﺮﺍﺟﻌﺔ ﻣﻨﻬﺠﻴﺔ‪ .‬ﺍﻟﺴﺮﻃﺎﻥ )ﺑﺎﺯﻝ( )‬
‫‪.118‬ﻳﻮﻥ ﺗﻲ ﺟﻴﻪ‪ ،‬ﻛﻮﺑﻮﻻ ﺇﺱ‪ ،‬ﻟﻲ ﻛﻴﻪ ﺇﺗﺶ‪ .‬ﺁﺛﺎﺭ ﺑﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ ﻋﻠﻰ ﻭﺭﻡ ﺧﺒﻴﺚ ﻓﻲ ﺍﻟﺴﺮﻃﺎﻥ‪ .‬ﺍﻟﻌﻮﺍﻣﻞ‬
‫‪ .(23)14 (2022‬ﺩﻭﻯ‪/10.3390:‬ﺍﻟﺴﺮﻃﺎﻥ‪14235955‬‬
‫ﺍﻟﻤﻀﺎﺩﺓﻟﻠﺴﺮﻃﺎﻥ ﻣﻴﺪ ﻛﻴﻢ )‪ .699-708:(5)13 (2013‬ﺩﻭﻯ‪10.2174/1871520611313050004:‬‬
‫‪.‬ﺍﻟﻌﻼﺝﺍﻟﺨﻠﻮﻱ ﻭﻋﻼﺟﺎﺕ ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﻟﻠﻮﺭﻡ ﺍﻟﻤﻴﻼﻧﻴﻨﻲ ‪93. Borgers JSW، Haanen J.‬‬
‫‪.119‬ﺳﺘﻴﻤﺒﺎﺥ ﺇﻝ‪ ،‬ﺑﻮﺭﺟﻤﺎﻥ ﺇﻳﻪ ﻓﻲ‪ ،‬ﺟﻮﻣﺎﺭ ﺟﻲ ﺟﻲ‪ ،‬ﻫﻮﻓﻤﺎﻥ ﺇﻝ ﻓﻲ‪ ،‬ﺭﻭﺗﻜﻴﻔﻴﺴﻜﻲ ﺁﺭ‪ ،‬ﺩﻱ‬ ‫ﻫﻴﻤﺎﺗﻮﻝﺃﻭﻧﻜﻮﻝ ﻛﻠﻴﻦ ﻧﻮﺭﺙ ﺁﻡ )‪ .44–129:(1)35 (2021‬ﺩﻭﻯ‪10.1016/j.hoc.2020.08.014:‬‬
‫ﺃﻧﺪﺭﺍﺩﻱﺩﻱ ﺑﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﺒﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ ﺍﻟﻔﻄﺮﻳﺔ ﻛﻤﻮﺍﺩ ﻣﺴﺎﻋﺪﺓ ﻟﻌﻼﺝ ﻣﺮﺿﻰ ﺍﻟﺴﺮﻃﺎﻥ ‪ -‬ﻣﺮﺍﺟﻌﺔ‬
‫ﻣﻨﻬﺠﻴﺔﻟﻠﺘﺠﺎﺭﺏ ﺍﻟﺴﺮﻳﺮﻳﺔ‪.‬ﻛﻠﻴﻦ ﻧﻮﺗﺮ )‪ .13–3104:(5)40 (2021‬ﺩﻭﻯ‪/ j.clnu.2020.11.029:‬‬ ‫‪.94‬ﻛﻮﻧﻠﻮﻥ ﻛﻴﻪ ﺳﻲ‪ ،‬ﻣﻴﻠﻴﻜﻮﻓﻴﺘﺶ ﺇﻡ ﺩﻱ‪ ،‬ﻓﺎﻟﺪﻣﺎﻥ ﺗﻲ ﺇﻳﻪ‪ .‬ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﻓﻲ ﻋﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ‪).‬‬
‫‪10.1016‬‬ ‫ﺍﻧﺘﺮﻓﻴﺮﻭﻥﺳﻴﺘﻮﻛﻴﻦ ﺍﻟﺪﻗﺔ ‪ .6-21:(1)39 (2019J‬ﺩﻭﻯ‪10.1089/jir.2018.0019:‬‬
‫‪.120‬ﺑﻮﺯ ﺇﻥ‪ ،‬ﺃﻭﺗﻮﺳﻮﻥ ﺇﻥ ﺁﺭ‪ ،‬ﺗﺸﻴﻮ ﺇﻛﺲ‪ ،‬ﻫﺎﺭﻳﺴﻮﻥ ﺑﻲ‪ ،‬ﻟﻮﻱ ﺟﻴﻪ ﺁﺭ‪ ،‬ﺃﻭﻫﻠﻴﻚ ﺇﻡ ﺗﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬ ‫‪.‬ﻟﻘﺎﺣﺎﺕﺧﺎﺻﺔ ﺑﻤﺴﺘﻀﺪﺍﺕ ﻟﻌﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ ‪ML، Buonaguro FM، Buonaguro L.‬‬
‫ﺍﻻﺳﺘﺠﺎﺑﺎﺕﺍﻟﺪﻳﻨﺎﻣﻴﻜﻴﺔ ﺍﻟﺪﻭﺍﺋﻴﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻠﺴﺮﻃﺎﻥ ﺍﻟﻌﻼﺟﻲ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﺠﺪﻳﺪ ‪ PGG‬ﻟﺪﻯ ﻣﺘﻄﻮﻋﻴﻦ‬ ‫‪95. Tagliamonte M، Petrizzo A، Tornesello‬ﻫﻮﻡ ﺍﻟﻠﻘﺎﺡ ﺍﻟﻤﻨﺎﻋﻲ )‪–3332:(11) 10 (2014‬‬
‫ﺃﺻﺤﺎء‪.‬ﻱ ﺇﻣﻮﻧﻮﻝ )‪ .56–2945:(10)202 (2019‬ﺩﻭﻯ‪/10.4049:‬ﺟﻴﻤﻮﻧﻮﻝ‪1801533.‬‬ ‫‪.46‬ﺩﻭﻯ‪10.4161/21645515.2014.973317:‬‬
‫‪.‬ﺍﻟﻜﺎﺋﻨﺎﺕﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻓﻲ ﺍﻟﻔﻢ ﻭﺍﻷﻣﻌﺎء ﻓﻲ ﺳﺮﻃﺎﻥ ﺍﻟﻘﻮﻟﻮﻥ ﻭﺍﻟﻤﺴﺘﻘﻴﻢ‪ :‬ﺍﻻﻟﺘﻬﺎﺏ ﻭﻛﺒﺖ‬ ‫‪.‬ﺗﺄﺛﻴﺮﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﺍﻟﻠﻔﺎﺋﻔﻴﺔ ﻋﻠﻰ ﺳﺮﻃﺎﻥ ﺍﻟﻘﻮﻟﻮﻥ ‪، Rauber C، Kroemer G، Zitvogel L.‬‬
‫ﺍﻟﻤﻨﺎﻋﺔ ‪ )121. Mo S، Ru H، Huang M، Cheng L، Mo X، Yan L.‬ﺍﻟﺘﻬﺎﺏ ﺍﻟﺪﻗﺔ ‪(2022J‬‬ ‫‪96. Roberti MP‬ﺳﺮﻃﺎﻥ ﺍﻟﺴﺎﺋﻞ ﺍﻟﻤﻨﻮﻱ ﺑﻴﻮﻝ )‪)86 (2022‬ﺍﻟﺠﺰء ‪ .66–955:(2‬ﺩﻭﻯ‪:‬‬
‫‪ .59–15:747‬ﺩﻭﻯ‪/10.2147:‬ﺟﻴﺮ‪S344321.‬‬ ‫‪10.1016/ j.semcancer.2021.09.016‬‬
‫‪.122‬ﺩﻳﺒﻨﺎﺙ ﺇﻥ‪ ،‬ﺛﺎﻛﻮﺭ ﺇﻡ‪ ،‬ﺧﻮﺷﺒﻮ ﺇﻥ ﺑﻲ‪ ،‬ﻏﻮﺗﺎﻡ ﺍﻟﺨﺎﻣﺲ‪ ،‬ﻛﻮﻣﺎﺭ ﻳﺎﺩﺍﻑ ﺃ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻧﻈﺮﺓ ﺛﺎﻗﺒﺔ‬ ‫‪.97‬ﺑﺎﺗﻴﻦ ﺇﻱ ﺳﻲ‪ ،‬ﻃﻮﻣﺴﻮﻥ ﺃ‪ ،‬ﺃﻭﺭ ﺇﺱ ﺟﻴﻪ‪ .‬ﻣﺴﺘﻘﺒﻼﺕ ﺍﻟﺘﻌﺮﻑ ﻋﻠﻰ ﺍﻷﻧﻤﺎﻁ ﻓﻲ ﺍﻟﻤﻨﺎﻋﺔ‬
‫ﺍﻟﻠﻘﺎﺣﺎﺕﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ ﻛﻨﻬﺞ ﺑﺪﻳﻞ ﻹﺩﺍﺭﺓ ﺍﻟﺼﺤﺔ ﻭﺍﻷﻣﺮﺍﺽ‪ :‬ﺣﺪﺱ ﻭﺗﺤﺪﻳﺎﺕ ﻣﺒﺘﻜﺮﺓ‪.‬ﺍﻟﺘﻜﻨﻮﻟﻮﺟﻴﺎ‬ ‫ﺍﻟﻔﻄﺮﻳﺔ‪.‬ﺳﻴﻤﻴﻦ ﺳﻴﻞ ﺩﻳﻒ ﺑﻴﻮﻝ )‪ .89:24-33 (2019‬ﺩﻭﻯ‪10.1016/j.semcdb.2018.03.003:‬‬
‫ﺍﻟﺤﻴﻮﻳﺔﺍﻟﺤﻴﻮﻳﺔ )‪ .46–327:(2)119 (2022‬ﺩﻭﻯ‪10.1002/bit.27987:‬‬ ‫‪.‬ﻓﻲﺗﻄﻮﺭ ﺍﻟﺴﺮﻃﺎﻥ ﻭﻋﻼﺟﻪ ‪ Toll-like 4‬ﺗﻨﺸﻴﻂ ﻣﺴﺘﻘﺒﻼﺕ ‪98. Oblak A، Jerala R.‬ﻛﻠﻴﻦ ﺩﻳﻒ‬
‫ﺇﻳﻤﻮﻧﻮﻝ)‪ .2011:609579 (2011‬ﺩﻭﻯ‪10.1155/2011/609579:‬‬
‫‪.123‬ﺳﺘﺎﻧﺪﺭ ﺟﻴﻪ‪ ،‬ﻣﺒﻴﻮﺍﻧﺎ ﺇﺱ‪ ،‬ﻣﺎﻳﺮﺯ ﺇﻳﻪ ﺇﻱ‪ .‬ﺍﻟﻠﻘﺎﺣﺎﺕ ﺍﻟﺒﺸﺮﻳﺔ ﺍﻟﻤﺸﺘﻘﺔ ﻣﻦ ﺍﻟﻨﺒﺎﺗﺎﺕ‪ :‬ﺍﻟﺘﻄﻮﺭﺍﺕ ﺍﻷﺧﻴﺮﺓ‪.‬‬ ‫‪.‬ﻭﺩﻭﺭﻫﺎﻓﻲ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺪﻣﻮﻳﺔ ﺍﻟﺨﺒﻴﺜﺔ ‪ Toll-like‬ﻣﺴﺘﻘﺒﻼﺕ ‪Wolska A، Lech-Maranda E، Robak T.‬‬
‫ﺍﻷﺩﻭﻳﺔﺍﻟﺤﻴﻮﻳﺔ )‪ .(2022‬ﺩﻭﻯ‪10.1007/s40259-022-00544-8:‬‬ ‫‪99.‬ﻛﻮﺭ ﻣﻮﻝ ﻣﻴﺪ )‪ .35–324:(3)9 (2009‬ﺩﻭﻯ‪10.2174/156652409787847182:‬‬

‫‪.147‬ﺟﻮﺑﺘﺎ ﺩ‪ ،‬ﺳﻴﻠﻔﺎ ﺇﻡ‪ ،‬ﺭﺍﺩﺯﻳﻮﻥ ﻛﻴﻪ‪ ،‬ﻣﺎﺭﺗﻴﻨﻴﺰ ﺩﻱ ﺳﻲ‪ ،‬ﻫﻴﻞ ﺳﻲ ﺟﻴﻪ‪ ،‬ﻣﺎﺭﺷﺎﻝ ﺟﻴﻪ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬ ‫‪.‬ﻣﺮﺍﺟﻌﺔﻋﻠﻰ ﺍﻟﻠﻘﺎﺣﺎﺕ ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ ﻭﺍﻟﻤﻨﺘﺠﺎﺕ ﺍﻟﺼﻴﺪﻻﻧﻴﺔ ﺍﻟﺤﻴﻮﻳﺔ ﻣﻦ ﺍﻟﻨﺒﺎﺗﺎﺕ ‪T، Jain A.‬‬
‫ﺗﺜﺒﻴﻂﺍﻟﻔﻮﻛﻮﻳﺪﺍﻥ ﻟﺨﻼﻳﺎ ﺍﻟﺴﺎﺭﻛﻮﻣﺎ ﺍﻟﻌﻈﻤﻴﺔ ﻳﻌﺘﻤﺪ ﻋﻠﻰ ﺍﻷﻧﻮﺍﻉ ﻭﺍﻟﻮﺯﻥ ﺍﻟﺠﺰﻳﺌﻲ‪.‬ﻣﺨﺪﺭﺍﺕ ﻣﺎﺭ )‪(2020‬‬ ‫‪124. Paradia PK، Bhavale R، Agnihotri‬ﻛﻮﺭ ﻓﺎﺭﻡ ﻟﻠﺘﻜﻨﻮﻟﻮﺟﻴﺎ ﺍﻟﺤﻴﻮﻳﺔ )‪ .(2022‬ﺩﻭﻯ‪/10.2174:‬‬
‫‪ .(2)18‬ﺩﻭﻯ‪10.3390/md18020104:‬‬ ‫‪1389201023666220803151039‬‬
‫‪.‬ﻣﺸﺘﻖﻣﻦ ﺍﻟﺤﻮﻳﺼﻠﺔ ﻓﻮﻗﻴﺔ ﻳﻤﻨﻊ ﺗﻄﻮﺭ ﺳﺮﻃﺎﻥ ﺍﻟﻤﺒﻴﺾ ﺍﻟﺒﺸﺮﻱ ﻋﻦ ﻃﺮﻳﻖ ﺍﺿﻄﺮﺍﺏ ﺗﻮﺍﺯﻥ‬ ‫‪.125‬ﺳﻤﻴﺚ ‪ ،KM‬ﺩﻳﻔﻴﺪﺳﻮﻥ ‪ .JM، Garside P‬ﻳﺤﺪﺙ ﺗﻨﺸﻴﻂ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﻓﻲ ﻭﻗﺖ ﻭﺍﺣﺪ‬
‫ﺍﻟﻜﺎﻟﺴﻴﻮﻡ‪،‬ﻭﺇﺟﻬﺎﺩ ﺍﻟﺸﺒﻜﺔ ﺍﻹﻧﺪﻭﺑﻼﺯﻣﻴﺔ‪ ،‬ﻭﺗﻮﻟﺪ ﺍﻷﻭﻋﻴﺔ ‪JY، Yang C، Song G، Lim W. Fucoidan‬‬ ‫ﻓﻲﺍﻷﻧﺴﺠﺔ ﺍﻟﻠﻤﻔﺎﻭﻳﺔ ﺍﻟﻤﺤﻠﻴﺔ ﻭﺍﻟﻤﺤﻴﻄﻴﺔ ﺑﻌﺪ ﺗﻨﺎﻭﻝ ﻣﺠﻤﻮﻋﺔ ﻣﻦ ﺟﺮﻋﺎﺕ ﻣﻦ ﺍﻟﻤﺴﺘﻀﺪ ﺍﻟﻤﻨﺎﻋﻲ ﺃﻭ‬
‫‪148. Bae H، Lee‬ﻣﺨﺪﺭﺍﺕ ﻣﺎﺭ )‪ .(1)18 (2020‬ﺩﻭﻯ‪10.3390/md18010045:‬‬ ‫ﺍﻟﻤﺘﺴﺎﻣﺢﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ ﻋﻠﻰ ﺍﻟﺮﻏﻢ ﻣﻦ ﺃﻥ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﻤﺘﺴﺎﻣﺤﺔ ﺗﻈﻬﺮ ﺧﻠﻼً ﻓﻲ ﺍﻧﻘﺴﺎﻡ ﺍﻟﺨﻼﻳﺎ‪.‬‬
‫ﻋﻠﻢﺍﻟﻤﻨﺎﻋﺔ )‪ .144-58:(2)106 (2002‬ﺩﻭﻯ‪10.1046/j.1365-2567.2002.01427.x:‬‬
‫‪.149‬ﺗﺸﺎﻧﻎ ﺟﻴﻪ‪ ،‬ﺭﻳﺒﻲ ﺟﻲ ﺇﻱ‪ ،‬ﻛﻮﻧﺪﻱ ﺇﻝ‪ ،‬ﺟﺮﻳﺰﻝ ﻭﻱ‪ ،‬ﻛﻮﻱ ﺇﻛﺲ‪ ،‬ﺳﻜﻴﺒﻮﻻ ﺳﻲ ﺇﻑ‪ .‬ﻳﻤﻨﻊ ﻣﺴﺘﺨﻠﺺ ﺍﻟﺤﻮﻳﺼﻠﺔ‬ ‫‪.126‬ﺟﺎﻟﻴﺸﺎﻥ ﺩﺑﻠﻴﻮ ﺇﺱ‪ ،‬ﺭﻭﺯﻧﺘﺎﻝ ﻛﻮﺍﻻﻟﻤﺒﻮﺭ‪ .‬ﺫﺍﻛﺮﺓ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻠﻤﻔﺎﻭﻳﺔ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﺴﺎﻣﺔ ﻟﻠﺨﻼﻳﺎ ﻃﻮﻳﻠﺔ ﺍﻷﻣﺪ‬
‫ﻓﻮﻕﺗﻨﺸﻴﻂ ﻣﺴﺘﻘﺒﻼﺕ ﻫﺮﻣﻮﻥ ﺍﻻﺳﺘﺮﻭﺟﻴﻦ ﻭﻳﺤﺚ ﻋﻠﻰ ﻣﻮﺕ ﺍﻟﺨﻼﻳﺎ ﻓﻲ ﺧﻄﻮﻁ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺴﺮﻃﺎﻧﻴﺔ ﺍﻷﻧﺜﻮﻳﺔ‪.‬ﻣﻜﻤﻞ‬ ‫ﻓﻲﺍﻷﻧﺴﺠﺔ ﺍﻟﻤﺨﺎﻃﻴﺔ ﺑﻌﺪ ﺍﻟﺘﺤﺼﻴﻦ ﺍﻟﻤﺨﺎﻃﻲ ﻭﻟﻜﻦ ﻟﻴﺲ ﺍﻟﺠﻬﺎﺯﻱ‪.‬ﺟﻲ ﺇﻛﺴﺐ ﻣﻴﺪ )‪184 (1996‬‬
‫‪ BMC‬ﺍﻟﺒﺪﻳﻞ ﺍﻟﻤﺘﻮﺳﻂ )‪ .16:151 (2016‬ﺩﻭﻯ‪10.1186/s12906- 016-1129-6:‬‬ ‫)‪ .90–1879:(5‬ﺩﻭﻯ‪10.1084/jem.184.5.1879:‬‬
‫‪.150‬ﺑﻼﺯﻛﺰﺍﻙ ﺩﺑﻠﻴﻮ‪ ،‬ﻻﺗﺶ ﺇﻡ ﺇﺱ‪ ،‬ﺑﺎﺭﻛﺰﺍﻙ ﺩﺑﻠﻴﻮ‪ ،‬ﺳﻮﺷﻮﺭﺳﻜﺎ ﺩﺑﻠﻴﻮ ﺇﻡ‪ .‬ﻳﻤﺎﺭﺱ ﺍﻟﻔﻮﻛﻮﻳﺪﺍﻥ ﺗﺄﺛﻴﺮﺍﺕ‬ ‫‪.127‬ﻭﻭﻟﻔﺮﺗﻮﻥ ﺳﻲ ﺟﻴﻪ‪ ،‬ﻫﻮﻟﺖ ﺇﻝ ﺳﻲ‪ ،‬ﻣﻴﺘﺸﻞ ﺩ‪ ،‬ﺳﺎﺭﺗﻮﺭ ﺁﺭ ﺑﻲ‪ .‬ﺗﺤﺪﻳﺪ ﻭﺗﻮﺻﻴﻒ ﺧﻼﻳﺎ‬
‫ﻣﻀﺎﺩﺓﻟﻠﺴﺮﻃﺎﻥ ﺿﺪ ﺳﺮﻃﺎﻥ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺤﺮﺷﻔﻴﺔ ﻓﻲ ﺍﻟﺮﺃﺱ ﻭﺍﻟﺮﻗﺒﺔ ﻓﻲ ﺍﻟﻤﺨﺘﺒﺮ‪.‬ﺍﻟﺠﺰﻳﺌﺎﺕ )‪.(12) 23 (2018‬‬ ‫ﺍﻟﺼﻔﻴﺤﺔﺍﻟﻤﺨﺼﻮﺻﺔ ﺍﻟﻤﻌﻮﻳﺔ ﻟﺪﻯ ﺍﻟﻔﺌﺮﺍﻥ‪ :‬ﻋﻮﺍﻗﺐ ﺍﻻﺳﺘﻌﻤﺎﺭ ﺍﻟﻤﻴﻜﺮﻭﺑﻲ‪.‬ﺍﻟﻄﺒﻴﺐ ﺍﻟﺒﻴﻄﺮﻱ ﺇﻣﻮﻧﻮﻝ‬
‫ﺩﻭﻯ‪/10.3390:‬ﺟﺰﻳﺌﺎﺕ‪23123302‬‬ ‫ﺇﻣﻮﻧﻮﺑﺎﺛﻮﻝ)‪ .38–127:(1-2)34 (1992‬ﺩﻭﻯ‪-90156(92)2427 -10.1016/0165:‬ﻙ‬
‫‪.151‬ﺷﻴﻦ ﺇﺗﺶ ﻭﺍﻱ‪ ،‬ﻟﻲ ﺇﻝ ﺯﺩ‪ ،‬ﺷﻴﻮﻳﻪ ﻛﻴﻪ ﺳﻲ‪ ،‬ﻫﻮ ﺩﻱ ﺩﻱ‪ ،‬ﺟﺎﻭ ﻭﺍﻱ ﺟﻲ‪ .‬ﺍﻟﻨﺸﺎﻁ ﺍﻟﻤﻀﺎﺩ ﻟﻠﻮﺭﻡ ﻟﻠﻔﻮﻛﻮﻳﺪﺍﻥ ﻓﻲ ﺳﺮﻃﺎﻥ‬
‫ﺍﻟﻐﺪﺓﺍﻟﺪﺭﻗﻴﺔ ﺍﻟﻜﺸﻤﻲ ﻋﻦ ﻃﺮﻳﻖ ﻣﻮﺕ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻤﺒﺮﻣﺞ ﻭﻣﻜﺎﻓﺤﺔ ﺗﻜﻮﻳﻦ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺪﻣﻮﻳﺔ‪.‬ﻣﻤﺜﻞ ﻣﻮﻝ ﻣﻴﺪ‪.4–2620:(5) 201715‬‬ ‫‪.‬ﻭﺍﻟﺒﻼﻋﻢ‪ LPS‬ﻃﺮﻕ ﺍﻟﻮﻗﺎﻳﺔ ﻣﻦ ﺍﻷﻣﺮﺍﺽ ﺍﻟﻤﻘﺎﻭﻣﺔ ﻟﻠﻌﻼﺝ ﺃﻭ ﻋﻼﺟﻬﺎ ﻣﻦ ﺧﻼﻝ ﺍﻟﺘﺮﻛﻴﺰ ﻋﻠﻰ‬
‫ﺩﻭﻯ‪10.3892/mmr.2017.6338:‬‬ ‫ﺍﻟﻤﻴﻜﺮﻭﺑﺎﺕﺍﻟﻤﻌﻮﻳﺔ ﺑﺎﺳﺘﺨﺪﺍﻡ ‪128. Soma G، Inagawa H.‬ﺍﻟﺪﻗﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ )‪)35 (2015‬‬
‫‪.152‬ﺟﺎﻳﺴﻦ ﻳﻮ‪ ،‬ﺯﻳﻨﺜﻮﻓﺮ ﺇﻡ‪ ،‬ﺑﻴﺐ ﺇﻡ‪ ،‬ﻛﻴﺮﺑﺮ ﺟﻴﻪ‪ ،‬ﺑﻠﻨﺞ ﺟﻴﻪ‪ ،‬ﻣﺎﻧﺎﺟﻮ ﺇﻳﻪ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻵﻟﻴﺎﺕ ﺍﻟﺠﺰﻳﺌﻴﺔ‬ ‫‪.4393-6:(8‬‬
‫ﺍﻟﺘﻲﻣﻦ ﺧﻼﻟﻬﺎ ﻳﺴﺘﺨﻠﺺ ﺍﻟﺤﻮﻳﺼﻠﺔ ﻓﻮﻗﻴﺔ ﺗﺜﺒﻴﻂ ﺩﻭﺭﺓ ﺍﻟﺨﻠﻴﺔ ﻭﻣﻮﺕ ﺍﻟﺨﻼﻳﺎ ﻓﻲ ﺧﻼﻳﺎ ﺳﺮﻃﺎﻥ‬ ‫‪.129‬ﺇﺟﻨﺎﺳﻴﻮ ﺁﺭ ﺇﻡ ﺳﻲ‪ ،‬ﻟﻲ ﺇﺱ‪ ،‬ﺳﻮﻥ ﺩﻱ ﺇﺱ‪ .‬ﺍﻷﺩﻭﺍﺭ ﺍﻟﻤﺤﺘﻤﻠﺔ ﻟﻠﻜﻴﻮﻛﻴﻤﻴﻦ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻔﻄﺮﻱ‬
‫ﺍﻟﺒﻨﻜﺮﻳﺎﺱ‪.‬ﺃﺩﻭﻳﺔ ﻣﺎﺭ )‪ .91–4470:(7)13 (2015‬ﺩﻭﻯ‪10.3390/md13074470:‬‬ ‫ﻭﺷﺒﻜﺔﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﻋﻠﻰ ﺍﻟﻨﻬﺞ ﺍﻟﻌﻼﺟﻲ ﺍﻟﻘﺎﺋﻢ ﻋﻠﻰ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻓﻲ ﺳﺮﻃﺎﻥ ﺍﻟﻤﺒﻴﺾ‪.‬‬
‫ﺷﺒﻜﺔﺍﻟﻤﻨﺎﻋﺔ )‪:‬ﺩﻭﻯ ‪10.4110/in.2019.19.e222019( 19)3(:e22.‬‬
‫‪.153‬ﺗﺸﺎﻧﻎ ﺩﺑﻠﻴﻮ‪ ،‬ﺁﻥ ﺇﻱ ﻛﻴﻪ‪ ،‬ﺑﺎﺭﻙ ﺇﺗﺶ ﺑﻲ‪ ،‬ﻫﻮﺍﻧﻎ ﺟﻴﻪ‪ ،‬ﺩﺍﻧﺎﻧﺠﺎﻱ ﻭﺍﻱ‪ ،‬ﻛﻴﻢ ﺇﺱ ﺟﻴﻪ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻤﺘﻠﻚ ‪fucoidan‬‬ ‫‪.‬ﺗﻤﻨﻊﻧﻤﻮ ﺍﻟﻮﺭﻡ ﺑﻄﺮﻳﻘﺔ ﺗﻌﺘﻤﺪ ﻋﻠﻰ ﻣﺴﺘﻘﺒﻼﺕ ﺗﺸﺒﻪ ﺍﻟﺮﻗﻢ ‪ 4‬ﻋﻦ ﻃﺮﻳﻖ ﺗﻐﻴﻴﺮ ﺑﻴﺌﺔ ﺍﻟﺴﻴﺘﻮﻛﻴﻦ‬
‫‪ Ecklonia cava‬ﺍﻟﻘﺪﺭﺓ ﻋﻠﻰ ﺗﺤﻔﻴﺰ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻘﺎﺗﻠﺔ ﺍﻟﻄﺒﻴﻌﻴﺔ ﻓﻲ ﺍﻟﺠﺴﻢ ﺍﻟﺤﻲ‪.‬ﺇﻧﺖ ‪ J‬ﺑﻴﻮﻝ ﻣﺎﻛﺮﻭﻣﻮﻝ )‪(2021‬‬ ‫ﻣﻦﺇﻧﺘﺮﻟﻮﻛﻴﻦ ‪ / 17-‬ﺇﻧﺘﺮﻟﻮﻛﻴﻦ ‪ 23-‬ﺇﻟﻰ ﺇﻧﺘﺮﻓﻴﺮﻭﻥ ‪ -‬ﺟﺎﻣﺎ ‪S. Spirulina lipopolysaccharides‬‬
‫‪.185:111-21‬ﺩﻭﻯ‪10.1016/j.ijbiomac.2021.06.045:‬‬ ‫‪130. Okuyama H، Tominaga A، Fukuoka S، Taguchi T، Kusumoto Y، Ono‬ﻣﻨﺪﻭﺏ‬
‫‪.154‬ﺑﺎﺭﻙ ﺁﻱ‪ ،‬ﻧﺎﻓﻴﺔ ﺍﻷﻭﻝ‪ ،‬ﺳﺘﺮﻳﻨﺠﺮ ﺩﻱ ﺇﻥ‪ ،‬ﻛﺎﺭﺑﻴﻨﻴﻚ ﺇﺱ ﺇﺱ‪ ،‬ﻓﻴﺘﻮﻥ ﺟﻴﻪ ﺇﺗﺶ‪ .‬ﻳﻌﺰﺯ‬ ‫ﺃﻭﻧﻜﻮﻝ)‪ .94–684:(2)37 (2017‬ﺩﻭﻯ‪/10.3892:‬ﺃﻭ‪2017.5346.‬‬
‫ﺍﻟﻔﻮﻛﻮﻳﺪﺍﻥﺑﺸﻜﻞ ﻣﺴﺘﻘﻞ ﻧﺸﺎﻁ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺍﻟﺒﺸﺮﻳﺔ ﻭﻟﻪ ﺗﺄﺛﻴﺮ ﻣﺜﺒﻂ ﻟﻠﺨﻼﻳﺎ ﻋﻠﻰ ﺧﻼﻳﺎ ﺳﺮﻃﺎﻥ‬ ‫‪.131‬ﻭﻭﻥ ﺇﻱ ﻛﻴﻪ‪ ،‬ﺯﺍﻫﻨﺮ ﺇﻡ ﺳﻲ‪ ،‬ﺟﺮﺍﻧﺖ ﺇﻱ ﺇﻳﻪ‪ ،‬ﺟﻮﺭ ﺑﻲ‪ ،‬ﺗﺸﻴﻜﻮﻳﻦ ﺇﻡ ﺁﺭ‪ .‬ﺗﺤﻠﻴﻞ ﺍﻵﻟﻴﺎﺕ‬
‫ﺍﻟﺒﺮﻭﺳﺘﺎﺗﺎﻓﻲ ﻭﺟﻮﺩ ﻧﻴﻔﻮﻟﻮﻣﺎﺏ‪.‬ﺃﺩﻭﻳﺔ ﻣﺎﺭ )‪ .(1)20 (2021‬ﺩﻭﻯ‪10.3390/md20010012:‬‬ ‫ﺍﻟﻤﻀﺎﺩﺓﻟﻸﻭﺭﺍﻡ ﻣﻦ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﺿﺪ ﻭﺭﻡ ﺃﺭﻭﻣﻲ ﺩﺑﻘﻲ ﻣﺘﻌﺪﺩ ﺍﻷﺷﻜﺎﻝ‪ .‬ﺍﻷﺩﻭﻳﺔ ﺍﻟﻤﻀﺎﺩﺓ‬
‫ﻟﻠﺴﺮﻃﺎﻥ)‪ .457-66:(6)14 (2003‬ﺩﻭﻯ‪10.1097/00001813-200307000-00012:‬‬
‫‪.155‬ﺟﻴﻮﺭﺯ ﺇﺗﺶ‪ ،‬ﻣﻴﺮﺟﻴﻨﻬﺎﺟﻦ ﺇﺱ ﺇﻱ‪ ،‬ﻧﻮﻓﻮﺗﻨﻲ ﺇﻳﻪ‪ ،‬ﻓﻴﻠﻴﺒﺲ ﺟﻲ ﻛﻴﻪ‪ .‬ﺗﻔﺎﻋﻼﺕ ﺍﻟﻨﻈﺎﻡ‬ ‫‪.132‬ﻓﻴﺠﻨﻴﺮﻭﻥ ﺳﻲ‪ ،‬ﻣﻴﺮﻭﺯ ﺃ‪ ،‬ﻣﻴﺮﺩﺟﻲ ﺇﺗﺶ‪ ،‬ﺭﻭﺳﻮ ﺳﻲ‪ ،‬ﻛﻮﺯﻳﻦ ﺳﻲ‪ ،‬ﺃﻟﺒﻲ ﻟﻮﺭﺍﻥ ﺇﻑ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬
‫ﺍﻟﺘﻜﻤﻴﻠﻲﻣﻊ ﺍﻟﺴﻤﻮﻡ ﺍﻟﺪﺍﺧﻠﻴﺔ ﺍﻷﺻﻠﻴﺔ ﻭﺍﻟﻤﻌﺪﻟﺔ ﻛﻴﻤﻴﺎﺋﻴﺎ‪.‬ﻱ ﺑﻜﺘﻴﺮﻳﻮﻝ ‪ .397-405:(2)196895‬ﺩﻭﻯ‪:‬‬ ‫ﻳﻤﻨﻊﺍﻹﻧﺘﺎﻥ ﻧﻤﻮ ﺍﻟﻮﺭﻡ ﻓﻲ ﺍﻟﻔﺌﺮﺍﻥ ﺍﻟﻤﺼﺎﺑﺔ ﺑﺎﻟﺴﺮﻃﺎﻥ ﻣﻦ ﺧﻼﻝ ﻧﺸﺎﻁ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻘﺎﺗﻠﺔ ﺍﻟﻄﺒﻴﻌﻴﺔ ﺍﻟﻤﻌﺰﺯ‬
‫‪10.1128/jb.95.2.397-405.1968‬‬ ‫ﺍﻟﻤﺮﺗﺒﻂﺑﺎﻟﻤﺴﺘﻘﺒﻼﺕ ‪.4‬ﻋﻠﻢ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻷﻭﺭﺍﻡ ‪:(11)82019‬ﻫـ‪ .1641391‬ﺩﻭﻯ‪X.2019.1641391:‬‬
‫‪.‬ﺩﺭﺍﺳﺔﺍﻟﺒﻨﻴﺔ ﺍﻟﺘﺤﺘﻴﺔ ﻟﻠﺴﻜﺮﻳﺎﺕ ﺍﻟﺪﻫﻨﻴﺔ ﺍﻟﺪﻫﻨﻴﺔ ﻭﺍﻟﺘﻐﻴﺮﺍﺕ ﺍﻟﻨﺎﺟﻤﺔ ﻋﻦ ﺍﻟﺒﻮﻟﻴﻤﻴﻜﺴﻴﻦ ﻓﻲ‬ ‫‪10.1080/2162402‬‬
‫ﺍﻟﻐﺸﺎءﺍﻟﺨﺎﺭﺟﻲ ﻟﻠﺴﺮﻃﺎﻧﻴﺔ ﺍﻟﺬﺍﺑﻠﺔ ‪156. Acker G.‬ﺯﻳﻨﺘﺮﺍﻟﺒﻞ ﺑﺎﻛﺘﻴﺮﻳﻮﻝ ﺃﻭﺭﻳﺞ ﺃ )‪(1977‬‬ ‫‪ MH134.‬ﺩﻭﻥ ﺗﻌﺰﻳﺰ ﻓﻘﺪﺍﻥ ﻭﺯﻥ ﺍﻟﺠﺴﻢ ﻓﻲ ﺍﻟﻔﺌﺮﺍﻥ ﺍﻟﺘﻲ ﺗﺤﻤﻞ ﻭﺭﻡ ﺍﻟﻜﺒﺪ ‪ g-CSF‬ﺍﻟﺘﺄﺛﻴﺮ ﺍﻟﻤﻌﺰﺯ‬
‫‪.30–213:(2)239‬‬ ‫ﺍﻟﻤﻀﺎﺩﻟﻠﻮﺭﻡ ﻟﻌﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻣﻊ ‪133. Tanaka M، Abe S.‬ﻳﻮﺭﻭ ﺟﻲ ﻓﺎﺭﻣﺎﻛﻮﻝ )‪(2022‬‬
‫‪.‬ﺗﺤﻔﻴﺰﺍﻟﺨﻼﻳﺎ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻓﻲ ﺍﻟﻤﺨﺘﺒﺮ ﺑﻮﺍﺳﻄﺔ ﻣﺸﺘﻘﺎﺕ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﺍﻟﺒﻜﺘﻴﺮﻱ ﻏﻴﺮ ﺍﻟﺴﺎﻣﺔ ‪H.‬‬
‫‪.934:175206‬ﺩﻭﻯ‪10.1016/j.ejphar.2022.175206:‬‬
‫‪157. Frank S، Spectre S، Nowotny A، Friedman‬ﻱ ﺇﻣﻮﻧﻮﻝ )‪.855-60:(3)119 (1977‬‬ ‫‪.134‬ﺟﺎﻧﻮﺗﻮﻓﺎ ﺗﻲ‪ ،‬ﺟﺎﻟﻮﻓﻴﺴﻜﺎ ﺇﻡ‪ ،‬ﺃﻭﻳﺮﻭﻓﺎ ﺇﻡ‪ ،‬ﺳﻔﻴﻜﻮﻓﺎ ﺁﻱ‪ ،‬ﺑﺮﻭﺯﻟﻮﻓﺎ ﺑﻲ‪ ،‬ﻣﺎﻳﺮﻭﻓﺎ ﻓﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬
‫‪.158‬ﺩﻭ ﺩﺑﻠﻴﻮ ﺇﻑ‪ ،‬ﻳﺎﻧﻎ ﺇﺱ ﺗﻲ‪ ،‬ﻣﻮﺭﻳﺴﻮﻥ ﺩﻱ ﺳﻲ‪ ،‬ﺑﻴﺘﺰ ﺇﺱ ﺟﻴﻪ‪ ،‬ﻫﻨﺴﻮﻥ ﺑﻲ ﺇﻡ‪ .‬ﺗﺤﻔﻴﺰ ﺍﻟﺒﻼﻋﻢ‬ ‫ﺍﺳﺘﺨﺪﺍﻡﻣﻨﺒﻬﺎﺕ ﺍﻟﻤﺴﺘﻘﺒﻼﺕ ﺍﻟﺒﻠﻌﻤﻴﺔ ﻟﻠﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ ﻟﻠﺴﺮﻃﺎﻥ‪ :‬ﻧﻤﻮﺫﺝ ﺳﺮﻃﺎﻥ ﺍﻟﺠﻠﺪ ﺍﻟﻔﺌﺮﺍﻥ‬
‫ﺑﻮﺍﺳﻄﺔﻋﺪﻳﺪﺍﺕ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻴﺔ ﺍﻟﺒﻜﺘﻴﺮﻳﺔ‪ .‬ﺛﺎﻧﻴﺎ‪ .‬ﺩﻟﻴﻞ ﻋﻠﻰ ﺇﺷﺎﺭﺍﺕ ﺍﻟﺘﻤﺎﻳﺰ ﺍﻟﺘﻲ ﻳﺘﻢ ﺗﺴﻠﻴﻤﻬﺎ ﻋﻦ‬ ‫‪.B16-F10‬ﺑﻠﻮﺱ ﻭﺍﺣﺪ )‪:‬ﺩﻭﻯ ‪10.1371/ Journal.pone.00852222014( 9)1(:e85222.‬‬
‫ﻃﺮﻳﻖﺍﻟﺪﻫﻮﻥ ﻭﺟﺰء ﻏﻨﻲ ﺑﺎﻟﺒﺮﻭﺗﻴﻦ ﻣﻦ ﻋﺪﻳﺪﺍﺕ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻴﺔ‪.‬ﺇﻛﺴﺐ ﻣﻴﺪ ‪–557:(2) 148J‬‬
‫‪.68:1978‬ﺩﻭﻯ‪10.1084/jem.148.2.557:‬‬ ‫‪.135‬ﺷﻴﻜﻮﻳﻦ ﺇﻡ ﺁﺭ‪ ،‬ﻭﻭﻥ ﺇﻱ ﻛﻴﻪ‪ ،‬ﺯﺍﻫﻨﺮ ﺇﻡ ﺳﻲ‪ .‬ﻳﺆﺩﻱ ﺍﻟﺤﻘﻦ ﺩﺍﺧﻞ ﺍﻟﻔﻢ ﻟﻌﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ‬
‫‪.159‬ﺑﺮﺍﻭﻥ‪-‬ﻓﺎﺭﻻﻧﺪﺭ ﺳﻲ‪ ،‬ﺭﻳﺪﻟﺮ ﺟﻴﻪ‪ ،‬ﻫﻴﺮﺯ ﻳﻮ‪ ،‬ﺇﻳﺪﻳﺮ ﺩﺑﻠﻴﻮ‪ ،‬ﻭﺍﺳﺮ ﺇﻡ‪ ،‬ﺟﺮﻳﺰ ﺇﻝ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﺘﻌﺮﺽ‬ ‫ﺇﻟﻰﺗﺮﺍﺟﻊ ﻭﺭﻡ ﺃﺭﻭﻣﻲ ﺩﺑﻘﻲ ﻣﺘﻌﺪﺩ ﺍﻷﺷﻜﺎﻝ ﻣﺰﺭﻭﻉ ﺗﺤﺖ ﺍﻟﺠﻠﺪ‪.‬ﺟﺮﺍﺣﺔ ﺍﻻﻋﺼﺎﺏ )‪(3)48 (2001‬‬
‫ﺍﻟﺒﻴﺌﻲﻟﻠﺴﻤﻮﻡ ﺍﻟﺪﺍﺧﻠﻴﺔ ﻭﻋﻼﻗﺘﻪ ﺑﺎﻟﺮﺑﻮ ﻟﺪﻯ ﺍﻷﻃﻔﺎﻝ ﻓﻲ ﺳﻦ ﺍﻟﻤﺪﺭﺳﺔ‪ .‬ﺇﻥ ﺇﻧﺠﻞ ﺟﻲ ﻣﻴﺪ )‪(2002‬‬ ‫‪.607-14:‬ﺩﻭﻯ‪200103000-00032 -10.1097/00006123:‬‬
‫‪ .77–869:(12)347‬ﺩﻭﻯ‪10.1056/NEJMoa020057:‬‬
‫‪.136‬ﺷﻴﻜﻮﻳﻦ ﺇﻡ ﺁﺭ‪ ،‬ﺯﺍﻫﻨﺮ ﺇﻡ‪ ،‬ﻭﻭﻥ ﺇﻱ ﻛﻴﻪ‪ ،‬ﻛﺎﻟﺮﺍ ﺁﺭ ﺁﺭ‪ ،‬ﻛﻴﺘﺎﻣﻮﺭﺍ ﺗﻲ‪ ،‬ﺑﻴﺮﻱ ﺇﻳﻪ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺘﻢ ﺍﻟﺘﻮﺳﻂ ﻓﻲ‬
‫‪.‬ﺍﻟﺘﺄﺛﻴﺮﺍﻟﻤﻀﺎﺩ ﻟﻠﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﺿﺪ ﺍﻟﻮﻓﻴﺎﺕ ﺍﻟﻨﺎﺟﻤﺔ ﻋﻦ ﺍﻷﺳﻴﺘﺎﻣﻴﻨﻮﻓﻴﻦ ﻓﻲ ﺍﻟﻔﺌﺮﺍﻥ ‪K.‬‬
‫ﺍﻟﺘﺄﺛﻴﺮﺍﺕﺍﻟﻤﻀﺎﺩﺓ ﻟﻸﻭﺭﺍﻡ ﻓﻲ ﺍﻟﺠﺴﻢ ﺍﻟﺤﻲ ﻟﻌﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﺿﺪ ﻭﺭﻡ ﺃﺭﻭﻣﻲ ﺩﺑﻘﻲ ﻣﺘﻌﺪﺩ ﺍﻷﺷﻜﺎﻝ‬
‫‪160. Ishikawa M، Tanno K، Sasaki M، Takayanagi Y، Sasaki‬ﻓﺎﺭﻣﺎﻛﻮﻝ ﺗﻮﻛﺴﻴﻜﻮﻝ )‬
‫ﺟﺰﺋﻴﺎًﺑﻮﺍﺳﻄﺔ ﻣﺴﺘﻘﺒﻞ ﻳﺸﺒﻪ ﺍﻟﺮﻗﻢ ‪.4‬ﺟﺮﺍﺣﺔ ﺍﻻﻋﺼﺎﺏ )‪ .372-80:(2)60 (2007‬ﺩﻭﻯ‪:‬‬
‫‪ .91–387:(5)67 (1990‬ﺩﻭﻯ‪10.1111/j.1600-0773.1990.tb00850.x:‬‬
‫‪10.1227/01.NEU.0000249280.61761.2E‬‬
‫‪.‬ﻟﻼﻟﺘﻬﺎﺑﺎﺕﻭﺍﻟﻌﺪﻭﻯ ﻭﺍﻟﺴﺮﻃﺎﻥ‪ :‬ﻣﻨﻈﻮﺭ ﻟﻤﺤﺎﻛﺎﺓ ﺍﻟﺪﻫﻮﻥ ﺛﻨﺎﺋﻴﺔ ﺍﻟﺴﻜﺎﺭﻳﺪ ‪ TLR4‬ﺍﻻﺳﺘﻬﺪﺍﻑ‬
‫ﺍﻟﻌﻼﺟﻲﻟـ ‪161. Heine H، Zamyatina A.‬ﻓﺎﺭﻡ )ﺑﺎﺯﻝ( )‪ .(1)16 (2022‬ﺩﻭﻯ‪/ph16010023:‬‬ ‫‪.137‬ﻣﻮﺭﻳﺸﻴﻤﺎ ‪ ،A‬ﺇﻳﻨﺎﺟﺎﻭﺍ ‪ .H‬ﺍﻟﺘﺄﺛﻴﺮﺍﺕ ﺍﻟﺴﺮﻳﺮﻳﺔ ﻟﻠﺴﻜﺮﻳﺎﺕ ﺍﻟﺪﻫﻨﻴﺔ ﺍﻟﺪﻫﻨﻴﺔ ﺍﻟﺘﻲ ﻳﺘﻢ ﺗﻨﺎﻭﻟﻬﺎ‬
‫‪10.3390‬‬ ‫ﻋﻦﻃﺮﻳﻖ ﺍﻟﻔﻢ ﻭﺍﻟﻤﺸﺘﻘﺔ ﻣﻦ ﺗﻜﺘﻼﺕ ﺍﻟﺒﺎﻧﺘﻮﻳﺎ ﻋﻠﻰ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺨﺒﻴﺜﺔ‪ .‬ﺍﻟﺪﻗﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﺴﺮﻃﺎﻥ )‪(2016‬‬
‫‪.51–3747:(7)36‬‬
‫‪.‬ﺫﺍﺕﺍﻟﺠﺰﻳﺌﺎﺕ ﺍﻟﺼﻐﻴﺮﺓ‪ :‬ﻧﻈﺮﺓ ﻋﺎﻣﺔ ‪ TLR4‬ﺯﻳﺎﺩﺓ ﺍﻟﺘﻨﻮﻉ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ ﻟﻤﻌﺪﻻِّﺕ ‪A، Peri F.‬‬
‫‪162. Romerio‬ﺍﻟﺠﺒﻬﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ )‪ .11:1210 (2020‬ﺩﻭﻯ‪ /10.3389:‬ﻓﻴﻤﻮ‪2020.01210.‬‬ ‫‪.138‬ﻛﻴﻢ ﺟﻴﻪ ﺇﺗﺶ‪ ،‬ﻛﻴﻢ ﺩﻱ ﺇﺗﺶ‪ ،‬ﺟﻮ ﺇﺱ‪ ،‬ﺗﺸﻮ ﺇﻡ ﺟﻴﻪ‪ ،‬ﺗﺸﻮ ﻭﺍﻱ ﺁﺭ‪ ،‬ﻟﻲ ﻭﺍﻱ ﺟﺎﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬
‫ﺍﻷﻃﻌﻤﺔﺍﻟﻮﻇﻴﻔﻴﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻭﺁﻟﻴﺎﺗﻬﺎ ﺍﻟﺠﺰﻳﺌﻴﺔ‪.‬ﺇﻛﺴﺐ ﻣﻮﻝ ﻣﻴﺪ )‪ .1-11:(1)54 (2022‬ﺩﻭﻯ‪:‬‬
‫‪10.1038/s12276-022-00724-0‬‬
‫‪.163‬ﺟﻮ ﺇﺗﺶ‪ ،‬ﻫﻮ ﺯﻱ‪ ،‬ﻟﻮ ﻭﺍﻱ‪ ،‬ﻭﻭ ﻭﺍﻱ‪ ،‬ﺗﺸﺎﻧﻎ ﺇﻝ‪ ،‬ﻭﻱ ﺩﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺆﺩﻱ ﺗﻨﺸﻴﻂ ‪ TLR4‬ﺇﻟﻰ ﻣﻘﺎﻭﻣﺔ‬
‫ﺍﻟﻌﻼﺝﺍﻟﻤﻀﺎﺩ ﻟـ ‪ EGFR‬ﻓﻲ ﺳﺮﻃﺎﻥ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺤﺮﺷﻔﻴﺔ ﻓﻲ ﺍﻟﺮﺃﺱ ﻭﺍﻟﺮﻗﺒﺔ‪.‬ﺻﺒﺎﺣﺎ ‪ J‬ﺍﻟﺴﺮﻃﺎﻥ ﺍﻟﺪﻗﺔ )‪)10 (2020‬‬
‫‪.‬ﺍﻟﺒﺒﺘﻴﺪﺍﺕﺍﻟﻨﺸﻄﺔ ﺑﻴﻮﻟﻮﺟﻴﺎً ﻣﻦ ﺍﻟﻄﺤﺎﻟﺐ ﺍﻟﺪﻗﻴﻘﺔ‪ :‬ﺍﻟﺘﺮﻛﻴﺰ ﻋﻠﻰ ﺍﻟﻨﺸﺎﻁ ﺍﻟﻤﻀﺎﺩ ﻟﻠﺴﺮﻃﺎﻥ‬
‫‪.454-72:(2‬‬ ‫ﻭﺍﻟﺘﻌﺪﻳﻞﺍﻟﻤﻨﺎﻋﻲ ‪139. Skjanes K، Aesoy R، Herfindal L، Skomedal H.‬ﻧﺒﺎﺕ ﺍﻟﻔﻴﺰﻳﻮﻝ )‬
‫‪ .23–612:(2)173 (2021‬ﺩﻭﻯ‪10.1111/ppl.13472:‬‬
‫‪.164‬ﺗﺸﻮ ﺇﺱ‪ ،‬ﺩﻭ ﺁﺭ‪ ،‬ﻭﺍﻧﻎ ﺯﻱ‪ ،‬ﺷﻴﻦ ﺩﺑﻠﻴﻮ‪ ،‬ﺟﺎﻭ ﺁﺭ‪ ،‬ﺟﻴﺎﻧﻎ ﺇﺱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺰﻳﺪ ‪ TLR4‬ﻣﻦ ﺍﻟﺠﺎﺫﺑﻴﺔ‬
‫ﻭﻳﺘﻢﺍﻟﺘﻌﺒﻴﺮ ﻋﻨﻪ ﺑﺸﻜﻞ ﻛﺒﻴﺮ ﻓﻲ ﺳﺮﻃﺎﻥ ﺍﻟﻜﺒﺪ ﺍﻟﺒﺸﺮﻱ ﺍﻟﻤﻨﺘﻜﺲ‪.‬ﺍﻟﺴﺮﻃﺎﻥ ﻣﻴﺪ )‪–2325:(5)8 (2019‬‬ ‫‪.140‬ﺇﻳﺸﻴﺠﻮﺭﻭ ﺇﺱ‪ ،‬ﺭﻭﺑﻦ ﺇﻥ‪ ،‬ﺑﻮﺭﻏﺎﺭﺕ ﺁﺭ‪ ،‬ﻛﻮﺕ ﺑﻲ‪ ،‬ﺟﺮﻳﻨﻮﺍﻱ ﺇﺱ‪ ،‬ﺛﻜﺎﺭ ﺁﺭ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺟﺰء ﻏﺸﺎء‬
‫‪.37‬ﺩﻭﻯ‪10.1002/cam4.2070:‬‬ ‫ﺟﺪﺍﺭﺍﻟﺨﻠﻴﺔ ﻣﻦ ﺷﻠﻮﺭﻳﻼ ﺳﻮﺭﻭﻛﻴﻨﻴﺎﻧﺎ ﻳﻌﺰﺯ ﻣﻨﺎﻋﺔ ﺍﻟﻤﻀﻴﻒ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻸﻭﺭﺍﻡ ﻭﻳﻤﻨﻊ ﻧﻤﻮ ﺳﺮﻃﺎﻥ‬
‫ﺍﻟﻘﻮﻟﻮﻥﻓﻲ ﺍﻟﻔﺌﺮﺍﻥ‪.‬ﺍﻟﺘﻜﺎﻣﻞ ﻣﻊ ﺍﻟﺴﺮﻃﺎﻥ )‪ .19:1534735419900555 (2020‬ﺩﻭﻯ‪:‬‬
‫‪.165‬ﺗﺸﻲ ﺇﻑ‪ ،‬ﻳﻴﻦ ﺟﻲ‪ ،‬ﻛﻮﺍﻥ ﻭﺍﻱ‪ ،‬ﺷﻴﻪ ﺇﻛﺲ‪ ،‬ﻫﻨﻎ ﺇﻛﺲ‪ ،‬ﺩﻭ ﻭﺍﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﻔﺎﻋﻞ ‪ TLR4‬ﻣﻊ ‪ LPS‬ﻓﻲ‬ ‫‪10.1177/1534735419900555‬‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔ ﺍﻟﺴﺮﻃﺎﻧﻴﺔ ﻟﻠﻮﺭﻡ ﺍﻟﺪﺑﻘﻲ ‪ + CD133‬ﻳﺆﺩﻱ ﺇﻟﻰ ﺗﻜﺎﺛﺮ ﺍﻟﺨﻼﻳﺎ ﻭﻣﻘﺎﻭﻣﺔ ﺍﻟﻌﻼﺝ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ‬
‫‪.141‬ﻳﻮﺍﻥ ﻭﺍﻱ ﻓﻲ‪ ،‬ﻭﺍﻟﺶ‪ ،‬ﻧﺎ‪ .‬ﺍﻷﻧﺸﻄﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻸﻛﺴﺪﺓ ﻭﺍﻟﺘﻜﺎﺛﺮ ﻟﻤﺴﺘﺨﻠﺼﺎﺕ ﻣﻦ ﻣﺠﻤﻮﻋﺔ ﻣﺘﻨﻮﻋﺔ‬
‫ﻭﺍﻟﺘﻬﺮﺏﻣﻦ ﺍﻟﺘﺤﻠﻞ ﺍﻟﺨﻠﻮﻱ ﺍﻟﻨﺎﺟﻢ ﻋﻦ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻠﻤﻔﺎﻭﻳﺔ ﺍﻟﺴﺎﻣﺔ ﻟﻠﺨﻼﻳﺎ‪.‬ﺃﻭﻧﻜﻮﺗﺎﺭﻏﺖ )‪(32) 8 (2017‬‬
‫ﻣﻦﺍﻷﻋﺸﺎﺏ ﺍﻟﺒﺤﺮﻳﺔ ﺍﻟﺼﺎﻟﺤﺔ ﻟﻸﻛﻞ‪.‬ﺍﻟﻤﻮﺍﺩ ﺍﻟﻐﺬﺍﺋﻴﺔ ﺍﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺍﻟﺴﺎﻣﺔ )‪ .50–1144:(7)44 (2006‬ﺩﻭﻯ‪:‬‬
‫‪.53495-507:‬ﺩﻭﻯ‪10.18632/oncotarget.18586:‬‬
‫‪10.1016/j.fct.2006.02.002‬‬
‫‪.166‬ﺑﻴﺮﻳﺖ ‪ ،V‬ﻧﺰﺍﺭ ‪ ،M‬ﻣﺎﺭﺗﻦ ‪ ،M، Quintar AA‬ﻓﺮﻧﺎﻧﺪﻳﺰ ‪ ،EA، Geysels RC‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻹﻓﺮﺍﻁ‬
‫ﻓﻲﺍﻟﺘﻌﺒﻴﺮ ﻋﻦ ﻣﺴﺘﻘﺒﻼﺕ ﺗﺸﺒﻪ ﺍﻟﺮﻗﻢ ‪ 4‬ﻓﻲ ﺳﺮﻃﺎﻥ ﺍﻟﻐﺪﺓ ﺍﻟﺪﺭﻗﻴﺔ ﺍﻟﺤﻠﻴﻤﻲ ﺑﻮﺍﺳﻄﺔ ﻧﺸﺎﻁ ﺍﻟﻨﺴﺦ‬ ‫‪.142‬ﺳﻜﻴﺒﻮﻻ ﺳﻲ ﺇﻑ‪ ،‬ﻛﺎﺭﻱ ﺟﻴﻪ ﺩﻱ‪ ،‬ﻓﺎﻧﺪﻳﻔﻮﺭﺕ ﺳﻲ‪ ،‬ﻛﻮﻧﻠﻲ ﺇﻳﻪ‪ ،‬ﺳﻤﻴﺚ ﺇﻡ ﺗﻲ‪ .‬ﻳﻨﻈﻢ ﻋﺸﺐ‬
‫‪ ETS1‬ﺍﻟﻨﺎﺟﻢ ﻋﻦ ‪MAPK / ERK‬ﻣﻮﻝ ﺍﻟﺴﺮﻃﺎﻥ ﺍﻟﺪﻗﺔ )‪ .45–833:(5)16 (2018‬ﺩﻭﻯ‪-17-0433:‬‬ ‫ﺍﻟﺒﺤﺮﺍﻟﺒﻨﻲ ﻫﺮﻣﻮﻧﺎﺕ ﺍﻟﻐﺪﺩ ﺍﻟﺼﻤﺎء ﻓﻲ ﺇﻧﺎﺙ ﻓﺌﺮﺍﻥ ﺳﺒﺮﺍﻍ ﺩﺍﻭﻟﻲ ﻭﻓﻲ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺤﺒﻴﺒﻴﺔ ﺍﻟﻤﻠﻮﺛﺔ‬
‫‪10.1158/1541-7786.MCR‬‬ ‫ﺍﻟﺒﺸﺮﻳﺔ‪.‬ﺟﻲ ﻧﻮﺗﺮ )‪ .296-300:(2)135 (2005‬ﺩﻭﻯ‪/10.1093:‬ﺟﻦ‪135.2.296/‬‬
‫‪.143‬ﺭﻭﺯﻳﻦ ﺟﻲ ﺇﻱ‪ ،‬ﺟﺎﺭﺩﻳﻨﺮ ﺑﻲ‪ ،‬ﺳﺎﺑﺮ ﺁﺭ ﺑﻲ‪ ،‬ﺑﻴﺮﺱ ﺇﻥ‪ ،‬ﻫﺎﻣﺮ ﻛﻴﻪ‪ ،‬ﺟﻮﺑﺘﺎ ﻟﻮﺭﺍﻧﺲ ﺁﺭ ﺇﻝ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﺳﺘﺨﺪﺍﻡ ﻋﺸﺐ‬
‫‪:‬ﺇﺷﺎﺭﺍﺕﻣﺴﺘﻘﺒﻼﺕ ﺗﺸﺒﻪ ﺍﻟﺮﻗﻢ ‪ 4‬ﺍﻟﻨﺎﺗﺠﺔ ﻋﻦ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺸﺤﻤﻲ ﻓﻲ ﺳﺮﻃﺎﻥ ﺍﻟﺨﻼﻳﺎ‬
‫ﺍﻟﺒﺤﺮﻓﻲ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﺳﺮﻃﺎﻥ ﺍﻟﻐﺪﺓ ﺍﻟﺪﺭﻗﻴﺔ‪.‬ﺍﻟﻐﺪﺩ ﺍﻟﺼﻤﺎء )‪ .30–123:(1)46 (2014‬ﺩﻭﻯ‪:‬‬
‫ﺍﻟﺤﺮﺷﻔﻴﺔﺍﻟﻤﺮﻳﺌﻲ ﺗﻌﺰﺯ ﺗﻜﺎﺛﺮ ﺍﻟﻮﺭﻡ ﻭﺗﻨﻈﻢ ﺗﻌﺒﻴﺮ ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﺍﻻﻟﺘﻬﺎﺑﻴﺔ ﻓﻲ ﺍﻟﻤﺮﻱء‪(2) 30 (2017) .‬‬
‫‪10.1007/s12020-013-0048-2‬‬
‫‪.8-1:‬ﺩﻭﻯ ‪10.1111/dote.12466167. Zu Y، Ping W، Deng T، Zhang N، Fu X، Sun W.‬‬
‫‪.144‬ﺍﻟﺒﻄﺸﺎﻥ ‪ ،HA‬ﺍﻟﻤﻔﺮﺝ ‪ ،SI‬ﺍﻟﺤﻤﻴﺪﺍﻥ ‪ ،AA‬ﻗﺮﻳﺸﻲ ‪ .MA‬ﺗﻌﺰﻳﺰ ﻭﻇﻴﻔﺔ ﺍﻟﺒﻠﻌﻤﺔ ﺍﻟﺒﻠﻌﻤﻴﺔ‬
‫‪.168‬ﺗﺎﻧﻎ ﺇﺱ‪ ،‬ﻟﻴﺎﻥ ﺇﻛﺲ‪ ،‬ﺗﺸﻴﻨﺞ ﺇﺗﺶ‪ ،‬ﺟﻮﻭ ﺟﻲ‪ ،‬ﻧﻲ ﺩﻱ‪ ،‬ﻫﻮﺍﻧﺞ ﺳﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺃﺩﻯ ﻋﺪﻳﺪ‬ ‫ﻟﻠﺪﺟﺎﺝﻭﺇﻧﺘﺎﺝ ﺍﻟﻨﺘﺮﻳﺖ ﻋﻦ ﻃﺮﻳﻖ ﺳﺒﻴﺮﻭﻟﻴﻨﺎ ﺑﻼﺗﻨﺴﻴﺲ ﺍﻟﻐﺬﺍﺋﻲ‪.‬ﺇﻣﻮﻧﻮﻓﺎﺭﻣﺎﻛﻮﻝ ﺇﻣﻮﻧﻮﺗﻮﻛﺴﻴﻜﻮﻝ )‬
‫ﺍﻟﺴﻜﺎﺭﻳﺪﺍﻟﺪﻫﻨﻲ ﺍﻟﺒﻜﺘﻴﺮﻱ ﺇﻟﻰ ﺯﻳﺎﺩﺓ ﺍﻟﺘﺤﻮﻝ ﺍﻟﺨﺒﻴﺚ ﻭﺗﻌﺰﻳﺰ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻈﻬﺎﺭﻳﺔ ﻟﺴﺮﻃﺎﻥ ﺍﻟﺒﺮﻭﺳﺘﺎﺗﺎ‪.‬ﻱ‬ ‫‪ .281-9:(2)23 (2001‬ﺩﻭﻯ‪10.1081/iph-100103866:‬‬
‫ﺇﻧﻔﻼﻡﺭﻳﺲ )‪ .62–14:5849 (2021‬ﺩﻭﻯ‪/10.2147:‬ﺟﻴﺮ‪S332943.‬‬
‫‪.169‬ﻻﻱ ﺇﻑ ﺑﻲ‪ ،‬ﻟﻴﻮ ﻭﺕ‪ ،‬ﺟﻴﻨﻎ ﻭﺍﻱ‪ ،‬ﻳﻮ ﺟﻲ ﺇﻑ‪ ،‬ﻫﺎﻥ ﺯﻱ ﺑﻲ‪ ،‬ﻳﺎﻧﻎ ﺇﻛﺲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺪﻋﻢ ﻋﺪﻳﺪ‬ ‫‪.145‬ﻧﻴﻠﺴﻮﻥ ﺇﺱ ﺇﻡ‪ ،‬ﺟﺎﻭ ﻭﺍﻱ ﺗﻲ‪ ،‬ﻧﻮﻏﻴﺮﺍ ﺇﻝ ﺇﻡ‪ ،‬ﺷﻴﻦ ﺇﻡ ﺳﻲ‪ ،‬ﻭﺍﻧﻎ ﺑﻲ‪ ،‬ﺭﺷﻴﺪ ﺃ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﻨﻈﺎﻡ ﺍﻟﻐﺬﺍﺋﻲ ﻭﺧﻄﺮ‬
‫ﺍﻟﺴﻜﺎﺭﻳﺪﺍﻟﺪﻫﻨﻲ ﺍﻟﺤﻔﺎﻅ ﻋﻠﻰ ﺟﺬﻋﻴﺔ ﺧﻼﻳﺎ ﺳﺮﻃﺎﻥ ﺍﻟﻜﺒﺪ ‪ (+)CD133‬ﻣﻦ ﺧﻼﻝ ﺗﻨﺸﻴﻂ ﻣﺴﺎﺭ ‪alpha‬‬ ‫ﺍﻹﺻﺎﺑﺔﺑﺴﺮﻃﺎﻥ ﺍﻟﻘﻨﺎﺓ ﺍﻟﺼﻔﺮﺍﻭﻳﺔ ﻓﻲ ﺷﻨﻐﻬﺎﻱ‪ ،‬ﺍﻟﺼﻴﻦ‪.‬ﺑﻠﻮﺱ ﻭﺍﺣﺪ )‪:‬ﺩﻭﻯ ‪2017( 12)3(:e0173935.‬‬
‫‪.NF-kappaB/HIF-1‬ﺍﻟﺴﺮﻃﺎﻥ ﻟﻴﺖ )‪ .41–131:(2)378 (2016‬ﺩﻭﻯ‪/ j.canlet.2016.05.014:‬‬ ‫‪10.1371/journal.pone.0173935‬‬
‫‪10.1016‬‬ ‫‪.146‬ﺃﻭﻧﻮ ﻭﺍﻱ‪ ،‬ﻳﻮﺷﻴﺪﺍ ﺃﻭ‪ ،‬ﺃﻭﻳﺸﻲ ﻛﻴﻪ‪ ،‬ﺃﻭﻛﺎﺩﺍ ﻛﻴﻪ‪ ،‬ﻳﺎﻣﺎﺑﻲ ﺇﺗﺶ‪ ،‬ﺷﺮﻭﺩﺭ ﺇﻑ ﺇﺗﺶ‪ .‬ﺍﻟﺒﻴﺘﺎﻛﺎﺭﻭﺗﻴﻦ‬
‫‪.170‬ﻭﺍﻧﻎ ﺟﻲ ﺳﻲ‪ ،‬ﻫﻮﺍﻧﻎ ﺗﻲ ﺁﺭ‪ ،‬ﻭﺍﻧﻎ ﻛﻲ‪ ،‬ﻭﻭ ﺯﺩ ﺇﻝ‪ ،‬ﺷﻴﻪ ﺟﻴﻪ ﺑﻲ‪ ،‬ﺗﺸﺎﻧﻎ ﺇﺗﺶ ﺇﻝ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬ ‫ﺍﻟﻐﺬﺍﺋﻲﻭﺳﺮﻃﺎﻥ ﺍﻟﺒﺮﻭﺳﺘﺎﺗﺎ‪ :‬ﺩﺭﺍﺳﺔ ﺍﻟﺤﺎﻻﺕ ﻭﺍﻟﺸﻮﺍﻫﺪ ﻓﻲ ﻛﻴﻮﺗﻮ‪ ،‬ﺍﻟﻴﺎﺑﺎﻥ‪.‬ﺍﻟﺪﻗﺔ ﺍﻟﺴﺮﻃﺎﻥ )‪(1988‬‬
‫ﺍﻻﻟﺘﻬﺎﺏﺍﻟﻨﺎﺟﻢ ﻋﻦ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﺍﻟﻤﺘﻄﻮﺭ ﻟﻠﺘﻌﺒﻴﺮ ﻋﻦ ﻣﺴﺘﻘﺒﻼﺕ ﺍﻻﻧﺪﺭﻭﺟﻴﻦ‬ ‫‪.6–1331:(5)48‬‬

‫‪.193‬ﻛﺎﻣﻴﺮﻭﻥ ﺩﻱ ﺟﻲ‪ .‬ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﻤﺜﺒﻄﺔ ﺍﻟﻤﺴﺘﻤﺪﺓ ﻣﻦ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺒﺸﺮﻳﺔ‪ :‬ﻋﺰﻝ ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﺘﻲ ﺗﺜﺒﻂ‬ ‫ﻭﺍﻟﺘﻘﺪﻡﺍﻻﻧﺘﻘﺎﻟﻲ ﺍﻟﻈﻬﺎﺭﻱ ﺍﻟﻮﺳﻴﻄﻲ ﻓﻲ ﺍﻟﺘﻬﺎﺏ ﺍﻟﺒﺮﻭﺳﺘﺎﺗﺎ ﻭﺳﺮﻃﺎﻥ ﺍﻟﺒﺮﻭﺳﺘﺎﺗﺎ‪ .‬ﺗﺮﺟﻤﺔ ﺃﻧﺪﺭﻭﻝ‬
‫ﺍﻟﺴﻤﻴﺔﺍﻟﺨﻠﻮﻳﺔ ﺑﻮﺳﺎﻃﺔ ﺍﻟﺒﻼﻋﻢ‪.‬ﺇﻧﺖ ‪ J‬ﺇﻣﻮﻧﻮﻓﺎﺭﻣﺎﻛﻮﻝ )‪ .345-52:(4)5 (1983‬ﺩﻭﻯ‪/0192-0561:‬‬ ‫ﺃﻭﺭﻭﻝ)‪ .87–4275:(11)10 (2021‬ﺩﻭﻯ‪/10.21037:‬ﺗﺎﻭ‪964-21-‬‬
‫‪90038-3(83)10.1016‬‬ ‫‪.171‬ﺗﺸﻮ ﺑﻲ‪ ،‬ﺗﺸﻮ ﺇﺗﺶ‪ ،‬ﻟﻴﻨﻎ ﺇﺱ‪ ،‬ﻗﻮﻩ ﺩﻱ‪ ،‬ﻳﺎﻥ ﻭﺍﻱ‪ ،‬ﺗﺸﻮ ﺇﻑ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺆﺩﻱ ﺗﻨﺸﻴﻂ ‪ PAR2‬ﺃﻭ‬
‫‪.194‬ﻣﻴﺘﺎﺭ ﺑﻲ‪ ،‬ﻭﻟﻮﺯﻳﻦ ﺇﻡ‪ ،‬ﺳﺰﺍﺗﺎﻧﻴﻚ ﺁﺭ‪ ،‬ﺑﺎﺝ‪-‬ﻛﺮﺯﻳﻮﻭﺭﺯﻳﻜﺎ ﺇﻡ‪ ،‬ﺳﻴﺪﻻﺭ ﺇﻡ‪ ،‬ﺭﻭﺟﻴﺮﻭ ﺁﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬ ‫‪ /‬ﻭ ‪ TLR4‬ﺇﻟﻰ ﺗﻌﺰﻳﺰ ﺗﻜﺎﺛﺮ ﺧﻼﻳﺎ ‪ SW620‬ﻭﺍﻟﻬﺠﺮﺓ ﻋﺒﺮ ﺍﻟﻔﺴﻔﺮﺓ ‪.ERK1 / 2‬ﻣﻨﺪﻭﺏ ﺃﻭﻧﻜﻮﻝ )‪(2011‬‬
‫ﺍﻟﺘﻌﻄﻴﻞﺍﻟﻨﺎﺟﻢ ﻋﻦ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺴﺮﻃﺎﻧﻴﺔ ﻟﻠﺨﻼﻳﺎ ﺍﻟﻮﺣﻴﺪﺓ ﺍﻟﺒﺸﺮﻳﺔ‪.‬ﺟﻲ ﻟﻴﻮﻛﻮﻙ ﺑﻴﻮﻝ )‪(6) 74 (2003‬‬ ‫‪ .11–503:(2)25‬ﺩﻭﻯ‪/10.3892:‬ﺃﻭ‪2010.1077.‬‬
‫‪.1094-101:‬ﺩﻭﻯ‪10.1189/jlb.0403140:‬‬ ‫‪.172‬ﺗﺎﻛﺎﺯﺍﻭﺍ ﻭﺍﻱ‪ ،‬ﻛﻴﻨﻴﻮﺍ ﻭﺍﻱ‪ ،‬ﺃﻭﻏﺎﻭﺍ ﺇﻱ‪ ،‬ﺃﻭﺷﻴﺎﻣﺎ ﺃ‪ ،‬ﺃﺷﻴﺪﺍ ﺃ‪ ،‬ﺃﻭﻫﺎﺭﺍ ﺇﺗﺶ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﻌﻤﻞ‬
‫‪.‬ﻓﻲﺍﻟﻤﺮﺍﻗﺒﺔ ﺍﻟﻤﻨﺎﻋﻴﺔ ‪ SER‬ﺩﻭﺭ ﻣﺜﺒﻂ ﺍﻟﻤﻨﺎﻋﺔ ‪195. Oh SK، Ross S، Walker J، Zeisel S.‬ﻋﻠﻢ‬ ‫ﺇﺷﺎﺭﺍﺕﻣﺴﺘﻘﺒﻞ ‪ Tolllike 4‬ﻋﻠﻰ ﺗﻌﺰﻳﺰ ﻫﺠﺮﺓ ﺧﻼﻳﺎ ﺳﺮﻃﺎﻥ ﺍﻟﺠﻠﺪ ﺍﻟﺒﺸﺮﻳﺔ‪.‬ﺗﻮﻫﻮﻛﻮ ﺟﻲ ﺇﻛﺴﺐ ﻣﻴﺪ )‬
‫ﺍﻟﻤﻨﺎﻋﺔ)‪.73-9:(1)64 (1988‬‬ ‫‪ .57-65:(1)234 (2014‬ﺩﻭﻯ‪10.1620/tjem.234.57:‬‬
‫‪.196‬ﻏﻮﻧﺘﺮ ﺇﻡ‪ ،‬ﺟﻴﻞ ﺇﻝ‪ ،‬ﺳﻮﺭﻳﻨﺪﺭﺍﻥ ﺇﺱ ﺇﻳﻪ‪ ،‬ﺑﺎﻟﻢ ﺇﻡ ﺇﻳﻪ‪ ،‬ﻫﺎﻳﻨﻤﺎﻥ ﻓﻲ‪ ،‬ﻓﻮﻥ ﺑﻴﺮﺟﻮﻳﻠﺖ‪-‬ﺑﻴﻠﺪﻭﻥ ﺇﻡ‪،‬‬ ‫‪.173‬ﺭﻭﺳﻮ ﺇﻡ ﺳﻲ‪ ،‬ﻫﺴﻮ ﺁﺭﻱ‪ ،‬ﺳﺒﺎﻳﺴﺮ ﺟﻴﻪ ﺩﻱ‪ ،‬ﻣﺎﻛﺪﻭﻧﺎﻟﺪ ﺑﻲ‪ ،‬ﺗﺸﺎﻥ ﺳﻲ ﺇﺗﺶ‪ ،‬ﺑﻴﺮﻳﺮﺍ ﺁﺭ ﺇﻡ‪،‬‬
‫ﻭﺁﺧﺮﻭﻥ‪.‬ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﺍﻟﺒﻜﺘﻴﺮﻱ ﻛﻤﺆﺷﺮ ﺳﻠﺒﻲ ﻟﻔﻌﺎﻟﻴﺔ ﺟﻴﻤﺴﻴﺘﺎﺑﻴﻦ ﺍﻟﻤﺴﺎﻋﺪ ﻓﻲ ﺳﺮﻃﺎﻥ‬ ‫ﻭﺁﺧﺮﻭﻥ‪.‬ﺗﻌﻤﻞ ﺇﺷﺎﺭﺍﺕ ﺍﻟﻤﺴﺘﻘﺒﻼﺕ ‪ 4‬ﺍﻟﺘﻲ ﻳﺴﺒﺒﻬﺎ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻋﻠﻰ ﺗﻌﺰﻳﺰ ﺍﻟﻘﺪﺭﺓ‬
‫ﺍﻟﺒﻨﻜﺮﻳﺎﺱ‪ ).‬ﺳﺮﻃﺎﻥ ﺍﻟﻄﻴﻒ ‪ .(3)6 (2022JNCI‬ﺩﻭﻯ‪/10.1093:‬ﺟﻨﻜﺲ‪pkac039/‬‬ ‫ﺍﻟﻤﻬﺎﺟﺮﺓﻟﺨﻼﻳﺎ ﺳﺮﻃﺎﻥ ﺍﻟﻤﺮﻱء ﺍﻟﺒﺸﺮﻳﺔ ﺑﻄﺮﻳﻘﺔ ﺗﻌﺘﻤﺪ ﻋﻠﻰ ﺍﻟﺘﺤﺪﻳﺪ‪.‬ﺟﺮﺍﺣﺔ )‪.69-77:(1)154 (2013‬‬
‫ﺩﻭﻯ‪10.1016/j.surg.2013.03.006:‬‬
‫‪.197‬ﺟﻴﻮﻧﺞ ﻭﺍﻱ‪ ،‬ﻛﻴﻢ ﺟﻲ ﺑﻲ‪ ،‬ﺟﻲ ﻭﺍﻱ‪ ،‬ﻛﻮﺍﻙ ﺟﻲ ﺟﻲ‪ ،‬ﻧﺎﻡ ﺟﻲ ﺇﺗﺶ‪ ،‬ﻫﻮﻧﻎ ﻭﺍﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﻨﺸﻴﻂ ﺍﻟﺨﻼﻳﺎ‬ ‫‪.174‬ﻫﻮ ﺟﻲ‪ ،‬ﺷﻲ ﺑﻲ‪ ،‬ﻟﻴﻮ ﺇﻛﺲ‪ ،‬ﺟﻴﺎﻧﻎ ﺇﻡ‪ ،‬ﻳﻮﺍﻥ ﺳﻲ‪ ،‬ﺟﻴﺎﻧﻎ ﺑﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺆﺩﻱ ﺗﻨﺸﻴﻂ‬
‫ﺍﻟﺠﺬﻋﻴﺔﺑﻮﺍﺳﻄﺔ ‪ .e‬ﺍﻟﺪﻫﻦ ﺃﺣﺎﺩﻱ ﺍﻟﻔﻮﺳﻔﻮﺭﻳﻞ ﺍﻟﻤﺸﺘﻖ ﻣﻦ ﺍﻟﻘﻮﻟﻮﻧﻴﺔ ﻳﻌﺰﺯ ﻓﻌﺎﻟﻴﺔ ﺣﺼﺎﺭ ‪.PD-1‬ﺍﻟﺴﺮﻃﺎﻥ‬ ‫ﺍﻟﻤﺴﺘﻘﺒﻞﺍﻟﺸﺒﻴﻪ ﺑﺎﻟﺮﻗﻢ ‪ 4‬ﺇﻟﻰ ﻋﻜﺲ ﺗﻤﺎﻳﺰ ﺍﻟﻮﺭﻡ ﻓﻲ ﺧﻼﻳﺎ ﺍﻟﻮﺭﻡ ﺍﻟﺪﺑﻘﻲ ﺍﻟﺒﺸﺮﻱ ‪ U251‬ﻋﺒﺮ ﻣﺴﺎﺭ‬
‫ﻟﻴﺖ)‪ .28–472:19 (2020‬ﺩﻭﻯ‪10.1016/j.canlet.2019.12.012:‬‬ ‫ﺍﻟﺸﻖ‪.‬ﺇﻧﺖ ﺇﻣﻮﻧﻮﻓﺎﺭﻣﺎﻛﻮﻝ )‪ .41–64:33 (2018‬ﺩﻭﻯ‪10.1016/j.intimp.2018.08.019:‬‬
‫‪.198‬ﻓﺎﺭﻳﺎﺱ ﺃ‪ ،‬ﺳﻮﺗﻮ ﺃ‪ ،‬ﺑﻮﺗﻮﺭ ﺇﻑ‪ ،‬ﺟﻮﻟﺪﻳﻦ ﺳﻲ ﺟﻴﻪ‪ ،‬ﺳﻮﺳﺎ ﺇﺱ‪ ،‬ﺟﻴﻞ ﺳﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻌﻤﻞ‬ ‫‪.175‬ﺟﺎﺭﺍﻱ ﺁﺭ ﺑﻲ‪ ،‬ﻓﻴﻴﻨﺰ ﺑﻲ‪ ،‬ﺑﺎﻭﺭ ﺟﻴﻪ‪ ،‬ﻧﻮﺭﻣﻴﺮ ﺟﻲ‪ ،‬ﺑﺎﺭﺩﻭ ﺇﻡ‪ ،‬ﺟﺎﻧﻴﻦ ﺟﻲ ﺇﻑ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻧﺘﻜﺎﺳﺔ ﺍﻟﺴﺮﻃﺎﻥ‬
‫ﻧﺎﻫﺾ‪ TLR4‬ﻋﻠﻰ ﺗﺤﺴﻴﻦ ﻋﻼﺝ ﺣﺼﺎﺭ ﻧﻘﻄﺔ ﺍﻟﺘﻔﺘﻴﺶ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻋﻦ ﻃﺮﻳﻖ ﺯﻳﺎﺩﺓ ﻧﺴﺒﺔ ﺍﻟﻤﺴﺘﺠﻴﺐ‬ ‫ﺗﺤﺖﺍﻟﻌﻼﺝ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ‪ :‬ﻟﻤﺎﺫﺍ ﻳﻤﻜﻦ ﺃﻥ ﺗﺴﺎﻋﺪ ﻣﻨﺒﻬﺎﺕ ﻣﺴﺘﻘﺒﻼﺕ ‪TLR2 / 4‬ﻳﻮﺭﻭ ‪ J‬ﻓﺎﺭﻣﺎﻛﻮﻝ )‪)563 (2007‬‬
‫ﺇﻟﻰﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﻨﻈﻴﻤﻴﺔ ﺩﺍﺧﻞ ﺍﻟﺒﻴﺌﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻟﻠﻮﺭﻡ‪.‬ﻣﻨﺪﻭﺏ ﺍﻟﻌﻠﻮﻡ )‪ .15406:(1)11 (2021‬ﺩﻭﻯ‪:‬‬ ‫‪ .1-17:(1-3‬ﺩﻭﻯ‪10.1016/j.ejphar.2007.02.018:‬‬
‫‪10.1038/s41598-021-94837-7‬‬ ‫‪.176‬ﺑﺎﻥ ﺳﻲ‪ ،‬ﻭﻭ ﻛﻴﻮ‪ ،‬ﻭﺍﻧﻎ ﺇﺱ‪ ،‬ﻣﻲ ﺯﻱ‪ ،‬ﺗﺸﺎﻧﻎ ﺇﻝ‪ ،‬ﺟﺎﻭ ﺇﻛﺲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﺠﻤﻊ ﻣﻊ ﻧﺎﻫﺾ‬
‫‪.199‬ﻳﻴﻦ ﺇﺗﺶ‪ ،‬ﺑﻮ ﺇﻥ‪ ،‬ﺗﺸﻦ ﻛﻴﻮ‪ ،‬ﺗﺸﺎﻧﻎ ﺟﻴﻪ‪ ،‬ﺗﺸﺎﻭ ﺟﻲ‪ ،‬ﺷﻮ ﺇﻛﺲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻌﻴﺪ ﻋﺪﻳﺪ‬ ‫ﻣﺴﺘﻘﺒﻼﺕﺗﺸﺒﻪ ﺍﻟﺮﻗﻢ ‪ (TLR4) 4‬ﻳﻌﻜﺲ ﻧﺎﻫﺾ ‪ GITR‬ﺑﻮﺳﺎﻃﺔ ﺍﺳﺘﻘﻄﺎﺏ ‪ M2‬ﻟﻠﺒﻼﻋﻢ ﻓﻲ ﺳﺮﻃﺎﻥ‬
‫ﺍﻟﺴﻜﺎﺭﻳﺪﺍﻟﺪﻫﻨﻲ ﺍﻟﻤﺸﺘﻖ ﻣﻦ ﺍﻟﻘﻨﺎﺓ ﺍﻟﻬﻀﻤﻴﺔ ﺗﺸﻜﻴﻞ ﺍﻟﺒﻴﺌﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻟﻠﻮﺭﻡ ﻭﻳﺘﺂﺯﺭ ﻣﻊ ﺣﺼﺎﺭ ﻧﻘﻄﺔ‬ ‫ﺍﻟﺨﻼﻳﺎﺍﻟﻜﺒﺪﻳﺔ‪.‬ﻋﻠﻢ ﺍﻟﻤﻨﺎﻋﺔ ﺍﻷﻭﺭﺍﻡ )‪ .2073010:(1)11 (2022‬ﺩﻭﻯ‪/2162402X.2022.2073010:‬‬
‫ﺗﻔﺘﻴﺶ‪ PD-L1‬ﻋﺒﺮ ﻣﺴﺎﺭ ‪ TLR4 / MyD88 / AKT / NF-kappaB‬ﻓﻲ ﺳﺮﻃﺎﻥ ﺍﻟﺒﻨﻜﺮﻳﺎﺱ‪ .‬ﺩﻳﺲ‬ ‫‪10.1080‬‬
‫ﻣﻮﺕﺍﻟﺨﻠﻴﺔ )‪ .1033:(11)12 (2021‬ﺩﻭﻯ‪10.1038/s41419-021-04293-4:‬‬ ‫‪.177‬ﻟﻴﻮ ﺯﻱ‪ ،‬ﻟﻲ ﺇﻛﺲ‪ ،‬ﻟﻲ ﺇﻛﺲ‪ ،‬ﻛﺎﻱ ﺟﻴﻪ ﺇﻡ‪ ،‬ﺟﺎﻭ ﺇﻑ‪ ،‬ﻳﺎﻧﺞ ﻭﺍﻱ ﻭﺍﻱ‪ .‬ﻣﺴﺘﻘﺒﻼﺕ ﺗﺸﺒﻪ ﺍﻟﺮﻗﻢ‬
‫‪.200‬ﻭﺍﻧﻎ ﺇﺱ‪ ،‬ﺃﺳﺘﺎﺗﻮﺭﻭﻑ ﺁﻱ ﺇﻳﻪ‪ ،‬ﺑﻴﻨﻐﻬﺎﻡ ﺳﻲ ﺇﻳﻪ‪ ،‬ﻣﻜﺎﺭﺛﻲ ﻛﻴﻪ ﺇﻡ‪ ،‬ﻓﻮﻥ ﻣﻬﺮﻳﻦ ﺇﻡ‪ ،‬ﺷﻮ ﺩﺑﻠﻴﻮ‪،‬‬ ‫ﻭﺍﻟﺤﻤﺎﻳﺔﻣﻦ ﺍﻹﺷﻌﺎﻉ‪.‬ﻳﻮﺭﻭ ﺭﻳﻒ ﻣﻴﺪ ﻓﺎﺭﻣﺎﻛﻮﻝ ﺳﺎﻱ )‪ .9–31:(1)22 (2018‬ﺩﻭﻯ‪:‬‬
‫ﻭﺁﺧﺮﻭﻥ‪.‬ﻳﺆﺩﻱ ﺍﻟﻌﻼﺝ ﺍﻟﻔﻌﺎﻝ ﻟﻸﺟﺴﺎﻡ ﺍﻟﻤﻀﺎﺩﺓ ﺇﻟﻰ ﺗﺤﻔﻴﺰ ﻣﻨﺎﻋﺔ ﻣﻀﺎﺩﺓ ﻟﻸﻭﺭﺍﻡ ﻭﻗﺎﺋﻴﺔ ﻟﻠﻤﻀﻴﻒ‬ ‫‪10.26355/ eurrev_201801_14097‬‬
‫ﻭﺍﻟﺘﻲﻳﺘﻢ ﺗﻌﺰﻳﺰﻫﺎ ﻋﻦ ﻃﺮﻳﻖ ﻋﻼﺝ ﻧﺎﻫﺾ ‪.TLR4‬ﺍﻟﺴﺮﻃﺎﻥ ﺍﻟﻤﻨﺎﻋﻲ )‪ .49-61:(1)61 (2012‬ﺩﻭﻯ‪:‬‬ ‫‪.178‬ﺟﻴﺎﻧﻎ ﺯﻱ‪ ،‬ﺟﻮﺭﺟﻴﻞ ﺑﻲ‪ ،‬ﺩﻭ ﺇﻛﺲ‪ ،‬ﺷﺎﻣﻞ ﺇﻝ‪ ،‬ﺳﻮﻓﺎﺙ ﺇﺱ‪ ،‬ﻣﻮﺩ ﺇﺱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻣﻄﻠﻮﺏ‬
‫‪10.1007/s00262-011-1090-7‬‬ ‫‪ CD14‬ﻹﺷﺎﺭﺓ ‪ LPS‬ﺍﻟﻤﺴﺘﻘﻠﺔ ﻋﻦ ‪.MyD88‬ﻧﺎﺕ ﺇﻳﻤﻮﻧﻮﻝ )‪ .565-70:(6)6 (2005‬ﺩﻭﻯ‪/ni1207:‬‬
‫‪.201‬ﻭﺍﻧﻎ ﻳﻞ‪ ،‬ﺑﻨﻎ ﺳﻤﻮ‪ ،‬ﺳﻮ ﺳﻲ‪ ،‬ﻟﻴﻦ ﺳﻲ ﺗﻲ‪ .‬ﺍﻟﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﺸﺘﺮﻙ )‪-OK-432، IL‬‬ ‫‪10.1038‬‬
‫‪ (2‬ﻣﻊ ﺍﻟﻌﻼﺝ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ ﻳﻘﻠﻞ ﻣﻦ ﻣﻌﺪﻝ ﺗﻜﺮﺍﺭ ﺍﻹﺻﺎﺑﺔ ﺑﺴﺮﻃﺎﻥ ﺍﻟﻤﺒﻴﺾ ﺍﻟﻤﺘﻘﺪﻡ‪.‬ﺇﻋﺎﺩﺓ ﺇﻧﺘﺎﺝ ﺍﻟﻌﻠﻮﻡ )‪(2019‬‬
‫‪.179‬ﺭﻳﺴﻤﺎﻥ ﺇﻥ‪ ،‬ﻓﺎﺳﻞ ﺟﻲ‪ ،‬ﺃﻭﺑﻼﻙ ﺇﻳﻪ‪ ،‬ﺑﺮﻳﺴﺘﻮﻓﺴﻴﻚ ﺑﻲ‪ ،‬ﺟﻴﻮﺍﻧﻴﻨﻲ ﺗﻲ ﺇﻝ‪ ،‬ﻓﺎﻳﺲ ﺟﻲ ﺑﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬
‫‪ .9–244:(2)26‬ﺩﻭﻯ‪10.1177/1933719118768684:‬‬
‫ﺍﻷﺩﻭﺍﺭﺍﻷﺳﺎﺳﻴﺔ ﻟﻠﻤﺨﻠﻔﺎﺕ ﺍﻟﻜﺎﺭﻫﺔ ﻟﻠﻤﺎء ﻓﻲ ﻛﻞ ﻣﻦ ‪ MD-2‬ﻭﺍﻟﻤﺴﺘﻘﺒﻼﺕ ﺍﻟﺸﺒﻴﻬﺔ ﺑﺎﻟﺮﻗﻢ ‪ 4‬ﻓﻲ ﺍﻟﺘﻨﺸﻴﻂ‬
‫‪.202‬ﻳﺎﻧﻎ ﺩ‪ ،‬ﻟﻮﻩ ﺇﻛﺲ‪ ،‬ﻟﻴﺎﻥ ﻛﻴﻮ‪ ،‬ﺟﺎﻭ ﺇﻝ‪ ،‬ﻭﺍﻧﻎ ﺳﻲ‪ ،‬ﺗﺸﻲ ﺇﻛﺲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻟﻘﺎﺡ ﺍﻟﺴﺮﻃﺎﻥ ﺛﻼﺛﻲ‬ ‫ﺑﻮﺍﺳﻄﺔﺍﻟﺴﻤﻮﻡ ﺍﻟﺪﺍﺧﻠﻴﺔ‪.‬ﺟﻲ ﺑﻴﻮﻝ ﻛﻴﻢ )‪ .60–15052:(22)284 (2009‬ﺩﻭﻯ‪ /10.1074:‬ﺟﻲ ﺑﻲ ﺳﻲ‬
‫ﺍﻟﻤﻜﻮﻧﺎﺕﺍﻻﺻﻄﻨﺎﻋﻲ ﺑﺎﻟﻜﺎﻣﻞ ﺍﻟﻘﺎﺋﻢ ﻋﻠﻰ ‪ TN‬ﺑﺎﺳﺘﺨﺪﺍﻡ ‪ ligandMPLA‬ﻭ‪ iNKT‬ﺍﻟﻤﺮﺗﺒﻂ ﺗﺴﺎﻫﻤﻴ ًﺎ‬ ‫‪M901429200.‬‬
‫‪ KRN-7000‬ﻛﻤﺴﺎﻋﺪ ﻣﺪﻣﺞ ﻳﺤﻤﻲ ﺍﻟﻔﺌﺮﺍﻥ ﺑﺸﻜﻞ ﻓﻌﺎﻝ ﻣﻦ ﺗﻄﻮﺭ ﺍﻟﻮﺭﻡ‪.‬ﺍﻛﺘﺎ ﻓﺎﺭﻡ ﺳﻴﻦ ﺑﻲ )‪(2022‬‬ ‫‪.180‬ﻣﻮﻟﺮ ﺇﻱ‪ ،‬ﻛﺮﻳﺴﺘﻮﺑﻮﻟﻮﺱ ﺑﻲ ﺇﻑ‪ ،‬ﻫﺎﻟﺪﺭ ﺇﺱ‪ ،‬ﻟﻮﻧﺪﻱ ﺇﻳﻪ‪ ،‬ﺑﻴﺮﺍﻛﻲ ﻛﻴﻪ‪ ،‬ﺳﺒﻴﺚ ﺇﻡ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬
‫‪ .45–4432:(12)12‬ﺩﻭﻯ‪10.1016/j.apsb.2022.05.028:‬‬ ‫ﺗﺘﺂﺯﺭﺑﺮﻭﺍﺑﻂ ﻣﺴﺘﻘﺒﻼﺕ ‪ Tolllike‬ﻭ‪ interferon-gamma‬ﻟﺘﺤﺮﻳﺾ ﺍﻟﺒﻼﻋﻢ ‪ M1‬ﺍﻟﻤﻀﺎﺩﺓ ﻟﻠﻮﺭﻡ‪.‬‬
‫‪.‬ﺗﺼﻤﻴﻢﻟﻘﺎﺡ ﺟﺪﻳﺪ ﻣﺆﺗﻠﻒ ﻣﺘﻌﺪﺩ ﺍﻟﺤﻮﺍﺗﻢ ﺿﺪ ﺳﺮﻃﺎﻥ ﺍﻟﺜﺪﻱ ﺍﻟﺜﻼﺛﻲ ﺍﻟﺴﻠﺒﻲ ‪P.‬‬ ‫ﺍﻟﺠﺒﻬﺔﺍﻟﻤﻨﺎﻋﻴﺔ )‪ .8:1383 (2017‬ﺩﻭﻯ‪10.3389/fimmu.2017.01383:‬‬
‫‪203. Dariushnejad H، Ghorbanzadeh V، Akbari S، Hashemzadeh‬ﺇﻳﺮﺍﻥ ﺑﻴﻮﻣﻴﺪ ﺟﻲ )‬ ‫‪.181‬ﻛﺎﻟﻔﺎﻧﻮ ﺟﻲ ﺇﻱ‪ ،‬ﺃﻏﻨﻴﺴﻲ ﺩﻱ ﺇﻡ‪ ،‬ﺃﻭﻡ ﺟﻲ ﻭﺍﻱ‪ ،‬ﺟﻮﺷﻴﻤﺎ ﺇﻡ‪ ،‬ﺳﻴﻨﻐﺎﻝ ﺁﺭ‪ ،‬ﻛﻮﻳﻞ ﺇﺱ ﺇﻡ‪،‬‬
‫‪ .74–160:(2)26 (2022‬ﺩﻭﻯ‪10.52547/ibj.26.2.160:‬‬ ‫ﻭﺁﺧﺮﻭﻥ‪.‬ﺗﻌﺪﻳﻞ ﻣﺠﻤﻊ ﻣﺴﺘﻘﺒﻼﺕ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ )‪ (CD14، TLR4، MD-2‬ﻭﻣﺴﺘﻘﺒﻼﺕ ‪2‬‬
‫‪.‬ﺑﻌﺪﺍﻻﺳﺘﺌﺼﺎﻝ ﺍﻟﻌﻼﺟﻲ ﻟﺴﺮﻃﺎﻥ ﺍﻟﻤﻌﺪﺓ‪ :‬ﺗﺤﻠﻴﻞ ﺗﻠﻮﻱ ﻟﺒﻴﺎﻧﺎﺕ ﺍﻟﻤﺮﻳﺾ ﺍﻟﻔﺮﺩﻳﺔ ﻟﻠﺘﺠﺎﺭﺏ‬ ‫‪ tolllike‬ﻓﻲ ﺍﻟﻤﺮﺿﻰ ﺍﻟﻤﺼﺎﺑﻴﻦ ﺑﻤﺘﻼﺯﻣﺔ ﺍﻻﺳﺘﺠﺎﺑﺔ ﺍﻻﻟﺘﻬﺎﺑﻴﺔ ﺍﻟﺠﻬﺎﺯﻳﺔ ﻣﻊ ﺃﻭ ﺑﺪﻭﻥ ﻋﺪﻭﻯ‪ :‬ﺍﻟﻌﻼﻗﺔ‬
‫ﺍﻟﻌﺸﻮﺍﺋﻴﺔﺫﺍﺕ ﺍﻟﺸﻮﺍﻫﺪ ‪ OK-432‬ﻓﻌﺎﻟﻴﺔ ﺍﻟﻌﻼﺝ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﺴﺎﻋﺪ ﻣﻊ ‪Y، Sakamoto J.‬‬ ‫ﺑﺎﻟﺘﺴﺎﻣﺢ‪.‬ﺻﺪﻣﺔ )‪ .9–415:(5)20 (2003‬ﺩﻭﻯ‪10.1097/ 01.shk.0000092269.01859.44:‬‬
‫‪ 204. Oba MS، Teramukai S، Ohashi Y، Ogawa K، Maehara‬ﺳﺮﻃﺎﻥ ﺍﻟﻤﻌﺪﺓ )‪)19 (2016‬‬
‫‪ .616-24:(2‬ﺩﻭﻯ‪10.1007/s10120-015-0489-9:‬‬ ‫‪ LPS.‬ﺍﻟﻨﺎﺟﻢ ﻋﻦ ‪ M1‬ﺗﻨﻈﻢ ﺍﺳﺘﻘﻄﺎﺏ ﺍﻟﺒﻼﻋﻢ ‪ SENP1-KLF4‬ﺇﺷﺎﺭﺍﺕ ‪، Lu Y، Wang L، Tian T.‬‬
‫‪.205‬ﻫﺎﻳﻦ ﺇﺗﺶ‪ ،‬ﺃﺩﺍﻧﻴﺘﺶ ﺇﻑ‪ ،‬ﺑﻴﺘﺮﻧﻴﻠﺞ ﺗﻲ ﺗﻲ‪ ،‬ﻫﻴﺠﻤﺎﻥ ﺇﻡ‪ ،‬ﻛﺎﺳﺒﺮ ﺳﻲ‪ ،‬ﺇﻳﺘﻴﺞ ﺇﺱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬ ‫‪182. Wang K، Xiong J‬ﻱ )‪ .24–209:(1)290 (2023‬ﺩﻭﻯ‪ /10.1111:‬ﻓﺒﺮﺍﻳﺮ ‪16589‬‬
‫ﺗﻌﺪﻳﻞﻣﺼﻤﻢ ﻟﻼﺳﺘﺠﺎﺑﺎﺕ ﺍﻟﺨﻠﻮﻳﺔ ﺍﻟﻤﺆﻳﺪﺓ ﻟﻼﻟﺘﻬﺎﺑﺎﺕ ﻣﻊ ﻣﻘﻠﺪﺍﺕ ﺍﻟﺪﻫﻮﻥ ﺍﻟﺜﻨﺎﺋﻴﺔ ﺍﻟﺴﻜﺎﺭﻳﺪ‪.‬ﺍﻟﺠﺒﻬﺔ‬
‫ﺍﻟﻤﻨﺎﻋﻴﺔ)‪ .12:631797 (2021‬ﺩﻭﻯ‪10.3389/fimmu.2021.631797:‬‬ ‫‪.‬ﺍﻟﻠﺪﻭﻧﺔﺍﻟﺒﻠﻌﻤﻴﺔ ﻭﺍﻟﻮﻇﻴﻔﺔ ﻓﻲ ﺍﻟﺒﻴﺌﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻟﻮﺭﻡ ﺍﻟﺮﺋﺔ ﺍﻟﺘﻲ ﺗﻢ ﺍﻟﻜﺸﻒ ﻋﻨﻬﺎ ﻓﻲ ﺍﻟﻨﻤﺎﺫﺝ ﺍﻟﻜﺮﻭﻳﺔ‬
‫‪.206‬ﻧﻴﻠﺴﻮﻥ ﺇﻡ ﺇﺗﺶ‪ ،‬ﺑﺎﻭﺭﺯ ﺟﻲ ﺇﺱ‪ ،‬ﺑﻴﻠﻲ ﺇﺱ ﺁﺭ‪ ،‬ﺩﻳﻔﻴﻦ ﺇﻡ ﺇﻳﻪ‪ ،‬ﻓﻮﻏﻞ ﺳﻲ ﺩﺑﻠﻴﻮ‪ ،‬ﻛﺎﻳﺰﺭ ﺇﻳﻪ ﺩﻱ‪،‬‬ ‫ﻏﻴﺮﺍﻟﻤﺘﺠﺎﻧﺴﺔ ﺛﻼﺛﻴﺔ ﺍﻷﺑﻌﺎﺩ ﻭﺍﻟﻨﻤﺎﺫﺝ ﺍﻟﻤﺰﺭﻭﻋﺔ ‪Attanoos R، Clayton A، Errington R، Tabi Z.‬‬
‫ﻭﺁﺧﺮﻭﻥ‪.‬ﻳﻤﻜﻦ ﻟﻠﻌﻼﺝ ﺑﻨﺎﻫﺾ ﻣﺴﺘﻘﺒﻼﺕ ‪ Tolllike‬ﺃﻥ ﻳﺰﻳﺪ ﺑﺸﻜﻞ ﻛﺒﻴﺮ ﻣﻦ ﺍﻟﻨﺸﺎﻁ ﺍﻟﻤﻀﺎﺩ ﻟﻸﻭﺭﺍﻡ‬ ‫‪183. Evans L، Milward K،‬ﺍﻷﺩﻭﻳﺔ ﺍﻟﺤﻴﻮﻳﺔ )‪ .(3)9 (2021‬ﺩﻭﻯ‪ /10.3390:‬ﺍﻷﺩﻭﻳﺔ‬
‫ﻟﻠﺨﻼﻳﺎﺍﻟﺘﺎﺋﻴﺔ ‪ (+) CD8‬ﺍﻟﻤﻨﻘﻮﻟﺔ ﺑﺎﻟﺘﺒﻨﻲ ﺩﻭﻥ ﺷﺮﻭﻁ ﻣﺴﺒﻘﺔ ﻟﻠﻤﻀﻴﻒ‪ ).‬ﺍﻟﻤﻨﺎﻋﻲ ﻟﻠﺴﺮﻃﺎﻥ ‪(2016J‬‬ ‫ﺍﻟﺤﻴﻮﻳﺔ‪9030302‬‬
‫‪.4:6‬ﺩﻭﻯ‪10.1186/s40425-016-0110-8:‬‬ ‫‪.184‬ﺷﻮﻫﺎﻥ ﺍﻟﺨﺎﻣﺲ‪ ،‬ﻛﺎﻧﻮﺍﺭ ﺇﺱ ﺇﺱ‪ .‬ﺍﻟﺒﺒﺘﻴﺪﺍﺕ ﺍﻟﺪﻫﻨﻴﺔ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﺒﺸﺮﻱ ﻛﺪﻭﺍء‬
‫‪.207‬ﺑﺎﺭﻙ ﺇﺗﺶ ﺟﻴﻪ‪ ،‬ﺟﺎﻧﺞ ﺟﻲ ﻭﺍﻱ‪ ،‬ﻛﻴﻢ ﻳﺲ‪ ،‬ﺑﺎﺭﻙ ﺟﻴﻪ ﺇﺗﺶ‪ ،‬ﻟﻲ ﺇﺱ ﺇﻱ‪ ،‬ﻓﻮ ﺇﻡ ﺳﻲ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬ ‫ﻗﻮﻱﻟﻠﺴﺮﻃﺎﻥ‪.‬ﺳﺮﻃﺎﻥ ﺍﻟﺴﺎﺋﻞ ﺍﻟﻤﻨﻮﻱ ﺑﻴﻮﻝ )‪ .33–70:128 (2021‬ﺩﻭﻯ‪:‬‬
‫ﺑﺮﻭﺗﻴﻦﺭﺑﻂ ‪ TLR4‬ﺍﻟﺠﺪﻳﺪ‪ ،‬ﺑﺮﻭﺗﻴﻦ ﺍﻟﺮﻳﺒﻮﺳﻮﻡ ‪ ،40S S3‬ﻟﻪ ﻓﺎﺋﺪﺓ ﻣﺤﺘﻤﻠﺔ ﻛﻤﺴﺎﻋﺪ ﻓﻲ ﻟﻘﺎﺡ ﻗﺎﺋﻢ ﻋﻠﻰ‬ ‫‪10.1016/ j.semcancer.2020.06.012‬‬
‫ﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔ‪ ).‬ﺍﻟﻤﻨﺎﻋﻲ ﻟﻠﺴﺮﻃﺎﻥ ‪ .60:(1)7 (2019J‬ﺩﻭﻯ‪10.1186/s40425- 019-0539-7:‬‬ ‫‪.185‬ﻏﻮﺗﺸﻴﻜﻴﺎﻥ ﺃ‪ ،‬ﺑﻴﺘﺸﻮﻏﻴﻦ ﺃ‪ ،‬ﺑﺎﺟﺎﻳﻒ ﺃ‪ ،‬ﺩﺍﻓﺘﻴﺎﻥ ﺃ‪ ،‬ﻫﻮﻓﺎﻛﻴﻤﻴﺎﻥ ﺃ‪ ،‬ﺗﻮﺧﺎﺗﻮﻟﻴﻦ‬
‫ﺃ‪،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﺳﺘﻬﺪﺍﻑ ‪ TLR-4‬ﺑﺎﺳﺘﺨﺪﺍﻡ ﻧﺎﻫﺾ ﻣﺸﺘﻖ ﻣﻦ ﺍﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﺼﻴﺪﻻﻧﻴﺔ‪Immunomax)R( ،‬‬
‫‪.208‬ﺟﺮﻭﻓﺮ ﻙ‪ ،‬ﺟﺮﻳﺠﻮﺭﻱ ﺇﺱ‪ ،‬ﺟﻴﺒﺲ ﺟﻴﻪ ﺇﻑ‪ ،‬ﺇﻳﻤﻴﻨﺎﻛﺮ ﻧﻴﻮﺟﻴﺮﺳﻲ‪ .‬ﻣﻨﺎﻗﺸﺔ ﺣﻮﻝ ﺗﻄﻮﺭ‬ ‫‪،‬ﻛﺈﺳﺘﺮﺍﺗﻴﺠﻴﺔ ﻋﻼﺟﻴﺔ ﻟﺴﺮﻃﺎﻥ ﺍﻟﺜﺪﻱ ﺍﻟﻨﻘﻴﻠﻲ‪.‬ﻱ ﺗﺮﺟﻤﺔ ﻣﻴﺪ )‪ .12:322 (2014‬ﺩﻭﻯ‪:‬‬
‫ﻣﻴﻜﺮﻭﺑﻴﻮﻡﺍﻷﻣﻌﺎء‪ ،‬ﻭﻣﺤﺪﺩﺍﺗﻪ‪ ،‬ﻭﺩﻳﺴﺒﻴﻮﺳﻴﺲ ﻓﻲ ﺳﺮﻃﺎﻧﺎﺕ ﺍﻟﻤﺮﻱء ﻭﺍﻟﻤﻌﺪﺓ‪.‬ﻱ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ‬ ‫‪10.1186/s12967-014-0322-y‬‬
‫ﺃﻭﻧﻜﻮﻝ)‪) 12 (2021‬ﻣﻠﺤﻖ ‪ .S290-300:(2‬ﺩﻭﻯ‪/10.21037:‬ﺟﻐﻮ‪-2019-‬ﺟﻲ‪07-‬‬ ‫‪.186‬ﻛﻮﻳﺪﻭ ﺇﺱ‪ ،‬ﻫﻮﻣﺎ ﺇﺱ‪ ،‬ﺃﻭﻛﺎﻣﻮﺗﻮ ﺇﻡ‪ ،‬ﻧﺎﻣﻴﻜﻲ ﻭﺍﻱ‪ ،‬ﺗﺎﻛﺎﻛﻮﺭﺍ ﻛﻴﻪ‪ ،‬ﺗﺎﻛﺎﻫﺎﺭﺍ ﺇﻳﻪ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺆﺩﻱ‬
‫ﺍﻧﺪﻣﺎﺝﺍﻟﺨﻼﻳﺎ ﺍﻟﺠﺬﻋﻴﺔ ‪ /‬ﺍﻟﻮﺭﻣﻴﺔ ﺍﻟﻤﻨﺸﻂ ‪ TLR2 / 4‬ﺇﻟﻰ ﺯﻳﺎﺩﺓ ﺍﻟﺨﻼﻳﺎ ﺍﻟﻠﻴﻤﻔﺎﻭﻳﺔ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﺴﺎﻣﺔ‬
‫‪.‬ﻛﻌﻮﺍﻣﻞﺧﻄﺮ ﻣﺤﺘﻤﻠﺔ ﻻﻟﺘﻬﺎﺏ ﺍﻟﻘﻮﻟﻮﻥ ﻭﺳﺮﻃﺎﻥ ﺍﻟﻘﻮﻟﻮﻥ‪ :‬ﺃﺩﻭﺍﺭ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻓﻲ ﺍﻷﻣﻌﺎء‬ ‫ﻟﻠﺨﻼﻳﺎ‪.‬ﺑﻠﻮﺱ ﻭﺍﺣﺪ )‪:‬ﺩﻭﻯ ‪10.1371/journal.pone.00592802013( 8)3(:e59280.‬‬
‫ﺍﻟﻤﻌﻨﻴﺔ‪209. Sanidad KZ، Wang G، Panigrahy A، Zhang G. Triclosan and triclocarban‬‬
‫‪.187‬ﻟﻴﻦ ﻳﺲ‪ ،‬ﻫﻮﺍﻧﻎ ﺇﻝ ﺩﻱ‪ ،‬ﻟﻴﻦ ﺗﺶ‪ ،‬ﻫﻮﺍﻧﻎ ﺑﻲ ﺇﺗﺶ‪ ،‬ﺗﺸﻦ ﻭﺍﻱ ﺟﻲ‪ ،‬ﻭﻭﻧﻎ ﺇﻑ ﺇﺗﺶ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﻨﺸﺎﻁ‬
‫ﺍﻟﻌﻠﻮﻡﻣﺠﻤﻮﻉ ﺍﻟﺒﻴﺌﺔ )‪ .842:156776 (2022‬ﺩﻭﻯ‪10.1016/j.scitotenv.2022.156776:‬‬
‫ﺍﻟﻤﻀﺎﺩﻟﻠﺴﺮﻃﺎﻥ ﻓﻲ ﺍﻟﻤﺨﺘﺒﺮ ﻭﻓﻲ ﺍﻟﺠﺴﻢ ﺍﻟﺤﻲ ﻟﻠﺠﻠﻴﻜﻮﻟﻴﺒﻴﺪ ﺍﻻﺻﻄﻨﺎﻋﻲ ﻛﻤﻨﺸﻂ ﻟﻤﺴﺘﻘﺒﻼﺕ ‪.(TLR4) 4‬‬
‫‪.210‬ﺻﺪﻳﻘﻲ ﺁﺭ‪ ،‬ﻣﻮﻧﻐﺮﻭ ﺇﻡ ﺁﺭ‪ ،‬ﺍﻟﺤﺮﺑﻲ ﺁﻡ‪ ،‬ﺍﻟﻔﻬﻴﻤﻲ ﺇﺗﺶ‪ ،‬ﺧﺎﻥ ﺇﻥ ﺇﻳﻪ‪ .‬ﺍﺳﺘﺨﺪﺍﻡ ﺍﺳﺘﺮﺍﺗﻴﺠﻴﺎﺕ‬ ‫ﺟﻲﺑﻴﻮﻝ ﻛﻴﻢ )‪ .92–43782:(51)286 (2011‬ﺩﻭﻯ‪10.1074/jbc.M111.285171:‬‬
‫ﺍﻟﺘﻌﺪﻳﻞﺍﻟﻤﻴﻜﺮﻭﺑﻲ ﻟﻸﻣﻌﺎء ﻛﺎﺳﺘﺮﺍﺗﻴﺠﻴﺎﺕ ﺗﺪﺧﻠﻴﺔ ﻟﻠﺸﻴﺨﻮﺧﺔ‪.‬ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺪﻗﻴﻘﺔ )‪ .(9)10 (2022‬ﺩﻭﻯ‪:‬‬ ‫‪.188‬ﺃﻛﺎﺯﺍﻭﺍ ﺗﻲ‪ ،‬ﻣﺎﺳﻮﺩﺍ ﺇﺗﺶ‪ ،‬ﺳﺎﻳﻜﻲ ﻭﺍﻱ‪ ،‬ﻣﺎﺗﺴﻮﻣﻮﺗﻮ ﺇﻡ‪ ،‬ﺗﺎﻛﻴﺪﺍ ﻛﻴﻪ‪ ،‬ﺗﺴﻮﺟﻴﻤﻮﺭﺍ ﻛﻴﻪ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬
‫‪/10.3390‬ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ‪10091869‬‬ ‫ﻳﺘﻢﺿﻌﻒ ﺍﻧﺤﺪﺍﺭ ﺍﻟﻮﺭﻡ ﺑﻮﺳﺎﻃﺔ ﺍﻟﻤﻮﺍﺩ ﺍﻟﻤﺴﺎﻋﺪﺓ ﻭﺍﻻﺳﺘﺠﺎﺑﺔ ﺍﻟﺴﺎﻣﺔ ﻟﻠﺨﻼﻳﺎ ﺍﻟﺨﺎﺻﺔ ﺑﺎﻟﻮﺭﻡ ﻓﻲ‬
‫‪.211‬ﺳﺎﻣﺒﺴﻴﻞ ﻛﻴﻪ‪ ،‬ﻭﺍﻧﻎ ﺩﺑﻠﻴﻮ‪ ،‬ﺃﻭﻫﻼﻧﺪ ﺳﻲ‪ ،‬ﻣﺎﺟﺮ ﺇﻝ ﺇﻑ‪ ،‬ﺑﻴﺖ ﺇﻥ‪ ،‬ﻟﻮﺭﻱ ﺩﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺗﻮﻓﺮ ﺍﻟﺘﻤﺎﺭﻳﻦ‬ ‫ﺍﻟﻔﺌﺮﺍﻥﺍﻟﺘﻲ ﺗﻌﺎﻧﻲ ﻣﻦ ﻧﻘﺺ ‪.MyD88‬ﺩﻗﺔ ﺍﻟﺴﺮﻃﺎﻥ )‪ .64–757:(2)64 (2004‬ﺩﻭﻯ‪can-03-1518:‬‬
‫ﺍﻟﺮﻳﺎﺿﻴﺔﻭﺍﻷﻟﻴﺎﻑ ﺍﻟﺒﺮﻳﺒﺎﻳﻮﺗﻴﻜﻴﺔ ﻓﺎﺋﺪﺓ ﺗﻌﺘﻤﺪ ﻋﻠﻰ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻓﻲ ﺍﻷﻣﻌﺎء ﻟﺪﻯ ﺍﻟﻨﺎﺟﻴﻦ ﻣﻦ‬ ‫‪10.1158/ 0008-5472.‬‬
‫ﻧﻤﻮﺫﺝﺍﻧﺘﻘﺎﻟﻲ ﺧﺎﻝ ٍﻣﻦ ﺍﻟﺠﺮﺍﺛﻴﻢ ﻟﺴﺮﻃﺎﻥ ﺍﻟﺜﺪﻱ‪.‬ﺍﻟﺴﺮﻃﺎﻥ )ﺑﺎﺯﻝ( )‪ .(11)14 (2022‬ﺩﻭﻯ‪/10.3390:‬‬
‫‪.189‬ﺩﻱ ﻛﻴﺮﻭﺯ ﺇﻥ‪ ،‬ﻣﺎﺭﻳﻨﻴﻮ ﺇﻑ ﻓﻲ‪ ،‬ﺩﻱ ﺃﺭﻭﺟﻮ ﺇﻳﻪ‪ ،‬ﻓﺎﻫﻴﻞ ﺟﻲ ﺇﺱ‪ ،‬ﺃﻭﻟﻴﻔﻴﺮﺍ ﺇﺱ ﺳﻲ‪ .‬ﺍﻟﻌﻼﺝ‬
‫ﺳﺮﻃﺎﻧﺎﺕ‪14112722‬‬
‫ﺍﻟﻤﻨﺎﻋﻲ‪ BCG‬ﺍﻟﻤﻌﺘﻤﺪ ﻋﻠﻰ ‪ MyD88‬ﻳﻘﻠﻞ ﻣﻦ ﺍﻟﻮﺭﻡ ﻭﻳﻨﻈﻢ ﺍﻟﺒﻴﺌﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻟﻠﻮﺭﻡ ﻓﻲ ﻧﻤﻮﺫﺝ ﺍﻟﻔﺌﺮﺍﻥ‬
‫‪.212‬ﺗﺸﺎﻧﻎ ﺯﺩ‪ ،‬ﻓﻨﻎ ﺇﺗﺶ‪ ،‬ﺗﺸﻴﻮ ﻭﺍﻱ‪ ،‬ﺷﻮ ﺯﺩ‪ ،‬ﺷﻴﻪ ﻛﻴﻮ‪ ،‬ﺩﻳﻨﻎ ﺩﺑﻠﻴﻮ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ Dysbiosis .‬ﻣﻦ ﺍﻟﻜﺎﺋﻨﺎﺕ‬ ‫ﻟﺴﺮﻃﺎﻥﺍﻟﻤﺜﺎﻧﺔﻣﻨﺪﻭﺏ ﺍﻟﻌﻠﻮﻡ )‪ .15648:(1)11 (2021‬ﺩﻭﻯ‪10.1038/s41598-021- 95157-6:‬‬
‫ﺍﻟﺤﻴﺔﺍﻟﺪﻗﻴﻘﺔ ﺍﻟﻔﻄﺮﻳﺔ ﺍﻟﻤﺨﺎﻃﻴﺔ ﻓﻲ ﺍﻟﻤﻌﺪﺓ ﻓﻲ ﺍﻟﺒﻴﺌﺔ ﺍﻟﺪﻗﻴﻘﺔ ﻟﺴﺮﻃﺎﻥ ﺍﻟﻤﻌﺪﺓ‪.‬ﻱ ﺇﻳﻤﻮﻧﻮﻝ ﺍﻟﺪﻗﺔ )‪(2022‬‬
‫‪.2022:6011632‬ﺩﻭﻯ‪10.1155/2022/6011632:‬‬
‫‪.190‬ﺃﺣﻤﺪ ﺃ‪ ،‬ﻭﺍﻧﻎ ﺟﻴﻪ ﺇﺗﺶ‪ ،‬ﺭﻳﺪﻣﻮﻧﺪ ﺇﺗﺶ ﺑﻲ‪ .‬ﻳﺆﺩﻱ ﺇﺳﻜﺎﺕ ‪ TLR4‬ﺇﻟﻰ ﺯﻳﺎﺩﺓ ﺗﻄﻮﺭ ﺍﻟﻮﺭﻡ ﻭﺭﻡ‬
‫‪.213‬ﺗﺸﺎﻭ ﺇﺗﺶ‪ ،‬ﻟﻲ ﺩﻱ‪ ،‬ﻟﻴﻮ ﺟﻲ‪ ،‬ﺗﺸﻮ ﺇﻛﺲ‪ ،‬ﻫﺎﻥ ﺟﻲ‪ ،‬ﻭﺍﻧﻎ ﺇﻝ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺘﻨﺒﺄ ‪breve‬‬ ‫ﺧﺒﻴﺚﻓﻲ ﺍﻟﺮﺋﺔ ﻓﻲ ﻧﻤﻮﺫﺝ ﺍﻟﻔﺌﺮﺍﻥ ﻟﺴﺮﻃﺎﻥ ﺍﻟﺜﺪﻱ‪.‬ﺁﻥ ﺳﻮﺭﺝ ﺃﻭﻧﻜﻮﻝ )‪ 20 (2013‬ﻣﻠﺤﻖ ‪S389-96:3‬‬
‫‪ Bifidobacterium‬ﺑﻔﻌﺎﻟﻴﺔ ﺍﻟﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ ﺍﻟﻤﻀﺎﺩ ﻟـ ‪ PD-1‬ﻣﻊ ﺍﻟﻌﻼﺝ ﺍﻟﻜﻴﻤﻴﺎﺋﻲ ﻟﺪﻯ ﻣﺮﺿﻰ‬ ‫‪.‬ﺩﻭﻯ‪10.1245/s10434-012-2595-9:‬‬
‫‪ NSCLC‬ﺍﻟﺼﻴﻨﻴﻴﻦ‪.‬ﺍﻟﺴﺮﻃﺎﻥ ﻣﻴﺪ )‪ .(2022‬ﺩﻭﻯ‪10.1002/cam4.5312:‬‬ ‫‪.191‬ﻳﻴﻦ ﺩﺑﻠﻴﻮ‪ ،‬ﻟﻲ ﻭﺍﻱ‪ ،‬ﺳﻮﻧﻎ ﻭﺍﻱ‪ ،‬ﺗﺸﺎﻧﻎ ﺟﻲ‪ ،‬ﻭﻭ ﺳﻲ‪ ،‬ﺗﺸﻦ ﻭﺍﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﻌﺰﺯ ‪CCRL2‬‬
‫‪.214‬ﺳﺎﺭﻛﺎﺭ ﺑﻲ‪ ،‬ﻣﺎﻟﻚ ﺇﺱ‪ ،‬ﺑﺎﻧﻴﺮﺟﻲ ﺃ‪ ،‬ﺩﺍﺗﺎ ﺳﻲ‪ ،‬ﺑﺎﻝ ﺩﻱ ﻛﻴﻪ‪ ،‬ﻏﻮﺵ ﺃ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﺍﻟﺘﻮﻗﻴﻊ‬ ‫ﻣﻨﺎﻋﺔﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﺍﻟﻤﻀﺎﺩﺓ ﻟﻸﻭﺭﺍﻡ ﻋﻦ ﻃﺮﻳﻖ ﺗﻀﺨﻴﻢ ﺗﻨﺸﻴﻂ ﺍﻟﺒﻼﻋﻢ ﺍﻟﻤﻨﺎﻋﻴﺔ ﺑﻮﺳﺎﻃﺔ ‪.TLR4‬‬
‫ﺍﻟﻤﻴﻜﺮﻭﺑﻲﺍﻟﺘﻔﺎﺿﻠﻲ ﺍﻟﻤﺮﺗﺒﻂ ﺑﺘﻀﺨﻢ ﺍﻟﺒﺮﻭﺳﺘﺎﺗﺎ ﺍﻟﺤﻤﻴﺪ ﻭﺳﺮﻃﺎﻥ ﺍﻟﺒﺮﻭﺳﺘﺎﺗﺎ‪ .‬ﺍﻟﺨﻠﻴﺔ ﺍﻷﻣﺎﻣﻴﺔ‬ ‫) ‪ .(16)118 (2021Proc Natl Acad Sci USA‬ﺩﻭﻯ‪10.1073/pnas.2024171118:‬‬
‫ﺗﺼﻴﺐﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻝ )‪ .12:894777 (2022‬ﺩﻭﻯ‪10.3389/fcimb.2022.894777:‬‬ ‫‪ kappaB.‬ﺍﻷﻧﻤﺎﻁ ﺍﻟﻈﺎﻫﺮﻳﺔ ﺍﻟﻤﺆﻳﺪﺓ ﻟﻠﻮﺭﻡ ﺍﻟﻤﺸﺘﻘﺔ ﻣﻦ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺴﺮﻃﺎﻧﻴﺔ ﺍﻟﻤﺴﺘﺤﺜﺔ ﻓﻲ ﺍﻟﺨﻼﻳﺎ‬
‫‪.215‬ﺭﻭﻛﻮﺱ ﺗﻲ‪ ،‬ﻫﻮﻟﻮﺑﻴﻜﻮﻓﺎ ﻓﻲ‪ ،‬ﻛﻮﻟﻜﻮﻓﺎ ﺯﻱ‪ ،‬ﻫﻮﺭﻧﺎﻛﻮﻓﺎ ﺃ‪ ،‬ﺑﺮﻳﺒﻮﻟﻮﻓﺎ ﺗﻲ‪ ،‬ﻛﻮﺯﻭﺑﻴﻚ ﺇﻱ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪.‬‬ ‫ﺍﻟﺒﻠﻌﻤﻴﺔﻣﻦ ﺧﻼﻝ ﺗﻔﺎﻋﻞ ﻋﺎﻣﻞ ﺍﻟﻜﺎﻟﺴﻴﻮﻡ ﺍﻟﻨﻮﻭﻱ ‪Zhang Y، Zhang Z، Chen L، Zhang X.‬‬
‫ﻫﻞﻳﺘﻐﻴﺮ ﺍﻟﺘﺮﻛﻴﺐ ﺍﻟﻔﺴﻴﻮﻟﻮﺟﻲ ﻟﻠﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﺍﻟﻤﻬﺒﻠﻲ ﻓﻲ ﺍﻹﺻﺎﺑﺔ ﺑﻔﻴﺮﻭﺱ ﺍﻟﻮﺭﻡ ﺍﻟﺤﻠﻴﻤﻲ ﺍﻟﺒﺸﺮﻱ‬ ‫‪192.‬ﺳﺮﻃﺎﻥ ﺍﻟﺪﻡ )‪ .1327:(1)22 (2022‬ﺩﻭﻯ‪10.1186/s12885-022- 10431-8:‬‬
‫ﻋﺎﻟﻲﺍﻟﺨﻄﻮﺭﺓ ﻓﻲ ﻋﻨﻖ ﺍﻟﺮﺣﻢ؟ﺍﻟﻔﻴﺮﻭﺳﺎﺕ )‪ .(10)14 (2022‬ﺩﻭﻯ‪10.3390/v14102130:‬‬

‫‪.‬ﺗﺄﺛﻴﺮﻛﺮﻳﻢ ﺍﻟﺘﺮﻃﻴﺐ ﺍﻟﻤﺤﺘﻮﻱ ﻋﻠﻰ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻋﻠﻰ ﺍﻟﻌﻨﺎﻳﺔ ﺑﺎﻟﺒﺸﺮﺓ ﻟﺪﻯ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ‬ ‫‪.‬ﻣﻴﻜﺮﻭﺑﻴﻮﻡﺍﻟﺠﻠﺪ ﻭﺳﻤﻴﺎﺕ ﺍﻟﺠﻠﺪ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﻌﻼﺝ ﻟﺪﻯ ﻣﺮﺿﻰ ﺍﻟﺴﺮﻃﺎﻥ‪ :‬ﻣﺮﺍﺟﻌﺔ ﻣﺼﻐﺮﺓ ‪، Bai J.‬‬
‫ﻳﻌﺎﻧﻮﻥﻣﻦ ﺍﻟﺘﻬﺎﺏ ﺍﻟﺠﻠﺪ ﺍﻟﺘﺄﺗﺒﻲ ﺍﻟﺨﻔﻴﻒ ‪228. Nakai K، Kubota Y، Soma GI، Kohchi C.‬ﻓﻲ ﺍﻟﺠﺴﻢ‬ ‫‪216. Richardson BN، Lin J، Buchwald ZS‬ﺃﻭﻧﻜﻮﻝ ﺃﻣﺎﻣﻲ )‪ .12:924849 (2022‬ﺩﻭﻯ‪:‬‬
‫ﺍﻟﺤﻲ)‪ .14–109:(1)33 (2019‬ﺩﻭﻯ‪10.21873/invivo.11446:‬‬ ‫‪10.3389/fonc.2022.924849‬‬
‫‪.‬ﻳﺤﺎﻓﻆﻋﻠﻰ ﻛﺜﺎﻓﺔ ﺍﻟﻌﻈﺎﻡ ﻟﺪﻯ ﺍﻟﻨﺴﺎء ﻗﺒﻞ ﺍﻧﻘﻄﺎﻉ ﺍﻟﻄﻤﺚ‪ :‬ﺗﺠﺮﺑﺔ ﻋﺸﻮﺍﺋﻴﺔ‪ ،‬ﻣﺰﺩﻭﺟﺔ ﺍﻟﺘﻌﻤﻴﺔ‪ ،‬ﻣﺤﻜﻮﻣﺔ‬ ‫‪.‬ﺍﻟﻌﻼﻗﺔﺑﻴﻦ ﺍﻟﺒﻜﺘﻴﺮﻳﺎ ﺍﻟﻔﻤﻮﻳﺔ ﻭﺃﻭﺭﺍﻡ ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ )ﺇﻋﺎﺩﺓ ﺍﻟﻨﻈﺮ( ‪، Zhu S، Zhang T، Chen X.‬‬
‫ﺑﺎﻟﻐﻔﻞ‪H، Nakamo T، Yoshimura H، Soma G. Pantoea agglomerans lipopolysaccharide‬‬ ‫‪217. Li X‬ﻣﻨﺪﻭﺏ ﺃﻭﻧﻜﻮﻝ )‪ .(2)46 (2021‬ﺩﻭﻯ‪10.3892/or.2021.8111:‬‬
‫‪229. Nakata K، Nakata Y، Inagawa‬ﺍﻟﻐﺬﺍء ﺍﻟﻌﻠﻤﻲ ﻧﻮﺗﺮ )‪ .46–638:(6)2 (2014‬ﺩﻭﻯ‪/fsn3.145:‬‬
‫‪.218‬ﺭﻭﺧﺎﺱ‪-‬ﺗﺎﺑﻴﺎﺱ ﺩﻱ ﺇﻑ‪ ،‬ﺑﺮﺍﻭﻥ ﺇﻡ‪ ،‬ﺗﻤﺒﻞ ﺇﻱ ﺁﺭ‪ ،‬ﺃﻭﻧﻴﻜﺎﺑﺎ ﺇﻡ ﺇﻳﻪ‪ ،‬ﻣﺤﻤﺪ ﺃﻣﺖ‪ ،‬ﺩﻧﻜﺎﻥ ﻛﻴﻪ‪،‬‬
‫‪10.1002‬‬
‫ﻭﺁﺧﺮﻭﻥ‪.‬ﺍﻟﻨﺘﺮﺍﺕ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻻﻟﺘﻬﺎﺏ ﺗﺴﻬﻞ ﺍﻻﺳﺘﻌﻤﺎﺭ ﺧﺎﺭﺝ ﺍﻟﺮﺣﻢ ﻟﻠﺒﻜﺘﻴﺮﻳﺎ ﺍﻟﻔﻤﻮﻳﺔ ﻓﻴﻠﻮﻧﻴﻼ ﺑﺎﺭﻓﻮﻻ‬
‫‪.230‬ﺟﺎﻓﻤﻦ ﺃ‪ ،‬ﻧﻴﻤﻴﻜﺎﻳﺘﻲ‪-‬ﺳﻴﻨﻴﻴﻦ ﺃ‪ ،‬ﺑﺮﺍﺗﺸﻴﻜﻮﻑ ﺇﻡ‪ ،‬ﺟﺮﻳﺠﻴﺴﻜﻴﺲ ﺇﺱ‪ ،‬ﺟﺮﻳﺠﺎﺱ ﺇﻑ‪،‬‬ ‫ﻓﻲﺍﻷﻣﻌﺎء‪.‬ﻧﺎﺕ ﻣﻴﻜﺮﻭﺑﻴﻮﻝ )‪ .85–1673:(10)7 (2022‬ﺩﻭﻯ‪10.1038/s41564-022-01224-7:‬‬
‫ﺟﻮﻧﺎﻭﺳﻜﻴﻦﺍﻷﻭﻝ‪ ،‬ﻭﺁﺧﺮﻭﻥ‪ .‬ﻳﺤﻔﺰ ﺑﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ ﻣﻦ ﻓﻄﺮﻳﺎﺕ ﺍﻟﺴﻜﻴﺮﺍء ﺇﻧﺘﺎﺝ ﺍﻹﻧﺘﺮﻓﻴﺮﻭﻥ ﺟﺎﻣﺎ ﻓﻲ‬
‫ﺍﻟﺠﺴﻢﺍﻟﺤﻲ ﻟﺪﻯ ﺍﻟﻔﺌﺮﺍﻥ ‪.BALB/c‬ﻓﻲ ﺍﻟﺠﺴﻢ ﺍﻟﺤﻲ )‪.359-63:(3)29 (2015‬‬ ‫ﻟﻠﻌﻼﺟﺎﺕﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ؟ ‪ PDAC‬ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ ﻓﻲ ﻭﺟﻬﺔ ﻧﻈﺮ ‪A، Ammer-Herrmenau C.‬‬
‫‪.‬ﺁﺛﺎﺭﻣﻜﻤﻼﺕ ﺑﻴﺘﺎ ﺟﻠﻮﻛﺎﻥ ﺍﻟﻐﺬﺍﺋﻴﺔ ﻋﻠﻰ ﺗﻌﺒﻴﺮ ﺍﻟﺴﻴﺘﻮﻛﻴﻦ ﻓﻲ ﻛﺒﺪ ﺍﻟﺨﻨﺎﺯﻳﺮ ‪JV، Sweeney T.‬‬ ‫‪219. Pfisterer N، Lingens C، Heuer C، Dang L، Neesse‬ﺍﻟﺴﺮﻃﺎﻥ )ﺑﺎﺯﻝ( )‪(23) 14 (2022‬‬
‫‪231. Ryan MT، Collins CB، O'Doherty‬ﻱ ﺃﻧﻴﻢ ﺍﻟﻌﻠﻮﻡ )‪ 90 (2012‬ﻣﻠﺤﻖ ‪ .2-40 :4‬ﺩﻭﻯ‪:‬‬ ‫‪.‬ﺩﻭﻯ‪/10.3390:‬ﺍﻟﺴﺮﻃﺎﻥ‪14235974‬‬
‫‪10.2527/jas.53763‬‬ ‫‪.‬ﻣﺤﻮﺭﺍﻷﻣﻌﺎء ﻭﺍﻟﻜﺒﺪ‪ :‬ﺗﻔﺎﻋﻼﺕ ﺍﻟﻜﺎﺋﻨﺎﺕ ﺍﻟﺤﻴﺔ ﺍﻟﺪﻗﻴﻘﺔ ﺍﻟﻤﻀﻴﻔﺔ ﺗﺸﻜﻞ ﺳﺮﻃﺎﻥ ﺍﻟﻜﺒﺪ ‪، Trinchieri G.‬‬
‫‪.‬ﺍﻟﻤﻨﺎﻋﻴﺔﻭﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﻛﻤﺤﻔﺰﺍﺕ ﻟﻼﻟﺘﻬﺎﺏ ﺍﻟﺮﺋﻮﻱ ﻓﻲ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﺍﻟﺘﻠﻴﻒ‬ ‫‪220. Silveira MAD، Bilodeau S، Greten TF، Wang XW‬ﺍﺗﺠﺎﻫﺎﺕ ﺍﻟﺴﺮﻃﺎﻥ )‪–583:(7) 8 (2022‬‬
‫ﺍﻟﻜﻴﺴﻲﻭﻋﺪﻭﻯ ﺍﻟﺮﺋﺔ ﺍﻟﻤﺰﻣﻨﺔ ﺑﺎﻟﺰﺍﺋﻔﺔ ﺍﻟﺰﻧﺠﺎﺭﻳﺔ ‪ LPS‬ﻭﻣﺠﻤﻌﺎﺕ ‪G. Lipopolysaccharide )LPS(،‬‬ ‫‪.97‬ﺩﻭﻯ‪10.1016/j.trecan.2022.02.009:‬‬
‫‪232. Kronborg‬ﻣﻠﺤﻖ ‪.1-30 :50 (1995) APMIS‬‬ ‫‪.‬ﻣﻴﻜﺮﻭﺑﺎﺕﺍﻟﺜﺪﻱ ﺍﻟﻤﺤﻠﻴﺔ‪ :‬ﻻﻋﺐ "ﺟﺪﻳﺪ" ﻋﻠﻰ ﺍﻟﻜﺘﻠﺔ ‪D، Vicente R، Caleca T، Santos C.‬‬
‫‪ TLR4 / NF-kappaB.‬ﻋﻠﻰ ﻧﻤﻮﺫﺝ ﺍﻟﻔﺌﺮﺍﻥ ﻟﻤﺮﺽ ﺍﻻﻧﺴﺪﺍﺩ ﺍﻟﺮﺋﻮﻱ ﺍﻟﻤﺰﻣﻦ ﺍﺳﺘﻨﺎﺩﺍً ﺇﻟﻰ ﻣﺴﺎﺭ‬ ‫‪221. VitorinoM، AlpuimCosta‬ﺍﻟﺴﺮﻃﺎﻥ )ﺑﺎﺯﻝ( )‪ .(15)14 (2022‬ﺩﻭﻯ‪/10.3390:‬ﺍﻟﺴﺮﻃﺎﻥ‪14153811‬‬
‫‪ trollius altaicus‬ﺍﻟﺘﺄﺛﻴﺮ ﺍﻟﻮﻗﺎﺋﻲ ﻟﻤﺠﻤﻮﻉ ﻣﺮﻛﺒﺎﺕ ﺍﻟﻔﻼﻓﻮﻧﻮﻳﺪ ﻓﻲ ‪Shao H، Jia W، Su D، Liu T.‬‬ ‫‪.‬ﻣﻴﻜﺮﻭﺑﺎﺕﺍﻟﺜﺪﻱ ﺍﻟﻤﺤﻠﻴﺔ‪ :‬ﻻﻋﺐ "ﺟﺪﻳﺪ" ﻋﻠﻰ ﺍﻟﻜﺘﻠﺔ ‪D، Vicente R، Caleca T، Santos C.‬‬
‫‪233. Li Y، Zhao J،‬ﺁﻥ ﺗﺮﺍﻧﺲ ﻣﻴﺪ )‪ .222:(4)10 (2022‬ﺩﻭﻯ‪/10.21037:‬ﺍﻟﺼﺮﺍﻑ ﺍﻵﻟﻲ‪331-22-‬‬ ‫‪222. Vitorino M، Costa Alpuim‬ﺍﻟﺴﺮﻃﺎﻥ )ﺑﺎﺯﻝ( )‪ .(15)14 (2022‬ﺩﻭﻯ‪/10.3390:‬‬
‫ﺳﺮﻃﺎﻧﺎﺕ‪14153811‬‬
‫‪.‬ﻳﻌﺰﺯﺗﻜﻮﻳﻦ ﺍﻷﻭﺭﺍﻡ ﻓﻲ ﺭﺋﺔ ﺍﻟﻔﺄﺭ‪ :‬ﻧﻤﻮﺫﺝ ﻟﺴﺮﻃﺎﻥ ﺍﻟﺮﺋﺔ ﺍﻟﻨﺎﺟﻢ ﻋﻦ ﺍﻻﻟﺘﻬﺎﺏ‬ ‫‪.223‬ﺳﻴﺠﺎﻝ ﺑﻲ ﺇﺗﺶ‪ ،‬ﺟﻴﺮﻳﺪﺍﺭﺍﻥ ﺗﻲ‪ ،‬ﺳﻮﺯﻭﻛﻲ ﺇﺱ‪ ،‬ﺧﺎﻥ ﺁﻧﻪ‪ ،‬ﺯﺳﻴﺮﻭﺱ ﺇﻱ‪ ،‬ﺇﻳﻤﻮﻧﺰ ﺗﻲ ﺁﺭ‪،‬‬
‫‪Melkamu T، Qian X، Upadhyaya P، O'Sullivan MG، Kassie F. Lipopolysaccharide‬‬ ‫ﻭﺁﺧﺮﻭﻥ‪.‬ﺗﻔﺎﻋﻼﺕ ﺍﻟﻌﺪﻻﺕ ﻣﻊ ﺍﻟﺨﻼﻳﺎ ﺍﻟﺘﺎﺋﻴﺔ ﻭﺍﻟﺼﻔﺎﺋﺢ ﺍﻟﺪﻣﻮﻳﺔ ﻭﺍﻟﺨﻼﻳﺎ ﺍﻟﺒﻄﺎﻧﻴﺔ ﻭﺑﺎﻟﻄﺒﻊ ﺍﻟﺨﻼﻳﺎ‬
‫‪234.‬ﺍﻟﻄﺒﻴﺐ ﺍﻟﺒﻴﻄﺮﻱ ﺑﺎﺛﻮﻝ )‪ .895-902:(5)50 (2013‬ﺩﻭﻯ‪0300985813476061 /10.1177:‬‬ ‫ﺍﻟﺴﺮﻃﺎﻧﻴﺔ‪.‬ﺍﻟﻘﺲ ﺍﻟﻤﻨﺎﻋﻲ )‪ .(2022‬ﺩﻭﻯ‪10.1111/imr.13178:‬‬
‫‪.224‬ﺑﻴﻊ ‪ .S‬ﺍﻟﻌﻼﺝ ﺍﻟﻤﻨﺎﻋﻲ ﻟﻠﺴﺮﻃﺎﻥ‪ :‬ﺍﺧﺘﺮﺍﻕ ﺃﻭ "ﺩﻳﺠﺎﻓﻮ‪ ،‬ﻣﻦ ﺟﺪﻳﺪ"؟ ﺍﻟﻮﺭﻡ ﺍﻟﺒﻴﻮﻝ )‪6)39 (2017‬‬
‫‪ E2-EP2.‬ﻳﺴﺒﺐ ﺍﻻﻟﺘﻬﺎﺏ ﻭﻳﺴﻬﻞ ﻭﺭﻡ ﺧﺒﻴﺚ ﻓﻲ ﺍﻟﺮﺋﺔ ﻓﻲ ﻧﻤﻮﺫﺝ ﺳﺮﻃﺎﻥ ﺍﻟﺜﺪﻱ ﻋﺒﺮ ﻣﺴﺎﺭ‬ ‫(‪ .1010428317707764:‬ﺩﻭﻯ‪10.1177/1010428317707764:‬‬
‫ﺍﻟﺒﺮﻭﺳﺘﺎﺟﻼﻧﺪﻳﻦ‪235. Li S، Xu X، Jiang M، Bi Y، Xu J، Han M. Lipopolysaccharide‬ﻣﻤﺜﻞ‬ ‫‪.225‬ﺑﻮﻟﻴﺠﻴﻚ ﺁﺭ‪ ،‬ﺑﻴﻨﻴﺪﻳﻜﺘﻮﺱ ﺇﻱ‪ ،‬ﺑﻼﺗﺮ‪-‬ﺯﻳﺒﻴﺮﻙ ﺳﻲ‪ ،‬ﺑﺎﻭﺭﻟﻲ ﺑﻲ ﺇﻳﻪ‪ ،‬ﺳﺰﻳﻠﻴﻨﻲ ﺇﺱ‪ ،‬ﺑﺮﻭﻥ ﻛﻴﻪ‪،‬‬
‫ﻣﻮﻝﻣﻴﺪ )‪ .4454-62:(6)11 (2015‬ﺩﻭﻯ‪ /10.3892:‬ﻣﻢ‪2015.3258.‬‬ ‫ﻭﺁﺧﺮﻭﻥ‪.‬ﻳﺘﻢ ﺗﺜﺒﻴﻂ ﺍﻟﺘﻬﺎﺏ ﺍﻟﺮﺋﺔ ﺍﻟﻨﺎﺟﻢ ﻋﻦ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻋﻦ ﻃﺮﻳﻖ ﺗﺤﻴﻴﺪ ‪.GM-CSF‬ﻳﻮﺭﻭ‬
‫ﺟﻲﻓﺎﺭﻣﺎﻛﻮﻝ )‪ .230-5:(2-3)557 (2007‬ﺩﻭﻯ‪10.1016/j.ejphar.2006.11.023:‬‬
‫‪.236‬ﻛﻮﺗﻴﻨﻴﻮ‪-‬ﻭﻟﻴﻨﻮ ﻛﺎﻧﺴﺎﺱ‪ ،‬ﺃﻟﻤﻴﺪﺍ ﺑﻲ ﺑﻲ‪ ،‬ﻣﺎﻓﺮﺍ ﺩﻱ‪ ،‬ﺳﺘﻮﻛﻠﺮ‪-‬ﺑﻴﻨﺘﻮ ﺇﻡ ﺑﻲ‪ .‬ﺍﻟﻤﺮﻛﺒﺎﺕ ﺍﻟﻨﺸﻄﺔ‬ ‫‪.‬ﺍﺳﺘﻨﺸﺎﻕﺍﻷﻛﺮﻭﻟﻴﻦ ﻳﻤﻨﻊ ﺇﻧﺘﺎﺝ ﺍﻟﺴﻴﺘﻮﻛﻴﻨﺎﺕ ﺍﻻﻟﺘﻬﺎﺑﻴﺔ ﺍﻟﻨﺎﺟﻤﺔ ﻋﻦ ﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻭﻟﻜﻨﻪ‬
‫ﺑﻴﻮﻟﻮﺟﻴﺎﺍﻟﺘﻲ ﺗﻌﺪﻝ ﺍﻻﻟﺘﻬﺎﺏ ﺍﻟﺬﻱ ﻳﺸﺒﻪ ﻣﺴﺘﻘﺒﻼﺕ ‪ (TLR4) 4‬ﺑﻮﺳﺎﻃﺔ‪ :‬ﺍﻟﻤﺴﺎﺭﺍﺕ ﺍﻟﻤﻌﻨﻴﺔ‬ ‫ﻻﻳﺆﺛﺮ ﻋﻠﻰ ﺍﻟﻌﺪﻻﺕ ﺍﻟﺤﺎﺩﺓ ﻓﻲ ﺍﻟﺸﻌﺐ ﺍﻟﻬﻮﺍﺋﻴﺔ ‪، Othman Z، Hemenway D، van der Vliet A.‬‬
‫ﻭﻭﺟﻬﺎﺕﺍﻟﻨﻈﺮ ﺍﻟﻤﺴﺘﻘﺒﻠﻴﺔ‪.‬ﻧﻮﺗﺮ ﺭﻳﺲ )‪ .107:96-116 (2022‬ﺩﻭﻯ‪/ j.nutres.2022.09.001:‬‬ ‫‪226. Kasahara DI، Poynter ME‬ﻱ ﺇﻣﻮﻧﻮﻝ )‪ .45–736:(1)181 (2008‬ﺩﻭﻯ‪:‬‬
‫‪10.1016‬‬ ‫‪/10.4049‬ﺟﻴﻤﻮﻧﻮﻝ‪181.1.736.‬‬
‫‪.237‬ﻣﺎﻱ ﺳﻲ ﺩﺑﻠﻴﻮ‪ ،‬ﻛﺎﻧﻎ ﻭﺍﻱ ﺑﻲ‪ ،‬ﺑﻴﺘﺸﻴﻜﺎ ﺇﻡ ﺁﺭ‪ .‬ﻫﻞ ﻳﻨﺒﻐﻲ ﺗﺼﻤﻴﻢ ﻧﺎﻫﺾ ﺃﻭ ﻣﻀﺎﺩ‬ ‫‪.‬ﺗﻨﺎﻭﻝﻋﺪﻳﺪ ﺍﻟﺴﻜﺎﺭﻳﺪ ﺍﻟﺪﻫﻨﻲ ﻣﻦ ﺑﻜﺘﻴﺮﻳﺎ ﺣﻤﺾ ﺍﻷﺳﻴﺘﻴﻚ ﻋﻦ ﻃﺮﻳﻖ ﺍﻟﻔﻢ ﻳﺤﻤﻲ ﺣﺴﺎﺳﻴﺔ ﺣﺒﻮﺏ ﺍﻟﻠﻘﺎﺡ‬
‫ﻟﻤﺴﺘﻘﺒﻼﺕ (‪ Toll-like 4 )TLR-4‬ﻟﻌﻼﺝ ﺍﻟﺴﺮﻃﺎﻥ؟ ‪ :TLR-4‬ﺗﻌﺒﻴﺮﻩ ﻭﺗﺄﺛﻴﺮﺍﺗﻪ ﻓﻲ ﺍﻟﺴﺮﻃﺎﻧﺎﺕ ﺍﻟﻌﺸﺮﺓ‬ ‫ﻓﻲﻧﻤﻮﺫﺝ ﺍﻟﻔﺌﺮﺍﻥ ‪227. Amano S، Inagawa H، Nakata Y، Ohmori M، Kohchi C، Soma G.‬ﺍﻟﺪﻗﺔ‬
‫ﺍﻷﻛﺜﺮﺷﻴﻮﻋﺎً‪.‬ﺃﻫﺪﺍﻑ ‪ Onco‬ﻫﻨﺎﻙ )‪.87–6:1573 (2013‬‬ ‫ﺍﻟﻤﻀﺎﺩﺓﻟﻠﺴﺮﻃﺎﻥ )‪.4509-14:(8)35 (2015‬‬

fonc-13-1180084.en.ar

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

fonc-13-1180084.en.ar

Uploaded by

Copyright:

Available Formats

‫ﻣﺘﺮﺟﻢ ﻣﻦ ﺍﻹﻧﺠﻠﻴﺰﻳﺔ ﺇﻟﻰ ﺍﻟﻌﺮﺑﻴﺔ ‪www.onlinedoctranslator.

‫ﻧﺒﺎﺗﺎﺕﺿﺪ ﺍﻟﺴﺮﻃﺎﻥ‪ :‬ﺍﻷﻋﺸﺎﺏ‬

‫ﺍﻟﻤﻴﻜﺮﻭﺑﻴﻮﻡ‪:‬ﻟﻴﺲ ﻣﻦ ﺍﻟﻨﺒﺎﺕ‪ ،‬ﺑﻞ‬ ‫ﺣﺮﺭﺕﺑﻮﺍﺳﻄﺔ‬

‫ﻓﻲﺍﻟﻨﺒﺎﺕ‪ .‬ﺍﻟﻤﻔﺎﻫﻴﻢ ﺍﻷﺳﺎﺳﻴﺔ‬

‫ﻻﻛﺘﺸﺎﻑﺍﻟﻤﻮﺍﺩ ﺍﻟﻤﺴﺎﻋﺪﺓ ﻟﻠﻘﺎﺡ‬

‫ﺇﻟﻴﺰﺍﺑﻴﺚﻣﺎﺯﻳﻮ‪ ،1‬ﺃﻧﺪﺭﻭ ﺑﺎﺭﻧﺰ‪1‬ﺭﺍﻣﻴﺶ ﺑﺎﺩﻳﺴﺎ‪ ،1‬ﻣﺠﻠﺲ ﺳﺘﻴﻔﻲ‪2‬ﻭﻛﺮﻡ‬ ‫ﺗﻠﻘﻰ‪ 05‬ﻣﺎﺭﺱ ‪2023‬‬

‫ﻓﺆﺍﺩﺳﻠﻴﻤﺎﻥ‪*1‬‬ ‫ﻗﺒﻠﺖ‪ 30‬ﻣﺎﻳﻮ ‪2023‬‬

‫‪frontiersin.org‬‬ ‫‪01‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫ﺧﺎﻓﻀﺎﺕﺍﻟﺤﺮﺍﺭﺓ )ﺃﺳﻴﺘﺎﻣﻴﻨﻮﻓﻴﻦ( )‪ .(15‬ﻻ ﺗﺰﺍﻝ ﺍﻟﻌﺪﻭﻯ‪ ،‬ﺳﻮﺍء ﺑﻌﺪ ﺍﻟﻌﻤﻠﻴﺔ‬ ‫‪1‬ﺍﻟﻤﻘﺪﻣﺔ‬

‫ﻫﻨﺎﻙﺗﺠﺪﺩ ﺍﻻﻫﺘﻤﺎﻡ ﺑﺎﻟﻌﻼﺟﺎﺕ ﺍﻟﻤﻨﺎﻋﻴﺔ ﻟﻸﻭﺭﺍﻡ ﻟﺘﺤﻘﻴﻖ ﻧﻔﺲ ﺍﻟﻬﺪﻭء‬

‫‪frontiersin.org‬‬ ‫‪02‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪03‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪04‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪05‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫ﻻﺗﺰﺍﻝ ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﺘﻲ ﺗﺤﺎﻓﻆ ﻋﻠﻰ ﺍﻟﻨﻤﻂ ﺍﻟﻈﺎﻫﺮﻱ ‪ M2‬ﻣﺤﻞ ﻧﻘﺎﺵ‪،‬‬

‫ﻋﻨﺪﻣﺎﺗﺘﻔﻮﻕ ﺍﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﻤﺴﺒﺒﺔ ﻟﻸﻣﺮﺍﺽ ﻋﻠﻰ ﺍﻟﻨﺒﺎﺗﺎﺕ ﺍﻟﻄﺒﻴﻌﻴﺔ‪ ،‬ﻛﻤﺎ‬

‫‪frontiersin.org‬‬ ‫‪06‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪07‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫ﻗﺪﺭﺓ‪ MOCs‬ﻋﻠﻰ ﺗﻌﺰﻳﺰ ﺍﻟﺪﻓﺎﻉ ﺍﻟﺒﺸﺮﻱ ﺿﺪ ﻣﺴﺒﺒﺎﺕ ﺍﻷﻣﺮﺍﺽ ﻭﺗﺤﺴﻴﻦ‬ ‫‪.5‬ﺍﻟﺨﻼﺻﺔ‬

‫‪frontiersin.org‬‬ ‫‪08‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪09‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪10‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪11‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪12‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

‫‪frontiersin.org‬‬ ‫‪13‬‬ ‫ﺍﻟﺤﺪﻭﺩﻓﻲﻋﻠﻢ ﺍﻷﻭﺭﺍﻡ‬

You might also like